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Abstract	
Abstract  
Magnesium is the most abundant divalent cation in vivo. Despite this, Mg2+ 
homeostasis remains poorly understood compared to other biologically relevant 
cations. Literature-based chelates lack structural variety, with a number of 
intrinsic problems limiting their applications in vivo. The o-aminophenol-N,N,O-
triacetic acid (APTRA) chelate for example, is used extensively to sense Mg2+, 
but displays a higher selectivity towards Ca2+ and Zn2+, over  Mg2+.  
The synthesis of a series of four binding chelates is described, containing both 
carboxylate and phosphinate ligating groups. A new phosphinate analogue of 
APTRA, o-aminophenol-N,N-diacetic acid phosphinate (APDAP) was 
synthesised with a much improved Mg2+ / Ca2+ selectivity, notwithstanding a 
110-fold lower affinity for Ca2+, compared to APTRA. All ligands are analogues of 
APTRA, and have been conjugated into naphthalene-, lanthanide(III)- and 
ruthenium(II)-based systems to study the affinity and selectivity of Mg2+, Ca2+ and 
Zn2+, via absorbance and luminescence spectroscopy. 
The incorporation of the binding groups into an alkynyl-naphthalene fluorophore 
provided a model system to study the binding of Mg2+, Ca2+ and Zn2+. The 
APDAP-based naphthalene derivative displayed a significantly higher selectivity 
towards Mg2+ than the carboxylate analogues. A 10-fold weaker affinity for Ca2+ 
was reported, allowing the binding of Mg2+ to be investigated in a competitive 
medium, in the presence of biologically relevant cations at concentrations similar 
to those found in human serum.   
A dramatically enhanced selectivity towards Mg2+ was observed in the metal-
based APTRA analogues compared to the naphthalene series and literature 
APTRA sensors. Lanthanide complexes containing a pyridylalkynylaryl 
chromophore displayed the highest selectivity for Mg2+, with a 28-fold reduced 
affinity for Ca2+. The binding of Mg2+ in competitive media is described, using the 
first example of a europium-based luminescent probe to monitor ‘free’ Mg2+ in 
newborn calf serum. A dissociation constant of 0.6(1) mM was calculated, 
comparable to the ‘free’ Mg2+ concentration in human serum
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Abbreviations  
AAS Atomic Absorption Spectroscopy 
AC Adenylyl cyclase 
ADP Adenosine diphosphate  
AM Acetoxymethyl esters 
APDAP O-Aminophenol-N,N-diacetic acid phosphinate  
APTRA O-Aminophenol-N,N,O-triacetic acid  
ATP Adenosine triphosphate  
BAPTA (1,2-bis(o-aminophenoxy)ethane-N,N.N',N'-tetracetic acid  
BODIPY 4-bora-3a,4a-diaza-s-indacene 
bpy 2,2'-bipyridine 
br Broad 
BSA Bovine Serum Albumin 
cAMP Cyclic adenosine monophosphate  
COSY Correlation spectroscopy  
CT Computed Tomography 
d Day 
dd doublet of doublets  
DME Dimethoxyethane 
DMF Dimethylformamide  
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
dq doublet of quartets  
dt doublet of triplets  
DTPA Diethylene triamine pentacetic acid 
E Energy  
e.g.  exampli grati (for example) 
EDTA Ethylenediaminetetraacetic acid 
EDTMP Ethylenediamine tetra(methylene phosphonic acid) 
en Ethylenediamine 
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ESI Electrospray ionisation  
ET Energy transfer  
et al. et alia. (and others) 
EtOH ethanol 
F Fluorescence  
FI Fluorescent indicators  
FRET Fluorescence resonance energy transfer  
h Hour 
HEK  Human embryonic kidney cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMBC Heteronuclear multiple-bond correlation spectroscopy  
HPLC High Performance Liquid Chromatography  
HRMS High resolution mass spectrometry  
HSAB Hard-Soft Acid-Base theory 
HSH Hypermagnesaemia with secondary hypocalcemia 
i.e.  Id est (that is)  
ICP-MS Inductively coupled plasma mass spectrometry  
ICP-OES  Inductively coupled plasma optical emission spectrometry  
ICT Intramolecular Charge Transfer  
in cellulo  within cells 
in vivo within a living organism 
iPrOH iso-propanol 
ISC Intersystem crossing 
J Coupling constant  
Ka Association constant  
Kd Dissociation constant  
LC Ligand centered 
Ln3+ Lanthanide(III) ions  
LRMS Low resolution mass spectrometry  
LUMO  Lowest unoccupied molecular orbital  
m multiplet  
m.p. Melting point 
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MC Metal centered 
MCLT Metal-to-ligand charge transfer 
MeOH  methanol 
mg milligram 
min Minute 
mL millilitre  
mM millimolar 
mmol millimole  
MRI Magnetic Resonance Imaging 
MRS Magnetic Resonance Spectroscopy 
MW  Microwave  
NCS  Newborn calf serum 
nm nanometre 
nM nanomolar  
NMR Nuclear Magnetic Resonance  
NOESY Nuclear overhauser effect spectroscopy  
P Phosphorescence  
PET Photo-induced electron transfer  
PET Positron Emission Tomography  
phbpy 4,4'-biphenyl-2,2'-bipyridine 
pKa Acid dissociation constant  
pm picometre 
POPOP 1,4-bis(5-phenyloxazol-2-yl) benzene 
ppm parts per million  
PPT  Photon-induced Proton Transfer 
ppy 2-Phenylpyridine  
q quartet  
r1 Relaxivity 
Rf Retention factor  
RNA  Ribonucleic acid 
s singlet 
S0 Singlet ground state  
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S1 Singlet excited state  
t Triplet 
t1/2  Half-life  
T1 Longitudinal relaxation time  
T1 Triplet excited state  
T2 Transverse relaxation time  
TBAF Tetrabutylammonium fluoride  
TBDMS triflate  tert-Butyldimethylsilyl trifluoromethanesulphonate 
tBuOH tert-butanol 
td Delay time 
TD-DFT Time-Dependent Density Functional Theory  
TN Trimethylenediamine  
TFA Trifluoroacetic acid 
tg Fixed gate time 
THF Tetrahydrofuran  
TIPS Triisopropylsilyl 
TLC Thin-Layer Chromatography  
TOF Time of flight  
TRPM Transient receptor potential ion channels melastatin 
UV Ultraviolet  
wt. weight  
XMEN X-linked immunodeficiency with magnesium defect  
λ wavelength  
λem Emission wavelength 
λex Excitation wavelength  
λmax  Wavelength maximum 
μL microlitre 
μM micromolar  
Φ quantum yield 
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Chapter 1. Introduction 
1. Introduction 
Slow and steady progress has been made over the years in the 
development of magnesium-selective probes since Hasselbach first published 
work indicating the importance of Mg2+ within cells in 1957.1 This breakthrough 
was over half a century ago and yet there is still very little known about the 
homeostasis of Mg2+. Other biologically relevant cations, for instance Ca2+, H+ 
and Na+, have been studied in more depth, allowing detailed transportation and 
homeostatic information within mammalian cells to be acquired.  
The slow progress made in this area led Wolf and co-workers to label Mg2+ 
as the ‘forgotten cation’, in a review article published in 2010.2 In order for more 
information to be gained, more sensitive and selective methods are needed for 
its detection. Current methods such as Atomic Absorption Spectroscopy are 
inaccurate and impractical, while many of the current clinically available 
fluorescence probes have a number of selectivity issues with competing divalent 
cations, such as Ca2+.  
This introduction will outline the role of Mg2+ within cells, and what 
information is known about the transportation of Mg2+ in vivo. A summary of the 
current techniques used in vivo and in vitro to detect Mg2+ ions will also be 
critically discussed. 
1.1 Cellular Mg2+ Distribution  
Although Mg2+ is the second most abundant cation in most cells, it is the 
fourth in terms of body mass, behind Ca2+, K+ and Na+.3 A number of analytical 
techniques such as Atomic Absorption Spectroscopy (AAS) and Fluorescence 
Spectroscopy (FS) have been used to determine the concentration of Mg2+ within 
cells. The results from these techniques have indicated that the total intracellular 
concentration of Mg2+ in the majority of mammalian cells is within the range of 14 
to 20 mM.3  
Mg2+ is mineralised in bones and accumulates preferentially in the 
mitochondria and endo(sarco) plasmic reticulum because its positive divalent 
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charge allows it to preferentially bind to anionic species such as adenosine 
triphosphate (ATP) (Figure 1.1), polyphosphates and pyrophosphates, which are 
common in these compartments of the cell.4 The majority of total cellular 
magnesium is present in the cytoplasm bound to ATP, due to its high abundance 
and binding affinity (Kd ~78 μM)5. The concentration of ‘free’ Mg2+ is therefore 
significantly lower, with values in the range of 0.8 to 1.5 mM being measured in 
the matrix of cardiac and liver mitochondria by commercially available 
Mag-Fura-2.5-7 No such figure has yet been determined for the concentration of 
‘free’ Mg2+ in the endo(sarco) plasmic reticulum because of the elevated levels of 
Ca2+ that are present. The majority of current commercially available 
fluorescence probes such as Mag-Fura-2 express a much higher affinity towards 
Ca2+ than Mg2+ (Kd= 50 μM vs. 1.5 mM).5 Accurate Mg2+ concentrations in cellular 
compartments with Ca2+ concentrations above basal levels, therefore, remain 
challenging to obtain.  
 
Figure 1.1 Mg2+ bound to ATP forming MgATP2-. The β and γ phosphonate groups are 
primarily involved in Mg2+ ion coordination, forming the active species ready for hydrolysis 
to ADP.8,9 
 Within the cell, Mg2+ has a number of key and fundamental roles, for 
instance controlling channel regulation as well as the conformation of nucleic 
acids and proteins10 (such as calmodulin, troponin, parvalbumin and the S100 
protein) and the metabolic regulation of energy dependent mitochondrial and 
cytoplasmic pathways.5 It is an essential cofactor for more than 600 enzymatic 
reactions.11 Its catalytic nature is either direct or by modification of a substrate 
upon Mg2+ binding.12 Of particular importance is the activation of ATPase, an 
enzyme that catalytically dephosphorylates ATP to ADP in vivo (Figure 1.2).13 
The process is essential to life, and for the generation of energy within the cell.  
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Figure 1.2 The dephosphorylation of ATP to ADP catalysed by ATPase.13 
 Magnesium also plays a key role in numerous stages of the cell cycle 
(Figure 1.3), a recognised model characterising the stages of cell growth and 
replication. The various phases of the cell cycle, along with a description of the 
role of each, is highlighted in Table 1.1. The effect of Mg2+ concentration on the 
cell cycle was first highlighted experimentally in 1980, where it was found that 
yeast cells incubated in low Mg2+ concentrations had limited growth, with a 
decreased percentage of cells in the S Phase, in comparison with cells incubated 
in high Mg2+ concentrations.14 
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Figure 1.3 A schematic representation of the cell cycle. Where: G0 = Gap 0 resting state, 
G1 = Gap 1, S = Synthesis phase, G2 = Gap 2 and M = Mitosis phase where cell division 
commences. A description of each phase is provided in Table 1.1. 
 
Table 1.1 Highlighting the role of each stage within the cell cycle. The cycle is split into 
three states resting, interphase and cell division. 
 
 
In mammalian cells, the ability of Mg2+ to bind to ATP4– means it has a vital 
role in DNA duplication, as the phosphorylation of proteins by a kinase and 
ATP-activating proteins sends signals within the cell causing growth and 
proliferation.15 Mg2+ therefore plays an important role in the S phase, where the 
DNA replication commences, and in the G2 phase, the gap between the DNA 
synthesis and mitosis where the cell continues to grow. Studies in mammalian 
cells have shown that by increasing / decreasing the extracellular concentration 
Phase Description 
Gap 0 (G0) Resting state where no cell division occurs. 
Gap 1 (G1) Cells significantly increase in size in preparation for DNA 
synthesis. 
Synthesis 
(S) 
DNA replication occurs during the S phase. 
Gap 2 (G2) The cell continues to grow, a gap between the S phase and 
mitosis. 
Mitosis Cell growth halts and cell division commences. A checkpoint in 
the mitosis phase allows the cell to complete cell division. 
S 
G2 
M 
G1 G0 
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of Mg2+, the rate of cell proliferation can be accelerated or retarded respectively, 
highlighting the fact that proliferating cells have higher Mg2+ concentrations than 
non-proliferating cells. Such a significant increase in proliferation is because 
magnesium stabilises the DNA structure, promoting an increase in DNA 
replication and transcription.16  
Experiments involving smooth muscle cells have shown a 3-fold increase 
in DNA and protein synthesis in a 2 mM medium of Mg2+. Touyz and co-workers 
deemed this to be a significant increase and attributed it to the specific activation 
of the ERK1 / ERK2 extracellular signal reduction kinase-dependent pathway, 
important in the regulation of mitosis.16  
Across different mammalian cell types, however, the effect of extracellular 
magnesium concentration does not appear to show a consistent correlation with 
cell proliferation. A diverse range of cells are affected in a different manner. 
Tumour cells for instance, including HL-60 leukaemia cells, have shown an 
unchanged level of growth when extracellular Mg2+ concentrations were altered 
above or below their physiological values; their growth is therefore independent 
of Mg2+ intra- and extracellular concentrations.17 
 As the importance of Mg2+ within cells is evident, it is somewhat surprising 
that when compared to other biologically relevant cations including Ca2+ and Na+, 
the mechanism by which eukaryotic cells regulate total and ‘free’ Mg2+ is still 
relatively unknown. Recent advances over the last two decades are, however, 
encouraging, with a greater understanding of the cellular importance of Mg2+ 
being gradually proposed.  
1.2 Mg2+ in the Serum 
The concentration of magnesium in the serum is relatively unknown, with 
no specific sensing mechanism in the circulatory system to measure 
concentration changes of Mg2+ being identified to date. Alterations in circulating 
Mg2+ ions are, therefore, commonly determined by a Ca2+ sensing receptor that 
can also detect changes in Mg2+, because of the higher magnesium concentration 
Chapter 1. Introduction 
	
21 
	
in the serum.5 Using this approach it is believed that humans have between 0.7 
and 1.1 mM of Mg2+ circulating around the body in the blood plasma.18 
Maintaining a constant level of Mg2+ in serum is vital for health: elevated 
Mg2+ concentrations result in the onset of hypermagnesemia, causing muscle 
weakness and fatigue.11 In contrast, a deficiency of Mg2+ in plasma is linked to 
the onset of hypomagnesemia, an electrolytic disturbance with an abnormally low 
Mg2+ concentration present in the blood. An electrolytic disturbance in the serum 
has been related to the development of a number of chronic diseases such as 
Type 2 diabetes19, hypertension20 and chronic kidney disease.21 It is thought that 
hypomagnesemia affects up to around 15 % of the general population,22 
possessing little to no symptoms in its mild form making it difficult to detect and 
diagnose. Prescribed medication, an insufficient dietary intake of Mg2+ and 
genetic renal defects can all be linked to causing magnesium deficiency in the 
serum. 
A review by Tilmann and Wolf in 2017 highlighted a number inherited and 
acquired disorders that arise from the development of Mg2+ imbalances in the 
serum.11 The kidneys are the primary regulators of Mg2+ homeostasis, with 80 % 
of all serum Mg2+ being filtered in the glomerulus11 (a cluster of small blood 
vessels around the end of a kidney tubule). Maintaining a constant Mg2+ 
concentration in the serum is, therefore, vital for maintaining healthy kidney 
function, preventing the onset of disease.  
Tests have also been carried in conscious humans, where the 
administration of catecholamine-based hormones (e.g. adrenalin, norepinephrine 
and dopamine) over a time range of 30 min to 5 hours led to a variety of levels of 
hypomagnesia.23 The administration of norepinephrine to perfused rat hearts was 
found to cause an extrusion of Mg2+ from the organs into the perfusate, increasing 
the serum Mg2+ levels.23 
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1.3 Mg2+ Transport in Mammalian Cells  
Cellular cations such as Ca2+ are transported across the cell membrane 
and the membranes of cellular organelles via a series of well understood, highly 
selective mechanisms. Mg2+ is no different, with a series of selective channels for 
the accumulation of Mg2+ in cells (e.g. TRPM in the cell membrane) and 
organelles (Mrs2 in mitochondria) as well as selective exchange pathways for 
Mg2+ efflux (most notably the Na+ dependent and Na+ independent pathways).24  
Romani and Scarpa have carried out extensive work in this area, making 
significant developments into Mg2+ homeostasis.10,23,24 In 2002 Romani and 
Maguire reported that under resting conditions, Mg2+ flux on either side of the cell 
membrane is slow, taking place over a number of hours.24 Such a slow turnover 
led many researchers to believe that the cellular changes in Mg2+ are too small 
in scale to be physiologically relevant or that cellular Mg2+ concentrations remain 
constant over a period of time.5 The hypothesis proposed in 2002 was challenged 
after Romani and co-workers found that there were large fluxes of Mg2+ occurring 
either side of the cell membrane in a matter of minutes following hormonal or 
metabolic stimulation of mammalian cells.5   
Since this publication, multiple examples of large fluxes of Mg2+ in cells 
following stimulation have been reported over a variety of mammalian cells. Wolf 
and co-workers recorded the extrusion of Mg2+ in rat spleen lymphocytes. It was 
found that 30 min after cell stimulation by cyclic adenosine monophosphate 
(cAMP) there was an efflux of Mg2+ which accounted for 15 % of the total Mg2+ 
content.25  
1.3.1 Entry mechanisms of Mg2+ within cells 
	
Mg2+ is transported across the cell membrane via a series of well-regulated 
channels including the transient receptor protein (TRPM) ion channels and 
MagT1. TRPM6 and TRPM7 are two members of the eight-protein TRPM 
subfamily; they are primarily responsible for the homeostasis of Mg2+, and are 
famous for being the first Mg2+ channels identified in mammalian cells.5 Although 
TRPM6 and TRMP7 are structurally similar, and are both predominantly 
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responsible for the transportation of divalent cations (Mg2+, Ca2+ and to a lesser 
extent Zn2+ and Mn2+), one fundamental difference remains. Unlike TRPM6 which 
is only involved in Mg2+ homeostasis in the kidney and the colon, TRPM7 is not 
localised to a particular cell type and is involved in Mg2+ homeostasis in an array 
of cells.26  
Deficiencies in either the TRPM or MagT1 ion channel have been linked 
to a number of illnesses in humans, such as hypermagnesaemia with secondary 
hypocalcemia (HSH) and XMEN (X-linked immunodeficiency with magnesium 
defect, chronic Epstein Barr virus infections and Neoplasma).27 In 2016 it was 
found by Gudermann and co-workers that by inactivating the TRPM6 ion channel 
a reduction of cellular Mg2+ occurred, leading to the development of 
hypomagnesemia in adult mice.28 The disease was found to significantly reduce 
their lifespan and limit growth because of a reduced energy balance.28  
Mrs2 is another family of magnesium transporters, and is responsible for 
the influx of Mg2+ into the mitochondria. Mrs2 is structurally similar to CorA, a 
protein in prokaryotes responsible for mediating the uptake and efflux of Mg2+.29 
Its importance was first highlighted by Wiesenberger et al. where it was 
discovered to play a key role in RNA splicing in yeast mitochondria, a modification 
in pre-messenger RNA where introns are removed.30 It was not until a number of 
years later that Bui et al. identified the importance of Mrs2 as a Mg2+ transporter 
in the inner mitochondrial membrane.29 An under / over-expression of the Mrs2 
gene presented a decreased and increased concentration of ‘free’ Mg2+ in the 
yeast mitochondria respectively. These findings have since been supported by 
findings in mammalian HEK 293 cells, where a reduced mitochondrial Mg2+ 
concentration was observed after an under-expression of the Mrs2 gene.5    
1.3.2 Exit mechanisms: Mg2+ extrusion in living cells 
	
In living cells there are two fundamental extrusion mechanisms for the 
efflux of cellular Mg2+; the Na+ dependent (Na+/ Mg2+ exchange) and the Na+ 
independent exchange pathways.  
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The first evidence for the Na+ dependent Mg2+ exchange pathway was 
from work carried out by Gunther, Vorman and Forster in 1984.31 The study found 
that when the extracellular Na+ concentration is at a lower concentration than the 
physiological concentration, Mg2+ extrusion is inhibited, even after hormonal 
stimulation with isoproterenol and catecholamine. Subsequent work has been 
published since this breakthrough by the same group characterising Mg2+ efflux 
from chicken, rat and human erythrocytes supporting this Na+ dependent 
exchange pathway.32  
The Na+ dependent exchange mechanism is activated by cAMP- mediated 
phosphorylation. cAMP is derived from ATP (Figure 1.4) and is used in signal 
transduction, regulating metabolism in a number of organisms.33 The inhibition of 
the biological catalyst adenylyl cyclase with Rp-cAMP prevents the formation of 
cAMP and, therefore, blocks the extrusion of Mg2+ from mammalian cells, in turn 
increasing the intracellular concentration of Mg2+.33 
 
 
 
 
Figure 1.4 The cyclisation of ATP to cAMP catalysed by adenylyl cyclase (AC). 
Wolf and co-workers found that rat spleen lymphocytes incubated in a 
HEPES (50 mM), CaCl2 (1.3 mM), KCl (5 mM) and NaCl (130 mM) buffer 
expressed a 15 % extrusion of total cellular Mg2+ content after 30 mins.25 
Amiloride and imipramine, drugs used to treat hypertension, have been found to 
inhibit the Na+/ Mg2+ exchange pathway of efflux of Mg2+.33 The pre-treatment of 
the rat spleen lymphocytes with amiloride and imipramine resulted in a 35 % and 
29 % reduction in Mg2+ extrusion from the cells respectivly.25 The replacement of 
NaCl with choline chloride in the incubation medium resulted in a 56 % reduction 
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in Mg2+ extrusion, further supporting the evidence of a complex Na+ / Mg2+ 
exchange process.25,33  
Mg2+ extrusion from living cells in the absence of physiological 
concentrations of extracellular Na+ occurs via the Na+ independent exchange 
pathway. In comparison to the Na+ dependent pathway, the mechanism of the 
Na+ independent pathway is poorly understood. It is less selective, with a wide 
variety of physiological monovalent and divalent cations (Ca2+, Sr2+, Mn2+, and 
choline) and anions (HCO3-, Cl-) reported in the literature to use this mechanism 
for Mg2+ extrusion.34  
Garay and Feray have found evidence of a Mn2+ / Mg2+ (1:1) exchange 
mechanism, stimulating Mg2+ efflux from rat erythrocytes incubated in Na+ free 
media. Efflux of Mg2+ was also measured when the concentration of extracellular 
Na+ was raised; this reduced the efflux of Mg2+ via the Mn2+ / Mg2+ pathway, 
proving that the Na+ / Mg2+ exchange mechanism is favoured.35  
1.4 Intracellular and Extracellular Mg2+ Concentrations and Disease: Is 
there a link? 
Mg2+ deficiencies in humans have been linked to a range of illnesses such 
as HSH, XMEN (Section 1.3.1), brain diseases such as Alzheimer’s, Parkinson’s 
and migraines, as well as hypertension. There is also a link between significant 
exposure to alcohol and a decrease in Mg2+ concentration in liver cells.36 A large 
amount of research is devoted to understanding these processes, and looking 
into the potential of using magnesium as a therapeutic agent in the future to 
counteract these issues.  
1.4.1 Mg2+ and Hypertension  
	
Hypertension or high blood pressure is caused primarily by an increase in 
vascular resistance.37 For the last two decades it has been thought that the 
prolonged reduction of intracellular and extracellular magnesium concentrations 
as a result of magnesium-deficient diets is related to the development of 
hypertension. There is increasing evidence supported from results of multiple 
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animal testing studies showing a direct correlation between Mg2+ dietary intake 
and the development of hypertension.38 A study was carried out in which rats 
were subjected to a magnesium-deficient diet of 80 mg / kg. This resulted in an 
increase in the blood pressure and a reduction in the blood flow after 19 weeks, 
relative to the rats who maintained a healthy diet (960 mg / kg).38 Similar results 
have been found in humans, where magnesium-rich diets have been seen to 
reduce blood pressure levels. The early stages of hypertension or pre-eclampsia 
are commonly treated with Mg2+ salts, in an attempt to increase vasodilation and 
improve the blood flow.13   
Magnesium affects blood pressure by the modulation of vascular tone and 
reactivity. Low magnesium levels in the serum results in vasoconstriction, 
increasing vascular tone and reduction in the blood flow, resulting in the onset of 
hypertension. The exact mechanisms of action are relatively poorly understood, 
but it is believed that it occurs via two main processes. Firstly, Mg2+ acts as an 
antagonist for Ca2+ in smooth muscle cells, inhibiting extracellular calcium 
transport.37 Ca2+ concentrations in comparison to Mg2+ have been seen to cause 
blood vessel contraction, reducing the blood flow and increasing the blood 
pressure.13 Secondly, magnesium has anti-inflammatory properties and aids the 
release of nitric oxide and prostacyclin (PGI2) from the epithelial cells.  
Prostacyclin is a vasodilation agent that inhibits platelet activation in blood 
vessels, preventing the formation of blood clots, improving blood flow and 
reducing the blood pressure. As a result, prostacyclin and prostaglandin based 
drugs are common oral medication to reduce the effects and treat patients with 
hypertension.37  
The link between magnesium and diseases is evident; there is, however, 
still a great deal of work to be done in the area to develop a greater 
understanding, and to assess the potential of using Mg2+ therapeutically to treat 
hypertension and other chronic illnesses.  
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1.5 Techniques to Detect Mg2+ in vivo 
Mg2+ cellular homeostasis is poorly understood because of the lack of 
methods for its detection in vivo. Calcium homeostasis in contrast has been at 
the centre of a great deal of research over the past two decades. Numerous 
methods have been developed for detection of Ca2+, including the fluorescent 
probes Fura-2 and Indo-1 (Figure 1.5).39-41 These ligands are prime examples of 
exceptionally selective Ca2+ chelators that have allowed researchers to develop 
a detailed understanding of Ca2+ homeostasis in vivo. 
 
 
 
 
 
 
Figure 1.5 The structures of (A) Fura-2 and (B) Indo-1 APTRA developed by Tsien and 
co-workers.40  
A vast array of analytical methods for the detection of Mg2+ have been 
designed in order to develop a greater understanding of the role of Mg2+ in vivo. 
The most common techniques include Atomic Absorption Spectroscopy (AAS), 
NMR techniques such as 31P NMR and 19F NMR, the use of unstable and stable 
radioactive isotopes (RI), and more recently the development of Fluorescent 
Indicators (FI) for use in Fluorescence Spectroscopy. 
1.5.1 Atomic Absorption Spectroscopy (AAS) 
	
 Atomic Absorption Spectroscopy (AAS) has historically been an 
extensively used technique for measuring the concentration of magnesium in 
acidic extracts of biological samples. AAS has a number of limitations that restrict 
its use in vivo; firstly, the instrumentation is expensive and uncommon within 
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laboratories making its use impractical. Its major limitation, however, is that the 
technique is unable to differentiate between ‘free’ Mg2+ and Mg2+ bound to ATP4–  
(the most abundant form of Mg2+), with samples requiring dilution before 
measurements are taken.10 More sensitive techniques such as inductively 
coupled plasma mass spectrometry (ICP-MS) have been used by Long and co-
workers to determine K+, Ca2+ and Mg2+ concentrations in human serum.42 
However, ICP-MS also requires expensive instrumentation, limiting its potential 
and widespread use for the measuring of Mg2+ concentrations in biological 
samples.     
1.5.2 The use of Magnesium isotopes  
	
The radioactive isotope 28Mg (β–, t1/2 20.9 h)43 has been used as a tool to 
measure magnesium metabolism.44 Its use as a tracer in humans is problematic, 
as its short half-life means that its administration is strictly forbidden in a large 
proportion of the population, including young children and pregnant women. Such 
problems restrict its scope and applications for in vivo studies.   
Table 1.2 Isotope data for 24Mg, 25Mg, 26Mg and 28Mg.43 
Isotope Mass / Da Natural abundance 
(atom %) 
Half-life / h 
24Mg 23.9850423 78.99 stable 
25Mg 24.9858374 10.00 stable 
26Mg 25.9825937 11.01 stable 
28Mg 27.9838768 - 20.9 
 
Stable magnesium isotopes 24Mg, 25Mg and 26Mg have significantly longer 
half-lives than 28Mg and have been used as safer, more cost-effective alternatives 
to the radioactive 28Mg. Coudray and co-workers published a series of reports in 
which they have used 25Mg to determine the size of exchangeable pools of 
magnesium in animals and humans.45 The use of magnesium isotopes has also 
been developed to study the magnesium influx and efflux in erythrocytes of mice, 
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after it was determined that cancer patients have elevated erythrocyte Mg2+ 
concentrations.46 A great deal of research is, however, required in this area in 
order to develop a better understanding into magnesium cellular exchange 
processes. The use of magnesium isotopes has become more feasible in recent 
years, with the development of more sophisticated mass spectroscopy 
techniques such as ICP-MS, allowing the isotope content to be established more 
accurately.44     
1.5.3 The Use of Fluorescent Indicators (FI) in Fluorescence Spectroscopy 
	
Roger Tsien first published work in 1980 concerning the use of fluorescent 
chelating ligands to measure cytosolic ion concentrations, primarily for the study 
of Ca2+.39 After this work was reported, fluorescence spectroscopy has become 
an extremely powerful and extensively used tool in cell biology.47  
Fluorescence spectroscopy is an attractive technique because of its high 
temporal resolution and sensitivity, meaning that only a small concentration of 
the FI is required to provide a good signal-to-noise ratio.48 The credibility of this 
technique has further increased in recent years through its coupling to optical 
microscopy allowing a better visualisation of living cells in vivo.37 FIs can be 
subdivided into two main groups, either non-ratiometric or ratiometric. The latter 
class has a shift in the emission and / or excitation wavelength on binding of the 
desired metal ion in combination with a change (either increase – ‘turn on’, or 
decrease – ‘turn off’) in the fluorescence intensity. Ratiometric probes are highly 
desirable, because the ratio between two specific wavelengths provides 
quantitative information independent of the local concentration of the FI, the 
concentration of the metal ion, photo bleaching, uneven dye loading and 
instrumental effects. These particular characteristics make ratiometric probes 
highly advantageous for use in metal binding cellular studies.  
1.5.3.1 APTRA-based Fluorescent Sensors 
	
The development of a range of commercially available Mg2+ fluorescent 
indicators based on the O-aminophenol-N,N,O-triaceticacid (APTRA) structure 
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by London and co-workers in the late 1980’s was seen as a significant 
breakthrough in the search for indicators suitable for detecting cytosolic ‘free’ 
magnesium in vivo (Figure 1.6). These chelates are analogues of 
ethylenediaminetetraacetic acid (EDTA, a known Mg2+ binding ligand) and are 
made up of an APTRA binding unit which is connected to an aromatic reporter 
group providing the fluorescent properties.48-51 
  
 
 
 
 
 
 
Figure 1.6 (A) EDTA, (B) APTRA, (C) BAPTA39, (D) commercially available Mag-Fura-2 
(λex = 325 nm) 49, (E) Mag-S (λex 392 nm) 50, (F) Mag-Indo-1 (λex 340 nm)43 and a later 
generation APTRA ligand (G) (λex 325 nm) designed by London and co-workers.51 
Mag-Fura-2 (also sometimes referred to as FURAPTRA) and Mag-Indo-1 
were some of the first commercially available probes for Mg2+ with affinities in the 
low mM range (1.9 mM and 2.7 mM respectively).49 They are composed of the 
same fluorophore developed to visualise selective Ca2+ binding via fluorescence 
spectroscopy, Fura-2 and Indo-1.39 Their difference, however, arises with the 
introduction of an APTRA binding group at the expense of a BAPTA binding 
moiety used for Ca2+. The APTRA moiety was introduced as the smaller ionic 
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radius of Mg2+ allows it to form stable complexes containing ligands with a lower 
denticity. 
In 2001, an alternative synthetic approach to sp2–sp2 carbon-carbon bond 
formation was developed involving a palladium-catalysed cross-coupling 
reaction, allowing an array of different polyaromatic groups to be introduced onto 
the APTRA chelate to form a range of new APTRA fluorescent indicators 
(Figure 1.6, 1.6G). From fluorescence measurements, it was found that 
naphthalene based 1.6G acted as a ‘turn on’ ratiometric probe in the presence of 
Mg2+: a 7-fold increase in the fluorescence intensity was observed at 358 nm with 
a 1.8-fold increase at 499 nm.51  
Fluorescent indicators based around the APTRA framework are 
commonplace in the literature, but have a number of fundamental problems. 
Firstly, they are more selective towards Ca2+ than Mg2+ allowing them to be used 
as low affinity Ca2+ indicators. Secondly, commercially available Mag-Fura-2 and 
Mag-Indo-1 have relatively short emission and excitation wavelengths of 370 nm 
and 340 nm respectively. Low energy / high wavelength excitation is more 
favourable, reducing photo-damage and interference from background 
fluorescence in biological media.50,52  
To overcome the issue of relatively high energy excitation, Buccella and 
co-workers have been working to increase the emission and excitation 
wavelengths of APTRA based chelators to make them more suitable for live 
fluorescence imaging (Figure 1.6)50. However, very few examples of Mg2+ 
indicators requiring low energy excitation are to be found in the literature. One 
such example, is the incorporation of heavier chalcogens (S, Se, Te) into the 
structure of numerous APTRA chelators to increase the emission and excitation 
wavelengths (Mag-S, Figure 1.6)50. The replacement of an oxygen by either a 
sulphur or selenium atom resulted in a greater Stokes’ shift between the bound 
and unbound forms of the aromatic reporter group. Such a small and simple 
modification does not change the inherent ion selectivity; however, the affinity of 
the fluorescent indicators towards Mg2+ is slightly changed with Kd values of 
2.2 mM and 3.2 mM observed for Mag-Fura-2 and Mag-S respectively.50 
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Following on from this work in developing low energy Mg2+ fluorescent 
sensors, in 2016, the Buccella group synthesised a range of bright red-emitting 
Mg2+ BODIPY (4-bora-3a,4a-diaza-s-indacene)-based fluorescence sensors  
MagB1 and MagB2 with absorption and emission maxima in the visible range 
(Figure 1.7).53 This work was based on that of McClenaghan and co-workers in 
2012, who developed two ‘turn-on’ BODIPY-BAPTA conjugates for the selective 
binding of Ca2+ ions.54 The use of BODIPY fluorophores is highly advantageous, 
due in part to their high quantum yields, narrow emission and excitation profiles, 
low toxicity and the scope for structural modification. The introduction of groups 
onto the BODIPY core allows the possibility of colour tuning, while the 
introduction of binding moieties allows BODIPY based compounds to be utilised 
as metal binding fluorophores.53-56  
 
 
 
 
Figure 1.7 (A) MagB1 (λex = 496 nm)53, (B) Mag B2 (λex = 575 nm)53 examples of BODIPY-
based Mg2+ sensors and (C) BODIPY-BAPTA, a Ca2+ sensor (λex = 475 nm).54 
Similarly to BODIPY-BAPTA, MagB1 and MagB2 are ‘turn on’ fluorescent 
probes with excitation in the visible range. A 15-fold and 58-fold increase in the 
fluorescence emission intensity was observed respectively. The ‘turn on’ nature 
of the probes is due to the fact that the coordination of Mg2+ eliminates the photo-
induced electron transfer (PET) pathway that quenches the fluorescence of the 
unbound indicator in solution. A ‘turn-on’ response is highly advantageous and, 
coupled with binding constants in the low mM range (Kd = 4.3 mM for MagB1 and 
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2.1 mM for MagB2), make these probes potentially well suited for detecting ‘free’ 
or ‘ionised’ Mg2+ in vivo.53 No shift in the emission or excitation spectrum is 
observed, however, after the addition of Mg2+ and Ca2+ in each instance. 
BODIPY- BAPTA, MagB1 and MagB2 are, therefore, non-ratiometic indicators 
for metal ions.53,54  
The addition of specific targeting groups has allowed APTRA based 
fluorescent sensors to be used to detect ‘free’ Mg2+ in organelles with the 
development of Mag-mito-AM,57 and HaloTag-Mg-S-Tz.58 Mag-mito-AM is 
structurally similar to Mag-Fura-2, but contains a triazole linker between the 
APTRA binding unit and the mitochondrial targeting moiety (Figure 1.8). 
Acetoxymethyl esters (AM) are commonly introduced allowing indicators to enter 
cells, the ester groups are then hydrolysed to their resultant carboxylic acids 
within the cell. Mag-mito-AM has been used in ratiometric excitation imaging for 
the detection of Mg2+ in the mitochondria.57 The use of Mag-mito has provided 
evidence of Mg2+ fluctuations specific to the mitochondria in the early stages of 
cell apoptosis in HeLa cells, induced by Staurosporine.57 During apoptosis it was 
determined that there was an approximate 3-fold increase in ‘free’ Mg2+ to 
2.6 mM, whilst the control experiment without the addition of Staurosporine 
resulted in a constant ‘free’ Mg2+ concentration of 0.8 mM.57  
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Figure 1.8 (A) Mag-mito-AM, a mitochondrial targeted Mg2+ fluorescent sensor,57 (B) 
HaloTag-Mg-S-Tz for imaging in the nucleus, Golgi apparatus and the mitochondria,58 
~ indicates the start of the specific protein sequence enabling localisation within the cell. 
HaloTag-Mg-S-Tz uses HaloTag protein labelling technology, and has 
been developed for ratiometric imaging of Mg2+ in specific cellular compartments 
including the nucleus, mitochondria and Golgi apparatus.58 It achieves specific 
localisation within the cell by varying the protein sequence connected to the 
HaloTag domain.58 It was found that the addition of the protein enabling 
localisation did not affect the sensor’s affinity for Mg2+, remaining in the mM range 
(Kd = 3.1 mM).58 
1.5.3.2 β-Keto acid-based Fluorescent Sensors 
	
Over the last decade, a number of probes as an alternative to the APTRA 
binding framework have been developed for the binding of ‘free’ Mg2+. Examples 
include β-keto acids,59-63 crown ethers,64 porphyrin and the first genetically 
encoded fluorescent probe MagFRET-1, based on the high-affinity Mg2+ binding 
domain of human centrin 3 (HsCen3), with a Mg2+ affinity in the µM range 
(Kd = 148 µM).65  
β-Keto acids have emerged in recent years as an alternative to the APTRA 
binding site. Suzuki and co-workers are at the forefront of this research and have 
developed a range of β-keto acids that selectively bind Mg2+ in a bidentate 
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manner (Figure 1.9). KMG-20 was the first of the series to be synthesised in 
2002.62 The charged bidentate β-diketone binding site and coumarin fluorophore 
showed promise, with a 200-times greater selectivity observed for Mg2+ over Ca2+ 
compared to commercially available probes, such as Mag-Fura-2 and 
magnesium green.62 Nevertheless, KMG-20 has a number of significant 
disadvantages. The high dissociation constant (Kd) of 10 mM and the short 
wavelength absorption maxima observed meant that it was not excitable by the 
Ar+ laser that is commonly used in confocal microscopy experiments. The group 
later developed a range of alternative probes in the series with longer wavelength 
maxima, including KMG-10466 and KMG-301,59 which have fluorescence 
emission that is independent of pH within the biological range,66 allowing the 
binding of Mg2+ to be studied in the cytosol and the mitochondria.59  
 
 
 
 
 
 
Figure 1.9 (A) KMG-20,62 (B) KMG-30159 and (C) KMG-104,66 Mg2+ selective β-keto-acid 
fluorescent probes forming binary species with ‘free’ Mg2+. (D) The binding of KMG-301 to 
MgATP2– forming a ternary complex.60 
KMG-104 adopts a xanthene-based phore as an alternative to the 
coumarin group used for KMG-20, and has been used as a selective probe to 
model Mg2+ dynamics in the cytosol.66 A PET quenching process is observed in 
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the ground state, instead of the internal charge transfer (ICT) mechanism 
observed with KMG-20. The elimination of the PET quenching mechanism upon 
Mg2+ binding resulted in an 8-fold ‘turn-on’ response upon the addition of Mg2+ 
ions, with a Kd of 2.1 mM.66 No significant fluorescence response was observed 
with any competing biologically relevant metal ions including Ca2+, K+ and Na+. A 
significantly increased Mg2+ / Ca2+ selectivity was observed, with the affinity for 
Ca2+ in the mM range (Kd = 7.5 mM), instead of the usual µM range of binding 
seen with the APTRA chelators in the literature.  
The Ca2+ concentration in mammalian cells such as those in the brain is 
typically in the range of 50 to 100 nM, while extracellular Ca2+ concentrations are 
around 1.5 to 2.0 mM.67 The Kd for Ca2+, therefore, lies outside the range of intra- 
and extracellular Ca2+ concentrations.67   
KMG-301 has a molecular design based on rhodamine, whose cationic 
charge is known to favour localisation in the mitochondria because of its negative 
membrane potential.59 It was found that a 45-fold increase in the fluorescence 
emission was observed in the presence of 100 mM of Mg2+ with a Kd of 4.5 mM, 
an ideal range for the detection of Mg2+ in vivo.59 A substantial improvement in 
the selectivity towards Mg2+ in comparison with the APTRA chelators was 
observed, with the fluorescence intensity remaining unaffected in the presence 
of biological concentrations of a number of cations including Na+, K+ and most 
notably Ca2+.59 Mitochondria typically possess a higher concentration of Ca2+ 
than other areas of the body, and it was, therefore, vital in this instance that the 
ligand has a low affinity towards Ca2+, for the accurate measurements of Mg2+ 
dynamics to be measured.59  
The use of KMG-104 in combination with KMG-301 has allowed a greater 
understanding to be developed into details about the accumulation and extrusion 
of Mg2+ in the mitochondria.59  
β-Keto-acids have a number of significant advantages over APTRA based 
fluorescent sensors, primarily, their higher selectivity towards Mg2+ over Ca2+. 
However, they too have a number of limitations to consider. Ligands in the KMG 
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series are non-ratiometric, unlike many of the APTRA based fluorescent sensors, 
meaning that upon binding of Mg2+ no shift in the emission and / or excitation 
wavelength is observed. The bidentate binding nature of the β-keto acids, 
occupying only two sites in the coordination sphere of Mg2+, results in the 
formation of mixed species with Mg2+.60 Their low denticity means that β-keto 
acids can form both binary and ternary complexes with Mg2+, i.e. forming 
complexes with ‘free’ Mg2+ and Mg2+ bound to ATP4– respectively 
(Figure 1.9D).60 Simple fluorescent measurements cannot be used to distinguish 
between the bound and unbound forms of Mg2+ that can be formed in the cell, 
because the Kd values for both species are in the low mM range (3.8 mM for 
Mg2+, 14.2 mM for MgATP2–).60 Unless more sophisticated fluorescent 
measurements can be recorded, the ligands in the KMG series are not 
appropriate fluorescent indicators to develop a greater understanding of Mg2+ 
homeostasis in vivo and, therefore, a more accurate determination of intracellular 
concentrations of Mg2+ is required.   
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Table 1.3 Summary of Mg2+ fluorescence probes in order as discussed in Section 1.5.3.1 and Section 1.5.3.2. Measurements are recorded in 
H2O, errors calculated for each measurement are included in parenthesis (mM binding affinity for Ca2+).  
Compound λmax 
Absorption 
(nm) 
λmax Excitation 
(nm) 
λmax Emission 
(nm) 
Quantum yield, 
Φ 
 
Kd (Mg2+) (mM) Kd (Ca2+) (µM) 
Mag-fura-249,50 369 370 511 0.24 1.9 25 
Mag-S50 396 392 572 0.17(1) 3.2(1) 38(1) 
Mag-Se50 412 410 584 0.09(2) 3.3(3) 41(2) 
Mag-indo-143 - 340 - - 2.8 - 
MagB153 496 496 508 0.0051(2) 4.31(1) 25.2(2) 
MagB253 575 575 601 0.0050(2) 2.13(5) 15.4(7) 
Mag-mito57 356 356 495 - 6.7(3) 71(4) 
Mag-S-Tz 
activated58 
404 404 595 0.100(4) 3.1(1) 40.6(8) 
KMG-2062 425 - 485 - 10 30 
KMG-30159 540 - - 0.15 4.5 - 
KMG-10466 502 502 523 - 2.1 7.5 
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1.5.3.3 Alternative Fluorescent Sensors to monitor Mg2+ binding 
	
Crown ethers based upon diaza-18-crown-6-hydroxyquinoline are another 
example of ligands that have been used to bind Mg2+ selectively.64, 68 Iotti and co-
workers have synthesised a number of 8-hydroxyquinoline based probes, 
including DCHQ5, a fluorescent probe with a µM affinity for Mg2+ (Figure 1.10).68 
Such behaviour makes these ‘turn-on’ probes unsuitable for use in vivo for the 
detection of ‘free’ Mg2+, because its concentration lies in the low mM range in 
mammalian cells. They can, however, provide an insight into the total intracellular 
Mg2+ concentration. No significant changes were observed in either the 
absorption or emission spectra upon the addition of a number of divalent cations, 
including Ca2+ and Fe2+,64,68 highlighting their selectivity of binding Mg2+ over 
competing cations within this range.68 The ‘turn-on’ response observed is due to 
the de-protonation of the phenol group of 8-hydroxyquinoline, on binding to Mg2+, 
preventing an intramolecular photoinduced proton transfer (PPT) process 
occurring that is observed in the free ligand.68 
 
Figure 1.10 DCHQ5, an 8-hydroxyquinoline-based Mg2+ probe.68  
In contrast, Duan and co-workers have developed a range of nano-sized 
lanthanide complexes that can act as luminescent chemosensors for the 
selective sensing of Mg2+ ions. Three ligands have been synthesised H4DBOS, 
H4DBDS and H4DBBS that are selective towards the metal ions Mg2+ and Al3+ 
upon the addition of Ce3+ (Figure 1.11).69 It was found from X-ray crystallography 
studies that in each instance the ligands bridge two homochiral Ce3+ ions forming 
‘lantern like’ molecules with a stoichiometry of 2:3, metal:ligand. In the case of 
H4DBDS and H4DBBS upon the addition of Ce3+, a cavity is formed allowing the 
selective binding of Mg2+.69 
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Figure 1.11 Ligands (A) H4DBOS, (B) H4DBDS and (C) H4DBBS, (D) the crystal structure 
of H4DBBS a cavity is formed upon the addition of Ce3+, allowing metal ion binding to 
occur.69 
A fluorescence titration with Mg2+ found that both [Ce2(DBDS)3]2- and 
[Ce2(DBBS)3]2- were highly selective towards Mg2+ while [Ce2(DBOS)3]2- was 
found to be selective towards Al3+. [Ce2(DBDS)3]2- showed a 4.5-fold increase in 
the luminescence intensity after the addition of 10 equivalents of Mg2+. In 
comparison, a negligible change in the fluorescence intensity was observed with 
other alkali earth metals and biologically relevant cations such as Ca2+, Li+, Na+ 
and K+.69 The high selectivity towards Mg2+ can be explained by the ionic radius 
of the cations in question. Mg2+ with a coordination number of six, has a 
significantly smaller radius than Na+ and Ca2+ (0.7 Ȧ vs. 1.02 Ȧ) making it an ideal 
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size to fit into the cavity of [Ce2(DBDS)3]2-  and [Ce2(DBBS)3]2-, resulting in a highly 
selective binding.69  
1.5.4 19F NMR and 31P NMR 
	
 London first used 19F NMR to measure the concentration of cytosolic Mg2+ 
concentrations in 1988 by adapting the APTRA chelators and synthesising a 
range of fluorinated derivatives.70 4-Fluoro, 5-fluoro and 4-methyl-5-fluoro 
derivatives were made (Figure 1.12). Upon Mg2+ binding, a shift to higher 
frequency was observed for each of the three fluorinated derivatives in the 19F 
NMR spectrum.70 In cellulo experiments were carried out in human erythrocytes 
with the 4-methyl-5-fluoro derivative, where it was determined that the cytosolic 
‘free’ Mg2+ concentration was 0.25 mM.70 
 
 
 
 
Figure 1.12 The structure of (A) 4-fluoro, (B) 5-fluoro and (C) 4 methyl-5-fluoro APTRA 
derivatives for the 19F NMR studies.70 
The vast majority of Mg2+ within the cell is bound to phosphorus-containing 
anions such as ATP, rendering 31P NMR a more favourable technique for the 
measurement of the concentration of cytosolic free Mg2+ than 19F NMR.  
31P NMR is a non-invasive technique that can be used to measure the 
concentration of ‘free’ magnesium in both cells and tissues.10 Magnesium in its 
‘free’ and bound states exist in a chemical equilibrium, allowing the chemical shift 
changes for the binding of magnesium to ATP to be related to the free Mg2+ 
concentration.71 Upon magnesium binding, a shift in the NMR resonance is 
observed primarily at the β- and γ-phosphates in ATP as these phosphates play 
a key role in Mg2+ binding (Figure 1.1). The magnesium ion concentration can be 
determined from the separate 31P resonances of ATP in its ‘free’ and unbound 
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forms. A slow exchange is observed between the free and unbound forms, 
allowing the magnesium concentration to be determined from Equation 1.1.8,70  
Mg2+= Kd 
δo–δf
δb–δo
			   (Eq. 1.1) 
where: "# is the chemical shift for the observed resonance, "$ is the chemical 
shift for the fully complexed ligand and "% is the chemical shift for the 
uncomplexed ligand.8,70  
Other metabolites have been used in NMR studies as an alternative to 
ATP, such as ADP and citrate. ATP is favoured, however, because of its high 
concentration and broad distribution within cells.8 
31P NMR has been used to determine the ‘free’ Mg2+ concentration in 
muscle tissue, where a concentration of 0.6 mM was observed. Under different 
metabolic conditions, it was determined that during exercise the concentration of 
free Mg2+ increased from 0.33 mM to 0.56 mM.71 The potential use of 31P NMR 
commercially has a number of limiting factors. Firstly, no information can be 
derived on intracellular ‘free’ Mg2+ distribution because of its low sensitivity. ADP 
also represents a more attractive ligand than ATP because its Kd is similar to that 
seen with free Mg2+ ions; however, this is problematic because of the lower 
concentrations of ADP in relation to ATP within cells.10 
1.5.5 Magnetic Resonance Imaging (MRI)  
	
Since its introduction in 1980, Magnetic Resonance Imaging (MRI) has 
become one of the most important and recognised diagnostic techniques in 
clinical medicine.72 It is non-invasive, delivering non-ionising radiation to the 
patient, making it a safer alternative to other imaging modalities such as X-ray 
Computed Tomography (CT).73 The technique offers fast scan rates and 
exceptional resolution of images in the sub-millimetre (mm) range, producing a 
detailed visualisation of opaque organs and tissues in vivo.72 MRI is based on the 
principles of Nuclear Magnetic Resonance (NMR) and visualises water protons 
in the body. A natural contrast is present between different mammalian tissue 
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types because they possess both; different concentrations of water molecules 
and contrasting proton relaxation times. A greater contrast between tissue is 
achieved, however, following the introduction of contrast agents. Contrast agents 
lower the relaxation times (T1, T2) of the surrounding water protons increasing the 
sensitivity and relaxivity (r1- the ability of the contrast agent to enhance the rate 
of water proton relaxation per unit concentration).  
Allegedly, ‘smart’ contrast agents induce a significant increase in relaxivity 
upon a change in pH or the binding of biologically relevant cations or anions. 
Numerous examples are present in the literature of MRI contrast agents for cation 
sensing, but are primarily limited to the detection of Ca2+ and Zn2+ ions. Meade 
and co-workers developed the first example of a Ca2+ responsive MRI contrast 
agent, DOPTA-Gd, containing two gadolinium based DO3A chelates and a 
modified BATPA binding site related to that developed by Tsien in 198039 
(Figure 1.13). An 80 % increase in the relaxivity was observed upon the addition 
of Ca2+.74 
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Figure 1.13 (A) Ca2+ selective probe DOPTA-Gd,74 (B) Ca2+ and Mg2+ probe DTPA-Gd,75 
(D) APTRA based probe Gd-DOPTRA 76 (Mg2+ binding site in blue, Gd3+ in pink). 
MRI contrast agents for the detection of Mg2+ are much less developed 
with only a few examples present in the literature to date. The main reason for 
this is that there are very few commercially available ligands available to bind 
Mg2+ selectively. A gadolinium-based complex based upon a DTPA binding site 
was found to bind both Ca2+ (Kd = 0.25 mM) and Mg2+ (Kd = 2.0 mM).75 Logothetis 
and co-workers incorporated an APTRA binding moiety into a DO3A-based 
gadolinium complex.76 Synthesised to work predominantly as a low affinity Ca2+ 
responsive probe, relaxivity enhancements were also observed with Mg2+ and 
Zn2+, reflecting the non-selective binding nature of the APTRA chelates, 
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highlighted first in the early work undertaken by London and co-workers.49,51,70 A 
much more selective Mg2+ MRI based probe, however, has been reported by 
Suzuki and co-workers. They developed a novel gadolinium complex KMR-Mg, 
that is based on a well-recognised bidentate Mg2+ binding site, a β-keto acid 
moiety, that is known to bind Mg2+ selectively over Ca2+ (Figure 1.14).77  
 
 
 
 
 
Figure 1.14 Mg2+ selective probe KMR-Mg for use in MRI. (Mg2+ binding site in blue, Gd3+ 
in pink).77 
KMR-Mg is made up of a DTPA and β-keto acid framework for the binding 
of Gd3+ and Mg2+ respectively. A stable 9-coordinate complex with Gd3+ forms 
with the ninth coordination site occupied by an inner sphere water molecule.77 
It was found that the relaxivity decreased with increasing Mg2+ 
concentration, the addition of one equivalent of Mg2+ resulted in a 21 % decrease 
from 4.98 mM–1s–1 to 3.95 mM–1s–1.77 The reduced relaxivity observed can be 
attributed to a change in the second sphere of hydration of Gd3+ on Mg2+ binding.  
A relaxivity decrease was also observed in the presence of Ca2+, meaning 
that KMR-Mg does not bind Mg2+ selectively. A reduced binding affinity was, 
however, observed with Ca2+ (log K 2.39 vs. 2.08), with a mM affinity reported for 
the binding of both Mg2+ and Ca2+.77 Such an affinity is analogous to fluorescence 
based probes in the KMG-series, showing a higher Mg2+ / Ca2+ selectivity over 
the APTRA series.59-62 
In 2012, Charbonniere and co-workers developed a gadolinium-based 
smart contrast agent with a very high selectivity towards Mg2+ ions. Instead of the 
usual macrocycle framework to encapsulate the lanthanide ion, the complex is 
made up of a Gd3+ centre with a heptadentate polyphosphonate-based pyridyl 
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ligand (Figure 1.15). The complex [Gd(H2L)(H2O)]3– is thermodynamically stable 
with one bound water molecule in its primary hydration sphere, giving a total 
coordination number of eight.78   
 
 
 
 
 
Figure 1.15 (A) The polyphosphonated pyridyl ligand, L, (B) DFT calculation of the stable 
8-coordinate complex with Gd3+, [Gd(H2L)(H2O)]3–. 78 
From relaxivity measurements it is clear that the polyphosphonated pyridyl 
ligand is highly selective for the binding of Mg2+ over Ca2+, with an increase in the 
relaxivity observed from 8.5 mM-1s-1 to 12 mM-1s-1 a 37 % enhancement upon the 
addition of 30 equivalents of MgCl2.78 The xylenol orange test was used in order 
to determine whether the increase in the relaxivity was because of gadolinium 
displacement. No colour change was observed, indicating that no lanthanide 
displacement occurs. It was instead thought that the addition of Mg2+ could result 
in the formation of polynuclear complexes, resulting in the increase of the rotation 
tumbling time of the complex and increasing the observed relaxivity.78 The pH- 
dependence of the relaxivity of this system, however, is likely to inhibit any 
practicable utility.   
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1.6 Aims and Objectives  
The overwhelming majority of Mg2+ sensors in the literature are based on 
either the APTRA binding framework, developed by London and co-workers, or 
the β-keto acid bidentate binding structure, developed by Suzuki et al. It is 
apparent from a literature search that there is very little variation in overall ligand 
design. The novelty in new sensors typically comes from modifications to the 
chromophore, or the use of different chromophores to report the fluorescence 
change upon binding of divalent cations. With the only structural variation of 
ligands coming from the chromophore used, the binding of Mg2+ and Ca2+ is 
similar in each instance, with a higher selectivity for the binding of Ca2+ over Mg2+. 
The vast majority of APTRA-based probes in the literature, therefore, can also be 
used as low affinity Ca2+ sensors in the µM range.   
The aims of the research detailed here can be sub-divided into two main 
categories. Firstly, one aim was to incorporate the ATPRA moiety into a range of 
new luminescence systems including naphthalene, lanthanide and ruthenium-
based compounds to study Mg2+ binding. The primary objective, however, was to 
develop a range of new Mg2+ selective ligands containing both carboxylate and 
phosphinate binding groups. It was hoped that the introduction of a phosphinate 
group could influence the Mg2+ / Ca2+ selectivity while maintaining the desired 
low mM affinity towards Mg2+.  
Chapter 2 describes the synthesis of a series of carboxylate and 
phosphinate based ligands from commercially available starting materials. All 
analogues are based on the APTRA series, with an expected pentadentate L1, 
L2 and L4 and tridentate denticity, L6 (Figure 1.16).  
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Figure 1.16 APTRA analogues L1, L2, L4 and L6 
In Chapter 3 a direct comparison between the binding properties of 
APTRA48 with the newly synthesised phosphinate analogue APDAP is made via 
absorbance spectroscopy. Chapter 4 outlines the incorporation of L1, L2, L4 and 
L6 into naphthalene based fluorescence systems. The binding properties of novel 
ligands NapL4 and NapL6 is reported, and directly compared to the APTRA 
analogues NapL1 and NapL2. Finally, Chapter 5 details the incorporation of L1 
and L2 into lanthanide(III) and L2 into ruthenium(II)-based systems to study the 
binding of Mg2+.  
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2. Synthesis of Carboxylate and Phosphinate Ligands  
2.1 Introduction 
A number of factors must be considered when choosing and designing 
ligands for selective metal-binding applications. Some of these include the 
chelate effect, the Hard-Soft Acid-Base theory (HSAB) and ligand denticity.  
The chelate effect highlights the greater stability of complexes formed with 
polydentate and macrocyclic ligands compared with those containing the 
equivalent number of monodentate ligands.1 The higher stability arises from an 
enthalpic and entropic advantage of chelation, that makes the formation of metal 
complexes with bidentate ligands more thermodynamically favourable than 
complexes with the equivalent number of monodentate ligands. This can be 
demonstrated by comparing the reaction of Cd2+ with monodentate ammonia and 
bidentate ethylenediamine (en) (Table 2.1).2  
[Cd(H2O)6](aq)
2+ +	2NH3 (aq)	 ⇌ [Cd(NH3)2(H2O)4](aq)2+ +	2H2O(l) (Monodentate) 
[Cd(H2O)6] aq
2+ +	en aq  ⇌ [Cd(en)(H2O)4] aq2+ +	2H2O(l) (Bidentate) 
Table 2.1 Example of the chelate effect and the increase in stability of complexes formed 
when a polydentate ligand such as en is coordinated to a Cd2+ metal ion.2 ∆G was 
calculated at 298 K using the equation: ∆G = 	∆H	– T∆S.  
Complex ∆G (kJ mol-1) ∆H (kJ mol-1) ∆S (J K-1 mol-1) 
[Cd(en)(OH2)4]2+(aq) –33.3 –29.4 +13.0 
[Cd(NH3)2(OH2)4]2+(aq) –28.3 –29.8 –5.2 
 
5- and 6-membered rings are the most common chelate ring sizes formed. 
They are formed more favourably over 3- and 4-membered rings due to a more 
favourable bite angle around the metal ion generating less ring strain. Preference 
in chelate ring size varies from metal to metal, with larger metal ions of high 
coordination number favouring a 5-membered ring chelate, while smaller metal 
ions with a low coordination number have been found to favour 6-membered.3 
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Tuning the size of the chelate ring size can therefore improve metal binding 
selectivity.  
The choice of donor group is also critical to the formation of stable 
complexes. The HSAB is a model that helps to rationalise ligand to metal binding 
affinities. It states that hard metals favour the binding of hard ligands; likewise, 
soft metals favour the binding of soft ligands. Mg2+ is a small, non-polarisable, 
hard, divalent cation that forms stable complexes with hard ligands or bases, such 
as oxygen and nitrogen donor groups. A selection of hard and soft acids and 
bases is highlighted in Table 2.2.  
Table 2.2 Examples of hard and soft acids and bases, in the context of metal ions and 
ligands respectively.4 
 Hard Soft 
Metal ions Li+, Na+, Mg2+, Ca2+, Zn2+ Ag+, Au+, Pd2+, Pt2+ 
Ligands F–, Cl–, H2O, COO–, NH3, 
RNH2 
I–, HS–, CN–, PR3 
 
Ligand denticity is also an important factor to consider in ligand design, 
affecting the selectivity with which a ligand binds to metal ions. For example, Mg2+ 
(ionic radius = 72 pm in coordination number six)2 commonly forms 5- and 6-
coordinate complexes, while the larger Ca2+ ion (ionic radius = 100 pm in 
coordination number six, 112 pm in coordination number eight)2 tends to form 
stable 8-coordinate complexes, e.g. those formed with the ligand BAPTA (Figure 
2.1).5  
 
Figure 2.1 Structures of (A) BAPTA (octadentate),5 (B) APTRA (pentadentate)6,10 and (C) 
bidentate β-keto-acid KMG-301.7 
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By changing the ligand denticity, it is possible to change the Mg2+ / Ca2+ 
selectivity. This is evident from the comparison of the APTRA binding site 
(pentadentate with Mg2+)6 and the bidentate β-keto-acids (bidentate with Mg2+) 
(Figure 2.1).7 β-Keto-acids have been found to be more selective towards Mg2+, 
due in part to the larger Ca2+ ion favouring binding to a ligand with a denticity 
greater than two. Buccella and co-workers further highlighted this idea in 2016, 
showing that Ca2+ ions prefer to form complexes with a higher coordination 
number than Mg2+.6 From X-ray crystallographic data it was found that APTRA 
binds Mg2+ in a pentadentate fashion with the sixth coordination site of Mg2+ in 
the solid state coming from a bridging carboxylate from an adjacent complex.6 
Ca2+ ions in contrast, form an 8-coordinate, dimeric species in the solid state 
[Ca(OH2)3]2{[APTRA)Ca(OH2)2](µ-H2O)2}Cl2.6 Ligands with a lower denticity 
inherently favour the binding of the smaller Mg2+ ion over the larger Ca2+ ion.   
In this chapter the synthesis of a number of analogues of the APTRA 
binding framework will be discussed containing carboxylate and phosphinate 
binding groups. It was decided that ligands with a high denticity such as those in 
the APTRA series (pentadentate) would be studied throughout, in order to avoid 
the problems associated with formation of mixed species, which is 
characteristically observed with the bidentate β-keto-acids in vivo (highlighted in 
Section 1.5.3). It also presents the increased possibility of structural modification, 
allowing a range of ligands to be synthesised containing different binding groups.    
2.2 Synthesis of Carboxylate Ligands 
Carboxylate-based ligands have been used extensively in organic 
synthesis for selective ion binding. EDTA has been used to sequester metal ions 
such as Fe3+, while Tsien and co-workers have developed numerous carboxylate 
based ligands such as BAPTA5 and Fura-28 for selective binding to Ca2+. Sensors 
for Mg2+ are no different, with the two main binding groups in the literature the 
APTRA chelators and the β-keto acids also containing hard carboxylate binding 
groups.  
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Target carboxylate ligands are based upon the APTRA binding unit, first 
developed during the late 1980’s by London et al. which are thought to form 
[5, 5, 5] chelates with divalent metal ions (Figure 2.2). tert-Butyl and ethyl esters 
of ligands L1 and L2 vary only in the position of the nitrogen and oxygen donor 
atoms around the aromatic ring. Once conjugated into a luminescence system, 
and hydrolysed to their carboxylic acids, the difference in the position of the 
nitrogen and oxygen donor groups could potentially result in a different 
luminescence response, and differing selectivity and affinity towards different 
divalent cations such as Mg2+, Ca2+ and Zn2+.  
 
Figure 2.2 Target APTRA based tert-butyl and ethyl esters L1 and L2. The expected 
chelate ring size formed on coordination with Mg2+ is highlighted in bold. A pentadentate 
denticity of both ligands is expected around a divalent cation. 
2.2.1 Synthesis of L1 from o-aminophenol 
	
 A number of different methods are available for the synthesis of APTRA 
ligands, the method of choice being alkylation of an o-aminophenol precursor. A 
variety of conditions has been examined in the literature using a number of 
different bases and solvents. The original APTRA ligands synthesised by London 
and co-workers used alkylation conditions of methyl bromoacetate and proton 
sponge, heating under reflux in acetonitrile.9-11 More recently, Dehaen et al. 
employed an alternative strategy, by alkylating o-aminophenol with chloroacetic 
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acid and sodium hydroxide in water (with a pH between 10 and 11), before re-
esterifying with methyl- or ethyl bromoacetate.12 
In the case of pro-ligands L1 and L2, however, alkylation of 
o-aminophenols was carried out with both tert-butyl bromoacetate and ethyl 
bromoacetate heated at reflux in acetonitrile with N,N-diisopropylethylamine 
(Hünig’s base), in a method adapted from Sando and co-workers.13 The 
generation of both tert-butyl and ethyl esters allows both the acidic and basic 
ester hydrolysis to be carried out, subsequently.   
Alkylation of commercially available o-aminophenol with tert-butyl and 
ethyl bromoacetate formed (1) and (2) after heating at reflux in acetonitrile for 
4 days. Moderate yields were achieved after purification by silica gel column 
chromatography (Scheme 2.1).    
 
Scheme 2.1 General procedure for the synthesis of tert-butyl and ethyl esters (1) and (2). 
Bromination of (1) and (2) was achieved with a unique tribromide salt of 
18-crown-6, [K18-Crown-6]Br3 (3). Compound (3) was formed in high yields from 
the reaction of 18-crown-6 with potassium bromide and Br2 at room temperature, 
in a reaction first carried out by Ward and co-workers (Scheme 2.2).14 
 
Scheme 2.2 The formation of [K.18-Crown-6]Br3, (3) a tribromide salt used for the selective 
bromination of aromatic amines.14 
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  Compound (3) can be used for the selective para-bromination of a range 
of aromatic amines, and is viewed as a safer alternative to the use of elemental 
Br2 itself. The esters (4) and (5) were synthesised in moderate to high yields 
under mild conditions, with the reaction taking 1 to 2 h to reach completion 
(Scheme 2.3). Purification of (4) and (5) was achieved using an aqueous wash 
of a saturated solution of sodium bicarbonate to remove residual 18-crown-6, 
before purification by column chromatography.  
 
Scheme 2.3 General procedure for the selective bromination of tert-butyl and ethyl esters 
of L1 using [K.18-Crown-6]Br3. 
2.2.2 Synthesis of L2 from 2-amino-4-bromophenol 
	
The tert-butyl and ethyl protected esters (7) and (8) were synthesised in a 
similar manner to (1) and (2) under the same conditions, but starting from 
commercially available 2-amino-4-bromophenol (Scheme 2.4). In this instance, 
selective di-alkylation of the amine was achieved overnight forming (6), with no 
evidence of any O-alkylation after heating at reflux for 24 h as revealed by 
ESI-MS or 1H NMR spectroscopy. Full conversion to (7) and (8) was achieved 
under the same conditions albeit with much longer reaction times of 5 to 7 days.  
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Scheme 2.4 General procedure for the synthesis of tert-butyl and ethyl esters of L2. 
It was observed with the formation of (1) and (2) that O-alkylation was slow 
under the conditions used (Hünig’s base in acetonitrile). The formation of (7) and 
(8) is unsurprisingly no different with O-alkylation requiring several days even 
when 8-10 equivalents of the alkylating agent was used.  
In order to increase the reaction rates and yields, other conditions were 
attempted. It was observed, however, for the O-alkylation of (6) with both sodium 
hydride in THF, and potassium carbonate in acetonitrile, that on heating 
cyclisation occurred to form a 6-membered lactone, with the loss of tert-butoxide. 
Under each set of conditions only the cyclised product (9) was detected, with no 
evidence of any O-alkylation taking place as deduced by either ESI-MS and 1H 
NMR spectrometry (Scheme 2.5). The direct O-alkylation of (6) is apparently not 
feasible under these conditions.  
The reaction was repeated at room temperature using the same 
equivalents of reagents to determine whether cyclisation could be prevented. 
Longer reaction times were expected, but, after two days at room temperature, 
only starting material was evident from ESI-MS, with no evidence of either (7) or 
(9) forming.  
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Scheme 2.5 The cyclisation of (6), upon attempted alkylation under the conditions: i) NaH, 
THF and ii) K2CO3, CH3CN. 
2.3 Synthesis of Phosphinate Ligands  
A number of ligands bearing phosphinate groups have been used 
previously to study metal ion binding. Macrocyclic-based phosphinate ligands, 
developed by Parker and co-workers in the 1990’s, were found to form complexes 
with a range of divalent cations (Zn2+, Co2+) and trivalent cations (Fe3+ and Ga3+) 
(Figure 2.3).15 Analogues of these macrocycles have been used as probes for 
68Ga3+ in positron emission tomography (PET).16  
Phosphonate ligands have also been synthesised to bind to metal ions, in 
particular ethylenediamine tetra(methylene phosphonic acid) (EDTMP) an 
analogue of EDTA (Figure 2.3). Once coordinated to samarium-153, EDTMP has 
been used extensively as an anti-cancer drug to treat pain associated with bone 
metastases.17  
 
Figure 2.3 (A) and (B) phosphinate based macrocyclic ligands developed by Parker and 
co-workers for metal ion binding,15 (C) EDTMP, the phosphonic acid derivative of EDTA. 
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Acyclic ligands containing phosphinate groups for metal ion binding are 
few and far between, and to our knowledge no fluorescence sensors containing 
a phosphinate binding moiety have been reported for the selective binding of 
Mg2+. This is somewhat surprising, as phosphate groups such as those in ATP 
bind cellular Mg2+ strongly due to its high abundance and binding affinity 
(Kd ~78 μM).18 
The synthesis of a number of phosphinate-based target ligands will be 
discussed here. Each contains one phosphinate binding group and the ability to 
adopt different chelate ring sizes on binding of divalent metal ions, and form 
complexes with a different ligand denticity (either tetradentate or pentadentate) 
on the binding of metal ions (Figure 2.4). After the incorporation into 
luminescence-based systems, a direct comparison will be made to the 
carboxylate-based ligands synthesised in Section 2.2. It will be determined what 
effect the introduction of a phosphinate group and changing the chelate ring size 
will have on the Mg2+ / Ca2+ binding affinity and selectivity.  
 
Figure 2.4 Target phosphinate analogues of APTRA L3, L4 and L5. The expected chelate 
ring size formed on coordination with Mg2+ is highlighted in bold.  Pro-ligands L3 and L4 
expected pentadentate binding, L5 expected tetradentate binding to Mg2+. 
2.3.1 Synthesis of a [5, 5, 5] phosphinate ligand by N-alkylation, L3  
	
 The first step towards the synthesis of the ethyl ester of L3 is the synthesis 
of the phosphinate-based mesylate alkylating agent (12), which was formed from 
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a three-step procedure from diethyl methylphosphonite (Scheme 2.6). A reaction 
with one equivalent of water at room temperature formed ethyl 
methylphosphinate (10), with one equivalent of ethanol. Intermediate (11) was 
synthesised from a condensation reaction of (10) with paraformaldehyde in THF 
in a modest yield, before the alcohol was mesylated with methylsulfonyl chloride 
in the presence of triethylamine at room temperature to give (12) in quantitative 
yield. 
 
Scheme 2.6 The three-step synthesis of the mesylate (12), from diethyl 
methylphosphonite. 
The introduction of the mesylate group allows (12) to be used as an 
alkylating agent in nucleophilic substitution reactions, providing the opportunity 
for the introduction of phosphinate groups onto aromatic systems.  
Alkylation of 2-amino-4-bromophenol with (12) was very slow using the 
conditions that were reported for the alkylation of both 2-aminophenol and 
4-bromo-2-aminophenol with tert-butyl and ethyl bromoacetate (Scheme 2.7). 
Evidence for mono-alkylation only was observed in ESI-MS and the 31P NMR 
spectrum.  
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Scheme 2.7 The alkylation of 4-bromo-2-amino phenol with (10). 
The hydrolysis of the mesylate (12) was observed over the course of the 
reaction, re-forming the alcohol (11) (Figure 2.5). The slow rate of mono- 
alkylation could be due to both competitive hydrolysis of the mesylate starting 
material and because (12) is a much weaker electrophile than the carboxylate 
based tert-butyl and ethyl bromoacetate. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 31P NMR spectra illustrating the attempted alkylation of 2-amino-4-bromophenol 
with the mesylate (12) (CDCl3, 162 MHz, 298 K). 
The Arbuzov reaction of diethyl methylphosphonite with paraformaldyde in 
THF was seen as an alternative method to alkylation for the introduction of 
phosphinate binding groups. Such an approach has been used successfully in 
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Durham, for the introduction of phosphinate groups onto cyclen (12-N4) and 9-N3 
based macrocyclic ligands.15 The reaction with 2-amino-4-bromophenol was 
unsuccessful, however, with only starting material present in the ESI-MS and 1H 
NMR spectrum after heating at 85 oC overnight (Scheme 2.7).  
 
 
 
Scheme 2.7 Attempted Arbuzov reaction between methyl diethylphosphinite and 4-bromo-
2-aminophenol. 
 
Scheme 2.8 The synthetic approach for the formation of intermediate, (15). 
An alternative synthetic approach was designed, where the phenol 
substituent was first protected as a tert-butyldimethyl silyl ether (Scheme 2.8). 
Silyl protection was carried out under mild conditions in high yield. The resulting 
Arbuzov condensation was successful with (13), forming (14), albeit in low yield. 
These observed low yields could be ascribed to the presence of the sterically 
demanding ortho-substituted silyl ether. Silyl de-protection was achieved using 
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tetrabutylammonium fluoride (TBAF) in THF at room temperature, producing (15) 
in a moderate, but acceptable, yield after purification by column chromatography. 
Alkylation of (15) resulted in the formation of a mixture of compounds, 
including O-alkylation, N-alkylation and cyclisation products (Scheme 2.9). It was 
found that these products could not be separated by conventional 
chromatography due to close, if not identical, Rf values in a range of commonly 
used solvent systems. Reverse phase HPLC was also attempted. The desired 
product (L3) was, however, not isolated directly as co-elution with the cyclised 
product was observed.  
 
Scheme 2.9 The mixture of products formed after the alkylation of (15). 
The introduction of phosphinate groups via N-alkylation is, therefore, not 
straightforward due to the problems encountered along the multistep synthetic 
pathway.  
2.3.2 Synthesis of a [5, 5, 5] phosphinate ligand by O-alkylation, L4 
	
 Due to the problems associated with introducing the phosphinate group 
via N-alkylation (Section 2.3.1), an alternative strategy was attempted, where the 
phosphinate group is introduced in the first step of the reaction sequence by 
O-alkylation. The greater nucleophilicity of aromatic amines over phenol groups 
meant that the amine must either be protected, or introduced at a later stage from 
other functional groups such as nitro substituents.  
The synthesis of the ethyl ester of L4 was achieved from the O-alkylation 
of commercially available 2-nitrophenol using (12) as the mesylate-based 
alkylating agent (Scheme 2.10).  Alkylation of 2-nitrophenol in acetonitrile with 
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(12) and potassium carbonate as the base formed (16) in moderate yield after 
purification by column chromatography. Reaction completion was determined 
from a colour change from bright orange to pale brown, highlighting the 
consumption of the 2-nitrophenoxide salt.  
 
Scheme 2.10 The synthesis of the ethyl ester of L4, (19). 
Reduction of the nitro group was accomplished via hydrogenation using 
hydrogen gas catalysed by palladium on carbon (Pd / C), forming the amine (17) 
in high yield. Alkylation of (17) was achieved under the same conditions used for 
2-aminophenol and 2-amino-4-bromophenol with ethyl bromoacetate and 
Hünig’s base. Reaction completion was determined by ESI-MS, when only the 
N,N-di-alkylated product could be detected after 4 days of heating at reflux. 
Treatment of (18) with [K.18-Crown-6]Br3 (3), formed (19) in high yields after 
purification in a procedure identical to that reported previously (Scheme 2.3).  
An alternative synthetic approach was attempted in order to see if 
O-alkylation of (6) could be achieved with the phosphinate alkylating agent (12). 
This approach would allow the formation of an alternative phosphinate-based 
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observed when the O-alkylation of (6) was attempted with (12) under the same 
conditions used successfully when either tert-butyl or ethyl bromoacetate were 
used as the alkylating agent (Scheme 2.11). The poorer electrophilicity of the 
phosphinate alkylating agent means that ring cyclisation is favoured over 
alkylation.  
 
Scheme 2.11 The cyclisation of (6), upon attempted alkylation with (12). Conditions: 
i) K2CO3, CH3CN, 85 oC and ii) Hünig’s base, CH3CN, 85 oC. 
It was determined, therefore, that in the synthesis of phosphinate based 
ligands it is essential that the ethyl methylphosphinate group be introduced in the 
first step of the reaction sequence by O-alkylation. This eliminates the competitive 
kinetically favourable cyclisation reaction that has been observed consistently 
(Scheme 2.5 and 2.9).  
 It is also important to note that O-alkylation as the first step does not 
necessarily prevent cyclisation. Alkylation of 2-nitrophenol with tert-butyl 
bromoacetate forming (20), and subsequent hydrogenation, resulted in the 
spontaneous formation of (21). Cyclisation was seen to occur on standing at room 
temperature for a number of days, and was achieved in 1 h upon heating in 
acetonitrile at 85 oC (Scheme 2.12). Cyclisation didn’t occur with the phosphinate 
compound (17) because such nucleophilic substitution reactions will not occur at 
a pentavalent phosphorus atom.  
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Scheme 2.12 Showing spontaneous cyclisation of (21) at room temperature (RT = 298 K). 
2.3.3 Synthesis of a [6, 5, 5] phosphinate ligand, L5  
	
Ligand L5 differs significantly from the other ligands L4 and L5 bearing 
phosphinate binding groups discussed previously. Upon the binding of divalent 
cations such as Mg2+, it is expected that a [6, 5, 5] chelate ring arrangement would 
form, in contrast to the [5, 5, 5] chelate rings observed in the APTRA ligand 
series8-10 bearing both carboxylate and phosphinate groups (Figure 2.6). The 
number of binding groups is also varied between (L1-L4) (expected pentadentate 
binding of Mg2+) and L5 (expected tetradentate binding of Mg2+). These 
differences in denticity and ring size formed could dramatically change the 
binding selectivity of Mg2+ over Ca2+ and Zn2+.  
 
Figure 2.6 The difference in the size of chelate ring formed on binding of Mg2+ to L1, L4 and 
L5. Red highlights carboxylate ring, green highlights phosphinate ring. 
The first step in the synthetic route of L5 was the alkylation of commercially 
available 4-bromo-2-iodoaniline. It was found, however, that mono-alkylation 
occurred preferentially under a range of base and solvent combinations 
(Scheme 2.13, Table 2.3). Mono-alkylation using ethyl bromoacetate and 
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Hünig’s base formed (22) in moderate yield after heating at reflux for 3 days 
(Scheme 2.13 and Scheme 2.14). In each instance, the reaction was carried out 
with a significant excess of ethyl bromoacetate and Hünig’s base, in order to drive 
the reaction towards completion. No trace of any N,N-di-alkylated product could 
be identified from ESI-MS and 1H NMR analysis. The lack of reactivity observed 
could be due to the steric bulk of the ortho-iodo-substituent, preventing N,N-di-
alkylation from taking place. 
In order to successfully form the target pro-ligand L5 a number of 
alternative approaches were devised. It was hoped that N,N-di-alkylation could 
be carried out after alkylation of either: (23) (Scheme 2.14), or the phosphinate 
coupled product of 4-bromo-2-iodoaniline, ethyl (2-amino-5-bromo-phenyl) 
(methyl) phosphinate (Scheme 2.13).  
Coupling of ethyl methylphosphinate (10) with the secondary amine (22) 
was achieved selectively in moderate yield, with triethylamine in toluene, using 
[Pd(dppf)Cl2]CH2Cl2 as the catalyst. Alkylation of (23) was then undertaken using 
conditions identical to those used previously. It was thought that the introduction 
of an ortho-phosphinate group at the expense of a sterically bulky ortho-iodo-
substituent would favour the second alkylation reaction to form the target 
proligand L5. A number of conditions were attempted, highlighted in Table 2.3, 
with a variety of reaction times and equivalents of the base and alkylating agent 
used. In each instance, however, only trace amounts of the N,N-di-alkylated 
product were detected in ESI-MS, none of which was isolated during various 
purification procedures. 
The direct coupling of 4-bromo-2-iodoaniline with (10) was seen as the first 
step in another alterative synthetic pathway to the ethyl ester of L5 
(Scheme 2.13). The reaction was, however, unsuccessful under the same 
conditions used for (22), with only starting material present after heating at reflux 
overnight. This made the alternative approach of phosphinate coupling before 
N,N-di-alkylation in the formation of the ethyl ester of L5 an unfeasible synthetic 
pathway (Scheme 2.13). 
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Scheme 2.13 Initial synthetic routes to the ethyl ester of L5. Conditions i-iii are highlighted 
in Table 2.3. 
 
Scheme 2.14 The planned synthetic route to the ethyl ester of L5. Conditions iv-vi are 
highlighted in Table 2.3. 
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Table 2.3 Conditions i-vi used in the attempted synthesis of the ethyl ester of L5. 
Observations were made from both ESI-MS and 1H NMR. 
 Conditions Observations 
i Ethyl bromoacetate, Hünig’s base, 
NaI, CH3CN, 3 days, 85 oC. 
Complete conversion to (20) 
No starting material observed 
No N,N-di-alkylation observed. 
ii Ethyl bromoacetate, Cs2CO3, NaI, 
CH3CN, 3 days, 85 oC. 
Majority starting material 
Trace amounts of (22) < 5 % from 
crude NMR. 
iii Ethyl bromoacetate, NaH, NaI, DMF, 
2 days, 60 oC. 
Starting material, from ESI-MS. 
iv 4 equiv. ethyl bromoacetate, Hünig’s 
base, NaI, CH3CN, 9 days, 85 oC. 
Majority starting material 
Trace amounts of N,N-di-alkylated 
product – none isolated. 
v 10 equiv. ethyl bromoacetate, Hünig’s 
base, NaI, CH3CN, 7 days, 85 oC. 
Starting material 
vi Ethyl bromoacetate as the solvent, 
Hünig’s base, 7 days, 85 oC. 
Majority starting material 
Trace amounts of N,N-di-alkylated 
product – none isolated. 
 
With all attempts to form L5 unsuccessful, the binding properties of 
tridentate (23, ethyl ester of L6) with Mg2+, Ca2+ and Zn2+ will instead be reported 
in naphthalene-based systems. Upon ester hydrolysis (23) will form a [6, 5] ring 
chelate on coordination to divalent cations.  
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2.4 Conclusions of Synthetic Studies 
A selection of ligands bearing carboxylate and phosphinate groups have 
been synthesised and characterised that form different chelate ring sizes on the 
binding of divalent cations, i.e. [5, 5, 5] vs. [6, 5].  
Alkylation conditions involving the use of Hünig’s base in acetonitrile were 
seen to be the most successful and were used throughout to introduce 
carboxylate binding groups. However, a large excess of the alkylating agent was 
required in most cases. Ligands L1 and L2 were synthesised as both their 
tert-butyl and ethyl esters from the commercially available 2-aminophenol and 
2-amino-4-bromo-phenol respectively, in moderate overall yields (Figure 2.7).  
 
Figure 2.7 Functionalised ligands L1, L2, L4 and L6 synthesised during this chapter. 
Novel phosphinate pro-ligands L4 and L6 were synthesised as their ethyl 
esters.  The phosphinate group was introduced by one of two routes: by alkylation 
of 2-nitrophenol with (10) in the case of L3 and use of a palladium-catalysed cross-
coupling reaction of (22) with (10) in the case of L6. The introduction of a 
phosphinate group by O-alkylation was found to prevent the competitive 
cyclisation reaction that occurred in the N-alkylation pathway or when 
O-alkylation was carried out after N-alkylation (Scheme 2.9 and Scheme 2.11 
respectively).  
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A number of conditions (iv–vi, Table 2.3) were tried in an attempt to 
achieve N,N-di-alkylation of the ethyl ester of L6. In each of the conditions 
attempted, however, it was found that only trace amounts of the N,N-di-alkylated 
product were detected, none of which were isolated (Scheme 2.14 and 
Table 2.3).   
All pro-ligands L1, L2, L4 and L6 synthesised in this chapter have been 
functionalised with a bromine substituent on the aromatic ring. Functionalisation 
occurred either from commercially available starting materials or was introduced 
via a mild and effective bromination reaction, using the tribromide salt 
[K18-Crown-6]Br3, (3).  
In subsequent chapters, pro-ligands L1, L2, L4 and L6 will be incorporated 
into naphthalene-, lanthanide(III)- and ruthenium(II)-based luminescence 
systems to study the metal ion binding affinity and selectivity towards different 
divalent cations. Comparisons will be made between carboxylate and 
phosphinate binding groups to determine cation affinity and selectivity.  
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3. APTRA vs. APDAP: A direct comparison 
3.1 Introduction  
 The o-aminophenol-N,N,O-triacetic acid (APTRA) ligand developed by 
London has been used extensively in a range of metal ion binding applications.1-4 
It is known to bind ‘free’ Mg2+ in the low mM range, when incorporated into a wide 
range of fluorescence systems. Selectivity is an issue, however, with APTRA 
being more selective towards Ca2+ than Mg2+. In order to get around the 
selectivity issues during cell studies, the cells are often pre-treated with highly 
selective Ca2+ sensors based on BAPTA, to eliminate any Ca2+ interference.5  
The APTRA chelators were first reported nearly 40 years ago, yet there is 
still a remarkable lack of variety in ligand design for Mg2+ sensors in the literature. 
Bidentate β-keto acids have been found to have a higher selectivity towards 
Mg2+,6, 7 but they can bind to both ‘free’ Mg2+ and MgATP2–, limiting their use for 
in vivo applications.8 It is critical, therefore, that a greater emphasis be put into 
the development of new ligand types for Mg2+, in order to solve this selectivity 
conundrum.   
This chapter explores the development of an alternative binding moiety for 
Mg2+, namely o-aminophenol-N,N-diacetic acid phosphinate (APDAP). The 
APDAP ligand is structurally similar to APTRA with the introduction of a 
phosphinate group at the expense of a carboxylate binding group, maintaining a 
pentadentate denticity for divalent cations (Figure 3.1). It was hoped that this 
modification could improve the Mg2+ / Ca2+ selectivity, allowing the future 
possibility of determining Mg2+ concentrations in metal-rich cellular environments, 
such as the endo(sarco)plasmic reticulum. It is critical, however, to maintain the 
mM affinity that APTRA has for Mg2+, with ‘free’ Mg2+ believed to be in the low 
mM range in the majority of cells (0.8 to 1.2 mM).9  
The synthesis and characterisation of APDAP is reported here. Analysis 
of its pKa and binding of Mg2+, Ca2+ and Zn2+ via absorbance spectroscopy is also 
reported, with direct comparisons made to the absorbance binding studies 
undertaken on APTRA by Buccella et al.10  
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Figure 3.1 Pentadentate ligands APTRA and APDAP. 
3.2 Synthesis and characterisation  
 The synthesis of APDAP (24), was achieved in a multi-step reaction 
sequence from commercially available 2-nitrophenol. The formation of (18) was 
reported in Chapter 2 via a series of alkylation and hydrogenation reactions. 
Each step occurs in moderate to good yield, after purification.  
 
Scheme 3.1 The synthesis of APDAP, (24). 
 Ester hydrolysis of (18) was undertaken using sodium deuteroxide in D2O 
and CD3OD in quantitative yields. Deuterated solvents were used for the basic 
hydrolysis so that the course of the reaction could be monitored easily by 1H NMR 
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signalled that hydrolysis was complete. The purity of (24) was assessed by 
analytical HPLC, in an acetonitrile / ammonium bicarbonate buffered system.  
3.3 APDAP pH studies 
An investigation was undertaken to determine the effect of pH change on 
the absorbance spectrum of APDAP. Absorbance spectroscopy was used rather 
than fluorescence because APDAP shows only weak fluorescence at 
inconveniently high energy. An investigation via absorbance spectroscopy also 
allows a direct comparison to be made to APTRA absorbance studies in the 
literature.10 APTRA analogues have been found previously to be rather unstable 
in solution due to successive decarboxylation and oxidation reactions.10-11 These 
observations have resulted in the pKa not being accurately determined in the 
majority of cases.3, 5,6, 8, 10,12 Where pH studies have been made, a pKa of 5.5 was 
determined using absorbance spectroscopy.4  
In the case of APDAP, it was found that on protonation of the aniline 
nitrogen atom a decrease in the absorbance at 254 nm, 285 nm and an increase 
at 273 nm was observed over the pH range 4.5 to 8.5. A sigmoidal fit of the 
absorbance at 254 nm against the pH revealed a pKa of 6.03(8) (Figure 3.2).  
 
 
 
 
 
Figure 3.2 Absorbance pH titration of APDAP; the inset shows the sigmoidal fit of 
absorbance at 254 nm against pH with its calculated pKa, and given with an error 
associated with the fitting. Blue shows the corresponding change in pH of APDAP after 
saturation with Mg2+ (100 mM) in the physiological range. Ligand concentration = 50 μM, in 
100 mM KCl, 298 K.  
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Over the physiological pH range (pH 6.5 to 7.5), only small changes in the 
absorbance were observed, suggesting that the deprotonated carboxylate 
groups, the aniline nitrogen atom and the ether oxygen atom are each available 
for coordination to metal ions. Such an interpretation is supported by a number 
of pKa studies for APTRA analogues in the literature.1,6,10,12 It is important to note 
that it is essential that there be little / no absorbance change with pH in the 
physiological pH range so that any absorbance changes observed can be 
unequivocally ascribed to a binding event and not a pH fluctuation.  
The metal-bound APDAP ligand is insensitive to changes in pH within the 
physiological range. Following the addition of 100 mM Mg2+ to a solution of 
APDAP, minimal absorbance changes were observed in the range of pH 6.5 to 
7.5. The pH insensitivity in the Mg2+ ‘bound’ complex reported here, has been 
observed previously with carboxylate-based APTRA analogues of this type, 
allowing them to be used in a range of in vivo and in cellulo applications.5,8  
3.4 Binding studies of APDAP with Mg2+, Ca2+ and Zn2+ 
The absorption spectral changes of APDAP following addition of divalent 
cations Mg2+, Ca2+ and Zn2+ were investigated at 298 K in HEPES buffer 
(pH 7.21) (Figure 3.3). It was crucial that the system was buffered, in order to 
keep the pH constant within the physiological range. All reported errors for 
binding constants of Mg2+, Ca2+ and Zn2+ are due to experimental variability, 
generated from the three repeat measurements and not an error associated with 
the fitting. Direct comparisons between the binding affinity of Mg2+, Ca2+ and Zn2+ 
to APDAP and APTRA are highlighted in Table 3.1.  
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Figure 3.3 (Left) absorbance spectrum, (right) binding curve for the addition of (A) Mg2+, 
(B) Ca2+ and (C) Zn2+ in aqueous solutions. Ligand concentration = 50 μM, in 50 mM 
HEPES, 100 mM KCl, pH 7.21. The reported binding constants are an average of three 
separate metal ion titrations, and the associated experimental error is given in parenthesis. 
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Table 3.1 The direct comparison of APTRA and APDAP via absorbance spectroscopy. (a) Measured by Parker and co-workers,4 (b) measured by 
Buccella and co-workers.10 The reported binding constants for APDAP are an average of three separate metal ion titrations, and the associated 
experimental error is given in parenthesis. 
 pKa K (Mg2+) 
(M-1) 
Kd (Mg2+) 
 
K (Ca2+) 
(M-1) 
Kd (Ca2+) 
 
K (Zn2+) 
(M-1) 
Kd (Zn2+) 
 
 
 
 
APTRA 
5.5a 5.6(3) x102 b 1.79 mMb 1.02(7) 
x105 b 
9.80 µMb 7(1) x107 b 14 nMb 
 
 
 
APDAP 
6.03(8) 0.79(5) x102 12.7(8) mM 9.30(5) 
x102 
1.08(5) mM 6(1) x104 17(3.5) µM 
N
O
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O OH
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N
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OHO
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Addition of Mg2+ to a solution of APDAP resulted in a decrease in the 
observed absorbance at 254 nm and 285 nm. Fitting the absorbance at 254 nm 
against the concentration of MgCl2 added to a 1:1 binding model, revealed a 
dissociation constant (Kd) of 12.7(8) mM. An approximate 7-fold weaker affinity 
of ADAP to Mg2+ was observed, therefore, when directly compared to APTRA10 
(Table 3.1). A different spectral response was found for Mg2+ binding compared 
to the changes accompanying protonation of the aniline nitrogen atom. This 
behaviour suggests that on the addition of Mg2+ to the APDAP chelate, the aniline 
nitrogen atom does not play a prominent role in binding, instead it is possible that 
APDAP may bind to Mg2+ in a tetradentate manner (Figure 3.4). The possible 
reduction in the number of coordinating groups to Mg2+, could be a factor in the 
7-fold reduction in the affinity of APDAP for Mg2+, compared to APTRA.  
 
Figure 3.4 Different plausible coordination modes for APDAP to Mg2+.  
The addition of Ca2+ and Zn2+ to a solution of the APDAP chelator afforded 
a different response to that observed with Mg2+, but a similar response to that 
seen on protonation of the aniline nitrogen atom under acidic conditions 
(Figure 3.2). A decrease in the absorbance at 254 nm and 285 nm was seen, 
coupled with an increase in the absorbance at 273 nm. Such behaviour suggests 
that the aniline nitrogen atom does participate in binding to both Ca2+ and Zn2+. 
Dissociation constants of 1.08(5) mM and 17(4) µM were calculated respectively 
for Ca2+ and Zn2+, from non-linear least squares iterative fitting to a 1:1 binding 
model (Figure 3.3, Table 3.1).  
APTRA analogues are typically more selective towards Ca2+ than Mg2+, 
with a µM vs. mM affinity commonly displayed. Such an affinity profile allows them 
to be used as low affinity Ca2+ probes in calcium-rich regions of the body.13 The 
Mg2+ / Ca2+ selectivity is, however, seen to be significantly improved by 
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incorporating a phosphinate group in place of a carboxylate binding group 
maintaining a pentavalent denticity around the metal ion. A mM affinity for the 
binding of Mg2+ and Ca2+ to APDAP is reported, remarkably showing a 110-fold 
weaker affinity for the binding of Ca2+ compared to that observed for APTRA by 
Buccella et al 10 (Table 3.1). The mM selectivity to both Mg2+ and Ca2+ shown 
here hasn’t previously been reported for a ligand of this denticity. It is, however, 
typical of the bidentate β-keto acids such as KMG-10414 and KMG-301.15 
3.5 DFT studies: APTRA vs. APDAP  
3.5.1 X-ray crystal structures of APTRA with divalent metal ions 
	
The o-aminophenol-N,N,O-triacetic acid binding framework has been 
previously shown to bind a wide variety of divalent cations. Hualin and Peiyi 
synthesised and characterised a range of APTRA complexes with first row 
transition metals including Mn2+, Co2+, Ni2+ and Zn2+, where a single crystal was 
obtained for the complex containing Co2+.16 More recently, Buccella and co-
workers have characterised the solid state structures of APTRA with Mg2+, Ca2+ 
and Zn2+.10 It was found that the APTRA complexes containing Mg2+ and Zn2+ 
complemented the observation first made by Hualin and Peiyi in the Co2+ 
complex, where the metal complex of APTRA crystallises as 
[M(H2O)6][M(APTRA)]2 with a distorted octahedral geometry around the metal 
ion.10,16  All of the donor atoms in the pentadentate chelate are bound to the 
divalent metal ion, with the sixth and final coordination site of the metal ion 
occupied by a bridging carboxylate of a neighbouring complex, forming long 
chains of [M(APTRA)]– in the solid state (Figure 3.5).10,16   
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Figure 3.5 The crystal structure of (A) [Mg(APTRA)L]– and (B) long chains of 
[Mg(APTRA)L]– in the solid state with bridging carboxylates (L) of neighbouring complexes 
as reported by Buccella et al.10 An identical crystal structure was reported in the analogous 
Zn2+ complex, [Zn(APTRA)L]–. 
 
Complexation of APTRA with Ca2+ formed a dimeric species with the 
formula [Ca(OH2)3]2{[APTRA)Ca(OH2)2](µ-H2O)2}Cl2, and showed major 
structural differences in the solid state to the speciation observed with Mg2+, Zn2+ 
and Co2+ (Figure 3.6).10  The dimeric species formed is made up of two APTRA 
ligands that are bridged by two water molecules and two Ca(OH2)3 ions.  
 
Figure 3.6 The crystal structure of [Ca4(APTRA)2(H2O)10]2+ as reported by Buccella et al.10 
A) B) 
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It is interesting to note that unlike [M(H2O)6][M(APTRA)]2 (complexes 
formed following addition of Mg2+, Zn2+ and Co2+), each Ca2+ ion is bound to two 
APTRA ligands, and in total the two APTRA ligands are bound to four Ca2+ ions 
in the solid state. The larger Ca2+ ions (radius = 114 pm) each maintain a 
coordination number of eight, while the smaller Mg2+, Zn2+ and Co2+ ions favour 
a coordination number of six, in an octahedral geometry.   
3.5.2 DFT studies: The addition of divalent metal ions to APTRA and APDAP  
 
It has been shown in Section 3.4 that from absorbance binding studies of 
APDAP with Mg2+, Ca2+ and Zn2+, an enhancement of the Mg2+ / Ca2+ selectivity 
is reported, with a 110-fold weaker affinity for the binding of Ca2+ compared to 
that observed for APTRA by Buccella.10  
In order to gain a greater insight into the significantly weaker affinity for 
Ca2+ observed for the phosphinate chelate APDAP, a series of DFT calculations 
were carried out. The primary objective of the investigation was to calculate the 
binding energies and the bond distances / bite angles following complexation of 
Mg2+, Ca2+ and Zn2+ to APTRA and APDAP. It was hoped that these calculations 
could provide some insight into the enhanced Mg2+ selectivity reported for 
APDAP.  
In the crystal structure characterised by Buccella et al. (Figure 3.5), 
APTRA complexes containing Mg2+ and Zn2+ ions crystallised in long chains of 
[M(APTRA)]–, with a carboxylate ligand occupying the sixth coordination site. In 
an attempt to replicate experimental conditions in aqueous solutions, the DFT 
simulations were instead run primarily with a water molecule occupying the sixth 
coordination site of the metal ion.  
Simulated DFT structures of APTRA and APDAP bound to Mg2+, Ca2+ and 
Zn2+ in a distorted octahedral geometry are shown in Figure 3.7.  
 
 
 
 
 
Chapter 3. APTRA vs. APDAP: A direct comparison 
	
87 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 The simulated structures of APTRA and APDAP coordinated to Mg2+, Ca2+ and 
Zn2+. A metal coordination number of six has been assumed for the coordination of each 
metal ion. Functional / basis set / solvent (B3LYP / 6-311++G(d,p) / H2O). 
 
For the binding of each divalent metal ion a coordination number of six 
was assumed, although for Ca2+ a larger coordination number of eight was 
expected in solution because of its larger ionic radius, and the 8-coordinate 
complex formed in the solid state.10 The binding energies found for the binding of 
Ca2+, therefore, have a significant error associated with the calculation, as it is 
possible that multiple [Ca(APTRA)(H2O)n]– (where n = 1, 2 or 3) anions are 
present in aqueous solution. Depending on the coordination and hydration 
number of Ca2+ in the DFT simulation, the binding energies will change 
considerably. Results obtained, therefore, provided little information into the 
rationale behind the reduced Ca2+ binding affinity observed for APDAP.  
 
[Mg(APTRA)(H2O)] – [Ca(APTRA)(H2O)] – 
[Mg(APDAP)(H2O)] – [Ca(APDAP)(H2O)] – [Zn(APDAP)(H2O)] – 
[Zn(APTRA)(H2O)] – 
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The C–C, C–O, P–C and P–O bond lengths in APTRA and APDAP were 
calculated from the simulated structures in Figure 3.7, to provide a greater 
understanding into the experimental binding affinities observed for Mg2+ and 
Ca2+. Bond lengths of the M–O and M–N binding groups in both 
[M(APTRA)(H2O)]– and [M(APDAP)(H2O)]– (where M = Mg2+ and Ca2+) have also 
been determined to calculate the bite angles around the metal ions.  
It is apparent from Table 3.2, that C–C, C–O, P–C and P–O bond lengths 
are almost identical in APTRA and APDAP respectively for the binding of Mg2+ 
and Ca2+. There is, however, a noticeable difference in the relative C–C, C–O in 
APTRA and P–C and P–O bond lengths in APDAP, where longer P–C and P–O 
bonds are reported over their carboxylate analogues.  
 
Table 3.2 The C–C, C–O, P–C and P–O bond distances / Å in APTRA and APDAP when 
bound to Mg2+ and Ca2+. Functional / basis set / solvent (B3LYP / 6-311++G(d,p) / H2O). 
 
Bond distances 
/ Å 
 [M(APTRA)(H2O)]–  [M(APDAP)(H2O)]– 
M = Mg2+ M = Ca2+ M = Mg2+ M = Ca2+ 
C–C 1.539 1.538 - - 
C–O 1.275 1.271 - - 
P–C - - 1.868 1.858 
P–O - - 1.551 1.547 
 
Due to the complexity associated with the multiple possible coordination 
numbers of Ca2+ in solution ([M(APTRA)(H2O)n]–), a DFT study into the metal-
donor group bond distances and bite angles in APTRA and APDAP was 
investigated with Mg2+ and Zn2+ only. These divalent metal ions have a very 
similar ionic radius, and both form 6-coordinate complexes in solution. 
A comparison between the calculated bond lengths for APTRA has been 
made with those determined experimentally, taken from the X-ray crystal 
structure reported by Buccella.10 No such comparisons to experimental bond 
lengths were made with APDAP, as no conditions to isolate a single crystal of 
[Mg(APDAP)L]–, [Ca(APDAP)L]– or [Zn(APDAP)L]– have been established.  
The metal-donor group bond distances for APTRA and APDAP and the 
bite angle around the Mg2+ and Zn2+ metal ions are highlighted in Table 3.3, 
Table 3.4 and Table 3.5. Similar metal-donor group bond distances are displayed 
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in APTRA for the binding of both Mg2+ and Zn2+, and are comparable to the 
experimental values measured from the X-ray crystal structure of the 
[M(APTRA)(L)]– complexes (Table 3.3).  
The phosphinate-based chelate APDAP, however, displayed significant 
differences in the calculated bond distances for the binding of Mg2+ and Zn2+ to 
APTRA. In general, metal-donor group bond lengths were shorter in the 
[Mg(APDAP)L]–  complex, compared to its APTRA analogue. It is apparent from 
Table 3.4, that the M–O(CH2) bond length in [Mg(APDAP)L]– was noticeably 
shorter than the other three complexes studied, containing both Mg2+ and Zn2+. 
For example, a 0.262 Å shorter bond length was seen relative to the zinc complex 
[Zn(APDAP)L]–. It is interesting to note that much less bond length variation was 
displayed between [Zn(APTRA)L]–  and [Zn(APDAP)L]–, and was comparable to 
the values calculated for [Mg(APTRA)L]– (Table 3.3 and Table 3.4).  
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Figure 3.8 The simulated structures of (A) [Mg(APTRA)(H2O)]– and (B) 
[Mg(APDAP)(H2O)]–. 
 
Table 3.3 Comparison of the calculated and experimental bond distances in APTRA after 
coordination to Mg2+ and Zn2+. (B3LYP / 6-311++G(d,p) / H2O). Calculated bond distances 
are obtained from crystallographic data.10 Calc. L = H2O, Expt. L = carboxylate from an 
adjacent [M(APTRA)]– complex. 
	
M–L bond  [Mg(APTRA)L]– / Å  [Zn(APTRA)L]– / Å 
Calc Expt Calc Expt 
M–N12 2.336 2.307 2.382 2.248 
M–O11 2.161 2.140 2.251 2.198 
M–O27 2.037 2.042 2.037 2.052 
M–O28 2.033 2.038 2.019 2.044 
M–O29 2.028 2.013 2.013 2.069 
M–O(L) 2.135 2.045 2.258 2.042 
	
Table 3.4 The calculated bond distances in APDAP after coordination to Mg2+ and Zn2+. 
(B3LYP / 6-311++G(d,p) / H2O). L = H2O. No experimental bond distances were measured. 
	
M–L bond  [Mg(APDAP)L]– / Å  [Zn(APDAP)L]–  / Å 
Calc Expt Calc Expt 
M–N12 2.233 - 2.366 - 
M–O11 2.088 - 2.350 - 
M–O31 1.966 - 1.991 - 
M–O32 2.056 - 2.022 - 
M–O33 1.971 - 2.020 - 
M–O(L) 2.093 - 2.302 - 
 
Table 3.5 Comparison of the bite angles between the donor groups of APTRA and APDAP 
coordinated to Mg2+ and Zn2+. (B3LYP / 6-311++G(d,p) / H2O). L = H2O. 
Complex Bite angles / o 
O11–Mg–N12 O––Mg–N12 O––Mg–N12 O11–Mg–O– a 
[Mg(APTRA)L]– 73.94 77.31 77.12 75.18 
[Zn(APTRA)L]– 72.11 78.11 78.22 74.63 
[Mg(APDAP)L]– 78.39 79.83 80.07 83.89 
[Zn(APDAP)L]– 71.19 78.85 77.97 78.56 
a O– = phosphinate oxygen for APDAP, O-carboxylate for APTRA. 
A) B) 
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It is evident from Table 3.5 that the bite angles around the Mg2+ ion in 
[Mg(APDAP)L]– are larger than those calculated in both [Mg(APTRA)L]– and 
[Zn(APDAP)L]–. Similar to the metal-donor group bond lengths seen for 
[Zn(APDAP)L]–, the calculated bite angles are also comparable to those observed 
for the Mg2+ and Zn2+ complexes of APTRA.  
For the binding of Mg2+, the longer P–C and P–O bond lengths in APDAP, 
give rise to a larger chelate ring size, with less acute bite angles around the Mg2+ 
ion (Table 3.2 and Table 3.5). The largest difference was observed with the 
(CH2)O–Mg–O angle of the phosphinate ligating group, where a 9o less acute bite 
angle was seen relative to the carboxylate binding group in APTRA (Table 3.5 
and Table 3.6).  
 
3.5.3 APDAP vs. APTRA: Explaining the enhanced Mg2+ / Ca2+ selectivity  
	
Although no data was collected from DFT studies for the Ca2+ complex of 
APDAP ([Ca(APDAP)Ln]–), a number of important conclusions can be drawn from 
the information obtained for the Mg2+ and Zn2+ complexes. It has been shown in 
Section 3.5.2 that the phosphinate-based APDAP chelate possesses much 
longer P–C and P–O bonds, generating a less acute bite angles around Mg2+ 
than that observed for APTRA (Table 3.2). Consistent with this observation, 
shorter M–O(CH2), M–O(PO(CH3)CH2O) and M–N bond lengths were also found 
in [Mg(APDAP)L]– with the phosphinate chelate being more 6-membered in 
character than the smaller bite angles seen in the APTRA series.  
According to the chelate effect first introduced in Section 2.1, larger metal 
ions of a higher coordination number have a more pronounced reduction in 
complex stability with an increased chelate ring size.18,19 Larger cations such as 
Ca2+, therefore, preferentially favour the formation of 5-membered ring chelates 
over 6-membered, with an ideal bite angle of 69o.18,19 Smaller cations such as 
Mg2+ and Zn2+, have a lower coordination number and form more stable 6-
membered chelates.18,19 It is possible, therefore, to potentially tune the metal ion 
selectivity by changing the ring chelate size around a metal ion.18,19  
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A systematic comparison between the bite angle in carboxylate and 
phosphinate binding groups in APTRA and APDAP respectively is shown in 
Figure 3.9. A typical aliphatic 5-membered ring (ethylenediamine, EN)18 and a 6-
membered chelate (trimethylenediamine, TN) formed on the binding to divalent 
metal ions has been included in Figure 3.9 for comparison.18  
 
 
 
 
Figure 3.9 Calculated (CH2)O–Mg–O bite angles in (A) [Mg(APTRA)L]– and 
(B) [Mg(APDAP)L]–. Literature examples of (C) 5-membered ethylene diamine (EN) and 
(D) 6-membered trimethylenediamine (TN) on the binding of divalent metal ions, provided 
for a comparison.18 Blue is a Mg2+ ion, black represents a theoretical divalent metal ion.  
 
Table 3.6 The (CH2)O–Mg–O bite angles in [Mg(APTRA)L]– and [Mg(APDAP)L]–. 
Complex  (CH2)O–Mg–O 
bite angles, ! / o 
[Mg(APTRA)L]– (A) 75.18 
[Mg(APDAP)L]– (B) 83.89 
 
The increase in the (CH2)O–Mg–O bite angle and the reduced M–N and 
M–O bond lengths observed in [Mg(APDAP)L]–, suggests that the phosphinate-
based APDAP ligand possesses features similar to that observed with a 6-
membered ring chelate. In 6-memebered ring chelates, such as TN (Figure 3.9), 
an ideal bite angle of 109.5o is typically observed, significantly larger than those 
reported for 5-membered ring chelates (Figure 3.9 and Table 3.6).18,19 The larger 
ring chelate formed in [Mg(APDAP)L]–, therefore, will tend to thermodynamically 
favour the binding of the smaller Mg2+ cation over Ca2+. Such behaviour is 
identical to that observed by Martell and Hancock in a detailed investigation into 
the binding of metal ions to a range of both 5- and 6-membered ring chelates.18,19   
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Similar work involving the binding of metal cations to phosphinate ligating 
groups has been carried out previously in Durham. The introduction of 
phosphinate groups onto both 9-N3 and 12-N4 macrocyclic ligands has been 
reported to modify ion selectivity, identical to that observed for APDAP in this 
work. Parker and co-workers synthesised a range of carboxylate- and 
phosphinate-based macrocyclic ligands such as 1,4,7-triazacyclononane-1,4,7-
triyltrimethylelenetris-(phenylphosphinate), to bind to a range of divalent and 
trivalent metal ions, including Cu2+, Ga3+ and Fe3+.17 Similarly to the calculated 
bond lengths observed for [Mg(APDAP)L]–, longer P–C and P–O bonds were 
reported in the macrocyclic phosphinate series over their carboxylate analogues. 
A less acute bite angle around the metal ion was seen in the phosphinate series, 
that inherently favoured the binding of smaller metal ions.17 
3.6 Conclusions for the direct comparison of APTRA and APDAP  
A new pentadentate binding moiety for divalent cations, namely 
o-aminophenol-N,N-diacetic acid phosphinate (APDAP) has been synthesised in 
a four step reaction sequence from 2-nitrophenol in good yield. The APDAP 
chelate is a phosphinate analogue of APTRA, with the incorporation of a 
phosphinate binding group at the expense of a carboxylate ligating group to 
maintain a pentadentate denticity (Figure 3.10).     
 
Figure 3.10 Pentadentate ligands APTRA and APDAP. 
The APDAP chelate revealed a pKa of 6, slightly higher than the value of 
5.5 previously reported for APTRA via absorbance spectroscopy.10 Absorbance 
binding studies were carried out following addition of Mg2+, Ca2+ and Zn2+, where 
an enhanced selectivity for the binding of Mg2+ compared to APTRA was 
observed. Although APDAP displayed a 7-fold weaker affinity towards Mg2+, a 
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Chapter 3. APTRA vs. APDAP: A direct comparison 
	
94 
	
dramatically reduced affinity was reported following addition of Ca2+ and Zn2+. For 
the binding of Ca2+ ions for example, a 110-fold weaker binding affinity was 
observed, and a dissociation constant of 1.08(5) mM was calculated from a 1:1 
binding model. Kd values in this range for the binding of Ca2+ have never been 
seen before for ligands of this denticity, with a mid-µM affinities typically observed 
within the APTRA series of indicators.1-6,10,12  
In order to gain greater insight into the binding of Mg2+, Ca2+ and Zn2+ to 
APDAP a detailed DFT investigation was undertaken. All simulations were run 
with each of the oxygen and nitrogen donor groups coordinated to the metal ion, 
with a water molecule occupying the sixth and final coordination site in an attempt 
to replicate experimental solution conditions. A number of binding energies, bond 
lengths and bite angles were calculated for both APTRA and APDAP. 
The viability of the calculations was tested by comparing the data to experimental 
results obtained from the crystal structure of [Mg(APTRA)L]– (where M = Mg2+, 
Ca2+ and Zn2+).  
From the computational DFT study it was found that the APDAP chelate 
possesses longer P–C and P–O bonds compared to the carboxylate 
analogue APTRA. The metal-donor group bond lengths and bite angles 
around the metal ion were calculated with both Mg2+ and Zn2+, the similar ionic 
radius and coordination number of these ions eliminates complications 
resulting from the multiple hydration numbers possible for 
[Ca(APTRA)(H2O)n]— (where n = 1, 2 or 3) in solution. It was found that in the 
case of [Mg(APDAP)L]— the (CH2)O–Mg–O bond lengths were much shorter than 
their APTRA analogues with a 9o more obtuse bite angle. For [Zn(APDAP)L]—, 
however, all bond lengths and bite angles calculated were broadly similar to those 
measured with APTRA.  
The larger Ca2+ ion thermodynamically favours the formation of 5-
membered chelate rings. The increase in the bite angle observed for Mg2+ and 
the reduction in the M–O and M–N bond lengths, allows the APDAP chelate ring 
to possess more 6-membered ring chelate character around Mg2+ ions. Such 
behaviour provides a possible explanation into the dramatically reduced affinity 
observed for the binding of Ca2+ to APDAP. The larger ring size with the 
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phosphinate APDAP chelate formed inherently favours the binding of smaller 
cations, such as Mg2+ over Ca2+.  
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4. Ligands containing naphthalene as the fluorophore 
4.1 Introduction  
Levy et al. have previously demonstrated that the incorporation of the 
APTRA binding moiety into 1-naphthalene and 2-naphthalene systems generates 
indicators that display a ratiometric response towards Mg2+ and Ca2+.1 
Ratiometric indicators are highly advantageous in sensing applications. A 
wavelength shift on the binding of metal ions allows the concentration to be 
measured at two specific wavelengths. Such behaviour allows ratiometric 
methods of analysis to be used, meaning that the binding measurements of Mg2+ 
and other cations are unaffected by the concentration of the indicator, cell loading 
or photochemical bleaching during in vivo studies.1 The bi-aryl naphthalene 
derivatives developed by Levy et al. are shown in Figure 4.1.  
 
Figure 4.1 Naphthalene-based indicators developed by Levy et al. from (A) 1-naphthalene 
and (B) 2-naphthalene derivatives.1 
Building on the success of this work carried out in 2001, pro-ligands L1, 
L2, L4 and L6 have been incorporated into 1-naphthalene based systems, and are 
denoted as the naphthalene derivatives NapL1, NapL2, NapL4 and NapL6 
(Figure 4.2). The 1-naphthalene systems were preferred because of the greater 
wavelength shift upon saturation with Mg2+ in the excitation spectrum (30 nm shift 
for the 1-naphyl vs. 23 nm shift for the 2-naphthyl derivatives).1  
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Instead of the bi-aryl ligand utilised in the work undertaken by Levy et al., 
a naphthalene-1-alkynylaryl system has been developed with an alkyne link 
between the APTRA binding moiety and the naphthalene reporter group. This 
approach allows the possibility to use the ligands in the naphthalene series as 
fluorophores to analyse the behaviour of the new binding moieties of L4 and L6 
containing phosphinate groups. It also provides the opportunity for NapL1, NapL2, 
NapL4 and NapL6 to act as a model for related lanthanide-based systems 
(Chapter 5) as pyridylalkynylaryl-based compounds are commonly used as 
chromophores in 12-N4 macrocyclic ligands to sensitise europium-based 
emission.  
 
Figure 4.2 Target naphthalene-based ligands NapL1, NapL2, NapL4 and NapL6. 
 The synthesis and characterisation of the ligands is reported here. The 
analysis of pKa and the binding properties of NapL1, NapL2, NapL4 and NapL6 
via fluorescence spectroscopy is also discussed. Direct comparisons across the 
naphthalene series have been made, to determine how the binding affinity and 
selectivity is affected by the position of nitrogen and oxygen atoms on the APTRA 
binding moiety relative to the aromatic reporter group. Direct comparisons 
between the APTRA (NapL1, NapL2) and the newly synthesised APDAP (NapL4) 
binding moieties are made. The effect of different chelate ring sizes formed on 
binding of Mg2+, Ca2+ and Zn2+, typically [5, 5, 5] vs. [6, 5], is also assessed.   
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4.2 Synthesis and characterisation  
 The synthesis of the naphthalene-based ligands NapL1, NapL2, NapL4 
and NapL6 begins with the introduction of an alkyne group via a Sonogashira 
reaction of (triisopropylsilyl)acetylene (TIPS-acetylene) with the ethyl esters of L1, 
L2, L4 and L6 in THF (Scheme 4.1). It was found that relatively long reaction times 
were required, together with the addition of a large excess of TIPS-acetylene (5-6 
equivalents). Shorter reaction times and fewer equivalents of TIPS-acetylene 
resulted in incomplete conversion. Such a behaviour presented problems during 
purification, as similar Rf values were observed for the starting material and 
product, making purification via conventional chromatography rather difficult to 
achieve. Typically, Pd(PPh3)2Cl2 is used as the catalyst in Sonogashira cross-
coupling reactions. However, only starting material was observed by both ESI-
MS and 1H NMR after heating at reflux in THF for 3 days when this catalyst was 
used. The Pd(dppf)Cl2 catalyst was found to be the most suitable, forming 
(25)-(28) in high yields after purification by column chromatography. 
 
Scheme 4.1 Sonogashira cross-coupling reactions of ethyl esters of L1, L2, L4 and L6 with 
TIPS-acetylene. 
Alkyne de-protection was attempted under a number of conditions to form 
the unprotected alkyne (Scheme 4.2). Carbon-silicon bond cleavage using 
triethylamine trihydrofluoride (NEt3.3HF) has been used previously to de-protect 
trimethylsilyl (TMS) alkynes in high yields.2 The reaction, however, was 
unsuccessful in this instance, with no evidence of any reaction by ESI-MS after 
4 days heating at 35 oC. It is possible that the increased steric hindrance provided 
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by the TIPS group may inhibit the attack of fluoride at the silicon centre. The use 
of tetrabutylammonium fluoride (TBAF) in THF at room temperature was used as 
an alternative de-protection method which led to the formation of (30) in moderate 
yield, after purification by column chromatography (Scheme 4.2).  
 
Scheme 4.2 Attempted alkyne de-protection of (29) with NEt3.3HF2 or TBAF in THF. 
In an effort to increase the overall yield of the Sonogashira cross-coupling 
reaction, a one pot de-protection and cross-coupling reaction with 
1-bromonaphthalene was undertaken. Initially Pd(PPh3)4 was used as the 
catalyst. However, this led to the formation of triphenylphosphine oxide as a by-
product which was difficult to remove by conventional column chromatography. 
Pd(dppf)Cl2 was used as an alternative catalyst with copper iodide forming 
(31)-(34) in low yields after purification by column chromatography. It was 
essential that silyl protected alkynes (25)-(28) were added in a 1:1 stoichiometry 
with 1-bromonaphthalene. Similar Rf values in common solvent systems between 
the de-protected alkyne and the cross-coupled product resulted in purification 
problems, even when only a slight excess was used.   
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Scheme 4.3 One pot de-protection reaction of silyl acetylenes and Sonogashira cross- 
coupling reaction with 1-bromonaphthalene. 
The ‘one pot’ method was low yielding, especially for the ligands bearing 
phosphinate groups (33) and (34).  
Ethyl ester hydrolysis of (31)-(34) was undertaken in basic conditions, 
using sodium deuteroxide and deuterated solvents to allow the the hydrolysis 
reaction to be monitored easily by 1H NMR (Scheme 4.4). Each hydrolysis 
reaction proceeded smoothly, forming NapL1 (35), NapL2 (36), NapL4 (37) and 
NapL6 (38) in quantitative yields. Product purity was determined by ESI-MS, 
accurate mass analysis and analytical HPLC.    
 
Scheme 4.4 Ethyl ester hydrolysis of (31) to form NapL1 (35). The same procedure was 
repeated for (32), (33) and (34) to form NapL2 (36), NapL4 (37) and NapL6 (38) 
respectively.  
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4.3 Photophysical studies of NapL1, NapL2, NapL4 and NapL6 
The photophysical properties of NapL1, NapL2, NapL4 and NapL6 were 
examined in aqueous solutions at 298 K. pH titrations were carried out at a 
constant ionic strength in 100 mM KCl. Metal binding titrations with Mg2+, Ca2+ 
and Zn2+ were carried out in 50 mM HEPES buffer and 100 mM KCl at a constant 
pH of 7.21 to simulate physiological conditions.  
The absorption spectra for NapL1, NapL2, NapL4 and NapL6 in water are 
shown in Figure 4.3, and the absorption maximum for each naphthalene 
derivative is listed in Table 4.1. Molar extinction coefficients were calculated from 
a linear plot of the absorbance maximum at four different concentrations 
according to the Beer-Lambert law (Equation 3.1).  
A = #cl        Eq.3.1 
where: A is the absorbance, # is the molar extinction coefficient, c is the 
concentration and l is the path length of the cell (1 cm).  
The values of the calculated molar extinction coefficients and quantum 
yields are listed in Table 4.1, and as expected, are all comparable due to the fact 
that only small structural modifications have been made to the naphthalene 
derivatives in each instance. 
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Figure 4.3 Absorbance spectra of NapL1, NapL2, NapL4 and NapL6 in H2O, 298 K.  
Table 4.1 The absorption λmax and calculated molar extinction coefficients (#) for NapL1, 
NapL2, NapL4 and NapL6 in H2O, 298 K. The molar extinction coefficients (#) were 
determined from the Beer-Lambert Law, A = #cl. Quantum yields ($) ± 20 % measured in 
H2O. aQuinine sulphate (in 0.5 M H2SO4) and bPOPOP were used as the fluorescence 
standards.  
Ligand Absorption λmax 
/ nm 
& x103 / M-1cm-1 ΦH2O / % 
NapL1 354 14.1(3) 0.3a 
NapL2 318 13.8(6) 1.3b 
NapL4 350 10.7(2) 0.7a 
NapL6 341 12.9(4) 0.8a 
 
The excitation and emission spectra of the four naphthalene-1-alkynylaryl 
derivatives were recorded in water at 298 K; the normalised emission and 
excitation spectra are shown in Figure 4.4. The excitation and emission maxima 
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are listed in Table 4.2, with a comparison to the wavelength maximum exhibited 
by the commercially available Mag-Fura-2.3 
It is clear from the analysis of the absorption, excitation and emission 
profiles of NapL1, NapL2, NapL4 and NapL6 that the position of the aniline 
nitrogen atom on the aromatic system has a notable effect on the observed 
wavelength maximum in each instance. The derivatives NapL1, NapL4 and 
NapL6 each have an aniline nitrogen para to the fluorophore, displaying 
comparable maximum wavelengths in their absorption, excitation and emission 
spectra. Ligand NapL2, however, exhibits different photophysical properties, with 
the aniline nitrogen placed meta to the naphthalene fluorophore, displaying 
higher absorbance, excitation and emission energies.  
The higher emission energy observed when the aniline nitrogen is meta 
gives rise to a significantly smaller Stokes’ shift of 54 nm between the excitation 
and emission spectra for NapL2. When the aniline nitrogen is para to the 
naphthalene fluorophore in the case of NapL1, NapL4 and NapL6, however, a 
204 nm, 200 nm and 166 nm Stokes’ shift was seen respectively (Figure 4.4). 
Large Stokes’ shifts are indicative of organic fluorophores that contain an 
intramolecular charge transfer (ICT) transition. The donation of electron density 
in the aromatic system from the lone pair of the aniline nitrogen stabilises the 
excited state, resulting in a bathochromic shift of the absorbance, excitation and 
emission energy maxima towards the red region of the spectrum in NapL1, NapL4 
and NapL6. No such charge transfer process is conceivable with NapL2 with 
lower wavelength maxima reported in the absorbance, excitation and emission 
spectra.  
 
 
 
 
Chapter 4. Ligands containing naphthalene as the fluorophore 
	
106 
	
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Excitation and emission spectra of (A) NapL1 (λex = 354 nm, λem = 530 nm), (B) 
NapL2 (λex = 354 nm, λem = 370 nm), (C) NapL4 (λex = 350 nm, λem = 530 nm) and (D) 
NapL6 (λex = 347 nm, λem = 501 nm). Excitation is shown in blue; emission is shown in 
green, and the corresponding Stokes’ shifts are indicated. Ligand concentration 5 µM in 
50 mM HEPES, 100 mM KCl, pH = 7.21, 298 K. 
Table 4.2 Excitation and emission λmax comparison between NapL1, NapL2, NapL4, NapL6 
and Mag-Fura-2 in in 50 mM HEPES, 100 mM KCl, pH = 7.21, 298 K. λex and λem 
wavelengths for each derivative are displayed in Figure 4.4.  
Ligand Excitation λmax (nm) Emission λmax (nm) 
NapL1 358 562 
NapL2 318 372 
NapL4 350  550 
NapL6 341 507 
Mag-Fura-23 3703 5103 
 
Typically, Stokes’ shifts in comparable systems are below 200 nm. 
Mag-Fura-2 for example, has a Stokes’ shift of 140 nm,3 while the 
0
0.2
0.4
0.6
0.8
1
1.2
280 480 680
No
rm
al
ise
d	
Wavelength	(nm)
0
0.2
0.4
0.6
0.8
1
1.2
270 370 470
No
rm
al
ise
d	
Wavelength	(nm)
0
0.2
0.4
0.6
0.8
1
1.2
290 390 490 590
No
rm
al
ise
d	
Wavelength	(nm)	
0
0.2
0.4
0.6
0.8
1
1.2
290 390 490 590
No
rm
al
ise
d	
Wavelength	(nm)	
204 nm 54 nm 
200 nm 166 nm 
(A) NapL1 (B) NapL2 
(C) NapL4 (D) NapL6 
Chapter 4. Ligands containing naphthalene as the fluorophore 
	
107 
	
1-arylnaphthalene APTRA derivative, developed by London, shows a Stokes’ 
shift of 174 nm.1 The larger Stokes’ shift reported here is probably associated 
with the increased conjugation provided by the alkyne, compared to the single 
carbon-carbon bond between the APTRA binding moiety and the 1-naphthalene 
fluorophore. The increased planarity of the aromatic framework provided in the 
pyridylalkynylaryl system, also reduces the energy lost by non-radiative decay 
pathways, causing the wavelength maximum to increase. Such large Stokes’ 
shifts are a highly desirable feature of fluorescent sensors, reducing the 
interference between absorption and emission processes in photophysical 
studies.  
4.4 pH Studies of NapL1, NapL2, NapL4 and NapL6 
For the vast majority of APTRA analogues in the literature, the pKa is often 
not fully determined, as it is thought that APTRA binding moieties are unstable at 
a low pH and on prolonged standing in aqueous solution.4-6 An investigation into 
the response of NapL1, NapL2, NapL4 and NapL6 with pH in absorption and 
fluorescence spectroscopy is reported here. All titrations were carried out at a 
constant ionic strength in 100 mM KCl at 298 K.  
4.4.1 Absorbance pH studies of NapL1, NapL2, NapL4 and NapL6 
	
 Normalised absorbance spectra of the ligands in basic and acidic solutions 
are shown in Figure 4.5. In basic solutions, NapL1, NapL2, NapL4 and NapL6 
have an absorption maximum of 351 nm, 318 nm, 350 nm and 345 nm 
respectively. On protonation of the aniline nitrogen at low pH, a reduction in the 
absorbance and a blue shift is noted with NapL1, NapL4 and NapL6, with an 
increase in absorbance observed for NapL2.   
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Figure 4.5 Absorbance spectrum of NapL1, NapL2, NapL4 and NapL6 in basic and acidic 
solutions. Ligand concentration = 10 µM in 100 mM KCl, 298 K. 
 
4.4.2 Fluorescence pH studies of NapL1, NapL2, NapL4 and NapL6 
	
The effect of pH on the excitation spectrum of carboxylate-based NapL1 
and NapL2 is shown in Figure 4.6. pKa values of 6.2 and 5.7 were determined 
respectively. 
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Figure 4.6 (Left) the effect of the pH on the excitation spectrum; (right) the sigmoidal fit of 
(top) the excitation ratio and (bottom) the excitation intensity with pH of (A) NapL1 
(λem = 530 nm) and (B) NapL2 (λem = 370 nm). Ligand concentration = 10 µM in 100 mM 
KCl, 298 K. Calculated pKa values are given with an error associated with the fitting.  
It is apparent from analysis of Figure 4.6 that ligand NapL1 exhibits a 
ratiometric response to pH in excitation spectroscopy. A 20 nm hypsochromic 
shift towards the blue is noted in the excitation spectrum from 354 nm to 334 nm, 
following aniline nitrogen protonation (pH 8.2 to 4.0). This ratiometric pH 
response is consistent with the elimination of intramolecular charge transfer 
within the naphthalene ligand. Protonation stabilises the excited state, as the 
conjugation involving the aniline nitrogen lone pair is lost. Thus, a pronounced 
wavelength shift occurs towards the blue region of the spectrum, in both the 
excitation and absorbance spectra (Figure 4.5 and Figure 4.6). No pronounced 
changes were observed in the fluorescence emission spectrum of NapL1 with pH, 
however, following excitation at 351 nm.   
Ligand NapL2, in contrast, displayed a ‘turn-on’ response, following 
reduction of pH from 9.5 to 4.0, with no shift in the excitation or emission 
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wavelengths on protonation. A 3.5-fold ‘turn-on’ ratio was observed in both the 
fluorescence excitation and emission spectra. Such a ‘turn-on’ effect in solutions 
at reduced pH can be ascribed to the elimination of photo-induced electron 
transfer (PET) quenching of the excited state from the aniline lone pair of 
electrons, that occurs in basic solutions.  
Phosphinate-based NapL4 and NapL6 have pKa’s of 5.2 and 5.1 
respectively, comparable to those determined for NapL1 and NapL2. The effect 
of the pH on the excitation spectrum of NapL4 and the emission spectrum of 
NapL6 is shown in Figure 4.7. An almost identical ratiometric excitation response 
observed for NapL1 was found for the phosphinate derivative, NapL4, with a 
28 nm hypsochromic shift observed over the pH range 7.6 to 3.9.  
Ligand NapL6, in contrast to NapL1, NapL2 and NapL4, showed no 
pronounced pH sensitivity in the excitation spectrum. On excitation at 342 nm, 
however, a 2-fold reduction in the emission intensity was observed in acidic 
solutions. A pKa of 5.1 was calculated from fluorescence emission spectroscopy, 
comparable to the pKa values determined from excitation spectroscopy for 
NapL1, NapL2 and NapL4 (Figure 4.7).  
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Figure 4.7 (Left) the effect of the pH on the excitation (top) and emission spectrum 
(bottom); (right) the sigmoidal fit of the intensity with pH of (A) NapL4 (λem = 530 nm) and 
(B) NapL6 (λex = 342 nm). Ligand concentration 10 µM in 100 mM KCl, 298 K. Calculated 
pKa values are given with an error associated with the fitting in parenthesis. 
The presence of the aniline nitrogen either para or meta to the 
naphthalene fluorophore was seen to have little effect on the observed pKa values 
across the series. Naphthalene derivatives NapL1, NapL2, NapL4 and NapL6, 
each display pKa values in the range 5.1 to 6.2, comparable to APTRA based 
sensors in the literature. Mag-Fura-2, for example, has a pKa of 5.0 determined 
from fluorescence excitation spectroscopy.3 
It is also important to note that from the analysis of Figure 4.6 and 
Figure 4.7, naphthalene analogues NapL1, NapL2, NapL4 and NapL6 are all 
insensitive to pH changes in the physiological range pH 6.5 to 7.5. Insignificant 
changes in the fluorescence emission and excitation spectra were observed 
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within this region, making them suitable probes to sense the change in metal ion 
concentrations in vivo or in cellulo. Such pH insensitivity over the physiological 
range is a characteristic feature of the Fura-2 family of indicators, including 
Mag-Fura-2, where it is known that at physiological pH the aniline nitrogen and 
carboxylate groups are all deprotonated and available for the binding of divalent 
metal cations.3,7,8   
4.5 Binding studies of carboxylate-based NapL1 and NapL2 
The binding of carboxylate-based APTRA analogues NapL1 and NapL2 to 
Mg2+, Ca2+ and Zn2+ is reported here. It is expected that a [5, 5, 5] set of ring 
chelates will form in each instance on metal binding. Comparisons will be made 
between NapL1 and NapL2 to determine how the position of the aniline nitrogen 
atom on the APTRA binding moiety affects the selectivity and affinity for Mg2+, 
Ca2+ and Zn2+.  
4.5.1 Absorbance binding studies of NapL1 and NapL2 
	
The absorption spectra of NapL1 and NapL2 were recorded in 50 mM 
HEPES, 100 mM KCl at a pH maintained at 7.21. An absorbance maximum of 
354 nm and 326 nm in the ‘metal-free’ state was reported for NapL1 and NapL2 
respectively (Figure 4.8, Table 4.4).  
A 28 nm hypsochromic shift to lower wavelengths was observed following 
binding of Mg2+, Ca2+ and Zn2+ to NapL1 with a maximum of 326 nm in the metal-
bound state and an isosbestic point present at 330 nm. Ligand NapL2, however, 
displayed significant differences to NapL1, with no blue shift observed in the 
absorption spectrum on metal binding. A small increase in the absorbance 
intensity was, however, observed at 326 nm (Figure 4.8, Table 4.3).  
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Figure 4.8 The absorption spectrum of NapL1 and NapL2 in the ‘free’ and ‘metal-bound’ 
state after the addition of 40 mM Mg2+ in aqueous solutions. The same spectral response is 
observed after the addition of Ca2+ and Zn2+ for both NapL1 and NapL2 in 50 mM HEPES, 
100 mM KCl, pH = 7.21, 298 K 
 
Table 4.3 The absorption maximum for the ‘free’ ligand and the ‘metal-bound’ state after 
the addition of 40 mM Mg2+ to NapL1 and NapL2 in 50 mM HEPES, 100 mM KCl, 
pH = 7.21, 298 K. 
Ligand Absorption λmax (nm) 
NapL1 354, 326 
NapL2 326, 326 
 
4.5.2 Excitation and emission binding studies of NapL1  
	
Excitation and emission studies following the addition of Mg2+, Ca2+ and 
Zn2+ to NapL1 and NapL2 were carried out at 298 K in HEPES buffer at a constant 
pH of 7.21. All reported errors for the calculated dissociation constants (Kd) are 
due to an experimental variability.  
In the metal-free state, NapL1 exhibits an excitation maximum at 358 nm. 
On the addition of Mg2+, Ca2+ and Zn2+, a pronounced wavelength shift of 38 nm 
towards the blue was observed (Figure 4.9). The wavelength shift observed on 
metal binding is similar to that observed on protonation of the aniline nitrogen 
atom at a reduced pH (Section 4.4.2). Such behaviour implies that the aniline 
nitrogen atom is taking part in binding to Mg2+, Ca2+ and Zn2+.  
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Ligand NapL1 has the potential to be used as an excitation-based 
ratiometric sensor, with two distinct bands present in the excitation spectra in the 
‘free’ and ‘bound’ states.  
The excitation-based ratiometric behaviour seen here has been reported 
previously in a number of different cation sensors for Mg2+ and Ca2+,1,3,9,10 
including Mag-Fura-2 where a 35 nm shift towards the blue was observed in the 
metal-bound state.3 Ratiometric behaviour for sensors of this type was first 
highlighted by Tsien and co-workers in the development of the parent probe 
Fura-2, for Ca2+ sensing.7  
The wavelength shift observed in the absorbance and excitation spectrum 
for cation sensors of this type can be attributed to the change in character of the 
excited state. In the ‘metal-free’ form the excited state is based on intramolecular 
charge transfer from the lone pair of electrons on the aniline nitrogen atom to the 
aromatic fluorophore. On protonation and metal ion binding, the conjugation 
between the lone pair and the aromatic fluorophore is lost, disrupting the charge 
transfer process in the ‘metal-bound’ species.  
TD-DFT models have been utilised to study the effect of Mg2+ binding on 
the excited state of Mag-Fura-2. It was found that after complexation with Mg2+ 
ions, no charge transfer occurred, with the excited state possessing localised π π* 
character.8 The perturbation of the ICT state on metal binding, therefore, results 
in the hypsochromic shift observed in both the absorbance and excitation 
spectrum.   
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Figure 4.9 (Left) excitation spectrum; (right) fitting of excitation intensity against the added 
concentration of (A) Mg2+, (B) Ca2+ and (C) Zn2+ in a 1:1 binding model. NapL1 
concentration = 5 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K. λem = 530 nm. The 
reported binding constants are an average of two separate metal ion titrations, and are 
given with the experimental error in parenthesis. 
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Dissociation constants have been calculated from excitation spectra, using 
the ratio of the metal-free (350 nm) and metal-bound (320 nm) species in each 
instance. Data was fitted to a 1:1 binding model against the concentration of 
added Mg2+, Ca2+ and Zn2+. A 1:1 ligand:metal stoichiometry for the addition of 
metal ions has been assumed, based on the 1:1 binding present in multiple 
APTRA analogues in the literature.1,3,9,10 Dissociation constants of 4.5 mM, 
39.6 µM and 1.7 µM were obtained for Mg2+, Ca2+ and Zn2+ respectively 
(Figure 4.9). 
The emission spectrum of NapL1 has two maxima at 372 nm and 537 nm, 
observed following excitation at the isosbestic point in the absorbance spectrum 
(λex = 330 nm, Figure 4.10) in both the metal-free and bound states. Upon binding 
of Mg2+ a 5-fold and 2-fold increase in the intensity was seen at 372 nm and 
537 nm respectively. Addition of Ca2+, on the other hand, led to a 5-fold increase 
in the emission intensity at 372 nm, and a smaller decrease in the intensity at 
537 nm (See Appendix, Figure A.1). The ligand NapL1, therefore, also has the 
potential to be used as an emission-based ratiometric indicator, as a different 
‘turn-on’ emission spectral response is seen at both 372 nm and 537 nm.  
Excitation at the absorbance maximum of NapL1 (λex = 354 nm), resulted 
in a 3-fold decrease or ‘turn-off’ in the total emission intensity at 562 nm, and a 
small blue shift of 40 nm (Figure 4.10).  
Comparable dissociation constants for the binding of Mg2+, Ca2+ and Zn2+ 
were determined from fluorescence emission spectral changes, to those 
determined using excitation spectroscopy from Figure 4.9. The dissociation 
constants calculated for the binding of Mg2+ via emission spectroscopy are 
highlighted in Figure 4.10 (λex = 330 nm and λex = 354 nm). Dissociation 
constants fell in the low mM range. Excitation at the isosbestic point of 330 nm, 
allowed the Kd values to be calculated from the ratio of the emission intensity at 
372 nm and 537 nm reducing potential interference from environmental effects. 
The dissociation constants determined for the binding of Ca2+ and Zn2+ via 
changes observed in emission spectroscopy are very similar to those calculated 
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in Figure 4.9, and close to within the experimental error (See Appendix 
Figure A.1 and Figure A.2).  
 
 
 
 
 
 
 
 
 
 
Figure 4.10 (Left) emission spectrum of NapL1; (right) fitting of emission intensity against 
the added concentration with excitation at (A) λex = 330 nm and (B) λex = 354 nm after the 
addition of Mg2+. Ligand concentration = 5 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21.  
4.5.3 Excitation and emission binding studies of NapL2 
	
In contrast to the excitation- and emission-based ratiometric behaviour 
reported for NapL1, the behaviour of NapL2 was non-ratiometric, following 
addition of Mg2+, Ca2+ and Zn2+. No blue shift was observed in the absorbance, 
excitation or emission spectra, on binding of divalent cations. The wavelength 
maximum in the ‘metal-free’ and ‘bound’ states was 318 nm and 372 nm in the 
excitation and emission spectrum respectively (Figure 4.11).  
Unlike NapL1, the excited state of NapL2 is thought to possess localised 
π π* character, in both the ‘metal-free’ and the ‘metal-bound’ states. No significant 
0
5000
10000
15000
20000
460 560 660
Em
iss
io
n	
in
te
ns
ity
Wavelength	(nm)
0
5000
10000
15000
20000
25000
0 0.03 0.06
In
te
ns
ity
	56
2	
nm
	
Concentration	(M)
0
200000
400000
600000
340 440 540 640
Em
iss
io
n	
in
te
ns
ity
	
Wavelength	(nm)	
A)  
B)  Mg2+ 
0
2
4
6
8
0 0.02 0.04 0.06
I	(
37
2)
	/	
I	(
53
7)
Concentration	(M)
Mg2+ 
Kd = 1.6 mM 
Kd = 3.5 mM 
Chapter 4. Ligands containing naphthalene as the fluorophore 
	
118 
	
amounts of intramolecular charge transfer occurs in the ‘metal-free’ state of 
NapL2, because no conjugation of the meta aniline nitrogen lone pair of electrons 
into the naphthalene fluorophore is conceivable. The absence of any charge 
transfer processes in the ‘un-bound’ state of NapL2, means that no wavelength 
shift occurs on the binding of divalent metal ions. 
The ligand NapL2 can be considered as a ‘turn on’ sensor, with a 3.2-, 6- 
and 9-fold increase in the excitation and emission intensity respectively, following 
addition of Mg2+, Ca2+ and Zn2+ (Figure 4.11). The emission and excitation 
profiles after the addition of divalent cations are comparable to those found earlier 
following protonation of the aniline nitrogen, where a 3.5-fold ‘turn-on’ response 
was observed in acidic solution (see Section 4.4.2). This behaviour suggests that 
as with NapL1, the aniline nitrogen takes part in binding to Mg2+, Ca2+ and Zn2+. 
The ‘turn-on’ nature of NapL2 on protonation and metal ion binding, can be 
attributed to the suppression of photo-induced electron transfer (PET) quenching 
of the ligand excited state caused by the aniline nitrogen lone pair of electrons in 
basic and ‘metal-free’ solutions.  
 
 
 
Figure 4.11 The increase in the fluorescence (A) excitation and (B) emission intensity on 
the addition of 35 mM Mg2+. A 3.5- and 9-fold ‘turn-on’ in the excitation and emission 
intensity was observed on the addition of Ca2+ and Zn2+ respectively. Ligand concentration 
= 10 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21. λex = 326 nm, λem = 377 nm. 
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Fluorescence excitation titrations following addition of Mg2+, Ca2+ and Zn2+ 
to NapL2 are shown in Figure 4.12, along with their calculated dissociation 
constants (Kd), determined for a 1:1 ligand to metal binding stoichiometry.  
 
 
 
	
 
 
 
 
 
Figure 4.12 (Left) excitation spectrum; (right) fitting of excitation intensity against the added 
concentration of (A) Mg2+, (B) Ca2+ and (C) Zn2+ in a 1:1 binding model. NapL2 ligand 
concentration = 10 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K, λem = 377 nm. The 
reported dissociation constants are an average of two separate metal ion titrations, and are 
given with the experimental error in parenthesis. 
The dissociation constants for the 1:1 stoichiometry between metal ion and 
indicator were calculated by iteratively fitting the change in the excitation 
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maximum with the concentration of added Mg2+, Ca2+ and Zn2+. Dissociation 
constants of 1.3 mM, 32.7 µM and 3.2 µM were determined respectively. 
 Comparable dissociation constants, within the experimental error, to 
those calculated in Figure 4.12 were found for the binding of Mg2+, Ca2+ and Zn2+ 
to NapL2 via fluorescence emission spectroscopy (See Appendix Figure A.3, 
Figure A.4 and Figure A.5 respectively).    
4.5.4 Summary: Comparison of of the metal ion binding affinities and 
selectivities of NapL1 and NapL2  
	
Changing the position of the nitrogen and oxygen atoms on the APTRA 
binding framework was found not to dramatically affect the pKa of the four 
naphthalene derivatives (Section 4.4). The reported affinity and selectivity for 
Mg2+, Ca2+ and Zn2+ is also comparable, whether the aniline nitrogen atom is para 
or meta to the naphthalene fluorophore. A summary of the excitation and 
emission maxima and the calculated association constants for NapL1 and NapL2 
compared to commercially available Mag-Fura-2 is highlighted in Table 4.4.  
Both NapL1 and NapL2 have dissociation constants in the low mM range 
for the addition of Mg2+. These values align with the concentrations of ‘free’ Mg2+ 
in mammalian cells (0.8-1.5 mM)11 and the affinity of commercially available 
sensors such as Mag-Fura-2, where an association constant of 1.8 mM has been 
determined previously (Table 4.4).3 
In accordance with many APTRA analogues reported in the literature, 
NapL1 and NapL2 have dissociation constants for Ca2+ in the mid µM range. 
Dissociation constants of 39.6 µM and 32.7 µM were calculated for NapL1 and 
NapL2 respectively. In comparison, the aryl-naphthalene derivatives developed 
by London et al. gave a dissociation constant of 17 µM,1 while Mag-Fura-2 gave 
rise to a dissociation constant of 25 µM.3 The Ca2+ / Mg2+ selectivity of NapL1 and 
NapL2 is not a surprise, and is an ever present problem associated with the 
APTRA series of fluorescent indicators. The higher affinity reported for Ca2+ over 
Mg2+ allows sensors NapL1 and NapL2, along with many APTRA analogues 
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before them, to have the potential to also be used as low affinity Ca2+ sensors in 
calcium-rich regions of the body. 
The dissociation constants for Zn2+ binding with NapL1 and NapL2 are in 
the low µM range, and values of 1.7 µM and 3.2 were observed respectively 
(Table 4.4). This is a significantly lower affinity than the values observed for many 
APTRA analogues reported in the literature, where a nM affinity was typically 
observed. A 20 nM dissociation constant for Mag-Fura-2 has been previously 
observed, for example.12 
 
 
 
 
 
Figure 4.13 The structures of NapL1, NapL2 and Mag-Fura-2.3 
Table 4.4 The direct comparison of the excitation maximum, emission maximum and 
dissociation constants for the binding of Mg2+, Ca2+ and Zn2+ to NapL1, NapL2 and 
commercially available Mag-Fura-23 in aqueous solutions.  Mg2+ saturated wavelengths are 
highlighted in red.  
Ligand Excitation 
λmax (nm) 
Emission 
λmax (nm) 
Kd (Mg2+) Kd (Ca2+) Kd (Zn2+) 
NapL1 358, 320 562, 522 4.5(2) mM 39.6(4.9) 
µM 
1.7(1) µM 
NapL2 318, 318 372, 372 1.3(1) mM 32.7(3.7) 
µM 
3.2(2) µM 
Mag-Fura-23 370, 3353 510, 5103 1.9 mM3 25 µM3 20 nm12 
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The position of the aniline nitrogen on the APTRA binding moiety relative 
to the position of the fluorophore does, however, have a notable effect on the 
excitation and emission profiles in the ‘free’ and ‘metal-bound’ states of NapL1 
and NapL2. Ligand NapL1 is a ratiometric sensor in both excitation and emission, 
allowing dissociation constants to be calculated from two independent 
wavelengths. Such ratiometric behaviour has been seen in numerous APTRA 
analogues, and is due to the perturbation of the internal charge transfer from the 
aniline nitrogen to the aromatic fluorophore on metal ion binding.  
The NapL2 ligand, is, however, non-ratiometric. Instead a ‘turn-on’ 
response is observed in both the excitation and emission spectra following 
protonation or binding to Mg2+, Ca2+ and Zn2+.  
4.6 Binding studies of the phosphinate ligands NapL4 and NapL6 
The binding of the phosphinate-based APTRA analogues NapL4 and 
NapL6 to Mg2+, Ca2+ and Zn2+ is reported here. Ligand NapL4 contains the 
APDAP binding moiety previously discussed in Chapter 3 where a single 
phosphinate group is added at the expense of a carboxylate binding group. 
Ligand NapL6, unlike NapL1, NapL2 and NapL4, is tridentate, with one 
carboxylate, one phosphinate and the aniline nitrogen atom available to bind to a 
metal ion at physiological pH. It is expected that NapL6 will form a [6, 5] chelate 
ring arrangement on metal binding.  
Comparisons will be made with the carboxylate-based APTRA analogues 
NapL1 and NapL2 (Section 4.5) to assess the effect of introducing a phosphinate 
group at the expense of a carboxylate group on metal ion binding affinity and 
selectivity for Mg2+, Ca2+ and Zn2+.  
4.6.1 Absorbance binding studies of NapL4 and NapL6 
	
The phosphinate analogue, NapL4, was found to have a maximum 
absorption wavelength of 350 nm in the metal-free state. Unlike the carboxylate-
based ligand NapL1, NapL4 showed no blue shift or isosbestic point on the 
addition of Mg2+. A blue shift was, however, observed in the absorption spectrum 
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on the addition of Ca2+ and Zn2+ with an absorbance maximum at 314 nm in the 
metal-bound state and an isosbestic point at 330 nm (Figure 4.14, Table 4.5).  
 
Figure 4.14 Absorbance spectrum of NapL4 following addition of (A) Mg2+ (8 mM) (B) Ca2+ 
(4 mM) and (C) Zn2+ (20 µM). Ligand concentration = 10 µM in 50 mM HEPES, 100 mM 
KCl, pH = 7.21, 298 K. 
The absorbance spectrum of NapL6, in contrast, showed small changes 
following the addition of 150 mM Mg2+, 2.4 mM Ca2+ and 55.6 µM Zn2+. A 
wavelength maximum of 346 nm was measured in the absorbance spectrum both 
before and after the addition of divalent metal ions (Figure 4.15, Table 4.5). 
 
 
 
 
Figure 4.15 Absorbance spectrum of NapL6 for the addition of (A) Mg2+ (160 mM), (B) Ca2+ 
(2.4 mM) and (C) Zn2+ (56 µM). Ligand concentration = 5 µM in 50 mM HEPES, 100 mM 
KCl, pH = 7.21, 298 K. 
Table 4.5 The absorption maximum for the ‘free’ ligand and the metal-bound state after the 
addition of Mg2+, Ca2+ and Zn2+ to NapL4 and NapL6 in aqueous solutions.  
 
Ligand 
Absorbance λmax (nm) 
‘free’ Mg2+ Ca2+ Zn2+ 
NapL4 350 350 314 314 
NapL6 346 346 346 346 
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4.6.2 Fluorescence binding studies of phosphinate-based NapL4  
	
The binding of the phosphinate-based APTRA analogues NapL4 and 
NapL6 to Mg2+, Ca2+ and Zn2+ was investigated in aqueous solution by 
fluorescence emission and excitation spectroscopy.  
Unlike NapL1, the APDAP phosphinate analogue NapL4 showed no 
significant ratiometric behaviour in its absorption (Figure 4.13) or excitation 
spectra following the addition of Mg2+. A small shift of 10 nm to lower wavelength 
was observed between the ‘metal-free’ and the ‘metal-bound’ states 
(Figure 4.16). 
 
 
 
 
 
Figure 4.16 The excitation spectrum of NapL4 following addition of Mg2+. In 50 mM 
HEPES, 100 mM KCl, pH = 7.21, 298 K. 
A different response was, therefore, observed for the addition of Mg2+ 
compared to the excitation-based pH response of NapL4. At low pH, a 28 nm 
wavelength shift to lower wavelengths was reported (Section 4.4.2, Figure 4.7), 
suggesting that the aniline nitrogen of NapL4 does not take part in binding to Mg2+. 
Indeed, no ratiometric behaviour was observed in the excitation spectrum on 
saturation with Mg2+.  
The small changes observed in excitation intensity on addition of Mg2+ 
meant it was not feasible to generate dissociation constants via this method. 
Instead, dissociation constants were determined from variations in the 
fluorescence emission spectra, following excitation at 350 nm. An emission 
maximum at 545 nm was found in the ‘metal-free’ state, with an 18 nm shift to 
lower wavelengths on saturation with Mg2+ (Figure 4.17).   
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The emission spectrum of NapL4 for addition of Mg2+, and the excitation 
spectrum of NapL4 for addition of Ca2+ and Zn2+, are presented in Figure 4.17. 
Dissociation constants of 0.5 mM, 0.4 mM and 3.3 µM were obtained 
respectively, assuming a 1:1 stoichiometry between Mg2+, Ca2+ and Zn2+ ions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 (Left) emission / excitation spectra; (right) fitting of excitation intensity against 
the added concentration of (A) Mg2+, (B) Ca2+ and (C) Zn2+ to a 1:1 binding model. NapL4 
ligand concentration = 10 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K, 
λex = 350 nm, λem = 530 nm. The reported dissociation constants are an average of two 
separate metal ion titrations, and are given with the experimental error in parenthesis.  
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It is evident from analysis of Kd data shown in Figure 4.17 that the addition 
of Ca2+ and Zn2+ to NapL4 resulted in the same excitation-based ratiometric 
response observed on the protonation of NapL4. A 31 nm hypsochromic shift was 
observed following addition of both Ca2+ and Zn2+. A similar response was 
observed with the binding of Mg2+, Ca2+ and Zn2+ to the carboxylate analogue 
NapL1, suggesting that the aniline nitrogen atom of NapL4 takes part in binding 
to both Ca2+ and Zn2+. On binding, the intramolecular charge transfer process 
from the aniline nitrogen atom to the naphthalene fluorophore is disrupted, with 
the excited state possessing localised π π* character in the ‘bound’ state.8 
The emission spectral response of NapL4 following addition of Ca2+ and 
Zn2+ was studied, with excitation at 330 nm and 350 nm. Excitation at the 
isosbestic point in the absorbance spectra (λex = 330 nm) resulted in two emission 
maxima at 372 nm and 544 nm (Figure 4.18), as observed for NapL1. Upon the 
addition of Ca2+, inconsistent changes in the emission intensity at both 372 nm 
and 544 nm meant that a dissociation constant could not be calculated. Ligand 
NapL4, however, did possess an emission-based ratiometric behaviour for the 
addition of Zn2+, producing a comparable dissociation constant within the 
experimental error from that measured from excitation spectroscopy (See 
Appendix, Figure A.6).  
 
Figure 4.18 The emission spectrum of NapL4, in its ‘metal-unbound’ state. Ligand 
concentration = 10 µM in 50 mM HEPES, 100 mM KCl, pH = 7.21, 298 K. 
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Excitation at the absorbance maximum of NapL4 (λem = 350 nm), resulted 
in a 3-fold reduction of the total emission intensity at 544 nm (Figure 4.19). 
Comparable dissociation constants were calculated from the decrease in 
fluorescence emission at 544 nm that lie within the error of the Kd measured for 
the binding of Ca2+ by excitation spectroscopy.  
 
 
 
 
 
Figure 4.19 (Left) emission spectrum of NapL4; (right) fitting of emission intensity against 
the added concentration with excitation at λex = 350 nm following addition of Ca2+. Ligand 
concentration = 10 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K. 
4.6.3 Summary: Comparison of of the metal ion binding affinities and 
selectivities of NapL1 and NapL4 
	
Ligands NapL1 and NapL4 have significant differences in their spectral 
response, affinity and selectivity to Mg2+, Ca2+ and Zn2+.  
The carboxylate-based ligand, NapL1, can be incorporated into the Fura-2 
family of indicators. Metal ion sensors of this type, including Mag-Fura-2, are 
known to undergo intramolecular charge transfer processes, typically, showing 
ratiometric behaviour on protonation and on addition of Mg2+, Ca2+ and 
Zn2+.1,3,8,8,11 The protonation or metal ion binding of the aniline nitrogen, disrupts 
this charge transfer donation of the nitrogen lone pair, resulting in pronounced 
wavelength shifts both the absorbance and excitation spectra.8  
Ligand NapL4, however, showed no significant intensity change or 
hypsochromic shift on the binding of Mg2+, indicating that the aniline nitrogen 
does not take part in binding to Mg2+, with the intramolecular charge transfer 
process from the aniline nitrogen atom to the fluorophore still present in the 
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‘metal-bound’ state. Near identical behaviour was observed for the binding of 
Mg2+ to APDAP, (Section 3.4, Figure 3.4), where it was also thought that the 
aniline nitrogen atom, likewise, takes no part in binding to Mg2+. It is therefore, 
both interesting and surprising to note that NapL4 has a lower dissociation 
constant and, therefore, a higher affinity for Mg2+, compared to that reported for 
NapL1 and NapL2 (4.5 mM vs. 0.5 mM, Table 4.6).  
In contrast, the binding of NapL4 with Ca2+ and Zn2+ resulted in emission 
and excitation-based ratiometric behaviour, comparable to that found with NapL1 
and the pH response of NapL4. Such behaviour demonstrates that the aniline 
nitrogen of NapL4 takes part in binding to Ca2+ and Zn2+, eliminating the charge 
transfer process to the naphthalene fluorophore. Comparable affinity for Zn2+, 
Kd = 1.7 µM, 3.2 µM and 3.3 µM was evident for NapL1, NapL2 and NapL4 
respectively. The presence of a phosphinate group, instead of a carboxylate 
binding group, therefore, has no dramatic effect on Zn2+ binding affinity, with each 
dissociation constant remaining in the low µM range.   
The phosphinate-based APDAP chelate shows much higher Mg2+ / Ca2+ 
binding selectivity than the carboxylate analogue APTRA, with a 110-fold weaker 
binding affinity towards Ca2+. Ligand NapL4, predictably, follows the same trend, 
with a 10-fold reduced affinity for Ca2+, and a Kd value in the low mM range 
compared to the µM range observed for NapL1 and NapL2. Dissociation 
constants of 0.4 mM and 39.6 µM were calculated for NapL4 and NapL1 
respectively (Table 4.5).  
In Section 3.5, a detailed DFT investigation was carried out in an attempt 
to gain an improved understanding towards the increased Mg2+ selectivity 
observed for the APDAP chelate. It was found from a DFT computational study 
that longer P–O, and P–C bonds were present in the phosphinate chelate 
resulting in less acute bite angles around Mg2+ in [Mg(APDAP)(H2O)]–. 
Significantly shorter M–O and M–N bond lengths were measured in the Mg2+ 
complex, with the phosphinate chelate possessing features more characteristic 
of a 6-membered ring chelate than its carboxylate analogue. An enhanced 
selectivity for Mg2+ was also observed when the APDAP chelate was incorporated 
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into a naphthalene fluorophore. Although the P–O, P–C, M–N and M–O bond 
lengths were not calculated in NapL4, it is expected that they are longer than the 
C–O, C–C bond lengths in NapL1, contributing to the 10-fold reduced affinity 
reported for Ca2+. It is thought, therefore, that the increased binding selectivity 
observed for NapL4 with Mg2+, is due to binding of the larger Ca2+ being more 
thermodynamically unfavourable in the less acute APDAP ring chelate.  
The excitation and emission maxima of NapL1, NapL2 and NapL4, and the 
measured dissociation constants for the addition of Mg2+, Ca2+ and Zn2+ are 
highlighted in Table 4.6, with a comparison to Mag-Fura-2.3 
 
 
 
 
Figure 4.20 The structures of NapL1, NapL2, NapL4 and Mag-Fura-2.3 
Table 4.6 The direct comparison of the excitation maximum, emission maximum and 
association constants following addition of Mg2+, Ca2+ and Zn2+ to NapL1, NapL2, NapL4 
and commercially available Mag-Fura-25 in aqueous solutions.  Mg2+ saturated wavelengths 
are highlighted in red. The reported dissociation constants are an average of two separate 
metal ion titrations, given with an associated experimental error in parenthesis.  
Ligand Excitation 
λmax (nm) 
Emission 
λmax (nm) 
Kd (Mg2+) Kd (Ca2+) Kd (Zn2+) 
NapL1 358, 320 562, 522 4.5(2) mM 39.6(4.9) 
µM 
1.7(1) µM 
NapL2 318, 318 372, 372 1.3(1) mM 32.7(3.7) 
µM 
3.2(2) µM 
NapL4 350, 344 550, 547 0.5(2) mM 0.4(1) mM 3.3(3) µM 
Mag-Fura-23 370, 3353 510, 5103 1.9 mM3 25 µM3 20 nm12 
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The low mM affinity reported for the binding of Ca2+ is significant, 
eliminating the major drawback of the APTRA indicators, in that they are 
significantly more selective for Ca2+ over Mg2+. The reduction in affinity observed 
for Ca2+ with NapL4, and the APDAP binding moiety in particular, could allow 
‘free’ Mg2+ concentrations to be investigated in Ca2+ rich regions of the body 
including the end(sarco)plasmic reticulum.  
4.6.3 Fluorescence binding studies of the phosphinate-based ligand, NapL6 
	
The problems associated with the synthesis of the ethyl ester of L5 outlined 
in Chapter 2, meant that the binding affinity and selectivity for the tridentate 
ligand L6 was studied instead, as the naphthalene-1-alkynlaryl derivative, NapL6.  
Following addition of Mg2+ (150 mM), Ca2+ (2.4 mM) or Zn2+ (55.6 µM) only 
small changes were observed in the absorbance (Figure 4.15), emission and 
excitation spectra of NapL6 with no shift in the observed wavelength on metal 
binding. Such behaviour suggests that there is only weak binding between NapL6 
and Mg2+, Ca2+ and Zn2+. The addition of of Mg2+, for example, resulted in a 1.6-
fold reduction in emission intensity at 599 nm (Figure 4.21). A dissociation 
constant of 16.5 mM was calculated for the binding of Mg2+, but had a 40 % error 
associated with the fitting due to the small emission changes observed after each 
measurement.   
 
 
 
 
 
Figure 4.21 (Left) emission spectrum of NapL4; (right) fitting of the emission intensity 
against the added concentration of Mg2+ to a 1:1 binding model. NapL6 concentration = 
5 μM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K, λex = 347 nm.  
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The addition of Ca2+ (2.4 mM) and Zn2+ (55.6 µM) also resulted in 
negligible change in absorbance, emission and excitation spectra (Figure 4.22). 
Due to the small changes observed on the addition of Ca2+ and Zn2+, no accurate 
fluorescence titrations were undertaken with these metal ions.  
NapL6 is a tridentate ligand, compared to the five potential donor groups 
in pentadentate NapL1, NapL2 and NapL4. In coordination chemistry, ligands with 
a higher denticity are favoured for strong binding to larger metal ions. Ca2+ ions 
for example, typically favour the formation of complexes with larger coordination 
numbers than Mg2+ and Zn2+ due to their larger ionic radius. The octadentate 
ligand BAPTA, developed by Tsien, is a perfect example of this theory, forming 
8-coordinate complexes with Ca2+.13  
 
 
 
 
 
 
 
 
 
Figure 4.22 (Left) emission spectrum (λex = 347 nm); (right) excitation (λem = 501 nm) 
spectrum following addition of (A) Ca2+ (2.4 mM) and (B) Zn2+ (55.6 µM) in aqueous 
solutions. Ligand concentration = 5 μM, in 50 mM HEPES, 100 mM KCl, pH 7.21. 
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The low denticity of NapL6, accounts for the weakness of its binding to 
Mg2+, Ca2+ and Zn2+. The addition of further carboxylate groups into the structure 
to improve the binding affinity for divalent metal ions was found to be 
experimentally difficult, and wasn’t achieved under the conditions attempted in 
Chapter 2. 
4.7 Applications of NapL4: Measuring Mg2+ concentrations in serum  
 It is thought that ‘free’ Mg2+ concentrations are maintained within the 
narrow range of 0.7-1.1 mM in the blood plasma, comparable to the concentration 
of ‘free’ Mg2+ within the majority of mammalian cells.14 Maintaining a constant 
level of ‘free’ or ionised Mg2+ in serum is vital for human health, with Mg2+ 
imbalances resulting in the onset of hypermagnesemia and hypomagnesaemia. 
These electrolytic disturbances in the blood have been linked to a number of 
diseases, such as hypertension,15 Alzheimer’s, Parkinson’s disease, diabetes 
and chronic kidney disease.16  
Concentrations of ‘free’ Mg2+ in human serum are often not determined in 
clinical medicine due to the lack of selective techniques to detect ‘free’ Mg2+ ions. 
Commercially available Mag-Fura-2 has been used to determine the 
concentration of ‘free’ Mg2+ in cells where the ‘free’ Ca2+ concentration is 
100 nm.17 The concentration of ‘free’ Ca2+ in serum is, however, significantly 
higher with concentrations of 1.1 mM commonly observed in healthy humans.18 
APTRA indicators are, therefore, unsuitable for this role due to their µM binding 
affinity to Ca2+. The development of a technique to measure the concentration of 
‘free’ Mg2+ levels in the blood is of a critical importance in order to diagnose and 
to prevent the onset of a number of these diseases.   
 There is a real lack of Mg2+ fluorescent probes to detect ‘free’ Mg2+ 
concentrations in human serum. Ion sensitive electrodes have been used to 
determine the concentration of free Mg2+ within the serum.19-20 They have 
significant disadvantages, however, in that they are commonly not selective 
towards the detection of Mg2+, but are also able to monitor ‘free’ Ca2+ and Na+ 
ions in solution.19 More recently, DNAzyme-based electrochemical biosensors 
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have also been used to investigate the concentration of Mg2+ in serum, displaying 
a high selectivity for Mg2+ over Ca2+ and Zn2+.21  
Ligand NapL4 possesses many characteristics that make it suitable to 
detect ‘free’ Mg2+ in human serum. It has no pH interference in the physiological 
range and a low mM binding affinity for Ca2+ (Kd = 0.4 mM), compared to the µM 
affinity displayed by the APTRA fluorescence sensors. Excitation of NapL4 at 
350 nm in newborn-calf serum (NCS) resulted in only background fluorescence 
from the proteins in serum being observed. (Figure 4.23). The binding studies of 
NapL4 with Mg2+ were instead carried out in a buffered ‘serum mimic’ containing 
50 mM HEPES and concentrations of Na+, K+, Ca2+ and Mg2+ in accordance with 
the mean values found in human serum shown in Table 4.8.  
 
Figure 4.23 The normalised emission of NapL4 in 50 mM HEPES, 100 mM KCl, pH 7.21, 
298 K shown in red, and NapL4 in newborn calf serum (NCS) at 298 K shown in blue. 
Table 4.8 Representative concentrations of selected cations in serum for healthy patients.18 
Ion Mean concentration 
in serum (mM) 
H+ 5 x10-5 
Li+ < 0.01 
Na+ 140 
K+ 4 
Mg2+ 0.6 
Ca2+ 1.1 
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Absorption and emission studies following the addition of Mg2+ to NapL4 
were carried out in the ‘serum mimic’. Studies both with and without 0.6 mM Mg2+ 
were acquired to determine how the affinity and the measured dissociation 
constants were affected.  
 It is apparent from the analysis of the absorbance spectra in Figure 4.24 
that partial saturation of NapL4 was observed in the ‘serum mimic’ with a 
hypsochromic shift displayed and an isosbestic point at 330 nm. Such a 
wavelength shift is characteristic of Ca2+ binding and has been observed 
previously for NapL4 in Section 4.6.2. The 1.1 mM concentrations of Ca2+ 
present in the buffered solution did not completely saturate NapL4. On the 
addition of a further 1.0 mM Mg2+, saturation was achieved, with a further 
reduction in the absorbance at 324 nm observed.  
 
 
 
 
 
 
 
Figure 4.24 Absorbance spectra of NapL4 in the ‘unbound’ state shown in red. Partial 
saturation with 1.1 mM Ca2+ and 1.1 mM Ca2+, 0.6 mM Mg2+ from the ‘serum mimic’. 
Complete saturation was observed following addition of a further 1 mM Mg2+, 298 K.  
The emission spectra of NapL4 in the buffered ‘serum mimic’, both with 
and without 0.6 mM Mg2+, are shown in Figure 4.25. Ligand NapL4, displays a 
wavelength maximum at 545 nm following excitation at the absorbance maximum 
in the ‘unbound state’ of NapL4 (λex = 350 nm). Upon the binding of Mg2+, a non-
ratiometric behaviour was reported, with a 1.6- and 1.5-fold decrease in 
fluorescence emission intensity at 545 nm in Figure 4.25 A) and B) respectively.  
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Figure 4.25 (Left) emission spectrum; (right) fitting of the emission intensity against the 
added concentration of Mg2+. Titration in ‘serum mimic’ (A) with and (B) without the 
presence of 0.6 mM MgCl2 typically found in human serum. NapL4 ligand concentration = 
10 µM, in 50 mM HEPES, 140 mM NaCl, 4 mM KCl, and 1.1 mM CaCl2, pH 7.21, 
λex = 350 nm, 298 K.  
Dissociation constants of 0.04 mM and 0.11 mM were calculated 
respectively for the 1:1 binding between Mg2+ and NapL4 in the ‘serum mimic’ 
with and without the presence of 0.6 mM Mg2+. As expected, the dissociation 
constants measured were lower than the 0.5 mM reported for the binding of Mg2+ 
in 50 mM HEPES at 298 K, as NapL4 is, initially, in its unbound state. The addition 
of 0.6 mM Mg2+ to the ‘serum mimic’ reduced the observed Kd value further, as a 
larger fraction of NapL4 was in its metal-bound state before commencing the Mg2+ 
titration.  
It is unlikely, however, that NapL4 will be suitable for the detection of Mg2+ 
in human serum. From the analysis of Figure 4.25 it is evident that NapL4 
displays an approximately 10-fold stronger affinity towards Mg2+ than the 
concentration of ‘free’ Mg2+ present in human serum (0.7-1.1 mM).14  
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4.8 Conclusions for the Naphthalene series  
Four naphthalene-1-alkynylaryl ligands, denoted NapL1, NapL2, NapL4 
and NapL6, were synthesised from their respective ligating units, L1, L2, L4 and 
L6 via multiple carbon-carbon cross-coupling reactions (Figure 4.26). 
Photophysical studies revealed that the position of the aniline nitrogen atom 
(either para or meta to the fluorophore) had a significant effect on the absorbance, 
emission and excitation profiles. As expected NapL1, NapL4 and NapL6 have 
pronounced Stokes’ shifts of 166-204 nm, which are larger than those observed 
for fluorescent APTRA indicators in the literature such as Mag-Fura-2.3  
From fluorescent emission and excitation studies, ligands NapL1, NapL2, 
NapL4 and NapL6 were found to be insensitive to pH in the physiological range 
(6.5-7.5). All pKa values calculated are in the range 5.2-6.2, comparable to the 
pKa of commercially available Mag-Fura-2.3 
 
Figure 4.26 Structures of naphthalene based ligands NapL1, NapL2, NapL4 and NapL6. 
Fluorescence emission and excitation binding studies were conducted 
with Mg2+, Ca2+ and Zn2+ in 50 mM HEPES and 100 mM KCl at a constant pH of 
7.21.  In the case of NapL1 and NapL2, it was found that changing the position of 
the aniline nitrogen atom on the aromatic system produced comparable affinities 
for divalent metal cations. A typical Mg2+ / Ca2+ selectivity for NapL1 and NapL2 
was observed supporting literature precedent in the APTRA series. The position 
of the aniline nitrogen atom did, however, determine whether a ratiometric or non-
ratiometric response towards the binding of Mg2+, Ca2+ and Zn2+ was observed.  
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The introduction of a phosphinate group at the expense of a carboxylate 
binding group was found to increase the affinity for Mg2+ and reduce the affinity 
for Ca2+, compared to NapL1 and NapL2. Phosphinate-based NapL4 was found 
to be significantly more selective for the binding of Mg2+, displaying a 10–fold 
weaker affinity for Ca2+ than that reported for carboxylate-based NapL1 and 
NapL2. DFT studies in Chapter 3 on the APDAP binding group showed a less 
acute bite angle around the Mg2+, with smaller M–N and M–O reported. Such 
behaviour suggests that it is more thermodynamically favourable for the binding 
of the smaller Mg2+ ion over the larger Ca2+ ion in the APDAP chelate. 
The reduced affinity found for the binding of Ca2+ to NapL4 (Kd = 0.4 mM) 
allowed an investigation into the binding of ‘free’ Mg2+ in serum to be explored. 
Analysis was carried out in a buffered ‘serum mimic’ containing representative 
concentrations of Na+, K+, Ca2+ and Mg2+. Kd values of 0.04 mM and 0.11 mM, in 
the presence and absence respectively of 0.6 mM Mg2+, were reported in the 
competitive media.  
Tridentate ligand NapL6 was found to have a low affinity for Mg2+ 
(Kd = 16.5 mM), with a significant 40 % error in the fitting because of the small 
fluorescence changes observed after each addition of Mg2+. No fluorescence 
emission or excitation studies for the addition of Ca2+ and Zn2+ were carried out 
with NapL6 because of the small changes observed even after the addition of 
2.4 mM Ca2+ and 55.6 µM Zn2+. The tridentate binding moiety displayed by L6 is, 
therefore, unsuitable to detect ‘free’ Mg2+, Ca2+, Zn2+. It has been demonstrated 
from NapL1, NapL4 and NapL6 that a larger denticity (pentadentate) on metal ion 
binding is preferred.  
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Table 4.9 A summary of the calculated pKa and dissociation constants of NapL1, NapL2, NapL4 and NapL6 via fluorescence excitation spectroscopy, 
All pKa values are given along with an error associated with the fitting. The reported binding constants following addition of Mg2+, Ca2+ and Zn2+ to 
NapL1, NapL2 and NapL4 are an average of 2-3 separate metal ion binding titrations, and are given with the experimental error in parenthesis.  Mg2+ 
saturated wavelengths are highlighted in red.
 Absorption 
λmax (nm) 
ε / 103 
(M-1cm-1) 
Excitation 
λmax (nm) 
Emission λmax 
(nm) 
λex = 354 nm 
pKa Log K 
(Mg2+) 
Kd 
(Mg2+) 
Log K 
(Ca2+) 
Kd 
(Ca2+) 
Log K 
(Zn2+) 
Kd 
(Zn2+) 
NapL1 354 
326 
14.1(3) 358 
320 
562 
522 
6.2(04) 2.4(2) 4.5(2) 
mM 
4.4(05) 39.6(4.9)  
μM 
5.8(02) 1.7(1) μM 
NapL2 326 
326 
13.8(6) 318 
318 
372 
372 
5.7(05) 2.9(1) 1.3(8) 
mM 
4.5(05) 32.7(3.7) 
μM 
5.5(02) 3.2(2) μM 
NapL4 350 
350 
10.7(2) 350 
336 
550 
547 
5.2(04) 3.3(2) 0.5(2) 
mM 
3.3(03) 0.4(1) mM 5.5(1) 3.3(3) μM 
NapL6 347 
347 
12.2(4) 341 
341 
507 
507 
5.1(02) 1.8 16.5 mM - - - - 
Mag-
Fura-
23 
369 - 370 511 - - 1.9  mM - 25 μM - 20 nm12 
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5. The APTRA binding group in metal-based systems  
5. Part 1: Lanthanide(III)-based systems 
5.1 Introduction 
Lanthanide complexes offer a number of fundamental advantages over 
other luminescent systems such as the naphthalene-based systems discussed 
in Chapter 4. They have sharp emission bands that are characteristic of each 
lanthanide, and their emission spectra are to a first approximation independent 
of the coordination environment. They possess large pseudo-Stokes’ shifts 
between the absorbance and emission of light. The Laporte and spin-forbidden 
nature of the f-f transitions of many of the lanthanide(III) ions result in a long 
lifetime of the excited state (µs – ms), allowing time-gated experiments to be 
carried out in biological media. The application of a short delay between 
excitation and observation of lanthanide emission eliminates all background 
(or auto) fluorescence, allowing the emission of the lanthanide complex to be 
observed selectively.1,2 
One significant drawback of lanthanide complexes, however, is their 
inability to be excited directly, due to their low molar extinction coefficients 
(typically < 3 mol-1 dm3 cm-1).3 To overcome this issue, an aromatic chromophore 
or ‘antenna’ is commonly used to ‘sensitise’ the lanthanide emission, by 
absorbing light and transferring it to the excited state of the lanthanide ion. This 
is commonly called the ‘antenna effect’, and is depicted by a Jablonski diagram 
(Figure 5.1).  
The choice of chromophore is an important factor to consider when 
designing highly emissive lanthanide complexes for biological applications. The 
energy gap between the T1 excited state of the chromophore and the Ln3+ excited 
states (Eu3+ 5D0 = 17,200 cm-1, Tb3+ 5D4 = 20,400 cm-1)1 must be sufficiently large 
for energy transfer to occur. Back energy transfer may occur at room temperature 
if this energy gap is less than 1800 cm-1, resulting in complexes with reduced 
lifetimes and quantum yields under ambient conditions.4 
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Figure 5.1 Jablonski diagram not to scale, showing the typical pathway for sensitised 
emission of Eu3+ and Tb3+ complexes via the antenna effect. Where F = sensitiser 
fluorescence, P = sensitiser phosphorescence, ISC = inter system crossing and 
ET = energy transfer. 
Lanthanide ions are hard metal ions, and are predominantly encapsulated 
within thermodynamically and kinetically stable 9-N3 and 12-N4 macrocycle 
ligands, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA). A coordination number of 8 or 9 is preferred to oxygen and nitrogen 
donors, forming complexes of high stability and preventing the premature release 
of the toxic lanthanide ion.  
 A vast array of lanthanide complexes have been used to study the affinity 
and selectivity of different cations (K+, Mg2+, Ca2+, Zn2+) and anions (HS-). In each 
example, the chromophore commonly also acts as the selective metal ion binding 
domain. Upon binding of the ion in question, a luminescence change occurs 
(either ‘turn on’ or ‘turn off’) which can then be plotted against the concentration 
of the guest added. Examples of a range of lanthanide-based cation sensors from 
the literature are shown in Figure 5.2.  
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Figure 5.2 Lanthanide-based metal ion sensors (A) [Ln.1] for Zn2+ (µM affinity) in 
extracellular fluid,5 (B) [Ln.2] APTRA-based sensor for Mg2+ (mM affinity), Ca2+ (µM 
affinity) and Zn2+ (µM) 6, (C) [Ln.3] for Zn2+,7 and (D) [Ln.4] for K+ ions (µM).8 Binding 
groups are highlighted in blue. 
In 2000 Parker and co-workers developed a number of Tb3+ based 
lanthanide probes for divalent cations.  These include [Ln.1] which was found to 
have a relatively high affinity for Zn2+, with a binding constant of 0.6 µM in a 
simulated extracellular background.5 The isomer, [Ln.2], is an APTRA-based 
probe, with low mM affinity for Mg2+ and µM affinity for Ca2+ and Zn2+ ions.6 
Later, Pope et al. reported a highly emissive europium-based probe, 
[Ln.3], for the detection of Zn2+ in competitive ionic media containing biological 
concentrations of Mg2+, Ca2+, Na+ and K+.7 Upon the addition of one equivalent 
of Zn2+ an increase in the number of inner sphere water molecules was observed, 
from 0 to 2. Such behaviour indicates that the pyridine donor in the 
tris(2-pyridylmethyl)amine (TPA) binding moiety is no longer bound to the 
europium centre. The change in coordination environment of Eu3+ on Zn2+ binding 
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changes the lifetime of the complex, as the coordination environment around the 
europium centre is altered. The sensor can, therefore, be used to study the 
binding of Zn2+ via both intensity and lifetime studies.7 
In the final example, in 2016, Sørensen and co-workers reported an 
18-crown-6 based sensor with a triazole link between the lanthanide complex and 
the chromophore for the sensing of K+ ([Ln.4]).8 No response was observed 
towards K+ in water with either the Eu3+ or Tb3+ complex, but a log K of 5.3(02) 
was observed for the Eu3+ complex in methanol, consistent with the affinity of 
18-benzocrown-6.8 
Taking this background literature into account, the aim of the work 
described in this chapter was to synthesise a range of lanthanide complexes in 
order to study the binding of Mg2+, Ca2+ and Zn2+ (Figure 5.3). APTRA based pro-
ligands L1 and L2 (synthesised previously in Chapter 2) were the ligands of 
choice and were incorporated into both pyridylalkynylaryl and pyridylaryl 
chromophores. Each complex synthesised is an analogue of a DOTA ligand 
based on a 12-N4 macrocycle, containing one chromophore to sensitise the 
lanthanide emission, and three pendent carboxylate groups to ensure that stable 
8- to 9-coordinate complexes are formed. The chromophore employed also acts 
as the binding moiety for divalent cations. A luminescence intensity change 
(either ‘turn on’ or ‘turn off’) with [Ln.L1], [Ln.L2] and [Ln.bL2] is expected, 
following the binding of Mg2+, Ca2+ and Zn2+.  
Direct comparisons are made between [Ln.L1], [Ln.L2] and [Ln.bL2], to 
determine whether the position of the nitrogen and oxygen atoms on the aromatic 
chromophore affects the affinity and selectivity towards Mg2+ and which 
chromophore – either a pyridylalkynylaryl or a pyridylaryl – is favoured for high 
Mg2+ affinity and selectivity. Target lanthanide complexes are highlighted in 
Figure 5.3.  
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Figure 5.3 Target lanthanide complexes [Ln.L1], [Ln.L2] and [Ln.bL2]. Expected binding 
groups to divalent metal ions are highlighted in blue. 
5.2 Synthesis and characterisation  
 The ethyl- and tert-butyl esters of 1,4,7,10-tetraazacyclododecane-
1,4,7-triacetic acid (DO3A), were prepared by literature procedures, forming (39)9 
and (40)10 in moderate yields after purification (Scheme 5.1). The triester (39) 
was used for pyridylalkynylaryl-based chromophores and was hydrolysed under 
basic conditions to avoid competitive acid-promoted hydration of the alkyne. The 
tert-butyl ester (40), however, was used with the pyridylaryl chromophore, where 
no such problems can arise under acidic hydrolysis conditions.  
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Scheme 5.1 Synthesis of the ethyl- and tert-butyl esters of DO3A.9,10 
The pyridine fragment of the chromophore 4-bromo-2-
(hydroxymethyl)pyridine (42) was synthesised from commercially available 
4-bromo-2-methylpyridine, using a procedure adapted from Canty and co-
workers (Scheme 5.2).11 Functionalising the 4-position of the pyridine with a 
bromine atom allows the binding moiety to be introduced to the chromophore, via 
palladium-catalysed cross-coupling reactions. The first step in the synthesis of 
(42) involved the formation of the pyridine N-oxide (41) from 4-bromo-2-
methylpyridine and m-CPBA. Moderate yields of the N-oxide were achieved, after 
purification by alumina column chromatography.   
 
Scheme 5.2 The synthesis of 4-bromo-2-(hydroxymethyl)pyridine, (42).11 
On treatment of the N-oxide, (41), with trifluoroacetic anhydride in 
chloroform, a trifluoroacetate ester intermediate is formed via a [3, 3] sigmatopic 
rearrangement reaction.12 Ester hydrolysis to the desired alcohol was undertaken 
in a biphasic mixture with sodium hydroxide (2 M) in dichloromethane, forming 
(42) in good yield after purification by column chromatography.  
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5.2.1 Synthesis of [Ln.L1] and [Ln.L2] 
	
 The complexes [Ln.L1] and [Ln.L2] were synthesised using identical 
procedures in a multi-step reaction sequence from their TIPS protected alkyne. 
Compounds (25) and (26) have previously been shown to form in high yields via 
Sonogashira cross-coupling reactions of TIPS-acetylene with the ethyl esters of 
L1 and L2 (Scheme 4.1). As reported in Chapter 4, the most effective 
Sonogashira cross-coupling reactions with aryl bromides were achieved in a one 
pot reaction involving de-protection of the silyl alkyne and cross-coupling of the 
aryl bromide. It was found that using Pd(dppf)Cl2 and copper iodide as the 
catalysts, the compounds (43) and (47) were obtained in moderate yields 
(Scheme 5.3). Purification was achieved, in each instance, via silica gel column 
chromatography.  
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Scheme 5.3 The synthesis of [Ln.L1]. An identical procedure was used for the synthesis of 
[Ln.L2]. The numbering of analogous intermediates for the synthesis of [Ln.L2] is given in 
red. 
Before alkylating onto macrocycles can be accomplished, the 
chromophore is commonly converted into its mesylate, acting as the leaving 
group in nucleophilic substitution reactions. Mesylate (44), however, was found 
to be rather unstable, and no alkylation was observed when the reaction was 
attempted with both potassium carbonate and caesium carbonate in anhydrous 
acetonitrile.  
An alternative approach was, therefore, used where the alcohol 
functionality in (43) and (47) was converted to a bromide by reacting with 
phosphorus tribromide (PBr3) in dichloromethane at room temperature. In most 
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instances the bromides (45) and (48) were not isolated but used immediately to 
alkylate (39) or (40) directly in 1:1 stoichiometry. 
Alkylation of the macrocycle (39) with (45) or (48) was achieved in 
anhydrous acetonitrile at 60 oC with caesium carbonate as the base. Purification 
by column chromatography on silica formed (46) and (49), before universal ester 
hydrolysis was undertaken under basic conditions at room temperature. After 
hydrolysis, lanthanide complexation was carried out by treatment with their 
respective chloride salts (LnCl3.6 H2O), in water at pH 5.5 and heating at 60 oC. 
Reaction progress was monitored by ESI-MS, showing the characteristic isotope 
patterns of the lanthanide in question. The pH of the solution was then raised to 
pH 8-10, allowing any unreacted Ln3+ to precipitate out as Ln(OH)3, which was 
then removed via syringe filtration.  
Purification of [Ln.L1] and [Ln.L2] was performed using semi-preparative 
reverse phase HPLC with an acetonitrile and ammonium carbonate buffered 
system. Complex purity was assessed by ESI-MS, and by HPLC analysis.  
5.2.2 Synthesis of [Ln.bL2]  
	
 The bi-aryl complex [Ln.bL2] was synthesised in a multi-step reaction 
sequence from the tert-butyl ester of L2, (7). The synthesis of the boronate ester 
(50) was achieved via the Miyaura borylation reaction, a versatile method for the 
coupling of aryl halides and triflates with diboronate esters such as 
bis(pinacolato)diboron (B2pin2).13-15 The Miyaura borylation reaction was carried 
out with (7) in a microwave reactor using a procedure adapted from Dehaen and 
co-workers.13 The boronate (50) was formed quickly within 2 h and is isolated in 
moderate yield, after purification by silica gel column chromatography. With the 
boronate in place, the next step was a palladium-catalysed Suzuki cross-coupling 
reaction of (50) and 4-bromo-2-(hydroxymethyl)pyridine,  (26). The alcohol (51) 
was formed in moderate yield, in a mixture of dimethoxyethane (DME) and water 
at 85 oC (Scheme 5.4).  
Chapter 5. The APTRA binding group in metal-based systems  
	
150 
	
 
Scheme 5.4 The synthesis of [Ln.bL2]. 
Treatment of the alcohol (51) with phosphorus tribromide (PBr3) in 
dichloromethane at room temperature formed the benzylic bromide (52). The 
procedure is identical to that utilised in the synthesis of (45) and (48). The 
benzylic bromides were used directly, without being purified or fully 
characterised. Alkylation of DO3A-tert-butyl ester (40) with (52) was followed by 
universal tert-butyl ester hydrolysis under acidic conditions, using a 1:1 ratio of 
trifluoroacetic acid (TFA) and dichloromethane. Lanthanide complexation to form 
[Ln.bL2] was carried out using the same conditions as those used for the 
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synthesis of [Ln.L1] and [Ln.L2] (Scheme 5.3). Purification of [Ln.bL2] was 
achieved by semi-preparative reverse phase HPLC, with the purity of [Ln.bL2] 
determined by analytical HPLC and ESI-MS.   
5.3 Photophysical properties of [Ln.L1], [Ln.L2] and [Ln.bL2] 
5.3.1 The pyridylalkynylaryl chromophore, [Ln.L1] and [Ln.L2] 
	
The absorbance spectrum of [Eu.L1] is presented in Figure 5.4, with three 
absorbance maxima at 270 nm, 318 nm and 380 nm. The transitions at 270 nm 
and 318 nm are characteristic of a localised π π* excited state. The broad 
structureless transition at 380 nm, however, is assigned to an ICT transition 
associated with electron donation from the para aniline nitrogen atom relative to 
the aromatic chromophore. 
 
 
 
 
 
 
Figure 5.4 Absorbance spectrum of [Eu.L2]. Complex concentration = 5 µM in water, 
298 K. 
Excitation at 380 nm gave rise to very weak Eu3+ emission at room 
temperature in both acidic and basic solutions, eliminating the possibility of 
quenching arising from photo-induced electron transfer (PET). At 77 K, however, 
highly structured and characteristic Eu3+ emission was observed with 
characteristic emission bands present, associated with the ∆J = 0 to ∆J = 4 
transitions (Figure 5.5). Such behaviour suggests that at room temperature the 
ICT excited state is too low in energy for an efficient energy transfer to the 5D0 
excited state of Eu3+. Charge transfer (CT) transitions are thermally activated, 
with the loss of energy due to back energy transfer from the 5D0 excited state 
suppressed at low temperatures.16,17 Lowering the temperature reduces the rate 
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of the back energy transfer reaction, allowing efficient sensitisation of Eu3+ to 
occur at 77 K. 
The localised π π* transition at 318 nm, however, was found to be 
sufficiently high in energy to sensitise Eu3+ emission. Upon excitation at 318 nm 
under ambient conditions no ligand phosphorescence was observed in the 
emission spectrum, only Eu3+ emission bands (Figure 5.6).  
 
 
Figure 5.5 (Left) normalised emission spectrum of [Eu.L1] at 298 K in water; (right) 
emission at 77 K in an ethanol glass. λex = 380 nm. 
 
Figure 5.6 Normalised emission spectra of [Eu.L1] and [Eu.L2] in water, λex = 318 nm at 
298 K. 
The absorbance spectrum of [Eu.L2], in comparison, shows a broad 
shoulder at 360 nm and a structured wavelength maximum at 318 nm, due to a 
localised π π* transfer transition within the chromophore (Figure 5.7). A broad 
shoulder is present in the absorbance spectrum with a maximum of 368 nm, and 
is assigned to an ICT transition. The ICT transition observed for [Eu.L2] is less 
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pronounced than that of [Eu.L1], due to the poorer electron donation ability of the 
phenolic oxygen atom.  
 
 
 
 
 
Figure 5.7 Absorbance spectrum of [Eu.L2]. Complex concentration = 5 µM in water, 
298 K. 
The emission spectrum of [Eu.L2] was recorded after excitation at 318 nm 
(Figure 5.6). An identical emission spectral response to that of [Eu.L1] was 
observed, with a ratio of 0.4 between the ‘hypersensitive’ ∆J = 2 and ∆J = 4 
emission bands. Excitation at the localised π π* transition of the pyridylalkynylaryl 
chromophore, however, was found not to sensitise Tb3+ emission efficiently at 
room temperature, even in deoxygenated solutions (See Appendix, Figure A.8). 
The weak terbium-emission observed for [Tb.L2], has been seen previously in 
the literature with chromophores bearing electron donating substituents.18,19 The 
5D4 excited state of Tb3+ (20,400 cm-1) is higher in energy than the 5D0 of Eu3+ 
(17,200 cm-1), and closer in energy to the excited state of the chromophore. A 
thermally activated back energy transfer process is, therefore, possible at room 
temperature. The rate of back energy transfer is much slower at low temperatures 
(77 K), allowing the chromophore to sensitise terbium-centred emission more 
efficiently (See Appendix, Figure A.9).  
The weak terbium-centred emission observed with [Tb.L2], at room 
temperature, led to the pKa and the binding studies of Mg2+, Ca2+ and Zn2+ being 
carried out only with the europium-based analogue [Eu.L2].  
The photophysical properties of [Eu.L1], [Eu.L2] and [Tb.L2] are compared 
in Table 5.1. Luminescence lifetime measurements in both H2O and D2O at room 
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temperature revealed hydration numbers of one (q = 1) for both [Eu.L1] and 
[Eu.L2], with a total lanthanide coordination number of nine (Equation 5.1).20 
qEu=	1.2 kH2O – kD2O – 0.25 – 0.075n     Eq. 5.1 
As expected, the lifetime of the Eu3+ excited state of both [Eu.L1] and 
[Eu.L2] is shorter in H2O, because of a more favourable non-radiative O-H 
vibrational pathway to quench europium emission. No luminescence lifetimes 
were measured for [Tb.L2], owing to the very weak Tb3+ emission at room 
temperature. It was assumed that the hydration number, like for [Eu.L2], was one 
(q = 1). 
Table 5.1 Photophysical data of [Eu.L1], [Eu.L2] and [Tb.L2]  in H2O, 298 K. For 
luminescence lifetime measurements of [Eu.L1] and [Eu.L2], λex = 315 nm, λem = 613 nm, 
298 K. Quantum yields (") ± 20 % measured using a [Ru(bpy)3]2+ standard in H2O. a Not 
measured because of the weak emission observed at room temperature. 
Complex λex (nm) $ / 103 
(M-1cm-1) 
%&'( 
(ms) 
%)'( 
(ms) 
q *&'( / % 
[Eu.L1] 315 11.5(2) 0.61 1.87 1.0 13 
[Eu.L2] 315 18.4(4) 0.61 1.89 1.0 11 
[Tb.L2] 314 17.9(2) a a a a 
 
The pyridylalkynylaryl chromophore exhibits solvatochromism in both 
lanthanide complexes [Eu.L1] and [Eu.L2]. In less polar solvents such as 
methanol, ethanol and tert-butanol, a small bathochromic shift is observed of the 
localised π π* maximum with the disappearance of the broad structureless 
transition assigned to an ICT state at 368 nm. A linear increase in the total 
emission intensity was reported for [Eu.L1] with a decrease in solvent polarity. 
No apparent correlation with solvent polarity was seen, however, with [Eu.L2] 
where the aniline nitrogen is meta to the chromophore (Figure 5.8). Lanthanide 
complexes containing similar push-pull electron rich chromophores are well 
known to exhibit solvatochromic behaviour.19 It has been shown previously that 
complexes bearing aniline nitrogen atoms para to the chromophore also display 
a linear dependence to solvent polarity.21 An increase in the total emission 
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intensity was observed in less polar solvents, and can be attributed to the ICT 
state becoming increasingly destabilised as the solvent polarity is reduced.21  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 (Right) Normalised absorbance spectra of (A) [Eu.L1] and (B) [Eu.L2] in water, 
methanol, tert-butanol and ethanol at 298 K. (Left) the relationship of the integrated 
emission intensity against the Reichardt’s normalised solvent polarity (ETN).22 
5.3.2 The pyridylaryl chromophore, [Ln.bL2] 
	
The absorbance spectrum of [Tb.bL2] is shown in Figure 5.9. The 
presence of a pyridylaryl chromophore instead of a pyridylalkynylaryl 
chromophore (as seen with [Eu.L1] and [Eu.L2]), shifts the absorbance maximum 
towards the blue. The effect is similar to that observed in the naphthalene series 
in Chapter 4, and can be attributed to the reduction in the conjugation length, 
and the loss of planarity in the bi-aryl system, allowing aryl-aryl carbon-carbon 
bond rotation to occur. An absorbance wavelength maximum of 280 nm was seen 
in aqueous solutions, arising from to a localised π π* excited state transition in the 
chromophore (Figure 5.9). A broad shoulder was seen at lower energy with a 
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maximum of 348 nm and could arise from intramolecular charge transfer (ICT) 
within the bi-aryl chromophore.  
 
 
 
 
 
Figure 5.9 Absorbance spectrum of [Tb.bL2] in water at 298 K.  
The triplet excited state of the chromophore was too high in energy to 
efficiently sensitise europium-centred emission, with the loss of energy due to 
non-radiative vibrational quenching pathways. A significant amount of ligand 
phosphorescence was also seen at ambient temperatures (Figure 5.10). There 
was, however, efficient energy transfer to the higher lying 5D4 excited state of 
Tb3+, resulting in the characteristic terbium-centred emission with the ∆J = -2 to 
∆J = 1 emission bands observed at room temperature (Figure 5.10).  
	
	
Figure 5.10 Normalised emission spectra of (left) [Eu.bL2] and (right); [Tb.bL2] in water, 
λex = 280 nm at 298 K. 
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Table 5.2 Photophysical data for [Eu.bL2] and [Tb.bL2]. Lifetimes for [Tb.bL2] were measured under both aerated (A) and deoxygenated (D) 
conditions  (λex = 280 nm, λem = 544 nm for [Tb.bL2] and λex = 280 nm, λem = 613 nm for [Eu.bL2]). The hydration number (q) was determined under 
deoxygentated conditions. Quantum yields (!) ± 20 % were measured in aerated and deoxygenated samples in H2O and ethanol using a quinine 
sulphate standard in 0.5 M H2SO4. a Data not collected. 
 
 
 
 
 
 
Complex 
 
λex 
(nm) 
 # / 103 
(M-1cm-1) 
$%&' (ms) $(&' (ms) $)*+,-./* 
(ms) 
!%&' / % !01'% / %  
q 
A D A D A D A D A D 
[Eu.bL2] 280 a 0.50 0.56 1.70 1.82 0.77 a a a a a a 
[Tb.bL2] 280 6.0 0.42 1.52 0.72 2.30 1.13 a 3.4 5.4 1.5 3.1 0.9 
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The photophysical properties of [Eu.bL2] and [Tb.bL2] are reported in 
Table 5.2. Luminescence lifetime measurements and quantum yields (!) of 
[Tb.bL2] were determined in both aerated and deoxygenated samples at room 
temperature. Significantly shorter lifetimes were recorded at ambient 
temperatures for the bi-aryl [Eu.bL2] and [Tb.bL2] complexes, compared to 
[Eu.L1] and [Eu.L2], comprised of a pyridylalkynylaryl chromophore. At room 
temperature a large error of 13 % was associated with the excited state lifetimes 
of [Tb.bL2] in D2O, calculated from the standard deviation of four separate 
measurements. This behaviour led to discrepancies in the calculated hydration 
number (q) according to Equation 5.2.  
Due to the uncertainty in the measurements under aerated conditions, 
possibly due to the presence of back energy transfer, the hydration number was 
instead determined from deoxygenated samples of bi-aryl [Tb.bL2] where 
quenching from triplet oxygen is eliminated (Table 5.2 and Equation 5.2).20 A 
hydration number of one (q = 1) was determined from deoxygenated solution, 
with an overall lanthanide coordination number of nine (Table 5.2).    
qTb=	5.0 (kH2O	– kD2O	–0.06 –0.010n)    Eq. 5.2 
The bi-aryl complex [Tb.bL2], displayed a brighter emission intensity and 
a much longer excited state lifetime in deoxygenated samples in both H2O and 
D2O. A 1.6-fold increase in the total luminescence emission intensity was 
observed with a 3.6- and 3.2-fold increase in the excited state lifetime in H2O and 
D2O respectively. Such behaviour is characteristic of the reduction of quenching 
of the triplet excited state of the chromophore by 3O2, and suggests that back 
energy transfer from the 5D4 excited state of Tb3+ to the triplet excited state of the 
chromophore is taking place at room temperature. The bi-aryl complex [Tb.bL2], 
therefore, could be used as an emission- and lifetime-based pO2 sensor.  
Lifetimes of this order of magnitude are uncommon for Tb3+ complexes. In 
the majority of lanthanide-based systems, the higher energy of the 5D4 excited 
state of Tb3+, and the poorer overlap with O-H and O-D vibrational oscillators, 
results in a longer lifetime than their europium-based analogues.23 Surprising, 
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and uncharacteristically short Tb3+ excited state lifetimes have been seen in 
comparable bi-aryl systems containing pyridylaryl chromophores with electron-
donating substituents, including multiple reports by Maury and co-workers.24,25  
Increasing the viscosity of the solution was found to increase the lifetime 
of the excited state in both [Eu.bL2] and [Tb.bL2], where a 1.5- and 2.7-fold 
increase was observed in glycerol compared to water respectively. This 
behaviour was first observed by Maury and co-workers, and a number of 
millisecond-scale viscosity probes containing bi-aryl chromophores have been 
very recently developed.24,25 All terbium complexes studied by Maury displayed 
low millisecond lifetimes in methanol, with a 4-fold increase in the excited state 
lifetime seen in glycerol (0.24 to 0.89 ms).25 Maury and co-workers attributed this 
observation to the perturbation of carbon-carbon rotation of the bi-aryl 
chromophore in more viscous solutions, reducing the energy lost by non-radiative 
relaxation pathways. Unlike [Eu.bL2], however, europium complexes studied by 
Maury were found to be insensitive to changes in viscosity. It was suggested that 
back energy transfer from the 5D4 state was essential to viscosity sensitivity.24,25 
An energy gap of less than 1800 cm-1 is typically required for back energy transfer 
to occur, and is much more commonly observed with Tb3+ as the 5D4 state is 
higher in energy than the 5D0 of Eu3+.4,19  
In order to further understand the short lifetimes observed for [Tb.bL2] and 
the effect of solution viscosity proposed by Maury, a study into the solvent effect 
on the excited state lifetime was carried out, under both oxygenated and 
deoxygenated conditions, with solvents of varying viscosity and polarity.  
The absorbance spectra of [Tb.bL2] in a range of solvents is shown in 
Figure 5.11. It is clear that in less polar alcoholic solvents, for example, methanol, 
isopropanol and tert-butanol, a bathochromic shift in the absorbance wavelength 
was observed. A 5 nm shift of the wavelength maximum (π π*) was seen in 
methanol and a 10 nm red shift in isopropanol, ethanol and tert-butanol 
(Figure 5.11). The solvatochromic behaviour and the general decrease in lifetime 
observed in more polar solvents implies that the triplet excited state is stabilised 
by dipolar interactions, and is lower in energy.4,26 Ethanol was seen to be an 
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exception of this rule with a lifetime of 0.23 ms reported in aerated conditions, 
significantly lower than the 0.43 ms observed for water.  
 
Figure 5.11 Normalised absorbance spectra of [Tb.bL2] in water, methanol, ethanol, 
isopropanol and tert-butanol at 298 K. 
 
Table 5.3 Excited state lifetimes of [Tb.bL2] in a range of solvents with varying viscosity 
and polarity (determined from the Reichardt’s normalised solvent polarity parameter 
(ETN))22 at 298 K. Where (A) is in aerated and (D) is in deoxygenated solutions 
(λex = 280 nm, λem = 544 nm). a No excited state lifetime was measured. 
  
 
Solvent 
 
Viscosity (cP) 
at 298 K 
Lifetime (ms)   
ETN 22  A D 
H2O 0.89 0.43 1.52 1.000 
Methanol 0.54 0.59 1.87 0.765 
Ethanol 1.02 0.23 1.70 0.655 
t-Butanol 4.31 0.85 1.51 0.602 
i-Propanol 2.04 0.67 1.33 0.552 
Glycerol 934 1.13 a - 
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Figure 5.12 The excited state lifetime of [Tb.bL2] relative to (A) the solvent viscosity and 
(B) the Reichardt’s normalised solvent polarity parameter (ETN)22 of water, methanol, 
ethanol, isopropanol and tert-butanol. Square highlights deoxygenated and diamond shows 
aerated conditions at 298 K. 
It is evident from the analysis of Table 5.3 and Figure 5.12, that there is 
no significant correlation observed between the excited state lifetime of [Tb.bL2] 
with viscosity or solvent polarity, in both aerated and deoxygenated solutions 
(Figure 5.12). A similar response to solvent polarity was observed for [Eu.L2] in 
Section 5.3.1 where the aniline nitrogen is meta to the chromophore.  
Significantly longer lifetimes and larger quantum yields were seen in 
deoxygenated conditions of all solvents studied, due to the elimination of the 
competitive quenching of the T1 state of the chromophore by triplet oxygen. Such 
behaviour all but confirms the presence of back energy transfer from the 5D4 state 
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of Tb3+ to the excited state of the chromophore. The energy of the ligand triplet 
excited state was estimated by studying the phosphorescence spectrum of 
[Gd.bL2] at 77 K in an ethanol glass. The energy of the 0-0 component of the π 
π* transition was estimated to be 22,250 cm-1, which is sufficiently high to permit 
efficient energy transfer to Tb3+ in [Tb.bL2] (See Appendix Figure A.10). A broad 
ICT excited state was also observed centred around 25,000 cm-1 but extending 
beyond 22,000 cm-1, suggesting that the system may be prone to thermally 
activated back-energy transfer from Tb3+ (energy of 5D4 = 20,500 cm-1) to 
repopulate the ICT excited state (or indeed even the 3π–π*).  
The presence of back energy transfer was also reported in the bi-aryl 
systems studied by Maury, and it was deemed essential for viscosity 
sensitivity.24,25 Luminescence lifetimes were measured in methanol / glycerol in 
varying proportions, with solutions displaying a range of viscosities.24,25 A linear 
increase in the lifetime was reported in solutions of an increased viscosity. No 
such linearity for viscosity is seen here in the case of [Tb.bL2], suggesting that 
the mechanism for the reduction in the excited state lifetime is not due to non-
radiative vibrational relaxation via aryl-aryl rotation. Solvent viscosity will remain 
unchanged in both aerated and deoxygenated environments, so aryl-aryl rotation 
of the chromophore is unlikely be the reason for the reduced lifetime seen. 
 It is thought that instead of a viscosity sensitivity, what is observed in bi-
aryl complexes of this nature is a balance between the competing Tb3+ emission 
and quenching of the triplet excited state by dissolved oxygen. Schumpe and co-
workers investigated the solubility of oxygen in aqueous solutions, and found that 
as the mole fraction of glycerol increased there was a large linear decrease in 
oxygen solubility.48 It is likely, therefore, that an identical effect led to a linear 
increase in lifetime with viscosity presented in the work by Maury.24,25 Instead of 
an increased excited state lifetime due to restricted rotation, the lifetime is 
increasing because of a decreased oxygen solubility in solution as the mole 
fraction of glycerol is increased. Such behaviour reduces the amount of triplet 
oxygen quenching of the triplet excited state of the chromophore and increase 
the luminescence lifetime.  
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5.4. pKa studies of [Eu.L1], [Eu.L2]  and [Tb.bL2] 
A study into the effect of the pH on the absorbance and emission spectra 
of complexes containing a pyridylalkynylaryl chromophore in the case of [Eu.L1] 
and [Eu.L2],  and a pyridylaryl-based system [Tb.bL2] was carried out. As for the 
naphthalene series of ligands in Chapter 4, pH titrations were run at 298 K at a 
constant ionic strength in 100 mM KCl. The structures of [Eu.L1], [Eu.L2] and 
[Tb.bL2]  are shown in Figure 5.13 for reference.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 The structures of complexes [Eu.L1], [Eu.L2] and [Tb.bL2]. 
5.4.1 Absorbance pKa studies of [Eu.L1], [Eu.L2]  and [Tb.bL2]  
	
In basic solution, the absorbance spectrum of [Eu.L1] displays three 
maxima at 270 nm, 315 nm and 378 nm, in a profile identical to that shown in 
Figure 5.4. The change in the absorbance intensity at 316 nm and 378 nm was 
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investigated from pH 7.7 to 3.3. Following addition of acid and the reduction of 
the pH, a 15 nm hypsochromic shift of the ICT band from 378 nm to 363 nm was 
observed (Figure 5.14). The blue shift is attributed to protonation of the aniline 
nitrogen atom under acidic conditions. No pronounced changes in the 
absorbance intensities were reported at 270 nm or 315 nm in solutions of a 
reduced pH. An isosbestic point is present in the absorbance spectrum at 370 nm 
(Figure 5.14).  
 
 
 
Figure 5.14 (Left) Absorbance spectrum; (right) sigmoidal fit of the absorbance ratio at 
363 nm and 378 nm against the pH.  [Eu.L1] concentration = 10 µM in 100 mM KCl, 298 K.  
The observed blue shift allows the pKa to be determined from a ratio of the 
wavelength maxima in both acidic and basic solutions. A pKa of 4.5 was 
calculated, slightly lower than that of APTRA, where a value of 5.5 has been 
revealed previously from absorbance spectroscopy experiments.6 The lower pKa 
of [Eu.L1] compared to APTRA arises because the para nitrogen lone pair of 
electrons is conjugated within the aromatic chromophore, and is less readily 
available for protonation under acidic conditions.  
Absorbance spectra for [Eu.L2]  and [Tb.bL2] are shown in Figure 5.15. It 
is evident that the change in pH from basic to acidic conditions had no significant 
effect on the spectral form in absorption. No change in the absorbance intensity 
was reported at the wavelength maximum, and no hypsochromic shift occurred 
at low pH, e.g. with [Eu.L2]. Absorbance spectroscopy is, therefore, unsuitable to 
monitor meta aniline nitrogen protonation with [Eu.L2]  and [Tb.bL2], due to the 
absence of a pronounced ICT state. 
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Figure 5.15 Absorbance spectrum of [Eu.L2]  and [Ln.bL2] in basic and acidic solutions at 
constant ionic strength of 100 mM KCl, 298 K. 
5.4.2 Fluorescence emission pKa studies of [Eu.L1], [Eu.L2]  and [Tb.bL2]  
	
Fluorescence emission spectra of [Eu.L1], [Eu.L2]  and [Tb.bL2] were 
recorded with excitation at the localised π π* excited state in each case. It is 
apparent from the emission spectra shown in Figure 5.16, and the fluorescence 
excitation spectrum (See Appendix Figure A.11 and Figure A.13), that no pH 
sensitivity is observed over the pH range 4-8 for [Eu.L1]  and [Tb.bL2]. No pKa 
values can, therefore, be obtained for these two complexes by fluorescence 
spectroscopic methods. 
 
 
 
0
0.05
0.1
0.15
0.2
230 280 330 380 430
Ab
so
rb
an
ce
	
Wavelength	(nm)	
0
0.04
0.08
0.12
0.16
230 280 330 380 430
Ab
so
rb
an
ce
	
Wavelength	(nm)
Chapter 5. The APTRA binding group in metal-based systems  
	
166 
	
 
 
 
 
 
 
 
 
 
Figure 5.16 (Left) emission spectra; (right) sigmoidal fitting of the emission intensity against 
the pH of (A) [Eu.L1] (λex = 315 nm), (B) [Eu.L2] (λex = 315 nm) and (C) [Tb.bL2] 
(λex = 280 nm) in 100 mM KCl, 298 K.  
In contrast, [Eu.L2]  displayed a fluorescence emission and excitation 
response to pH in the range 7.5—5.3. A 2.2-fold ‘turn-off’ in the total emission 
intensity following protonation of the aniline nitrogen was seen. A pKa of 6.7 was 
0
50000
100000
150000
200000
250000
570 620 670 720
Em
iss
io
n	
in
te
ns
ity
	
Wavelength	(nm)
0
50000
100000
150000
200000
250000
300000
570 620 670 720
Em
iss
io
n	
in
te
ns
ity
	
Wavelength	(nm)
0
40000
80000
120000
160000
450 500 550 600 650
Em
iss
io
n	
in
te
ns
ity
	
Wavelength	9nm)
0
20000
40000
60000
80000
100000
4 5 6 7 8
In
te
ns
ity
	61
3	
nm
pH
30000
50000
70000
90000
110000
5.2 6.2 7.2
In
te
ns
ity
	61
3	
nm
pH
pKa =	6.7(04)	
60000
80000
100000
120000
140000
4 5 6 7 8
In
te
ns
ity
	54
4	
nm
	
pH
H+ 
A) 
B) 
C) 
Chapter 5. The APTRA binding group in metal-based systems  
	
167 
	
calculated from both fluorescence emission and excitation spectroscopy from a 
non-linear least squares iterative analysis (See Appendix for the pH dependence 
of the excitation spectrum, Figure A.12).  
It is clear from Figure 5.16 that [Eu.L1] and [Tb.bL2] are insensitive to pH 
changes in the physiological range, making then suitable probes to detect Mg2+ 
in vivo. The complex [Eu.L2], displayed a more pronounced luminescence 
change in the physiological range, where a 1.2-fold reduction in its emission 
intensity from pH 7.5 to 6.8 was observed. The Mg2+ complex of [Eu.L2] 
(saturated with 50 mM Mg2+), however, is insensitive to pH within the pH range 6 
to 8.2. Such behaviour indicates that following the addition of 50 mM Mg2+, the 
aniline nitrogen becomes bound to Mg2+, and is no longer available for 
protonation at reduced pH (Figure 5.17).  
 
 
 
 
 
Figure 5.17 Emission spectrum of [Eu.L2] from pH 6 to 8.2 after saturating with Mg2+ 
(50 mM), (λex = 315 nm). [Eu.L2] concentration = 5 µM in 100 mM KCl, 298 K.  
5.5 Binding studies of [Eu.L1] and [Eu.L2] 
The absorbance, emission and excitation binding studies of [Eu.L1] and 
[Eu.L2] with Mg2+, Ca2+ and Zn2+ in a buffered solution of 50 mM HEPES, 100 mM 
KCl at 298 K (pH 7.21) are reported here. Such studies probe how the affinity and 
selectivity of the APTRA binding moiety is affected once incorporated into both 
pyridylalkynylaryl- and pyridylaryl-based chromophores involved in coordination 
to lanthanide(III) ions. Direct comparisons will be made with NapL1 and NapL2 in 
the model naphthalene series, discussed in detail in Chapter 4. Similarly, to the 
analysis of NapL1 and NapL2, it will be determined what effect, if any, the position 
of the aniline nitrogen has on the affinity and selectivity for Mg2+, Ca2+ and Zn2+.  
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5.5.1 Absorbance binding studies of [Eu.L1] and [Eu.L2] 
	
In the ‘metal-free’ state [Eu.L1] has two wavelength maxima in the 
absorbance spectrum at 315 nm and 380 nm. After subsequent additions of Mg2+, 
Ca2+ and Zn2+, an increase in the absorbance at 315 nm, and a decrease in the 
absorbance intensity at 380 nm was observed, with no shift in either of the 
wavelength maxima. Following addition of Mg2+, Ca2+ and Zn2+, an isosbestic 
point is present in the absorption spectra, at 345 nm for Mg2+ and 339 nm for Ca2+ 
and Zn2+ (Figure 5.18). 
It is apparent from analysis of Figure 5.18, that following addition of Ca2+ 
and Zn2+ to [Eu.L1], the ICT state at 380 nm is perturbed, with the complete loss 
of the ICT transition in the absorbance spectrum on metal ion binding saturation. 
On binding of Mg2+, however, a different spectral response was seen, with a 1.6-
fold decrease in the absorbance of the ICT state at 380 nm. Such a spectral 
response indicates that the aniline nitrogen atom para to the chromophore in 
[Eu.L1] plays a more prominent role in binding to Ca2+ and Zn2+, compared to 
Mg2+. 
 
 
Figure 5.18 Absorbance spectrum of [Eu.L1] for the addition of (A) Mg2+ (150 mM), (B) 
Ca2+ (15 mM) and (C) Zn2+ (35 µM). [Eu.L1] concentration = 5 µM in 50 mM HEPES, 
100 mM KCl, pH 7.21, 298 K. 
The absorbance spectrum of [Eu.L2], in comparison, displays a 
wavelength maximum at 315 nm in HEPES buffered solution (pH 7.21), in both 
the metal-free and ‘bound’ states. An increase in the absorbance intensity was 
observed at 315 nm on the binding of divalent metal ions, with a 1.1-, 1.3- and 
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1.5-fold increase seen following the addition of Mg2+, Ca2+ and Zn2+ respectively. 
No shift in the wavelength maximum occurred on metal ion binding. The 
disappearance of the broad shoulder present at 368 nm in the metal-unbound 
state of [Eu.L2], gave rise to an isosbestic point at 343 nm following the binding 
of divalent metal ions (Figure 5.19).  
 
 
Figure 5.19 Absorbance spectrum of [Eu.L2] for the addition of (A) Mg2+ (20 mM), (B) Ca2+ 
(3.5 mM) and (C) Zn2+ (11 µM). [Eu.L2] concentration = 5 µM in 50 mM HEPES, 100 mM 
KCl, pH 7.21, 298 K 
 
5.5.2 Luminescence binding studies of [Eu.L1] and [Eu.L2] 
	
Luminescence emission binding studies of [Eu.L1] and [Eu.L2] with Mg2+, 
Ca2+ and Zn2+ were carried out with excitation at the isosbestic point (339 nm or 
343 nm). Following the addition of aliquots of Mg2+, Ca2+ and Zn2+, the change in 
the emission intensity of the ‘hypersensitive’ ∆J = 2 and ∆J = 4 transitions was 
monitored. Dissociation constants were calculated by iteratively fitting the change 
in the emission intensity at 613 nm of the ‘hypersensitive’ ∆J = 2 transition, 
against the concentration of added divalent metal ions to a 1:1 binding model.  
The luminescence emission spectra following the addition of Mg2+, Ca2+ 
and Zn2+ to [Eu.L1] are shown in Figure 5.20. After the addition of Mg2+ and Ca2+ 
to [Eu.L1] a decrease in the Eu3+ total emission intensity was observed. A 1.5-
fold and 1.8-fold reduction was reported at both 613 nm (∆J = 2) and 
699 nm (∆J = 4). The addition of Zn2+, however, resulted in a 1.8-fold ‘turn-on’ in 
the fluorescence emission intensity.  Dissociation constants of 7.5 mM, 0.9 mM 
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and 1.8 µM were calculated respectively using this data, following the addition of 
Mg2+, Ca2+ and Zn2+ (Figure 5.20).  
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 (Left) emission spectra; (right) fitting of the emission intensity against the 
added concentration of (A) Mg2+, (B) Ca2+ and (C) Zn2+ to a 1:1 binding model. [Eu.L1] 
complex concentration = 5 µM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K, λex = 
339 nm. The reported dissociation constants are an average of two separate metal ion 
titrations, and are given with the experimental error in parenthesis.  
The excitation spectrum of [Eu.L1] has two maxima at 287 nm and 314 nm. 
The maximum observed at 380 nm in the absorbance spectrum associated with 
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conjugation of the para aniline nitrogen lone pair is not present in the excitation 
spectrum. As for to NapL1 (Chapter 4), an excitation-based ratiometric response 
was observed following the addition of Mg2+, Ca2+ and Zn2+ to [Eu.L1]. No 
significant wavelength shifts of either of the peak maxima at 287 nm and 314 nm 
in the excitation spectrum were reported. The fluorescence intensities at 287 nm 
and 314 nm, however, decreased at different rates after the addition of divalent 
metal ions, allowing dissociation constants to be calculated from a ratio of the two 
peaks.  
The excitation spectrum for the binding of Mg2+ to [Eu.L1] is shown in 
Figure 5.21. Fluorescence excitation spectra for the addition of Ca2+ and Zn2+ 
showed a similar response to that of Mg2+. Their calculated dissociation constants 
are shown in the Appendix for reference (Figure A.14 and Figure A.15). 
Comparable Kd values, within the experimental error to those observed from 
emission spectroscopy (Figure 5.20), were calculated from the variation of the 
fluorescence excitation spectra, following addition of Mg2+ (Figure 5.21), Ca2+ 
and Zn2+ (See Appendix, Figure A.14 and Figure A.15). 
 
 
Figure 5.21 (Left) excitation spectrum; (right) fitting of the ratio of excitation intensity at 
287 nm and 314 nm against the added concentration of Mg2+ to a 1:1 binding model. 
[Eu.L1] concentration = 5 µM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K, 
λem = 613 nm. 
In contrast to the emission spectral response observed for [Eu.L1], the 
addition of Mg2+, Ca2+ and Zn2+ to [Eu.L2], resulted in a 1.4-, 2.5-, 6-fold 
fluorescence enhancement at 613 nm (Figure 5.22). Dissociation constants of 
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3.7 mM, 0.9 mM and 1.9 µM were calculated, for Mg2+, Ca2+ and Zn2+ 
respectively (Figure 5.22).  
 
 
 
 
 
 
 
Figure 5.22 (Left) emission spectra; (right) fitting of the emission intensity against the 
added concentration of (A) Mg2+, (B) Ca2+ and (C) Zn2+ to a 1:1 binding model. [Eu.L2] 
complex concentration = 5 µM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K, 
λex = 343 nm. The reported dissociation constants are an average of two separate metal 
ion titrations, and are given with the experimental error in parenthesis.  
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The excitation spectrum of [Eu.L2] displayed a peak maximum at 310 nm 
in aqueous buffered solution. Unlike [Eu.L1], a non-ratiometric excitation 
response was observed following the addition of Mg2+ (Figure 5.23), Ca2+ and 
Zn2+ (See Appendix Figure A.16 and Figure A.17). A non-ratiometric excitation-
based response was also observed for the model naphthalene ligand NapL2, and 
was attributed to the loss of intramolecular charge transfer from the aniline 
nitrogen atom.  
A Kd value of 9.0 mM was calculated from the fluorescence excitation 
spectrum for the binding of Mg2+ to [Eu.L2]. A significant error of 48 % was 
associated with the fitting, due to the small changes in the excitation intensity 
after each addition of Mg2+. At the wavelength maximum of 310 nm, only a 1.1-
fold increase in the excitation intensity was observed on saturation with Mg2+ 
(35 mM). A dissociation constant of 9.0 mM is outside the experimental error 
determined by emission spectroscopy in Figure 5.22, but the affinity for Mg2+ is 
close to the required low mM range.  
 
 
 
Figure 5.23 (Left) excitation spectrum of [Eu.L2]; (right) fitting of the excitation ratio at 
310 nm against the added concentration of Mg2+ (λem = 613 nm). [Eu.L2] concentration = 
5 μM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K.  
Unlike Mg2+, the excitation-based dissociation constants recorded for the 
binding of Ca2+ and Zn2+ were measured with higher accuracy and within the 
experimental error to those determined via emission spectroscopy (Figure 5.22).  
A 1.5- and 5.5-fold increase in the excitation maxima were observed, for Ca2+ 
and Zn2+ respectively. Dissociation constants of 1.1 mM and 2.3 µM were 
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calculated from the excitation spectral variation (See Appendix, Figure A.16 and 
Figure A.17).  
The enhancement effect observed in both emission and excitation spectra 
for the addition of Mg2+, Ca2+ and Zn2+, can be attributed to the elimination of 
photo-induced electron transfer (PET) present in the ‘metal-free’ state. Upon 
metal binding to the meta aniline nitrogen, the quenching pathway of the Eu3+ 
excited state is perturbed. An identical effect was observed for the addition to 
divalent cations to analogue NapL2 in Chapter 4.   
5.5.3 The effect of Mg2+ binding on the coordination environment of [Eu.L1] 
and [Eu.L2] 
	
It is apparent from the emission spectra shown in Figure 5.20 and 
Figure 5.22, that the coordination environment of Eu3+ in both [Eu.L1] and [Eu.L1] 
is unaffected by the binding of Mg2+. A total emission change is reported, either 
a reduction for [Eu.L1] or an increase following addition of Mg2+ to [Eu.L2]. No 
significant change was observed in the ratio of the ‘hypersensitive’ ∆J = 2 and 
∆J = 4 emission bands (Figure 5.24). 
 
 
 
 
 
Figure 5.24 The ratio of the hypersensitive ∆J = 2 (613 nm) and ∆J = 4 (699 nm) bands for 
[Eu.L1] and [Eu.L2] (50 mM HEPES, 100 mM KCl, pH 7.21, λex = 315 nm) following 
addition of Mg2+ (40 mM). 
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Table 5.4 The luminescence lifetimes of [Eu.L1] and [Eu.L2] in HEPES (50 mM, 100 mM 
KCl, pH 7.21) in both H2O and D2O (λex = 315 nm, λem = 613 nm). Red highlights the 
lifetimes after the addition of Mg2+ (40 mM).  
Complex $%&'&()%*+ 
(ms) 
$%&'&()	,*+ 
(ms) 
q 
EuL1 0.60 
0.59 
1.69 
1.61 
1 
1 
EuL2 0.65 
0.59 
1.85 
1.70 
1 
1 
 
Luminescence lifetime measurements of [Eu.L1] and [EuL2] were 
measured in 50 mM HEPES, 100 mM KCl at a constant pH of 7.21, in the absence 
or presence of Mg2+ (40 mM) (Table 5.4).The negligible changes in the 
luminescence lifetimes observed before and after the addition of Mg2+ also 
indicate that the coordination environment of the Eu3+ centre remains unchanged 
on metal ion binding. A hydration number of one (q = 1), and a total stable 
coordination number of nine is maintained throughout for each complex. 
5.5.4 Summary: Comparison of the binding affinities and selectivities of 
[Eu.L1] and [Eu.L2] with their naphthalene analogues  
	
Charge neutral lanthanide complexes [Eu.L1] and [Eu.L2] displayed low 
mM affinities for both Mg2+ and Ca2+, and low µM affinities for Zn2+. It is clear that 
the position of the nitrogen atom, either para or meta, relative to the aromatic 
chromophore had no significant effect on the affinity or selectivity towards the 
different metal ions studied. Following addition of Mg2+, for example, Kd values of 
7.5 mM and 3.7 mM for [Eu.L1] and [Eu.L2] were calculated respectively. The 
slightly higher affinity of [Eu.L2] for Mg2+, is likely be due to the meta aniline 
nitrogen atom playing a more prominent role in binding to Mg2+. It is thought from 
absorbance measurements, and the presence of the ICT state at 380 nm on Mg2+ 
saturation, that in the case of [Eu.L1] the aniline nitrogen atom does not play a 
prominent role in binding to Mg2+(Figure 5.18). For [Eu.L2], however, the pH 
insensitivity shown in the physiological range of the Mg2+ ‘bound’ complex 
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indicates that when the aniline nitrogen is meta to the chromophore, it does 
participate in binding to Mg2+ (Figure 5.15). The aniline nitrogen atom, when both 
para and meta, is thought to take part in binding to both Ca2+ and Zn2+ in [Eu.L1] 
and [Eu.L2]. Comparable dissociation constants are reported from both 
fluorescence emission and excitation spectroscopy. 
 
 
 
 
 
 
 
 
  
 
Figure 5.25 The structures of [Eu.L1], [Eu.L2] and [Tb.2] (Parker et al.).6  
Table 5.5 The direct comparison of the dissociation constants for the binding of Mg2+, Ca2+ 
and Zn2+ to [Eu.L1], [Eu.L2] and [Tb.2] (Parker et al.) in aqueous solutions at 298 K. All 
dissociation constants have been determined by luminescence emission spectra.  
Complex Kd (Mg2+) Kd (Ca2+) Kd (Zn2+) 
[Eu.L1] 7.5(8) mM 0.9(2) mM 1.8(5) µM 
[Eu.L2] 3.7(1.5) 
mM 
0.9(1) mM 1.9(1) µM 
[Tb.2]6 0.8 mM6 53.7 µM6 10.5 µM6 
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The pentadentate APTRA binding moiety has been incorporated into 
lanthanide systems previously in Durham.5,6 Complex [Ln.2] shown in Figure 5.2 
and Figure 5.25, was synthesised by Parker et al., and was designed to sense 
Zn2+ in a competitive ionic media.5,6 As with [Eu.L1] and [Eu.L2], low mM affinities 
were displayed for the binding of Mg2+ (log K = 3.17, Kd = 0.8 mM) and a low µM 
affinity was seen for Zn2+ (log K = 5.93, Kd = 1.2 µM). Typical µM affinities for the 
binding of Ca2+ (log K = 4.27, Kd = 53.7 µM) were also reported,5,6 consistent with 
the behaviour of the APTRA-based indicator Mag-Fura-2.27  
It is apparent from the analysis of Figure 5.20 and Figure 5.22 that both 
[Eu.L1] and [Eu.L2] display a much lower affinity for Ca2+ than their naphthalene 
analogues NapL1, NapL2 and the lanthanide-based APTRA complex [Tb.2].6 For 
example, the europium complexes [Eu.L1] and [Eu.L2], have a 23- and 28-fold 
weaker affinity towards Ca2+ compared to NapL1 and NapL2, and a 17-fold lower 
affinity than [Tb.2].6 A direct comparison of the Kd values for binding of Mg2+, Ca2+ 
and Zn2+ to [Eu.L1], [Eu.L2] and [Tb.2] is highlighted in Table 5.5. 
The significant improvement in the Mg2+ / Ca2+ selectivity displayed is 
extremely rare, and has never been observed previously for ligands and 
complexes of this type. In each instance, carboxylate-based APTRA indicators in 
the literature typically display a µM affinity towards Ca2+.5,6,28 The lower affinity 
observed for Ca2+ binding could be, due in part, to the highly electron-rich push-
pull system associated with pyridylalkynylaryl chromophores. In the case of 
[Eu.L1], for example, the aniline nitrogen lone pair is highly conjugated with the 
aromatic chromophore and, therefore, is less available for donation.  
The enhanced Mg2+ / Ca2+ selectivity of [Eu.L1] and [Eu.L2], reported here, 
could allow them to be used to study ‘free’ Mg2+ concentrations, even in calcium-
rich regions of the body. In the endo(sarco)plasmic reticulum and in serum 
elevated Ca2+ concentrations occur which are far above basal mammalian cell 
levels. Mg2+ homeostasis has, therefore, not been previously studied in these 
regions using any luminescent probe.  
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5.6 Binding studies of bi-aryl [Tb.bL2]   
The absorbance, emission and excitation binding studies of a terbium-
based complex, [Tb.bL2], containing a bi-aryl pyridylaryl chromophore are 
reported in aqueous solution. Binding studies were carried out with [Tb.bL2] 
rather than [Eu.bL2], due to the more efficient energy transfer arising from the 
triplet excited state of the chromophore to the 5D4 excited state of Tb3+. 
Comparisons will be made to [Eu.L1], and particularly [Eu.L2], which also 
possesses a meta aniline nitrogen atom on the APTRA binding moiety. It was 
decided that binding studies would be carried out with the bi-aryl system 
containing a meta aniline nitrogen, as [Eu.L2] displayed a higher affinity for Mg2+, 
compared to that observed with [Eu.L1], while maintaining almost identical 
affinities for Ca2+ and Zn2+.  
The study set out to examine how the use of a bi-aryl pyridylaryl 
chromophore, affects the affinity and selectivity towards Mg2+, Ca2+ and Zn2+, and 
which chromophore is preferred for the maximum Mg2+ affinity and best 
Mg2+ / Ca2+ selectivity. 
5.6.1 Absorbance binding studies of [Tb.bL2]   
	
The absorbance spectrum of [Tb.bL2]  displayed a peak maximum at 
280 nm, an identical response to that shown in Figure 5.9. Following the addition 
of Mg2+, Ca2+ or Zn2+, an increase in the absorbance intensity at 280 nm was 
observed, with no shift in the wavelength maximum. The absorbance spectra for 
[Tb.bL2] before and after addition of Mg2+, Ca2+ and Zn2+ are shown in 
Figure 5.26. 
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Figure 5.26 Absorbance spectrum of [Tb.bL2] following addition of (A) Mg2+ (200 mM), (B) 
Ca2+ (4.5 mM) and (C) Zn2+ (9.5 µM). [Tb.bL2] concentration = 5 µM in 50 mM HEPES, 
100 mM KCl, pH 7.21, 298 K 
5.6.2 Luminescence binding studies of [Tb.bL2]   
	
Titrations of [Tb.bL2] with Mg2+, Ca2+ and Zn2+ were carried out in buffered 
solution at a constant pH with excitation at 280 nm, the wavelength maximum 
from the absorbance spectrum.   
The terbium-centred emission spectra following addition of Mg2+, Ca2+ and 
Zn2+ to [Tb.bL2] are shown in Figure 5.27, displaying typical Tb3+ emission bands 
∆J = 2 to ∆J = –1. After addition of Mg2+ and Ca2+ a 2.6- and 2.5-fold reduction in 
emission intensity at 544 nm was found. The addition of Zn2+, however, resulted 
in a 1.8-fold increase in emission intensity. The emission response observed here 
is identical to that observed following the addition of Mg2+, Ca2+ and Zn2+ to 
[Eu.L1] (Figure 5.20). Dissociation constants of 16.9 mM, 0.8 mM and 0.5 µM 
were calculated respectively for the binding of Mg2+, Ca2+ and Zn2+ (Figure 5.27). 
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Figure 5.27 (Left) excitation spectrum of [Tb.bL2]; (right) fitting of the excitation ratio at 544 
nm against the added concentration of (A) Mg2+, (B) Ca2+ and (C) Zn2+ to a 1:1 binding 
model. [Tb.bL2] concentration = 5 μM in 50 mM HEPES, 100 mM KCl, pH 7.21, 
λex = 280 nm 298 K.  
The bi-aryl complex [Tb.bL2], displayed a ratiometric emissive response 
following addition of Mg2+ (Figure 5.28) and Zn2+ (Appendix A.18), but a non-
ratiometric response for the addition of Ca2+ (Appendix A.19). Such behaviour 
is surprising, and was not seen with [Eu.L1] and [Eu.L1], containing a 
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pyridylalkynylaryl chromophore. Following the addition of Mg2+ and Zn2+ to 
[Tb.bL2], comparable Kd values of 17.7 mM and 1 µM were calculated from the 
ratio of the ∆J = 2 (486 nm) and ∆J = 1 (544 nm) emission band intensities of 
[Tb.bL2] (Figure 5.28).  
 
Figure 5.28 The ratiometric response of [Tb.bL2] following addition of Mg2+. The 
dissociation constant was calculated from the intensity ratio of the ∆J = 2 (486 nm) and 
∆J = 1 (544 nm) emission bands. [Tb.bL2] concentration = 5 µM in 50 mM HEPES, 
100 mM KCl, pH 7.21, λex = 280 nm, 298 K. 
The excitation spectrum of [Tb.bL2] displays a peak maximum at 280 nm 
in both metal-free and ‘bound’ states (Figure 5.29), matching that observed in 
the absorbance spectrum. Following addition of Mg2+, a 2.4-fold reduction in the 
excitation intensity at 280 nm was observed. The fluorescence excitation spectra 
for the addition of Ca2+ and Zn2+ are shown in the appendix for reference, similarly 
showing no shift in the wavelength maxima on binding (Figure A.20 and Figure 
A.21). Comparable Kd values within experimental error, were measured for the 
binding of Mg2+ (Figure 5.29), Ca2+ (Figure A.20) and Zn2+ (Figure A.21) via 
fluorescence excitation spectroscopy.  
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Figure	5.29	(Left)	excitation	spectrum	of	[Tb.bL2];	(right)	fitting	of	the	excitation	ratio	at	
280	nm	against	the	added	concentration	of	Mg2+	(λem	=	544	nm).	[Tb.bL2]	concentration	=	5	μM	
in	50	mM	HEPES,	100	mM	KCl,	pH	7.21,	298	K.		
5.6.3 The effect of Mg2+ binding on the excited state lifetime of [Eu.bL2]  and 
[Tb.bL2]  
	
Luminescence lifetime measurements of [Eu.L1] and [EuL2], containing a 
pyridylalkynylaryl chromophore, were found to be invariant with addition of Mg2+. 
Such behaviour indicates that the coordination environment of Eu3+ remains 
unchanged on Mg2+ binding. In the case of the bi-aryl complex [Tb.bL2], however, 
a linear dependence between the luminescence lifetime of the 5D4 state of Tb3+, 
and increasing concentrations of Mg2+ was found (Figure 5.30, R2 = 0.985). 
Following the addition, and complete saturation of [Tb.bL2] with 200 mM Mg2+, a 
1.4-fold increase in the lifetime of the Tb3+ excited state was calculated 
(Figure 5.30, Table 5.6).  
Maury and co-workers have been carrying out extensive work into terbium-
based bi-aryl systems containing electron donating substituents, with apparent 
applications as viscosity probes.25 In a similar study to that reported by Maury, it 
was found that both [Eu.bL2] and [Tb.bL2] are sensitive to changes in viscosity, 
but significant longer lifetimes were also observed in less polar solvents and in 
deoxygenated solutions. Such behaviour suggests that the excited state lifetime 
is not dependent on vibrational quenching from aryl-aryl rotations, but instead 
from oxygen quenching of the triplet excited state of the chromophore 
(Section 5.3.2).  
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 The bi-aryl complex [Tb.bL2] showed a linear response in excited state 
lifetime following addition of Mg2+ (200 mM) in aqueous solution (Figure 5.30 and 
Table 5.6). It is tempting to speculate, therefore, that the binding of Mg2+ to 
[Tb.bL2], causes a destabilising effect on the triplet excited state and reduces the 
amount of back energy transfer and triplet oxygen quenching resulting in a longer 
excited state lifetime. Europium-based complex [Eu.bL2], in contrast showed no 
significant change in the excited state lifetime following the addition of Mg2+ 
(200 mM). A change of 0.50 ms to 0.43 ms was observed, and arguably lies within 
the error associated with the luminescence lifetime measurement.  
 
Figure 5.30 The linear dependence of the excited state lifetime of [Tb.bL2] following 
addition of Mg2+. [Tb.bL2] concentration = 5 µM in 50 mM HEPES, 100 mM KCl, 
pH = 7.21,λex = 280 nm, λem = 544 nm at 298 K. (R2 = 0.985).  
 
Table 5.6 The effect on the excited state lifetime of [Tb.bL2] and [Eu.bL2] following 
addition of 200 mM Mg2+.  
Complex $%&'&( 
(ms) 
$%&'&()-.*/ 
(ms) 
[Tb.bL2] 0.48 0.64 
[Eu.bL2] 0.50 0.43 
 
The increase in the luminescence lifetime of the 5D4 state following 
addition of Mg2+ is surprising, however, as it is apparent from Figure 5.27 that 
the total luminescence intensity of [Tb.bL2] decreased on Mg2+ binding. A 
decrease in the total luminescence intensity suggests that a quenching of the 
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excited state is taking place, and is usually coupled with a decrease in the lifetime 
rather than the increase observed.  
5.6.4 Summary: Pyridylalkynylaryl vs. pyridylaryl chromophores  
	
The complex [Tb.bL2] displays a number of fundamental disadvantages 
over the use of complexes containing pyridylalkynylaryl chromophores, including 
[Eu.L1] and [Eu.L2]. Although a similar low mM and low µM affinity is observed 
for the binding of Ca2+ and Zn2+, a weaker binding is reported for Mg2+. Kd values 
of 3.7 mM and 16.9 mM were observed for [Eu.L2] and [Tb.bL2] respectively. 
The affinity for Mg2+ is, therefore, approximately 10-times weaker than that 
required to follow changes in the concentration of ‘free’ Mg2+ in the majority of 
mammalian cells.  
However, [Tb.bL2] displayed a ratiometric emission response, following 
addition of Mg2+ and Zn2+. Comparable Kd values were calculated to those 
reported from excitation at the absorbance wavelength maximum.  
Complexes containing both a pyridylalkynylaryl ([Eu.L1] and [Eu.L2]) and 
a pyridylaryl chromophore ([Tb.bL1]) were found to have a low mM affinity for 
Ca2+. The significantly lower affinity for Ca2+ observed, compared to traditional 
APTRA indicators, shows that the effect can’t solely be down to the electron-rich 
push-pull system present in pyridylalkynylaryl chromophores, and must be 
caused by a combination of effects. 
The excited state lifetime of complexes bearing a bi-aryl chromophore 
were found to be significantly lower than their pyridylalkynylaryl counterparts, and 
showed no linearity with a viscosity or solvent polarity. A linear response of 
lifetime and concentration with [Mg2+] was found. Both [Eu.L1] and [Eu.L2], 
however, had emission lifetimes that were independent of added Mg2+.  
The high energy excitation required for the less conjugated pyridylaryl 
complex [Tb.bL2], is another important disadvantage and limits its possible 
biological applications in its current state. Its use in vivo and in cellulo is restricted, 
as confocal microscopy experiments for visualisation in cells typically require 
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excitation at 355 nm or longer.19,29 At this excitation wavelength, however, no 
Tb3+ emission would be observed with [Tb.bL2], as a higher energy excitation is 
required.  
The structure of [Tb.bL2] could be modified in order to shift the absorbance 
wavelength to lower energies and improve its performance for real biological 
applications. The addition of electron donating substituents, such as methoxy 
groups ortho to the chromophore, would shift the wavelength maximum towards 
the red. The use of different electron-donating groups has been previously used 
to great effect in Durham with pyridylalkynylaryl chromophores, to synthesise 
complexes with a wide range of wavelength maxima in the absorbance 
spectrum.19  
5.7 Applications of [Eu.L2]: Assessing ‘free’ Mg2+ in newborn calf serum 
Lanthanide complexes have been used for sensing of several bioactive 
species in biological fluids.23,30,31 Europium- and terbium-based complexes 
containing an azaxanthone sensitiser have been used, for example, as probes 
for bicarbonate anions in human serum.23 To date, however, no lanthanide-based 
complexes have been used to monitor ‘free’ Mg2+ in human serum because of 
the Mg2+ / Ca2+ selectivity conundrum displayed by the majority of Mg2+ binding 
groups.  
Measuring selectively the ‘free’ concentration of Mg2+ within human serum 
is of major interest. It is of critical importance that a greater understanding of the 
cause of Mg2+ imbalances within the serum is developed, for future disease 
prevention. In Chapter 4 fluorescence emission binding studies of APDAP 
analogue NapL4 with Mg2+ were carried out in a ‘serum mimic’. It was shown that 
a binding constant of 0.04 mM was calculated, making it unsuitable for the 
detection of ‘free’ Mg2+ in human serum as ‘free’ Mg2+ is present in the range of 
0.7-1.1 mM.32 
The use of an APTRA-based lanthanide luminescent probe was 
considered, to study the binding of Mg2+ in newborn calf serum (NCS). Europium-
based complexes [Eu.L1] and [Eu.L2] displayed encouraging results in metal ion 
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binding titrations, with a low mM affinity seen following addition of both Mg2+ and 
Ca2+ (Section 5.5). It was hoped that the 1.8-fold weaker affinity towards Ca2+ 
observed for [Eu.L1] and [Eu.L2] over NapL4, could allow them to be more 
suitable for the sensing of ‘free’ Mg2+ in human serum. Complex [Eu.L2] was 
chosen over [Eu.L1] for the Mg2+ titration in NCS, because of two main factors: 
first, [Eu.L2] displayed a higher affinity for Mg2+ (Kd  = 3.7 mM vs. 7.5 mM), and 
second the ‘turn-on’ emission response that occurred following addition of Mg2+.  
The emission spectra of [Eu.L2] in NCS are shown in Figure 5.31, with 
excitation at both the absorbance wavelength maximum in the ‘unbound state’ 
(315 nm), and at the isosbestic point (343 nm) in HEPES buffer. The complex 
[Eu.L2] was sufficiently bright at both of these excitation wavelengths, such that 
no time gated emission was required. A greater emission intensity, however, was 
observed following excitation at 315 nm, with a reduction in the interference from 
background fluorescence in the NCS.  
The total emission intensity observed for [Eu.L2] in NCS was significantly 
lower than that displayed in HEPES buffer solution, with a significantly reduced 
luminescence lifetime of 0.31 ms. Such behaviour can be attributed to the 
quenching effect of proteins such as bovine serum albumin (BSA) present in 
NCS. A titration of [Eu.L2] with BSA showed that following addition of BSA 
(110 µM), a 1.9-fold reduction in the total emission intensity of [Eu.L2]  was 
observed  (See Appendix, Figure A.22). The excited state lifetime of [Eu.L2], 
however, was unaffected by the addition of BSA with only a negligible change 
observed throughout the titration, that fell within the error associated with the 
measurement (See Appendix, Figure A.23). It is evident, therefore, that proteins 
other than BSA in NCS may also be causing a quenching of the 5D0 Eu3+ excited 
state of [Eu.L2], or that other electron-rich species in the serum may quench the 
intermediate ligand excited state.  
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Figure 5.31 The emission spectrum of [Eu.L2] in NCS (from ICP-OES concentrations of K+, 
Ca2+ and Mg2+ are 3.9 mM, 2.6 mM and 0.8 mM respectively). λex (A) = 315 nm and (B) 
346 nm, 298 K. [Eu.L2] concentration = 5 µM. 
The evolution of the emission spectrum upon addition of Mg2+ in NCS is 
shown in Figure 5.32. Following addition of 100 mM Mg2+ a 1.3-fold decrease in 
emission intensity at 613 nm was observed following excitation at 315 nm 
(Figure 5.32). In a non-competitive ionic medium, a 1.4-fold increase in emission 
was earlier found after such an addition of Mg2+. The decrease in the total 
emission observed can be attributed to the partial saturation of [Eu.L2] in NCS 
owing to the presence of low mM concentrations of Mg2+, and in particular Ca2+. 
A larger modulation was seen with Ca2+ binding, the addition of further 
concentrations of Mg2+ to the partially saturated [Eu.L2], therefore, resulted in a 
decrease in the total emission intensity.  
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Figure 5.32 (Left) The emission spectrum of [Eu.L2] in NCS following the addition of Mg2+. 
(Right) the fitting of the emission intensity against the concentration of Mg2+ added to a 1:1 
binding model. [Eu.L2] concentration = 5 µM, λex = 315 nm, 298 K.  
A binding constant of 0.6 mM was calculated from the variation of the 
emission intensity at 613 nm with added Mg2+ (Figure 5.32). The excited state 
lifetime on saturation with Mg2+ was almost identical to that observed without any 
added Mg2+, values of 0.30 ms and 0.31 ms were measured respectively.  Such 
behaviour is comparable to that seen with the Mg2+ titration of [Eu.L2] in 50 mM 
HEPES at pH 7.21, where no change in the luminescence lifetime was observed 
following addition of 40 mM Mg2+ (Table 5.4).  
A comparable dissociation constant of 0.7 mM was recorded after 
excitation at 343 nm. The error associated with the fitting was higher, however, 
due to the smaller intensity changes observed on binding Mg2+. A 10% decrease 
in emission intensity at 613 nm was observed at saturation with Mg2+, with a 50 % 
error in the fitting recorded (See Appendix, Figure A.24).  
The Kd values for Mg2+ binding determined from both of these spectral 
emission studies are comparable to the ‘free’ Mg2+ concentration in human serum 
(0.7-1.1 mM in healthy humans).32 The APTRA-based complex [Eu.L2], 
therefore, could have the ability to detect ‘free’ Mg2+ concentrations in human 
serum.   
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5. Part 2: Ruthenium(II)-based systems 
5.8 Introduction  
Over the last 30-40 years, [Ru(bpy)3]2+ has become one of the most 
recognised and extensively studied metal complexes.33-35 Its high chemical 
stability, reversible redox potentials and long excited state lifetime (µs) have 
allowed [Ru(bpy)3]2+ and its derivatives to be used in a range of applications, 
including solid-state light emitting devices.36 Unlike the Laporte forbidden f-f 
transitions that are characteristic of the lanthanide series, the observed deep red 
emission of [Ru(bpy)3]2+ emulates from a metal-to-ligand charge-transfer state of 
triplet character, giving rise to longer lived phosphorescent emission. From 
density functional theory (DFT) calculations electrochemical and Raman studies, 
it has previously been shown that the LUMO is predominantly localised on the 
bipyridine (bpy) ligands.37 The introduction of electron donating and electron 
withdrawing substituents can, therefore, be used in colour tuning applications by 
affecting the separation of the HOMO-LUMO energy gap.38   
An array of [Ru(bpy)3]2+ derivatives have been investigated for a range of 
sensing applications. For example, Sauvage39 and Thomas,40,41 amongst others, 
have published numerous papers based on Ru2+ polypyridyl complexes that bind 
reversibly to DNA.39-41 Complexes including [Ru(bpy)2(dppz)]2+ ([Ru.4]) are not 
significantly emissive in water, but luminescence is greatly enhanced upon 
intercalation into DNA.39,41  
Ruthenium-based complexes have also been explored as selective cation 
sensors. Structurally, many are analogues of [Ru(bpy)3]2+ containing two 
bipyridine ligands with the third N^N ligand incorporating the cation binding 
moiety. Complexes have been synthesised containing predominantly 
macrocycles, such as benzo-15-crown-5 for the binding of Na+ ([Ru.1] and 
[Ru.2])36 and 1,4-diaza-7,10,13-trithia-cyclopentadecane for the selective binding 
of Hg2+ ([Ru.3])42 (Figure 5.33). Solubility is often a problem. The vast majority 
of Ru2+ based complexes synthesised to bind metal ions are not water soluble, 
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with luminescence measurements instead having to be undertaken in organic 
solvents, such as acetonitrile and methanol.36,42   
 
Figure 5.33 Ru2+ based cation sensors from the literature for Na+ (A) and (B),36 Hg2+ (C) 42 
and (D) [Ru(bpy)2(dppz)]2+, a DNA intercalation complex developed by Sauvage et al.39 
 The aim of the work described in this section was to synthesise a Ru2+ 
based probe to study the binding of Mg2+, Ca2+ and Zn2+. Structurally, the complex 
contains two bipyridine ligands and a third bipyridine functionalised with an 
APTRA binding group to study the binding of divalent cations. Original targets are 
shown in Figure 5.34.  
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Figure 5.34 Target Ru2+ and Ir3+ complexes, [Ru.bL2]2+ and [Ir.bL2]+, with PF6– counter 
ions.  
Initially Ir3+ systems based on the well-known [Ir(ppy)2(bpy)]+ core were 
also considered as possible sensing probes. It was found, however, that the 
complexes functionalised with the desired metal binding unit were insoluble in 
water or even in 50 % water / 50 % methanol, limiting their ability to act as Mg2+ 
sensors in biological media. It was therefore decided that binding properties of 
the more water soluble [Ru.bL2] series would be analysed. The binding affinity 
and selectivity for Mg2+, Ca2+ and Zn2+ will be directly compared with that 
displayed by the bi-aryl Tb3+ system [Tb.bL2]. 
5.9 Synthesis and characterisation  
4-Bromo-2,2’-bipyridine [bpy-Br], (57) was obtained in a four-step 
procedure from bipyridine, in a method adapted from Wenkert and Woodward 
(Scheme 5.5).43 The mono-N-oxide, (54), was prepared from bipyridine and m-
CPBA, before nitrating with concentrated sulphuric acid and potassium nitrate to 
form (55) in moderate yield. A subsequent nucleophilic displacement reaction 
following addition of acetyl bromide and removal of the N-oxide with PBr3 at room 
temperature afforded (57) in excellent overall yield. 
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Scheme 5.5 The synthesis of 4- bromo-2,2’-bipyridine [bpy-Br], (57) from bipyridine.43 
[Ru(bpy)2(bpy-Br)]2+, (58) was synthesised from cis-bis(2,2’-bipyridine) 
dichlororuthenium(II) hydrate in methanol, using silver nitrate as the chloride 
scavenger (Scheme 5.6). Suzuki cross-coupling methodology was used to 
couple (58) with (50) in DMSO, using Pd(PPh3)4 as the catalyst and sodium 
carbonate as the base. This method for cross-coupling onto bromo-substituted 
Ir3+ and Ru2+ complexes has been utilised in Durham to form a range of complex 
multimetallic systems.44 The tris tert-butyl ester (59) was isolated as its PF6 salt, 
by adding the DMSO reaction solution to a saturated aqueous solution of KPF6. 
Purification was achieved by recrystallisation from a mixture of methanol and 
diethyl ether. tert-Butyl ester hydrolysis of (59) was carried out using 
trifluoroacetic acid in dichloromethane (1:1) to yield [Ru.bL2] (Scheme 5.6).  
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Scheme 5.6 The synthesis of [Ru.bL2]2+, isolated as its PF6 salt. 
5.10 Photophysical properties of [Ru.bL2]2+ 
The absorbance spectrum of [Ru.bL2]2+ in aqueous solution at 298 K is 
shown in Figure 5.35. It displays a broad band at 457 nm which is attributed to a 
d to π* metal-to-ligand charge transfer (1MLCT) transition. The sharp intense 
band at 288 nm is assigned to a π π* ligand centred (LC) transition of the 
bipyridine ligand.35,45 Its nature was first confirmed by Lytle and Hercules in 1969, 
from absorbance measurements on protonated bipyridine.45 The spectrum is 
almost identical to that of [Ru(bpy)3]2+.35 The introduction of an APTRA binding 
group onto one bipyridine ligand, therefore, does not have a significant effect on 
the spectrum other than a small 7 nm red shift in the MLCT maximum. 
The photophysical properties of [Ru.bL2]2+ are shown in Table 5.7, 
together with those of [Ru(bpy)3]2+ for comparison.  
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Figure 5.35 (A) The absorbance spectrum and (B) the emission spectrum of [Ru.bL2]2+ in 
H2O, 298 K, concentration = 15 µM, λex = 457 nm.  
Table 5.7 The photophysical properties of [Ru.bL2]2+ and [Ru(bpy)3]2+  at 298 K. Properties 
of [Ru.bL2]2+ were recorded in H2O (< 1% DMSO). The MLCT wavelength maximum for 
[Ru(bpy)3]2+ was measured in acetonitrile at 298 K.35 a Quantum yields (0) ± 20 % 
measured with a [Ru(bpy)3]2+ standard in H2O. 
Complex λMLCT (nm) 2 / 103 (M-1cm-1) 0%*+ / % 
[Ru.bL2]2+ 457 3.8(2) 7.0a 
[Ru(bpy)3]2+ 30 450 14.630 2.830 
 
The emission spectrum of [Ru.bL2]2+ was recorded in aqueous solution at 
298 K, upon excitation at 457 nm (Figure 5.35). A broad and structureless 
emission spectrum is displayed, with a peak maximum of 629 nm, and a large 
shift of 172 nm between the 1MLCT transition in the absorbance spectrum, and 
the 3MLCT emission maximum. The spectral response reported here is 
comparable with [Ru(bpy)3]2+ based complexes in the literature, where a 
wavelength maximum within the range of 610-620 nm is typically seen.35,38,46  
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5.11 pKa studies of [Ru.bL2]2+ 
5.11.1 Absorbance pKa studies  
	
The absorbance spectra of [Ru.bL2]2+ in acidic and basic solutions are 
shown in Figure 5.36, displaying peak maxima at 288 nm and 457 nm in 100 mM 
KCl. In both acidic conditions the spectrum is identical to that observed in 
Figure 5.35. It is apparent from the analysis of Figure 5.36, that there is no 
change in peak intensities of the LC, MC or MLCT bands, with no shift in the 
wavelength maxima observed over the pH range of 4 to 10. No pKa value for 
[Ru.bL2]2+ could, therefore, be determined from absorbance spectroscopy.  
 
 
 
 
 
Figure 5.36 Absorbance spectrum of [Ru.bL2]2+ in acidic (pH 4.8) and basic (pH 9.7) 
solutions. [Ru.bL2]2+ concentration = 30 µM in 100 mM KCl, 298 K. 
5.11.2 Emission pKa studies  
	
The variation of the emission spectrum with pH was monitored following 
excitation at 457 nm. In both acidic and basic solutions, an identically broad 
emission spectrum to that seen in Figure 5.35 was displayed. A small 1.1-fold 
increase in the emission intensity was observed in acidic solution (Figure 5.37).  
The emission intensity is insensitive to pH in the range 7-10, with a sharp 
increase in the emission intensity observed at around pH 7 from which a pKa 
value of 6.9 was determined.  
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Figure 5.37 (Left) emission spectrum of [Ru.bL2]2+ from pH from pH 9.7 to 5.8. (Right) the 
change in the emission intensity at 457 nm with pH. [Ru.bL2]2+ concentration = 30 µM in 
100 mM KCl, 100 mM KCl, 298 K. 
5.12 Binding studies of [Ru.bL2]2+ 
The evolution of the absorbance, emission and excitation spectra of 
[Ru.bL2]2+ upon binding with Mg2+, Ca2+ and Zn2+ in aqueous solutions is 
reported here. Comparisons of the affinities and selectivities of biologically 
relevant divalent cations will be made to APTRA-based lanthanide complexes 
[Eu.L1], [Eu.L2] and in particular [Tb.bL2], which contains a similar bi-aryl 
chromophore. 
5.12.1 Absorbance binding studies with Mg2+, Ca2+ and Zn2+  
	
It is evident from Figure 5.38 that, following addition of Mg2+, Ca2+, Zn2+ to 
[Ru.bL2]2+, no change in the wavelength maxima was observed at the LC, MC 
and MLCT transitions in the absorbance spectra. The wavelength maximum of 
[Ru.bL2]2+ is comparable to other ruthenium-based bi-aryl complexes including 
[Ru(bpy)2(phbpy)]2+ (phbpy = 4,4’-biphenyl-2,2’-bipyridine), where a wavelength 
maximum of 627 nm and an aerated quantum yield of 1.5 % was observed.47  
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Figure 5.38 Absorbance spectra of [Ru.bL2]2+ following the addition of (A) Mg2+ (60 mM), 
(B) Ca2+ (3.5 mM) and (C) Zn2+ (1.4 µM). [Ru.bL2]2+ concentration = 30 µM in 50 mM 
HEPES, 100 mM KCl, pH 7.21, 298 K. 
5.12.2 Emission binding studies with Mg2+, Ca2+ and Zn2+  
	
 Emission binding studies of [Ru.bL2]2+ with divalent metal ions were 
carried out with excitation at the 1MLCT state at 457 nm. A non-ratiometric 
emission- and excitation-based response was seen following the addition of the 
selected metal ions (Figure 5.39). In both the emission and excitation spectra of 
[Ru.bL2]2+, only small spectral intensity changes were observed. For example, a 
1.3-, 1.3- and 1.2-fold decrease in the emission intensity was observed at 629 nm, 
following the addition of Mg2+, Ca2+ and Zn2+ respectively. No wavelength shift of 
the emission or excitation peak maximum was observed upon binding saturation 
with any of the divalent metal ions tested. 
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Figure 5.39 (Left) emission spectra; (right) fitting of the emission intensity against the 
added concentration of (A) Mg2+ (60 mM), (B) Ca2+ (3.5 mM) and (C) Zn2+ (1.4 µM) to a 1:1 
binding model. [Ru.bL2]2+ concentration = 30 µM in 50 mM HEPES, 100 mM KCl, pH 7.21, 
298 K. Dissociations constants are provided with an error associated with the fitting.  
Dissociation constants were calculated by iteratively fitting the change in 
the emission intensity at 629 nm against the concentration of the added divalent 
metal ions to a 1:1 binding model. Kd values of 13.5 mM, 0.57 mM and 0.10 µM 
were calculated, following the addition of Mg2+, Ca2+ and Zn2+ respectively.  The 
dissociation constants highlighted here for Mg2+ and Ca2+ are comparable to 
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those seen with [Tb.bL2] (16.9 mM for Mg2+, and 0.8 mM for Ca2+), containing a 
bi-aryl chromophore. Complex [Ru.bL2]2+, however, was found to have a higher 
affinity for Zn2+, with a dissociation constant of 0.1 µM determined. The Mg2+ 
affinity for bi-aryl complexes in the case of [Tb.bL2] and [Ru.bL2] was found to 
be significantly lower than that observed for [Eu.L1] and [Eu.L2], containing a 
pyridylalkynylaryl chromophore.  
In contrast to the effect observed here for [Ru.bL2]2+ following the addition 
of divalent metal ions, a number of examples of complexes based on [Ru(bpy)3]2+ 
display emission-based hypsochromic shifts of their wavelength maximum on 
metal ion binding. The crown ether based [Ru.1], for example, shown in 
Figure 5.33, was developed by Beer and co-workers, and exhibited a 16 nm and 
3 nm shift towards the blue following the addition of Na+ and Mg2+ respectively.36 
The emission wavelength maximum of complex [Ru.2] displayed a 14 nm blue 
shift following addition of Na+, with a 2 nm hypsochromic shift observed on 
binding of Mg2+. The vinyl-link in the bipyridine ligand was found to be essential 
for the spectral behaviour observed, with no wavelength shifts observed in the 
absence of the vinyl group.  
5.13 Conclusions of this chapter   
 The synthesis and photophysical studies of three lanthanide complexes 
[Ln.L1], [Ln.L2] and [Ln.bL2] and one ruthenium complex [Ru.bL2]2+ bearing 
APTRA binding groups have been reported. Carboxylate-based pro-ligands L1 
and L2 were incorporated into both a pyridylalkynylaryl- or pyridylaryl-based 
chromophore for the sensitisation of lanthanide complexes, and a bipyridine 
ligand for coordination to Ru2+. Complexes [Eu.L1], [Eu.L2] and [Tb.bL2] possess 
a hydration number of one (q = 1) in a stable 9-coordinate lanthanide complex.  
The pH response and binding behaviour with Mg2+, Ca2+ and Zn2+ were 
studied using emission spectroscopy. Complexes containing a pyridylalkynylaryl 
chromophore [Eu.L1] and [Eu.L2], displayed a non-ratiometric response following 
addition of divalent metal cations, with no effect on the excited state lifetime 
observed. The bi-aryl complex [Tb.bL2], in contrast, showed a ratiometric 
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response following the addition of Mg2+ and Zn2+, with an increase in the excited 
state lifetime only for Mg2+ binding, tentatively attributed to the reduction in back 
energy transfer and reduced oxygen quenching of the triplet excited state of the 
chromophore.  
The complexes [Eu.L1], [Eu.L2], [Tb.bL2] and [Ru.bL2]2+ were found to 
have a significantly lower affinity towards Ca2+, than the typical mid µM affinity 
observed in the naphthalene series (Chapter 4), and related literature-based 
APTRA indicators.27,28 A low mM affinity for Ca2+ was found throughout this work, 
with Kd values in the range of 0.6-0.9 mM. For example, it was determined that 
[Eu.L2] had a 28-fold lower affinity for Ca2+ than NapL2, and a 17-fold weaker 
binding compared to [Tb.2] developed by Parker et al.5,6 (Table 5.6).  
Complexes containing a pyridylalkynylaryl chromophore were found to be 
the most selective for the binding of Mg2+. Both [Tb.bL2] and [Ru.bL2]2+ displayed 
a 2-5-fold lower affinity towards Mg2+ compared to [Eu.L1] and [Eu.L2], while 
showing comparable affinities for Ca2+ and Zn2+.  
The reduced affinity observed for Ca2+ in non-competitive media, allowed 
Mg2+ binding to be investigated in newborn calf serum (NCS). The study carried 
out with [Eu.L2] is the first reported APTRA-based complex developed that can 
sense Mg2+ in serum. Encouraging results in NCS were obtained, following the 
addition of Mg2+. A ‘turn-off’ response was seen in the emission spectrum, 
associated with a binding constant of 0.6 mM. This Kd value is comparable to the 
‘free’ Mg2+ concentration in human serum.32  
The pKa and dissociation constants of [Eu.L1], [Eu.L2], [Tb.bL2] and 
[Ru.bL2]2+ are shown in Table 5.8. Lanthanide-based complex [Tb.2] developed 
by Parker et al. has been included for comparison.   
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Table 5.8 A summary of the calculated pKa and dissociation constants of [Eu.L1], [Eu.L2], [Tb.bL2] and [Ru.bL2]2+ via fluorescence emission 
spectroscopy. All pKa values are given with an error associated with the fitting. The reported binding constants following the addition of Mg2+, Ca2+ and 
Zn2+ to [Eu.L1], [Eu.L2] and [Tb.bL2] are an average of 2-3 independent metal ion titrations, and are given with the experimental error given in 
parenthesis. Mg2+ saturated wavelengths are highlighted in red.† pKa value determined from absorbance spectroscopy. * Value determined from 
deoxygenated solutions in both H2O and D2O.   
Complex q Absorption 
λex (nm) 
ε / 103 
(M- 1cm-1) 
Excitation 
λmax (nm) 
Emission 
λmax (nm) 
pKa Log K 
(Mg2+) 
Kd 
(Mg2+) 
Log K 
(Ca2+) 
Kd 
(Ca2+) 
Log K 
(Zn2+) 
Kd 
(Zn2+) 
[Eu.L1] 1 316 
316 
11.5(2) 315 
315 
699 
699 
4.5(02)† 2.1(05) 7.5(8) 
mM 
3.0(1) 0.9(2) 
mM 
5.7(2) 1.8(5) 
µM 
[Eu.L2] 1 318 
318 
18.4(4) 314 
314 
699 
699 
6.7(04) 2.4(2) 3.7 
(1.5) 
mM 
3.0(05) 0.9(1) 
mM 
5.7(04) 1.9(1) 
μM 
[Tb.bL2] 1* 280 
280 
6.2 279 
274 
544 
544 
No pH 
response 
1.8(06) 16.9 
(2.3) 
mM 
3.1(05) 0.8(1) 
mM 
6.3 0.5  
μM 
[Ru.bL2]2+ - 457 
457 
3.8(2) 454 
454 
629 
629 
6.9(01) 1.9 13.5 
mM 
3.2 0.6 
mM 
7.0 0.1 
μM 
[Tb.2] 6 1 262  - - 544 
544 
6.4† 3.17 0.8 
mM 
4.14 53.7 
µM 
5.0 10.5 
µM 
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6. Conclusions and Future Work  
6.1 Conclusions 
The aim of the work described throughout this report was to develop new 
ligands and complexes to study the binding of Mg2+ via both absorbance and 
luminescence spectroscopy. Originally, the work was subdivided into two main 
objectives. The first was to incorporate the APTRA binding group into new 
naphthalene, lanthanide(III) and ruthenium(II)-based systems to study the 
binding of Mg2+ and its competing divalent cations Ca2+ and Zn2+. The APTRA 
binding group has been incorporated into numerous fluorophores over the years 
for a range of biological applications.1-3  It remains the chelate of choice in the 
vast majority of Mg2+ sensors in the literature, even though it is universally 
recognised to display a higher selectivity towards Ca2+ over Mg2+. The second 
and primary objective, therefore, was to develop new metal chelates containing 
phosphinate-based binding groups, in an attempt to increase the selectivity for 
the binding of Mg2+.  
Four pro-ligands bearing carboxylate and phosphinate groups were 
synthesised and characterised in Chapter 2, namely L1, L2, L4 and L6. These 
ligands were expected to form either a [5, 5, 5] (L1, L2 and L4) or [6, 5] (L6) ring 
chelate on the binding of divalent cations. Binding groups were introduced via a 
series of alkylation reactions on aminophenol precursors, with Hünig’s base in 
acetonitrile found to be the conditions of choice. The incorporation of ligands L1, 
L2, L4 and L6 into fluorescent naphthalene-1-alkynylaryl (Chapter 4) and 
luminescent metal-based systems (Chapter 5) allowed the binding of Mg2+ and 
other biologically relevant cations to be studied in both non-competitive and 
competitive aqueous ionic media.  
The development of the pentadentate APTRA analogue o-aminophenol-
N,N-diacetic acid phosphinate (APDAP), containing one phosphinate binding 
group, was highlighted in Chapter 3.  A direct comparison of the pH behaviour 
and the binding of divalent cations to that of its APTRA analogue, was studied 
via absorbance spectroscopy. Promising results were shown: a desirable lack of 
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sensitivity to pH in the range 6.5-7.5, and a reported 110-fold lower affinity for the 
binding of Ca2+ compared to APTRA. The enhanced selectivity for the binding of 
Mg2+ was linked to the longer C-P and P-O bonds in APDAP, generating a larger 
effective chelate ring size that inherently favours the binding of the smaller Mg2+ 
ion over Ca2+.  
The encouraging results obtained for APDAP in Chapter 3 were carried 
through into Chapter 4, with the incorporation of the APDAP binding moiety into 
a naphthalene-1-alkynylaryl system to study the binding of Mg2+. Phosphinate-
based ligand NapL4 displayed a 10-fold weaker affinity for Ca2+ than the 
carboxylate-based NapL1 and NapL2, which were seen to have values 
comparable to literature-based APTRA indicators.1,3,4 Interestingly, and 
surprisingly, however, NapL4 also displayed a higher affinity for Mg2+.  
Tridentate ligand NapL6 displayed the lowest affinity for Mg2+ throughout 
the naphthalene series, suggesting that a higher denticity, i.e. pentadentate for 
NapL1, NapL2 and NapL4, is preferred for a low mM binding affinity of Mg2+. 
Following the addition of Ca2+ and Zn2+, negligible changes in the fluorescence 
emission and excitation spectrum were observed, suggesting a weak binding to 
these cations in particular. It had been thought initially that a lower denticity may 
favour the binding of Mg2+ over Ca2+ and Zn2+ because the binding of Mg2+ carries 
the greatest enthalpic cost, with the reduction in the denticity causing the biggest 
entropic penalty for Ca2+ and Zn2+.4 Such behaviour is one possible explanation 
for the reduced affinity observed for Ca2+ in the β-keto acid series.5  
In Chapter 5, the APTRA binding group was incorporated into 
lanthanide(III)- and ruthenium(II)-based systems. It was found from luminescence 
spectroscopy that the Mg2+ / Ca2+ selectivity was significantly enhanced in the 
metal-based complexes [Eu.L1], [Eu.L2], [Tb.L2] and [Ru.bL2]. A low mM affinity 
for the binding of Ca2+ was observed in each complex, containing either a 
pyridylalkynlaryl or bi-aryl chromophore, and is significantly lower than the µM 
affinity seen for Ca2+ with NapL1 and NapL2.  
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The lanthanide systems were favoured over ruthenium complexes due to 
their higher quantum yields in solution, ‘turn-on’ enhancement in the case of 
[Eu.L2], and the observation of larger fluorescence changes on the binding of 
divalent metal ions. Complexes containing pyridylalkynylaryl chromophores 
[Eu.L1] and [Eu.L2] were found to be the most selective complexes for the 
binding of Mg2+ out of all the metal-based systems studied, with low mM affinities 
for both Mg2+ and Ca2+. They also displayed significantly longer excitation 
wavelengths than the bi-aryl lanthanide complexes, making them more suitable 
for future cellular studies in their present state.  
The lower affinity displayed for Ca2+ in the metal-based complexes could 
in part be due to the reduced donor ability of the aniline nitrogen lone pair of 
electrons. Complex [Eu.L2], for example, displayed a 28-fold weaker affinity for 
Ca2+ over the model naphthalene analogue NapL2. The Zn2+ affinity between the 
model naphthalene series and the metal-based systems was, however, 
comparable. Such behaviour could be explained by the fact that Zn2+ ions 
typically favour the binding to tertiary nitrogen donors over Mg2+ and Ca2+.6 
6.2 Future Work 
It has been highlighted over the course of this work that the incorporation 
of a phosphinate binding group at the expense of a carboxylate ligating group 
dramatically enhances the relative Mg2+ / Ca2+ selectivity. Promising results were 
achieved with APDAP in Chapter 3, and NapL4 in Chapter 4, with the 
phosphinate-based ligands displaying an improved Mg2+ / Ca2+ selectivity 
compared to literature-based APTRA ligands. It would be interesting, therefore, 
to incorporate the APDAP binding group into a pyridylalkynylaryl chromophore to 
form phosphinate-based lanthanide complex [Ln.L4] (Figure 6.1). A study into 
the pH behaviour and the binding of Mg2+ and its competing biologically relevant 
cations Ca2+ and Zn2+ to [Ln.L4], would allow a direct comparison to be made 
with carboxylate-based complexes [Ln.L1] and [Ln.L2].  
Another area of particular interest is to develop a targeted probe to study 
the binding of Mg2+ in cellular organelles such as the mitochondria. The vast 
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majority of mitochondrial targeting probes in the literature contain biologically 
stable lipophilic cations such as rhodamine and trialkylphosphonium cations 
(TPP+). These cations are well known to accumulate in the mitochondria because 
of its negative membrane potential.7 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Possible structures of future lanthanide complexes containing (A) the APDAP 
binding group [Ln.L4], and (B) an APTRA-based mitochondria-targeted luminescence 
probe containing a TPP+ group for localisation in the mitochondria [Ln.mito].   
Sensing Mg2+ in the mitochondria is of particular interest. It has been found 
that in HeLa cells an increase in ‘free’ Mg2+ was observed in the mitochondria in 
the early stages of Staurosporine-induced apoptosis.8 Progress in the area, 
however, has been restricted due to the lack of selective probes available for the 
binding of Mg2+. Many indicators, such as Mag-mito developed by Buccella et al, 
require the use of BAPTA in cellular studies to eliminate any Ca2+ interference.8  
The significantly higher Mg2+ / Ca2+ selectivity observed in Chapter 5 for 
lanthanide complexes [Eu.L1] and [Eu.L2], in particular, may allow the in vivo 
studies to be carried out without the use of BAPTA. Complexes [Eu.L1] and 
[Eu.L2] displayed a two order of magnitude reduction in their Ca2+ affinity 
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compared with APTRA analogues in the literature (mM vs. µM). It would be 
expected, therefore, that in cells the Ca2+ interference would be greatly reduced. 
Slight modifications would need to be made to both the complex and the 
chromophore structures for mitochondria-targeted in vivo studies. The proposed 
structure of [Ln.mito] is shown in Figure 6.1. The addition of a lipophilic TPP+ 
cation onto a pyridine group should favour accumulation of the complex within 
the mitochondria, whilst maintaining the same affinity and selectivity for Mg2+ 
observed for [Ln.L2]. The introduction of acetoxy methyl (AM) esters on the 
APTRA binding unit, will facilitate cell loading,1,5 with the esters cleaved readily 
in vivo by intracellular esterases.1,5,8 
Finally, another area of interest is to develop a metal responsive NMR-
based probe that could be used to detect ‘free’ Mg2+ in vivo. In Durham, extensive 
work has been carried out to develop pH responsive 1H PARASHIFT lanthanide-
based MRI probes that contain a tert-butyl reporter group.9,10 The tert-butyl group 
is typically 6 to 6.5 Å from the lanthanide centre, shifting the resonance away 
from the strong 1H signals arising from water (4.7 ppm) and fat (1.3 ppm) in vivo, 
and increasing the sensitivity of the technique.9   
 
Figure 6.2 Possible structure of a metal-responsive PARASHIFT NMR probe [Ln.L7], to 
study the binding of Mg2+ and other divalent cations.    
A PARASHIFT probe with a phosphinate-group adjacent to the tert-butyl 
reporter group has been shown to be temperature- and pH-dependent.10 Upon a 
change in pH for example, a significant shift of the tert-butyl resonance is 
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reported.10 The proposed structure of a Mg2+ responsive PARASHIFT probe, 
[Ln.L7], is shown in Figure 6.2 with a tert-butyl reporter group introduced onto 
the pyridylalkynylaryl chromophore. It is thought that following the addition of 
Mg2+ to [Ln.L7], a shift in the tert-butyl resonance could occur allowing the binding 
of Mg2+ to be monitored initially by 1H NMR spectroscopy. The incorporation of 
the APDAP binding group into a pyridylalkynylaryl chromophore [Ln.L7] (X = 
PMe), would also allow the binding of Mg2+ to be studied by 31P NMR.  
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7. Experimental 
 
7.1 General procedures 
7.1.1 Materials 
	
All commercially available reagents were used as received from suppliers 
without further purification. Solvents used were laboratory grade. Anhydrous 
solvents were dried over the appropriate drying agent. All moisture-sensitive 
reactions were carried out by Schlenk-line techniques, under an inert atmosphere 
of either argon or nitrogen. For air sensitive reactions, solvents were degassed 
using the freeze-pump-thaw cycle method. Water was purified by the 
‘PuriteSTILLplus’ system with a conductivity of < 0.04 µS cm-1.  
7.1.2 Chromatography 
	
Thin layer chromatography was performed on neutral alumina (Merck Art 
5550) or silica (Merck Art 5554) and visualized under UV irradiation (254 nm) or 
by staining with either iodine or potassium permanganate. Column 
chromatography was carried out either manually using neutral alumina or silica 
(Merck Silica Gel, 230 – 400 mesh) or using a Teledyne Combi-flash instrument 
equipped with RediSep Rf silica cartridges to perform automated elution.  
7.1.3 Instrumentation 
	
NMR: Routine 1H (400 MHz) and 13C (101 MHz) and 31P (162 MHz) NMR 
spectra were acquired on Bruker Avance or Varian Mercury 400 NMR 
spectrometers. 13C NMR and 31P NMR spectra were run on a proton decoupled 
experiment. Two-dimensional NMR spectra (COSY, NOESY, HSQC and HSBC) 
were carried out by the solution state NMR service at Durham University on 
Varian-600 (600 MHz) or VNMRS-700 (700 MHz) instruments.  
Mass spectrometry: ES-MS data was acquired on a Waters TQD mass 
spectrometer interfaced with an Acquity UPLC system. ASAP experiments were 
carried out on a Waters Xevo QToF mass spectrometer. Mass spectra of NapL1, 
NapL2, NapL4, NapL6, [Ln.L1] and [Ln.L2]  were recorded on a Waters Xevo 
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QToF instrument in an acetonitrile and ammonium bicarbonate buffered (25 mM) 
system.  
Melting points: Melting points were measured on a Gallenkamp melting 
point apparatus, and are uncorrected.  
7.1.4 pKa determination 
	
pH measurements were recorded using a Jenway 3510 pH meter in 
combination with a Jenway 924 005 pH electrode. The pH probe was calibrated 
before each independent titration using commercially available buffer solutions of 
pH 4, 7 and 10. Samples were prepared with a background of constant ionic 
strength (I = 0.1 M KCl, 298 K). Aqueous solutions were titrated to acid using 
0.025 M, 0.05 M and 0.1 M concentrations of HCl(aq). The resulting sigmoidal 
curve of either absorbance or fluorescence intensity vs. pH was fitted by a non-
linear least squares iterative analysis by Boltzmann using Origin 8.0 software. In 
each instance, pKa values were calculated with an error associated with the 
fitting.  
7.2 Optical techniques  
7.2.1 Absorption spectroscopy 
	
UV-Vis absorption spectra were measured using a UVIKON XS 
spectrometer operating with LabPower software. The sample was held in a quartz 
cuvette with a path length of 1 cm. Absorption spectra were recorded against 
pure solvent in an optically matched cuvette.  
Extinction coefficients were calculated using a sample dilution method, 
from a linear plot of absorbance against concentration according to the Beer-
Lambert law (Equation 7.1). 
A= εcl          Eq. 7.1 
where: A is absorbance (at !"#$), % is molar extinction coefficient, l is the path 
length of the cuvette (1 cm), and c is the concentration of the sample.  
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7.2.2 Fluorescence Spectroscopy 
	
 Emission and excitation spectra were acquired on a Jobin Yvon 
Fluoromax-2 spectrometer, in quartz cuvettes with a path length of 1 cm. 
Excitation and emission wavelengths were selected according to the specific 
sample. An integration time of 0.5 seconds and increment of 1.0 nm was used. 
Emission and excitation bandpasses used were either 2:2 or 3:3 (in nm) 
depending on the brightness of the sample. 
Lanthanide emission and excitation spectra were recorded using the 
appropriate glass filter (435 nm filter for Eu(III) complexes and 395 nm filter for 
Tb(III) complexes), to remove 2λex light from the fluorescence emission and &'()  
from the excitation spectrum.  
Degassed samples were measured in an adapted cuvette which can be 
attached to a vacuum line and degassed using the freeze-pump-thaw cycle 
method. 
Low temperature measurements were carried out at 77 K in a smooth 
glass of ethanol. In each case, the complex was first dissolved in the minimum 
amount of water, before ethanol was added.  
7.2.3 Luminescence lifetimes  
	
 Lifetime measurements were carried out using two instruments. Lifetimes 
of aerated samples were measured using a Perkin Elmer LS55 luminescence 
spectrometer. Lanthanide excited state lifetimes were measured by excitation of 
the sample by a short pulse of light, followed by the monitoring of the integrated 
intensity of light emitted during a fixed gate time tg, after a delay time of td. 
Measurements were made for at least 30 separate decay times over a period of 
a minimum of three lifetimes. A gate time of 0.1 ms was selected. The decay 
curves were fitted to Equation 7.2 using Origin 8.0 software.  
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I= A0	+ A1e-kt    Eq. 7.2 
where: I is the intensity at time t after the excitation pulse, A0 is the background 
intensity after the fluorescence decay, A1 is the pre-exponential factor and k is 
the rate constant for the excited state decay. The excited state lifetime, +, can be 
calculated according to Equation 7.3.   
τ= 1k     Eq. 7.3 
The inner sphere hydration numbers (q) of Eu3+ and Tb3+ complexes are 
calculated by measuring the luminescence lifetimes in both H2O and D2O. The q 
value was calculated from Equation 7.4 for Eu3+ complexes and Equation 7.5 
for Tb3+ complexes.1  
qEu=	1.2 kH2O	– kD2O	–0.25	–0.075n     Eq. 7.4 
qTb=	5.0 (kH2O	–  kD2O	– 	0.06	– 	0.010n)    Eq. 7.5 
where: qEu / qTb is the inner sphere hydration number, k is rate constant for 
luminescence decay and n is the number of proximal amide –NH oscillators. 
Degassed luminescence lifetimes were measured using an OB 920 
Fluorimeter, using a xenon flash lamp as the excitation source. For both 
instruments, excitation and emission wavelengths were selected based upon the 
individual lanthanide complex being measured.  
7.2.4 Quantum yields  
 
The luminescence quantum yields were determined relative to a well 
known luminescence standard. A reference of [Ru(bpy)3]2+ in H2O 
(Φ./0 = 0.028)2, quinine sulphate in 0.5 M H2SO4 (Φ2.0 = 0.546)3 or 
1,4-bis(5-phenyloxazol-2-yl) benzene (POPOP) in cyclohexane (Φ233 = 0.97)4 
were used. The standard was chosen depending on both the fluorescence 
emission spectrum, and the excitation wavelength that was required. In each 
instance, the luminescence standard used for each quantum yield measurement 
is included in the table caption for reference.   
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Solutions of both the sample and reference were prepared so that the 
absorbance intensity at the excitation wavelength (λ56) was 0.1. All 
measurements were recorded at room temperature under both aerated and 
deoxygenated conditions. Absorbance and emission spectra of the reference and 
the sample were run consecutively with identical parameters. The quantum yield 
for all ligands / complexes was calculated from Equation 7.6.  
Φa= IaIb  x 
Ab
Aa x
na
nb
2
x Φb    Eq. 7.6 
where: ‘a’ refers to the sample and ‘b’ refers to the standard. 7 is the quantum 
yield, I is the integrated intensity of the emission spectrum, A is the absorbance 
at the excitation wavelength (λ56 = ~ 0.1) and n is the refractive index of the 
solvent.  
7.3 HPLC analysis 
 Reverse phase HPLC was performed at 295 K using a Shimadzu system 
consisting of a Degassing Unit (DGU-20A5R), a Prominence Preparative Liquid 
Chromatograph (LC-20AP). An XBridge C18 10 x 100 mm, 5 µM column was 
used to purify the complexes on a preparative scale with a flow rate of 
17 mL / minute. Analytical scale purifications were performed on a Shimadzu 
ShimPacl VP-ODS column, 4.6 x 150 mm, 5 µM column with a flow rate of 
2 mL / min. A gradient elution was used with a total run time of 25 minutes for 
each individual injection. The conditions used for all preparative HPLC 
purifications of lanthanide complexes can be seen in Table 7.1.  
Table 7.1 Preparative HPLC procedure for all lanthanide complexes. 
Solvent A = Ammonium bicarbonate buffer (25 mM) in water, Solvent B = CH3CN. 
Time (min) Solvent A (%) Solvent B (%) 
0 100 0 
3 100 0 
13 0 100 
16 0 100 
25 100 0 
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7.4 Metal ion binding studies  
All divalent metal binding studies for the addition of Mg2+, Ca2+ and Zn2+ 
([M2+]) were carried out in buffered solutions of 50 mM HEPES and 100 mM KCl 
maintained at pH 7.2. Concentrations of the ligand / complex used during the 
titration are stated in the Figure caption in each instance. Stock solutions of [M2+] 
contained the same concentration of the sensor in the cuvette to avoid sample 
dilution over the course of the titration. Small aliquots of [M2+] were added in each 
instance, with the absorbance, emission and excitation spectra run 5 minutes 
after each addition to ensure the sample had equilibrated.   
New-born calf serum (NCS), for the titration of NapL4 and EuL2 was 
supplied from Thermo Fisher Scientific and stored at -20 oC. Small amounts of 
NCS were defrosted the morning prior to use. Stock solutions of [M2+] were also 
made in NCS to avoid dilution. ICP-OES was used to determine the 
concentrations of Ca2+ (2.6 mM), Mg2+ (0.8 mM) and K+ (3.9 mM) in the NCS prior 
to the Mg2+ titration. 100 µL of NCS was diluted to 2 mL using 200 µL ultrapure 
nitric acid (70 % wt.) and 1.7 mL H2O in a Teflon vial. The blank was prepared by 
an identical method with 200 µL ultrapure nitric acid (70 % wt.) and 1.7 mL H2O. 
Both the sample and the blank were diluted by a factor of 5 prior to analysis with 
dilute nitric acid.  
Dissociation constants (Kd’s) for the binding of Mg2+ and Ca2+ were 
generated from a 1:1 binding model obtained from a least square fitting iterative 
from www.supramolecular.org.5 Binding constants were verified with the 
comparison to those obtained from the linear plots of Equation 7.7 and 
Equation 7.8 for non-ratiometic indicators and Equation 7.9 for ratiometric 
indicators (See Appendix). In the case of Zn2+ binding, dissociation constants 
were calculated from a plot of (9:9(;<)(9(>?:9) in Chapter 3, and  (@:@(;<)(@(>?:@) or (A:A(;<)(A(>?:A) in 
Chapter 4 and Chapter 5, against the concentration of Zn2+ added. The 
dissociation constants were calculated from a reciprocal of the association 
constant obtained from the gradient of the straight line (Equation 7.10).  
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[M2+]	=	Kd (A	–	Amin)(Amax	–	A)       Eq. 7.7 
[M2+]	=	Kd (F	–	Fmin)(Fmax	–	F)       Eq. 7.8 
 M2+ =Kd
R	–	Rmin
Rmax	–	R Sf2Sb2     Eq. 7.9 
Kd	= 1Ka     Eq. 7.10 
where: [M2+] is the divalent cation concentration (Mg2+, Ca2+ and Zn2+), Amin / Fmin 
are the integrated fluorescence emission / absorbance of the metal-free sensor, 
Amax / Fmax is the integrated fluorescence emission / absorbance of the metal-
saturated sensor. A / F is the integrated fluorescence emission / absorbance at 
concentration [M2+]. Rmin is the ratio of fluorescence excitation / emission of the 
‘metal-free’ sensor, Rmax is the ratio of the fluorescence excitation / emission of 
the metal-saturated sensor. R is the ratio at a particular concentration [M2+]. Sf2 
and Sb2 are the fluorescence intensities with 0 mM [M2+] and saturating amounts 
of [M2+] respectively.  
 Errors associated with the Kd values were generated from 2 or more 
repetitions of the binding experiments, not from the error associated with the 
fitting of the binding curves. In each binding figure, the number of experimental 
repetitions is provided. 
7.5 Density Functional Theory (DFT)  
All computations were carried out with the Gaussian 09 package.6 The 
geometries were optimised at the hybrid-DFT B3LYP functional7 with no 
symmetry constraints using the 6-311++G(d,p) basis set8 for all atoms. The 
Gaussian default polarisation continuum model (IEFPCM)9 was applied to all 
calculations using water as solvent. Frequency calculations on these optimised 
geometries revealed no imaginary frequencies.  
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7.6 Synthetic Procedures  
7.6.1 Di-tert-butyl 2,2'-((2-(2-(tert-butoxy)-2-oxoethoxy)phenyl)azanediyl) 
diacetate, (1)10 
 
N,N-Diisopropylethylamine (15 mL, 86.1 mmol) and tert-butyl 
bromoacetate (9 mL, 60.9 mmol) were added to a solution of 2-aminophenol 
(1.56 g, 14.3 mmol) and sodium iodide (2.98 g, 19.9 mmol) in anhydrous 
acetonitrile (20 mL). The reaction was heated at 85 oC overnight under an inert 
atmosphere of argon before the addition of additional N,N- diisopropylethylamine 
(5 mL) and tert-butyl bromoacetate (4 mL). The reaction mixture was stirred for a 
further 3 d, before being cooled to room temperature and diluted with ethyl 
acetate (10 mL). Inorganic impurities were removed by filtration before the filtrate 
was washed with brine (10 mL) and water (20 mL). Organic extracts were 
combined and dried over MgSO4. The solvent was then removed under reduced 
pressure to form a dark brown residue. Purification by silica gel column 
chromatography (gradient 100 % hexane to 100 % CH2Cl2) formed the title 
compound as a red oil (3.45 g, 55 %). 1H NMR (400 MHz, CDCl3) 6.91 – 6.85 
(3 H, m), 6.80 – 6,77 (1 H, m), 4.56 (2 H, s, H7), 4.08 (4 H, s, H11), 1.47 (9 H, s, 
H10), 1.44 (18 H, s, H14); 13C NMR (101 MHz, CDCl3) 170.6 (C12), 168.3 (C8), 
149.9 (C1), 139.7 (C2), 122.1 (CH), 122.0 (CH), 119.6 (CH), 116.9 (CH), 114 4 
(CH), 82.0 (C9), 81.0 (C13), 66.6 (C7), 54.6 (C11), 28.1 (C14), 28.0 (C10); ESI-LRMS 
[C24H37NO7Na]+ (+) m/z 474.3; ESI-HRMS calcd for [C24H37NO7]+ 452.2648 found 
452.2641. 
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7.6.2 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)phenyl)azanediyl)diacetate, 
(2)10 
	
 
N,N-Diisopropylethylamine (22 mL, 126.3 mmol) and ethyl bromoacetate 
(10 mL, 90.2 mmol) were added to a solution of 2-aminophenol (2.34 g, 
21.4 mmol) and sodium iodide (4.2 g, 28.0 mmol) in anhydrous acetonitrile 
(20 mL). The reaction was heated at 85 oC overnight under an inert atmosphere 
of argon before the addition of N,N-diisopropylethylamine (11 mL) and tert-butyl 
bromoacetate (5 mL). The reaction mixture was stirred for a further 3 d, before 
being cooled to room temperature and diluted with ethyl acetate (10 mL). 
Inorganic impurities were removed by filtration before the filtrate was washed with 
brine (10 mL) and water (20 mL). Organic extracts were combined and dried over 
MgSO4. The solvent was then removed under reduced pressure to form a dark 
brown residue. Purification by silica gel column chromatography (gradient 100 % 
hexane to 100 % CH2Cl2) formed the title compound as an orange / red oil (4.3 g, 
54 %). 1H NMR (400 MHz, CDCl3) 6.96 – 6.89 (3 H, m), 6.83 (1 H, d, J 7), 4.68 
(2 H, s, H7), 4.29 – 4.15 (10 H, m, H9 and H11 and H13), 1.32 – 1.24 (18 H, m, H10 
and H14); 13C NMR (101 MHz, CDCl3) 171.3 (C12), 169.0 (C8), 149.8 (C1), 136.7 
(C2), 122.6 (CH), 122.5 (CH), 120.0 (CH), 115.0 (CH), 66.3 (C7), 61.2 (C9, C11 or 
C13), 60.7 (C9, C11 or C13), 53.8 (C9, C11 or C13), 14.2 (C14), 14.1 (C10); ESI-LRMS 
[C18H26NO7]+ (+) m/z 368.1; ESI-HRMS calcd for [C18H26NO7]+ 368.1709 found 
368.1704.  
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7.6.3 {[K.18-crown-6]Br3}n, (3)11
  
	
	
18-crown-6 (6.1 g, 23.2 mmol) was dissolved in ethanol (150 mL). 
Potassium bromide (4.2 g, 35.0 mmol) was added and the reaction was stirred at 
room temperature for 1 h. The resulting precipitate formed was isolated by 
filtration. Bromine (1.2 mL, 23.3 mmol) was added to the filtrate forming a 
yellow / orange precipitate. The precipitate was collected via filtration and re-
crystallised from acetonitrile, to form the title compound as an orange crystalline 
solid (8.6 g, 80 %). Compound (3) was used in substituent steps without any 
further purification or characterisation.  
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7.6.4 Di-tert-butyl 2,2'-((4-bromo-2- (2-(tert-butoxy)-2-oxoethoxy)phenyl) 
azanediyl) diacetate, (4)11 
	
 
{[K.18-crown-6]Br3}n (568.4 mg, 1.05 mmol) was added to a solution of (1) 
(398.7 mg, 0.88 mmol) in anhydrous acetonitrile (6 mL). The reaction was stirred 
at room temperature for 1 h under an inert atmosphere of argon. Reaction 
completion was confirmed via ESI mass spectrometry. The solution was diluted 
with ethyl acetate (10 mL) before being washed with water and dried over MgSO4. 
The solvent was removed under reduced pressure to form a yellow residue. 
Purification by silica gel column chromatography (gradient hexane to 4:1 
hexane / ethyl acetate) formed the title compound as a pale yellow oil (281 mg, 
61 %).  1H NMR (700 MHz, CDCl3) 6.99 (1 H, dd, J 2.2, 9, H4), 6.85 (1 H, d, J 2, 
H6), 6.72 (1 H, d, J 8.6, H3), 4.51 (2 H, s, H7), 4.01 (4 H, s, H11), 1.46 (9 H, s, H10), 
1.41 (18 H, s, H14), 13C NMR (176 MHz, CDCl3) 170.2 (C12), 167.6 (C8), 150.3 
(C1), 138.8 (C2), 124.8 (C4), 120.7 (C3), 117.3 (C6), 113.6 (C5), 82.4 (C13), 81.2 
(C9), 66.5 (C7), 54.5 9 (C11), 28.1 (C14), 28.0 (C10); ESI-LRMS [C24H3779BrNO7]+ 
(+) m/z 530.2; ESI-HRMS calcd for [C24H3779BrNO7]+ 530.1755 found 530.1753. 
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7.6.5 Diethyl 2,2'-((4-bromo-2-(2-ethoxy-2-oxoethoxy)phenyl)azanediyl) 
diacetate, (5)11 
 
{[K.18-crown-6]Br3}n (1.82 g, 3.36 mmol) was added to a solution of (2) 
(1.10 g, 2.99 mmol) in anhydrous acetonitrile (18 mL). The reaction was stirred 
at room temperature for 1 h under an inert atmosphere of argon. Reaction 
completion was confirmed via ESI mass spectrometry. The solution was diluted 
with ethyl acetate (10 mL) before being washed with brine (20 mL) and dried over 
MgSO4. The solvent was removed under reduced pressure to form a yellow / 
orange residue. Purification by silica gel column chromatography (gradient 
hexane to 3:1 hexane / ethyl acetate) formed the title compound as a pale yellow 
/ orange oil (1.04 g, 78 %). Rf (silica, hexane / ethyl acetate (3:1)) = 0.22; 1H NMR 
(600 MHz, CDCl3) 7.02 (1 H, dd, J 2, 9, H4), 6.91 (1 H, d, J 2, H6), 6.79 (1 H, d, J 
9, H3), 4.63 (2 H, s, H7), 4.25 (2 H, q, J 7, H9), 4.18 – 4.14 (8 H, m, H), 1.29 (3 H, 
t, J 7, H10), 1.24 (6 H, t, J 7, H14); 13C NMR (151 MHz, CDCl3) 170.9 (C12), 168.4 
(C8), 150.3 (C1), 138.8 (C2), 125.4 (C4), 121.2 (C3), 118.0 (C6), 114.2 (C5), 66.24 
(C7), 61.33 (C9), 60.75 (C11 or C13), 53.7 (C11 or C13), 14.2 (C14), 14.1 (C10); ESI-
LRMS [C18H2579BrNO7]+ (+) m/z 446.1; ESI-HRMS calcd for [C18H2579BrNO7]+ 
446.0814 found 446.0815. 
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7.6.6 Tert‐butyl 2‐[(5‐bromo‐2‐hydroxyphenyl)[2‐(tert‐butoxy)‐2‐oxoethyl] 
amino] acetate, (6) 
	
	
N,N-Diisopropylethylamine (1.04 g, 1.4 mL, 8.04 mmol) and tert-butyl 
bromoacetate (0.67 mL, 4.55 mmol) were added to a solution of 2-amino-4-
bromophenol (372.5 mg, 1.98 mmol) and sodium iodide (388.0 mg, 2.6 mmol) in 
anhydrous acetonitrile (3.6 mL). The reaction was heated at 85 oC for 21 h under 
an inert atmosphere of argon, before the reaction mixture was cooled to room 
temperature and diluted with the addition of ethyl acetate (10 mL). Inorganic 
impurities were removed by filtration before the filtrate was washed with brine 
(3 x 10 mL), and water (1 x 10 mL). Organic extracts were combined and dried 
over MgSO4, and the solvent was removed under reduced pressure to form a 
brown residue. Purification by silica gel column chromatography (gradient 2:1 
CH2Cl2 / hexane to 100 % CH2Cl2) formed the title compound as a pale brown oil 
which slowly solidified as a pale brown solid on prolonged standing at room 
temperature (518 mg, 63 %). Rf (silica, 5:1 (hexane / ethyl acetate) = 0.75; 
1H NMR (700 MHz, CDCl3) 6.71 (1 H, dd, J 2 and 8, H5), 6.56 (1 H, d, J 2, H3), 
6.50 (1 H, d, J 8, H6), 5.06 (1 H, br s, OH), 4.49 (2 H, s, H7 or H11), 3.78 (2 H, s, 
H7 or H11), 1.47 (9 H, s, H10), 1.47 (9 H, s, H14); 13C NMR (176 MHz, CDCl3) 169.5 
(C8), 167.6 (C12), 144.6 (C1), 139.0 (C2), 119.0 (C5), 114.9 (C4), 113.1 (C3), 112.6 
(C6), 82.4 (C9), 82.0 (C13), 66.5 (C7 or C11), 46.0 (C7 or C11) 28.0 (C10), 28.0 (C14); 
ASAP-LRMS [C18H26NO779Br]+  (+) m/z 416; ASAP-HRMS calcd for 
[C18H26NO779Br]+ 416.1073 found 416.1067.   
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7.6.7 Di-tert-butyl2,2'-((5-bromo-2-(2-(tert-butoxy)-2-oxoethoxy)phenyl) 
azanediyl) diacetate, (7)10 
	
N,N-Diisopropylethylamine (0.43 g, 0.57 mL, 3.27 mmol) and tert-butyl 
bromoacetate (367 μL, 2.49 mmol) were added to a solution of 2-amino-4-
bromophenol (146.1 mg, 0.78 mmol) and sodium iodide (155.6 mg, 1.04 mmol) 
in anhydrous acetonitrile (1.5 mL). The reaction was heated at 85 oC for 5 d under 
an inert atmosphere of argon, before the reaction mixture was cooled to room 
temperature and diluted with the addition of ethyl acetate (10 mL). Inorganic 
impurities were removed by filtration before the filtrate was washed with brine 
(3 x 10 mL), and water (1 x 10 mL). Organic extracts were combined and dried 
over MgSO4, and the solvent was removed under reduced pressure to form a 
brown residue. Purification by silica gel column chromatography (gradient 
2:1 CH2Cl2 / hexane to 100 % DCM) formed the title compound as a pale brown 
oil (121 mg, 29 %). Rf (silica, 100 % CH2Cl2) = 0.29; 1H NMR (700 MHz, CDCl3) 
6.95 – 6.92 (2 H, m, H3 and H5), 6.61 (1 H, d, J 8, H3), 4.49 (2 H, s, H11), 4.03 
(4 H, s, H8), 1.44 (9 H, s, H14), 1.43 (18 H, s, H10); 13C NMR (176 MHz, CDCl3) 
170.1 (C12), 167.8 (C8), 148.8 (C1), 140.9 (C2), 124.2 (C3 or C5), 122.5 (C3 or C5), 
115.4 (C4), 114.4 (C6), 82.3 (C13), 81.3 (C9), 66.6 (C11), 54.5 (C7), 28.1 (C10), 28.0 
(C14); ASAP-LRMS [C24H36NO779Br]+ (+) m/z 530.2; ASAP-HRMS calcd for 
[C24H36NO779Br]+ 530.1695 found 530.1700. 
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7.6.8 Diethyl 2,2'-((5-bromo-2-(2-ethoxy-2-oxoethoxy)phenyl)azanediyl) 
diacetate, (8)10 
	
 
N,N-Diisopropylethylamine (8.9 g, 12 mL, 68.8 mmol) and ethyl 
bromoacetate (4.79 mL, 43.2 mmol) were added to a solution of 2-amino-4-
bromophenol (2.0 g, 10.8 mmol) and sodium iodide (2.3 g, 15.1 mmol) in 
anhydrous acetonitrile (18 mL). The reaction was heated at 85 oC for 6 d under 
an inert atmosphere of argon, before the reaction mixture was cooled to room 
temperature and diluted with the addition of ethyl acetate (20 mL). Inorganic 
impurities were removed by filtration before the filtrate was washed with brine 
(3 x 20 mL), and water (1 x 10 mL). Organic extracts were combined and dried 
over MgSO4, and the solvent was removed under reduced pressure to form a 
brown residue. Purification by silica gel column chromatography (gradient 2:1 
DCM / hexane to 100 % DCM) formed the title compound as a pale brown oil 
(1.8 g, 38 %); 1H NMR (700 MHz, CDCl3) 6.99 – 6.97 (2 H, m, H3 and H5), 6.66 
(1 H, d, J 9, H6), 4.60 (2 H, s, H11), 4.23 (2 H, q, J 7, H13), 4.18 (4 H, q, J 7, H9), 
4.15 (4 H, s, H7), 1.28 – 1.24 (9 H, m, H10 and H14); 13C NMR (176 MHz, CDCl3) 
170.8 (C8), 168.6 (C12), 148.9 (C1), 141.0 (C2), 124.9 (C3 or C5), 123.0 (C3 or C5), 
116.2 (C6), 115.0 (C4), 66.3 (C11), 61.3 (C13), 60.8 (C9), 53.6 (C7), 14.2 (C10), 14.1 
(C14); ESI-LRMS [C18H2579BrNO7]+ (+) m/z 446.1; ESI-HRMS calcd for 
[C18H2579BrNO7]+ 446.0814 found 446.0812. 
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7.6.9 Tert-butyl 2-(6-bromo-2-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)acetate, 
(9) 
	
NaH (60 % wt. dispersed in mineral oil, 83.7 mg, 2.1 mmol) was added to 
a solution of (6) (240.3 mg, 0.58 mmol) and tert-butyl bromoacetate (0.3 mL, 
396 mg, 2.0 mmol) in anhydrous THF (1 mL). The reaction was stirred at 65 oC 
for 19 h under an inert atmosphere of argon. The reaction mixture was cooled to 
room temperature, and filtered through celite to remove inorganic impurities. The 
solvent was removed under reduced pressure to form a dark brown residue. 
Purification by silica gel column chromatography (gradient 100 % hexane to 
50 / 50, ethyl acetate / hexane) formed the title compound as a pale off-white 
solid (150 mg, 72 %); 1H NMR (700 MHz, CDCl3) 7.14 (1 H, dd, J 9, 2, H5), 6.90 
(1 H, d, J 9, H6), 6.87 (1 H, d, J 2, H3), 4.68 (2 H, s, H8), 4.55 (2 H, s, H9), 1.50 
(9 H, s, H12);  13C NMR (176 MHz, CDCl3) 166.4 (C10), 164.3 (C7), 144.2 (C1), 
130.0 (C2), 126.7 (C5), 118.5 (C6), 117.5 (C3), 114.9 (C4), 83.1 (C10), 67.3 (C8), 
43.5 (C9), 27.9 (C12); ESI-LRMS [C14H16NO479BrNa]+ (+) m/z 364.0; ESI-HRMS 
calcd for [C14H16NO479BrNa]+ 364.0174 found 364.0172. 
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7.6.10 Ethyl methylphosphinate, (10)12 
 
 
Water (264 µL, 14.7 mmol) was added to diethyl methylphosphinate (2 g, 
14.7 mmol) at room temperature. The colourless solution was stirred vigorously 
for 18 h under an inert atmosphere of argon. Reaction completion was 
determined by 31P NMR spectroscopy. The title compound formed with one 
equivalent of ethanol as a by-product and was used in situ in subsequent steps 
without any additional purification. 1H NMR (400 MHz, CDCl3) 7.25 (1 H, dq, J 
538, 2, H1), 4.17 – 3.16 (2 H, m, H3), 1.48 (3 H, dd, J 16, 4, H2), 1.24 (3 H, t, J 4, 
H4); 13C NMR (101 MHz, CDCl3) 62.38 (d, J 24, C3), 16.24 (d, J 24, C4), 14.62 (d, 
J 97, C2); 31P NMR (176 MHz, CDCl3) + 33.4; ESI-LRMS [C3H9PO2]+ (+) m/z 
109.0; ESI-HRMS cald for [C3H9PO2]+ 109.0419 found, 109.0414  
7.6.11 Ethyl (hydroxymethyl)(methyl)phosphinate, (11) 
 
Ethyl methyl phosphinate as its EtOH adduct, (10) (14.7 mmol) was heated 
at 85 oC in anhydrous THF (5 mL) for 30 min. Paraformaldehyde (707.9 mg, 
23.60 mmol) was then added. The reaction mixture was heated at 75 oC under 
an inert atmosphere of argon and monitored by 31 P NMR. After 5 h the colourless 
solution was cooled to room temperature before the THF was removed under 
reduced pressure. The residue was then dissolved in CH2Cl2 (20 mL) before the 
inorganic salts were removed by filtration. The solvent was removed under 
reduced pressure to form a colourless oil. Purification by silica gel 
chromatography (gradient from 100 % CH2Cl2 to 90 % CH2Cl2/ 10 % MeOH) 
formed the title compound as a pale yellow oil (747 mg, 37 %). Rf = 0.20 (silica, 
95 % DCM; 5 % MeOH, visualisation with KMnO4); 1H NMR (400 MHz, CDCl3) 
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4.13 (2 H, m, H3), 3.85 (2 H, m, H1), 3.07 (1H, br s, OH), 1.54 (3 H, d, J 12, H2), 
1.35 (3 H, J 4, H4); 31P NMR (176 MHz, CDCl3) + 52.01; 13C NMR (101 MHz, 
CDCl3) 61.1 (d, J 7, C3), 59.8 (d, J 110, C1), 17.7 (d, J 6, C4), 16.64 (d, J 91, C2); 
ESI-LRMS [C6H779BrN2]+ (+) m/z 139.0; ESI-HRMS calcd for [C6H779BrN2]+ 
139.0456 found, 139.0449.  
7.6.12 (Ethoxy(methyl)phosphoryl)methyl methanesulfonate, (12) 
	
 
 Methylsulfonyl chloride (0.65 mL, 8.4 mmol) was added to an ice cold 
solution of hydroxymethylmethyl phosphinic acid ethyl ester, (11) (808.8 mg, 
5.95 mmol) and triethylamine (1.25 mL, 8.96 mmol) in anhydrous THF (5.7 mL). 
The solution was warmed to room temperature and stirred for an additional 1 h 
under an inert atmosphere of argon. After 1 h, THF was removed under reduced 
pressure, the dark orange residue was re-dissolved in CH2Cl2 (20 mL) and 
washed with brine (15 mL). The organic extracts were dried over MgSO4, and the 
solvent was removed under reduced pressure to form an orange residue. 
Purification by silica gel column chromatography (gradient 100 % CH2Cl2 to 95 % 
CH2Cl2 / 5 % MeOH) formed the title compound as a yellow oil (1.03 g, 82 %). 1H 
(400 MHz, CDCl3) 4.46 – 4.34 (2 H, m, H2), 4.25 – 4.11 (2 H, m, H4), 3.15 (3 H, 
s, H1), 1.63 (3 H, d, J 16, H3), 1.39 (3 H, t, J 8, H5); 31P (162 MHz, CDCl3) + 43.7; 
13C (101 MHz, CDCl3) 63.0 (d, J 106, C2), 61.6 (d, J 7, C4), 37.8 (s, C1), 16.5 (d, 
J 6, C5), 12.6 (d, J 100, C3). ESI-LRMS [C5H13O5PS]+ (+) m/z 217.3; ESI-HRMS 
calcd for [C5H13O5PS]+ 217.0300 found, 217.0321. 
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7.6.13 5-Bromo-2-((tert-butyldimethylsilyl)oxy)aniline, (13) 
 
tert-Butyldimethylsilyl trifluoromethanesulfonate (TBDMS triflate) (1.38 g, 
1.2 mL, 4.29 mmol) was added to a solution of 2-amino-4-bromophenol 
(807.3 mg, 4.29 mmol) and imidazole (490.4 mg, 7.20 mmol) in anhydrous DMF 
(6.5 mL) at 0 oC. The solution was gradually warmed to warm temperature and 
stirred at room temperature for 2 h under an inert atmosphere of argon. The 
reaction was quenched with aqueous ammonium chloride (10 mL, saturated 
solution) and extracted with ethyl acetate (3 x 20 mL). The organic extracts were 
combined, washed with brine (20 mL) and water (10 mL) before being dried over 
potassium carbonate. The solvent was removed under reduced pressure to form 
a brown residue. Purification by silica gel column chromatography (gradient 100 
% hexane to 5:1 hexane / ethyl acetate) formed the title compound as a light red 
/ orange oil (1.09 g, 84 %). Rf (silica, 10:1 hexane/ ethyl acetate) = 0.58; 1H NMR 
(700 MHz, CDCl3) 6.82 (1 H, d, J 2, H3), 6.70 (1 H, dd, J 8, 2, H6), 6.58 (1 H, d, J 
8, H7), 3.74 (2 H, br s, NH2), 1.0 (9 H, s, H9), 0.22 (6 H, s, H8); 13C NMR (176 MHz, 
CDCl3) 142.0 (C1), 139.7 (C2), 120.7 (C5), 119.8 (C6), 117.9 (C3), 113.9 (C4), 25.8 
(C9), 18.2 (C8), -4.32 (C7); 29Si NMR (139 MHz, CDCl3) + 23.0; ESI-LRMS 
[C12H20NO79BrSi]+ (+) m/z 302.4; ESI-HRMS calcd for [C12H20NO79BrSi]+ 
302.0576, found 302.0569.  
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7.6.14 Ethyl (((5-bromo-2-((tert-butyldimethylsilyl)oxy)phenyl)amino) 
methyl)(methyl)phosphinate, (14) 
 
Paraformaldehyde (239.9 mg, 8 mmol) was added to a solution of 13 
(406 mg, 1.35 mmol) in anhydrous THF (28 mL). The reaction was stirred at 85 oC 
for 10 minutes before the addition of diethyl methylphosphinite (0.72 mL, 0.65 g, 
4.80 mmol). The reaction mixture was stirred at 85 oC for 19 h under an inert 
atmosphere of argon. The solvent was removed under reduced pressure to form 
an orange residue which was re-dissolved in CH2Cl2 (15 mL). All insoluble 
inorganics were then removed by filtration. The solvent was removed under 
reduced pressure to form a brown oil. Purification by alumina column 
chromatography (gradient 100 % hexane to hexane / ethyl acetate (1:1)) formed 
the title compound as an orange oil (84.2 mg, 15 %). 1H (700 MHz, CDCl3); 6.72 
(1 H, dd, J 8, 2, H5), 6.69 (1 H, d, J 2, H3), 6.58 (1 H, d, J 8, H6), 4.43 (1 H, br s, 
NH), 4.05 (2 H, m, H9), 3.37 (2 H, m, H7), 1.52 (3 H, d, J 14, H8), 1.32 (3 H, t, J 7, 
H10), 1.00 (9 H, s, H13), 0.23 (3 H, s, H11 or H11’), 0.21 (3 H, s, H11 or H11’); 
31P (283 MHz, CDCl3,) + 49.5; 13C (176 Hz, CDCl3) 142.0 (s, C1), 140.8 (d, J 11, 
C2), 120.1 (s, C5), 118.6 (s, C6), 114.3 (s, C4), 113.6 (s, C3),  60.9 (d, J 9, C9), 
42.4 (d, J 102, C7), 25.7 (s, C13), 18.1 (s, C12), 16.6 (d, J 6, C10), 13.0 (d, J 95, 
C8), -4.4 (C11 or C11’), -4.3 (C11 or C11’) ; 29Si (139 MHz, CDCl3) + 23.5; ESI-LRMS 
[C16H2979BrNO3PSi]+ (+) m/z 422.4; ESI-HRMS calcd for [C16H2979BrNO3PSi]+ 
422.0916 found, 422.0901.   
 
 
 
2
3
4
1
7
5
6
Br
H
N
OSi
8
9
P O
O
10
11
12
13
Chapter 7. Experimental  
	
232 
	
7.6.15 Ethyl (((5-bromo-2-hydroxyphenyl)amino)methyl)(methyl) 
phosphinate, (15) 
 
Tetrabutylammonium fluoride (TBAF) (1 M solution in THF, 0.5 mL, 
0.5 mmol) was added to an ice cold solution of 14 (173.4 mg, 0.41 mmol) in 
anhydrous THF (3 mL). The reaction was stirred in ice for 10 minutes, before 
being stirred at room temperature for 1 h under an inert atmosphere of argon. 
The reaction was quenched with aqueous ammonium chloride (10 mL saturated 
solution), extracted with CH2Cl2 (3 x 20 mL) and dried with MgSO4. The solvent 
was removed under reduced pressure to form a dark brown residue. Purification 
by silica column chromatography (gradient 100 % CH2Cl2 to 95 % CH2Cl2 / 5 % 
MeOH) formed the title compound as a pale brown oil (56.0 mg, 65 %). Rf (silica, 
95 % CH2Cl2 / 5 % MeOH) = 0.24; 1H (700 MHz, CDCl3) 9.70 (1 H, br s, OH), 
6.69 (2 H, m, H5 and H6), 6.63 (1 H, d, J 2, H3), 4.94 (1 H, br m, NH), 4.17 (2 H, 
m, H7), 3.44 (2 H, m, H9), 1.59 (3 H, d, J 14, H8), 1.34 (3 H, t, J 7, H10); 
31P (283 MHz, CDCl3) + 52.5; 13C (176 Hz, CDCl3) 144.2 (C1), 138.0 (d, J 12, C2), 
120.5 (C5 or C6), 115.2 (C5 or C6), 113.1 (C3), 111.9 (C4), 62.0 (d, J 7, C9), 42.8 
(d, J 103, C7), 16.6 (d, J 6, C10), 13.2 (d, J 95, C8); ESI-LRMS [C10H1579BrNO3P]+ 
(+) m/z 308.0; ESI-HRMS calcd for [C10H1579BrNO3P]+ 308.0051 found 308.0042.   
7.6.16 Ethyl methyl((2-nitrophenoxy)methyl)phosphinate, (16) 
	
 
Anhydrous potassium carbonate (302.9 mg, 2.19 mmol) was added to a 
solution of 2-nitrophenol (98.9 mg, 0.71 mmol) and (ethoxy(methyl)phosphoryl)- 
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methyl methanesulfonate, (12) (228.2 mg, 1.05 mmol) in anhydrous acetonitrile 
(1.2 mL). The reaction mixture was heated at 85 oC for 48 h under an inert 
atmosphere of argon. The pale yellow precipitate was removed by filtration and 
the solvent was removed under reduced pressure to form a yellow residue. 
Purification by silica gel column chromatography (gradient 100 % CH2Cl2 to 95 % 
CH2Cl2 / 5 % MeOH) formed the title product as a pale yellow oil (115.3 mg, 
63 %). 1H NMR (600 MHz, CDCl3) 7.88 – 7 85 (1 H, m) 7.58 – 7.54 (1 H, m), 
7.13 – 7.09 (2 H, m), 4.39 – 4.26 (4 H, m, H9 and H7), 1.69 (3 H, d, J 15, H8), 1.33 
(3 H, t, J 7, H10); 13C (151 MHz, CDCl3,) 151.8 (d, J 13, C1), 140.1 (C2), 134.4 
(CH), 125.8 (CH), 121.9 (CH), 114.7 (C3), 61.4 (d, J 7, C9), 65.2 (d, J 111, C7), 
16.5 (C9), 12.2 (C8); 31P NMR (242 MHz, CDCl3) + 48.5; ESI-LRMS 
[C10H14NO5P]+ (+) m/z 260.1; ESI-HRMS calcd for [C10H14NO5P]+ 260.0701 found 
260.0699.  
7.6.17 Ethyl ((2-aminophenoxy)methyl)(methyl)phosphinate, (17)  
 
Compound (16) (118.1 mg, 0.46 mmol) was dissolved in ethanol (20 mL). 
Palladium on charcoal (10 wt. %, 51.6 mg, 0.03 mmol) was added and the 
reaction mixture was stirred at room temperature for 2 h under an atmosphere of 
hydrogen. After this time, the reaction mixture was filtered through a celite plug. 
The solvent was removed under reduced pressure to form a pale yellow oil 
(104 mg, 96 %). Compound (17) was used in subsequent steps without any 
additional purification. 1H NMR (600 MHz, CDCl3) 6.86 – 6.82 (2 H, m, H3, H4, H5 
or H6), 6.74 – 6.70 (2 H, m, H3, H4, H5 or H6), 4.29 – 4.07 (4 H, m, H7 and H9), 
1.64 (3 H, d, J 14.6, H8), 1.34 (3 H, t, J 7, H10); 31P NMR (162 MHz, CDCl3) + 47.4; 
13C (151 MHz, CDCl3) 146.3 (d, J 11.9, C1), 136.4 (C2), 122.8 (C3, C4, C5 or C6), 
118.5 (C3, C4, C5 or C6), 115.7 (C3, C4, C5 or C6), 112.2 (C3, C4, C5 or C6), 64.6 
(d, J 111, C7), 61.0 (d, J 7, C9), 16.6 (s, C10), 12.6 (d, J 98, C8); ESI-LRMS 
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[C10H16NO3P]+ (+) m/z 230.6; ESI-HRMS calcd for [C10H16NO3P]+ 230.0946 found 
230.0949. 
7.6.18 Diethyl 2,2'-((2-((ethoxy(methyl)phosphoryl)methoxy)phenyl) 
azanediyl) diacetate, (18) 
	
 
N,N-Diisopropylamine (410 µL, 2.36 mmol) and ethyl bromoacetate 
(158 µL, 1.42 mmol) were added to a solution of (17) (107.5 mg, 0.46 mmol) and 
sodium iodide (125.6 mg, 0.97 mmol) in anhydrous acetonitrile. The reaction was 
heated for 2 d at 85 oC under an inert atmosphere of argon before the addition of 
further N,N-diisopropylamine (120 µL, 0.69 mmol) and ethyl bromoacetate 
(50 µL, 0.45 mmol). The reaction mixture was stirred at 85 oC for a further 2 d, 
before being cooled and diluted with ethyl acetate (10 mL). Inorganic impurities 
were removed by filtration before the organic filtrate was washed with water (10 
mL) and brine (10 mL). Organic extracts were combined and dried over MgSO4, 
and the solvent was removed under reduced pressure to form a pale brown 
residue. Purification by silica gel column chromatography (gradient 1:1 hexane / 
ethyl acetate to 100 % ethyl acetate) formed the title compound as a pale brown 
oil (97.3 mg, 53 %). 1H NMR (700 MHz, CDCl3) 6.95 – 6.93 (3 H, m, H3, H4, H5 or 
H6), 6.90 – 6.88 (1 H, m, H3, H4, H5 or H6), 4.32 – 4.05 (14 H, m, H7, H9, H11 and 
H13), 1.66 (3 H, d, J 15, H8), 1.33 (3 H, t, J 7, H10), 1.23 (6 H, t, J 7, H14); 31P NMR 
(283 MHz, CDCl3) + 48.3; 13C NMR (176 MHz, CDCl3,) 170.9 (s, C12), 150.9 (d, 
J 11, C1), 139.4 (s, C2), 122.9 (s, C3, C4, C5 or C6), 122.7 (s, C3, C4, C5 or C6), 
120.8 (s, C3, C4, C5 or C6), 117.4 (s, C3, C4, C5 or C6), 64.8 (d, J 6, C7 or C9), 60.9 
(d, J 7, C7 or C9), 60.7 (s, C11 or C13), 53.2 (s, C11 or C13), 16.5 (d, J 6, C10), 14.2 
(s, C14), 12.5 (d, J 97, C8); ESI-LRMS [C18H29NO7P]+ (+) m/z 402.6; ESI-HRMS 
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calcd for [C18H29NO7P]+ 402.1682 found 402.1694; Reverse phase HPLC (0 % - 
100 % - 0% CH3CN in ammonium bicarbonate buffer (25 mM), tR = 9.6 min).  
7.6.19 Diethyl 2,2'-((4-bromo-2-((ethoxy(methyl) phosphoryl)methoxy) 
phenyl) azanediyl)diacetate, (19) 
	
  
{[K.18-crown-6]Br3}n (132.3 mg, 0.24 mmol) was added to a solution of 
ethyl-2‐[(2‐ethoxy‐2‐oxoethyl)(2‐{[methoxy(methyl)phosphoryl] methoxy} phenyl) 
amino]acetate, (18) (82.5 mg, 0.21 mmol) in anhydrous acetonitrile (1.2 mL). The 
reaction was stirred at room temperature for 1 h under an inert atmosphere of 
argon. Reaction completion was confirmed via ESI mass spectrometry. The 
solution was diluted with ethyl acetate (10 mL) before being washed with water 
(10 mL) and dried over MgSO4. The solvent was removed under reduced 
pressure to form a dark yellow / brown oil. Purification by silica gel column 
chromatography (gradient 100 % hexane to 100 % ethyl acetate) formed the title 
compound as a colourless oil. (101 mg, 82 %). 1H NMR (700 MHz, CDCl3) 7.05 
(1 H, dd, J 9, 2, H4), 7.00 (1 H, d, J 2, H6), 6.81 (1 H, d, J 9, H3), 4.28 – 4.06 (12 H, 
m, H7, H9, H11, H13), 1.64 (3 H, d, J 15, H8), 1.33 (3 H, t, J 7, H10), 1.23 (6 H, t, J 
7, H14); 31P NMR (283 MHz, CDCl3) + 47.2; 13C NMR (176 MHz, CDCl3) 170.6 (s, 
C12), 151.4 (d, J 12, C1), 138.6 (s, C2), 125.5 (s, C4), 122.0 (s, C3), 117.7 (s, C6), 
114.7 (s, C5), 65.1 (d, J 110, C7), 61.0 (d, J 7, C9), 60.8 (s, C11 or C13), 53.2 (s, 
C11 or C13), 16.5 (d, J 6, C10), 14.1 (s, C14), 12.5 (d, J 98, C8); ESI-LRMS 
[C18H2879BrNO7P]+ (+) m/z 480.1; ESI-HRMS calcd for [C18H2879BrNO7P]+ 
480.0787 found 480.0778. 
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7.6.20 (2-Nitrophenoxy)- acetic acid tert- butyl ester, (20)13 
	
2-Nitrophenol (544.6 mg, 3.91 mmol) in anhydrous THF (3 mL) was added 
to a solution of NaH (60 % wt. dispersion in mineral oil, 380 mg, 9.54 mmol) in 
anhydrous THF (3 mL). The reaction mixture turned orange during the addition 
and was stirred at room temperature for 30 mins. tert-Butyl bromacetate (1.3 mL, 
8.80 mmol) was then added and the reaction mixture was heated at reflux under 
an inert atmosphere of argon for a further 24 h, with the reaction turning an off-
white colour. The precipitate was removed by filtration, the organic layer was 
washed with saturated aqueous NaHCO3 solution (10 mL), HCl (1 M, 10 mL) and 
brine (10 mL), and dried over MgSO4. The solvent was removed under reduced 
pressure to form a yellow oil. Purification by silica gel column chromatography 
(gradient hexane to 4:1 hexane / ethyl acetate) formed the title compound as a 
yellow oil (842 mg, 85 %). 1H NMR (700 MHz, CDCl3) 7.86 (1 H, dd, J 8, 2, H3), 
7.50 (1 H, td, J 10, 8, 2, H4), 7.07 (1 H, td, J 9, 7, 1, H5), 6.96 (1 H, dd, J 8, 1, H6), 
4.66 (2 H, s, H7), 1.45 (9 H, s, H10); 13C NMR (176 MHz, CDCl3) 166.7 (C8), 151.4 
(C1), 140.3 (C2), 133.8 (C3), 125.8 (C4), 121.4 (C5), 114.8 (C6), 83.0 (C9), 66.7 
(C7), 28.0 (C10); ESI-LRMS [C12H15NO5Na]+ (+) m/z 276.1; ESI-HRMS calcd for 
[C12H15NO5Na]+ 276.0848 found 276.0865.  
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7.6.21 Tert‐butyl 2‐(2‐aminophenoxy)acetate, (21) 
 
 
(2-Nitrophenoxy)-acetic acid tert-butyl ester, (20) (276.9 mg, 1.1 mmol) 
was dissolved in ethanol (20 mL). Palladium on charcoal (10 wt. %, 65.1 mg, 
0.06 mmol) was added and the reaction mixture was stirred at room temperature 
for 5 h under an atmosphere of hydrogen. After this time, the reaction mixture 
was filtered through a celite plug. The solvent was removed under reduced 
pressure to form a pale brown oil (104 mg, 96 %). Compound (21) was used in 
subsequent steps without any further purification. 1H NMR (400 MHz, CDCl3) 
6.87 – 6.82 (1 H, m), 6.77 – 6.67 (3 H, m), 4.55 (2 H, s, H7), 1.51 (9 H, s, H10).  
7.6.22 Ethyl 2-((4-bromo-2-iodophenyl)amino)acetate, (22) 
 
N,N-Diisopropylethylamine (0.96 g, 1.3 mL, 7.50 mmol) and ethyl 
bromoacetate (600 μL, 5.40 mmol) were added to a solution of 4-bromo-2-
iodophenol (641.4 mg, 2.15 mmol) and sodium iodide (130.2 mg, 2.87 mmol) in 
anhydrous acetonitrile (3.8 mL). The reaction was heated at 85 oC for 24 h under 
an inert atmosphere of nitrogen, before additional N,N-diisopropylethylamine 
(1.2 mL, 6.89 mmol) and ethyl bromoacetate (470μL, 4.24 mmol) were added. 
The reaction mixture was stirred for a further 40 h at 85 oC. After cooling to room 
temperature the brown reaction mixture was diluted with ethyl acetate (15 mL), 
filtered through celite, and washed with water (10 mL) and brine (10 mL). Organic 
extracts were combined and dried over MgSO4, and the solvent was removed 
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under reduced pressure to form a brown residue. Purification by silica gel column 
chromatography (gradient 100 % hexane to 80 % hexane / 20 % ethyl acetate) 
formed the title compound as an off white solid (565 mg, 68 %). Rf (80 % hexane 
/ 20 % ethyl acetate) = 0.72; m.p. 77 -78 oC; 1H (700 MHz, CDCl3) 7.77 (1 H, d, J 
2, H3), 7.29 (1 H, dd, J 9, 2, H5), 6.29 (1 H, d, J 9, H6), 4.86 (1 H, br t, J 5, -NH), 
4.26 (2 H, q, J 7, H9), 3.89 (2 H, d, J 5, H7), 1.30 (3 H, t, J 7, H10); 13C (176 MHz, 
CDCl3) 170.0 (C8), 145.4 (C1), 140.6 (C3), 132.1 (C5), 111.4 (C4), 109.6 (C6), 85.3 
(C2), 61.6 (C7), 46.0 (C9), 14.1 (C10); ESI-LRMS [C10H11NI79Br]+ (+) m/z 384.1; 
ESI-HRMS calcd for [C10H11NI79Br]+ 383.9096 found, 383.9099.   
7.6.23 Ethyl 2-((4-bromo-2-(ethoxy(methyl)phosphoryl)phenyl)amino) 
acetate, (23) 
	
 
Ethyl 2-((4-bromo-2-iodophenyl)amino)acetate, (22) (390.2 mg, 
1.02 mmol), ethyl methyl phosphinate (10) (as its EtOH adduct, 200.8 mg, 1.30 
mmol) and triethylamine (0.58 mL, 4.16 mmol) were added to dry toluene 
(degassed by three freeze-pump-thaw cycles). The solution was degassed by a 
further three cycles before the addition of Pd(dppf)Cl2.CH2Cl2 (19.2 mg, 
0.024 mmol). The reaction mixture was stirred at 118 oC under an inert 
atmosphere of argon for 22 h. After cooling to room temperature the solvent was 
removed under reduced pressure to form a dark brown residue. Purification by 
silica gel column chromatography (gradient 100 % hexane to 1:1 ethyl acetate / 
hexane) formed the title compound as a yellow oil (137 mg, 39 %). Rf (silica, 1:1 
ethyl acetate / hexane) = 0.52; 1H (600 MHz, CDCl3) 7.50 (1 H, br s, NH), 7.43 
(1 H, dd, J 12, 2, H3), 7.38 (1 H, dd, J 8, 2, H5), 6.38 (1 H, dd, J 8, 6, H6), 4.21 
(2 H, q, J 7, H9), 4.13 (2 H, m, H12), 3.89 (2 H, br s, H7), 1.66 (3 H, t, J 15, H11), 
1.32 (3 H, t, J 7, H13), 1.25 (3 H, t, J 8, H10);  13C (151 MHz, CDCl3) 170.1 (s, C8), 
150.1 (d, J 7, C1), 136.5 (d, J 2, C5), 134.8 (d, J 10, C3), 114.1 (d, J 122, C2), 
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113.7 (s, C), 112.9 (d, J 10, C6), 108.0 (d, J 15, C4), 61.3 (s, C9), 60.9 (d, J 7, 
C12), 45.1 (s, C7), 16.4 (d, J 7, C13), 16.3 (d, J 106, C11), 14.2 (s, C10); 31P (243 
MHz, CDCl3) + 45.6; ESI-LRMS [C13H1979BrNO4P]+ (+) m/z 364.5; ESI-HRMS 
calcd for [C13H1979BrNO4P]+ 364.0313 found, 364.0320. 
7.6.24 2,2'-((2-((Hydroxy(methyl)phosphoryl)methoxy)phenyl)azanediyl) 
diacetic acid (APDAP), (24) 
 
Diethyl-2,2'-((2-((ethoxy(methyl)phosphoryl)methoxy)phenyl)azanediyl) 
diacetate, (18) (82.6 mg, 0.21 mmol) was dissolved in CD3OD (4 mL) and NaOD 
(0.4 M in D2O, 1.4 mL). The pale yellow solution was stirred under an inert 
atmosphere of argon at room temperature for 20 h. Hydrolysis of the ethyl esters 
was monitored by 1H NMR spectrometry, 31P NMR spectrometry and ESI-LRMS. 
The solution was lyophilized to form the title compound as an off-white solid in a 
quantitative yield (62 mg, 93 %), without any further purification. 1H NMR 
(600 MHz, D2O) 6.95 (1 H, dd, J 1.8, 8, H6), 6.83 (2 H, m, H4 and H5), 6.78 (1 H, 
br m, H3), 3.93 (2 H, d, J 9, H7), 3.71 (4 H, s, H9), 1.29 (3 H, d, J 14, H8); 31P NMR 
(283 MHz, D2O) + 36.54; 13C NMR (176 MHz, D2O) 179.1 (C10), 150.6 (C1) 139.4 
(C2), 121.6 (C4 or C5), 118.5 (C4 or C5), 118.1 (C3), 113.4 (C6), 56.5 (C9), 14.2 (d, 
J 95, C8); Reverse phase HPLC (0 % - 100 % - 0% CH3CN in ammonium 
bicarbonate buffer (25 mM), tR = 1.2 min).  
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7.6.25 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-4-((triisopropylsilyl)ethynyl) 
phenyl)azanediyl)diacetate, (25) 
	
 
Compound (5) (816.0 mg, 1.83mmol) was dissolved in anhydrous THF 
(6 mL) and the solution was degassed via three freeze-pump-thaw cycles. 
(Triisopropylsilyl)acetylene (2.2 mL, 9.8 mmol), triethylamine (2.0 mL, 
14.3 mmol), Pd(dppf)Cl2 (147.0 mg, 0.2 mmol) and copper iodide (135.9 mg, 
0.72 mmol) were added, and the solution was degassed via a further three freeze- 
pump-thaw cycles. The solution was stirred at 65 oC for 3 d under an inert 
atmosphere of argon. Reaction completion was determined by ESI mass 
spectrometry. The solvent was removed under reduced pressure to form a dark 
brown residue. Purification by silica gel column chromatography (gradient hexane 
to 4:1 hexane / ethyl acetate) formed the title compound as a pale yellow / orange 
oil which slowly solidified to an off white solid (836 g, 92 %). m.p = 69 oC – 71 oC; 
1H NMR (600 MHz, CDCl3) 7.06 (1 H, dd, J 8, 2, H4), 6.87 (1 H, d, J 2, H6), 6.77 
(1 H, d, J 8, H3), 4.62 (2 H, s, H7), 4.26 (2 H, q, J 7, H9), 4.19 – 4.15 (8 H, m, H11 
and H13), 1.29 (3 H, t, J 7, H10), 1.25 (6 H, t, J 7, H14), 1.10 (21 H, br s, H17 and 
H18); 13C NMR (151 MHz, CDCl3) 171.0 (C12), 168.6 (C8), 148.8 (C1), 140.1 (C2), 
126.9 (C4), 119.1 (C3), 118.0 (C6), 116.9 (C5), 106.9 (C15), 89.3 (C16), 66.3 (C7), 
61.2 (C13), 60.8 (C9), 53.7 (C11), 18.7 (C18), 14.2 (C14), 14.1 (C10), 11.3 (C17); ESI-
LRMS [C29H46NO7Si]+ (+) m/z 548.3; ESI-HRMS calcd for [C29H46NO7Si]+ 
548.3047 found 548.3044. 
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7.6.26 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-5-((triisopropylsilyl)ethynyl) 
phenyl)azanediyl)diacetate, (26) 
 
 
Compound (8) (800.8 mg, 1.8 mmol) was dissolved in anhydrous THF 
(6 mL) and the solution was degassed via three freeze-pump-thaw cycles. 
(Triisopropylsilyl)acetylene (2.0 mL, 8.9 mmol), triethylamine (1.8 mL, 12.9 
mmol), Pd(dppf)Cl2 (142.5 mg, 0.19 mmol) and copper iodide (135.9 mg, 0.72 
mmol) were added, and the solution was degassed via a further three freeze- 
pump-thaw cycles. The solution was stirred at 65 oC for 3 d under an inert 
atmosphere of argon. Reaction completion was determined by ESI mass 
spectrometry. The solvent was removed under reduced pressure to form a dark 
brown residue. Purification by silica gel column chromatography (gradient hexane 
to 4:1 hexane / ethyl acetate) formed the title compound as a pale yellow oil which 
solidified overnight to an off white solid upon standing at room temperature 
(924 mg, 94 %). m.p = 64 oC – 66 oC; 1H NMR (700 MHz, CDCl3) 7.03 (1 H, dd, 
J 8, 2, H5), 6.97 (1 H, d, J 2, H3), 6.68 (1 H, d, J 8, H6), 4.63 (2 H, s, H11), 4.23 (2 
H, q, J 7, H13), 4.19 – 4.16 (8 H, m, H7 and H9), 1.28 – 1.24 (9 H, m, H10 and H14), 
1.09 (21 H, br s, H17 and H18); 13C NMR (176 MHz, CDCl3) 171.1 (C8), 168.5 (C12), 
150.1 (C1), 139.3 (C2), 126.6 (C5), 123.6 (C3), 117.6 (C4), 114.1 (C6), 107.0 (C15), 
88.9 (C16), 66.0 (C11), 61.3 (C13), 60.7 (C7 or C9), 53.6 (C7 or C9), 18.6 (C18), 14.2 
(C10), 14.1 (C14), 11.3 (C17); ESI-LRMS [C29H46NO7Si]+ (+) m/z 548.3; ESI-HRMS 
calcd for [C29H46NO7Si]+ 548.3044 found 548.3041. 
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7.6.27 Ethyl 2‐({2‐[(dimethyl phosphoryl)methoxy]‐4‐{2‐[tris(propan‐2‐
yl)silyl]ethynyl}phenyl}(2‐ethoxy‐2‐oxoethyl)amino)acetate, (27) 
 
 
Compound (19) (273.9 mg, 0.57 mmol) was dissolved in anhydrous THF 
(1.8 mL) and the solution was degassed via three freeze-pump-thaw cycles. 
(Triisopropylsilyl)acetylene (0.64 mL, 2.85 mmol), triethylamine (0.56 mL, 
4.02 mmol), Pd(dppf)Cl2 (56.7 mg, 0.08 mmol) and copper iodide (22.0 mg, 
0.1 mmol) were added, and the solution was degassed via a further three freeze-
pump-thaw cycles. The solution was stirred at 65 oC for 6 d under an inert 
atmosphere of argon, reaction completion was determined by ESI mass 
spectrometry. The solvent was removed under reduced pressure to form a dark 
brown residue. Purification by silica gel column chromatography (gradient 100 % 
CH2Cl2 to 95 % CH2Cl2 / 5 % MeOH) formed the title compound as a pale brown 
oil (270.9 mg, 86 %). Rf (silica, 95 % CH2Cl2 / 5 % MeOH) = 0.54; 1H NMR 
(600 MHz, CDCl3) 7.08 (1 H, dd, J 9, 2, H4), 6.97 (1 H, d, J 2, H6), 6.81 (1 H, d, J 
9, H3), 4.31 – 4.07 (12 H, m, H7, H9, H11 and H13), 1.65 (3 H, d, J 15, H8), 1.36 (3 
H, t, J 7, H10), 1.25 (6 H, t, J 7, H14), 1.13 (3 H, br m, H17), 1.11 (18 H, s, H18); 
31P NMR (243 MHz, CDCl3) + 47.5; 13C NMR (151 MHz, CDCl3) 170.7 (s, C12), 
149.9 (s, C1), 139.8 (s, C2), 126.8 (s, C4), 119.9 (s, C3), 117.5 (s, C6), 117.4 (s, 
C5), 106.6 (s, C15), 89.8 (s, C16), 65.3 (d, J 111, C7), 60.9 (d, J 7, C9), 60.8 (s, C11 
or C13), 53.3 (s, C11 or C13), 18.7 (s, C18), 16.5 (d, J 6, C10), 14.2 (s, C14), 12.6 (d, 
J 98, C8) 11.3 (s, C17);  ESI-LRMS [C29H49NO7PSi]+ (+) m/z 582.3; ESI-HRMS 
calcd for [C29H49NO7PSi]+ 582.3007 found 582.3016. 
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7.6.28 Ethyl 2-((2-(ethoxy(methyl)phosphoryl)-4-((triisopropylsilyl)ethynyl) 
phenyl)amino)acetate, (28) 
	
 
Compound (23) (757.0 mg, 2.09 mmol) was dissolved in anhydrous THF 
(7 mL) and the solution was degassed via three freeze-pump-thaw cycles. 
(Triisopropylsilyl)acetylene (2.4 mL, 10.7 mmol), triethylamine (2.2 mL, 
15.8 mmol), Pd(dppf)Cl2 (157.3 mg, 0.21 mmol) and copper iodide (116.3 mg, 
0.61 mmol) were added, and the solution was degassed via a further three freeze-
pump-thaw cycles. The solution was stirred at 65 oC for 3 d under an inert 
atmosphere of argon. Reaction completion was determined by ESI mass 
spectrometry. The solvent was removed under reduced pressure to form a dark 
brown residue. Purification by silica gel column chromatography (gradient 100 % 
hexane to 100 % ethyl acetate 4:1) formed the title compound as a pale brown 
oil which slowly solidified to a pale brown solid overnight (747 mg, 77 %). 
m.p = 82 oC – 83 oC; 1H NMR (600 MHz, CDCl3) 7.71 (1 H, br s, NH), 7.47 (1 H, 
dd, J 14, 2, H3), 7.42 (1 H, dd, J 9, 2, H5), 6.40 (1 H, dd, J 9, 6, H6), 4.21 (2 H, q, 
J 7, H12), 4.16 – 3.87 (4 H, m, H8 and H10), 1.68 (3 H, d, J 15, H7), 1.32 (3 H, t, J 
7, H9), 1.26 (3 H, t, J 7, H13), 1.10 (21 H, s, H16 and H17); 31P NMR (243 MHz, 
CDCl3) + 46.6; 13C NMR (151 MHz, CDCl3) 170.1 (s, C11), 150.8 (d, J 7, C1), 
137.6 (d, J 2, C5), 136.5 (d, J 10, C3), 113.4 (d, J 123, C2), 111.3 (d, J 14, C4), 
110.7 (d, J 10, C6), 61.3 (s, C12),106.8 (s, C14), 88.5 (s, C15) 60.9 (d, J, 6, C8), 
45.0 (s, C10), 18.7 (s, C17), 16.5 (d, J 105, C7), 16.3 (d, J 7, C9), 14.2 (s, C13), 11.3 
(s, C16); ESI-LRMS [C24H41NO4PSi]+ (+) m/z 466.2; ESI-HRMS calcd for 
[C24H41NO4PSi]+ 466.2543 found 466.2535. 
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7.6.29 Di-tert-butyl 2,2'-((2-(2-(tert-butoxy)-2-oxoethoxy)-5-((triisopropyl 
silyl)ethynyl)phenyl)azanediyl)diacetate, (29) 
 
 
Compound (7) (243.7 mg, 0.46 mmol) was dissolved in anhydrous THF 
(1.5 mL) and the solution was degassed via three freeze-pump-thaw cycles. 
(Triisopropylsilyl)acetylene (0.2 mL, 0.89 mmol), triethylamine (0.35 mL, 
2.5 mmol), Pd(dppf)Cl2 (37.2 mg, 0.05 mmol) and copper iodide (21.1 mg, 
0.11 mmol) were added, and the solution was degassed via a further three freeze-
pump-thaw cycles. The solution was stirred at 65 oC for 5 d under an inert 
atmosphere of argon. Reaction completion was determined by ESI mass 
spectrometry. The solvent was removed under reduced pressure to form a dark 
brown residue. Purification by silica gel column chromatography (gradient hexane 
to 9:1 hexane / ethyl acetate) formed the title compound as a pale yellow oil 
(222 mg, 86 %). 1H NMR (700 MHz, CDCl3) 7.00 (1 H, dd, J 8, 2, H5), 6.91 
(1 H, d, J 2, H3), 6.63 (1 H, d, J 8, H6), 4.52 (2 H, s, H11), 4.04 (4 H, s, H7), 1.45 
(9 H, s, H14), 1.44 (18 H, s, H10), 1.09 (21 H, br s, H17 and H18); 13C NMR (176 
MHz, CDCl3) 170.4 (C12), 167.8 (C8), 150.0 (C1), 139.2 (C2), 125.9 (C5), 123.0 
(C3), 117.0 (C4), 113.2 (C6), 107.2 (C15), 98.3 (C16), 82.3  (C13), 81.2 (C14), 66.2 
(C11), 54.5 (C7), 28.0 (C14), 28.1 (C10), 18.65 (C18), 11.3 (C17); ASAP-LRMS 
[C35H58NO7Si]+ (+) m/z 632.4; ASAP-HRMS calcd for [C35H58NO7Si]+ 632.3983 
found 632.3983. 
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7.6.30 Di-tert-butyl 2,2'-((2-(2-(tert-butoxy)-2-oxoethoxy)-5-ethynylphenyl) 
azanediyl)diacetate, (30) 
 
Tetrabutylammonium fluoride (TBAF, 1 M solution in THF, 0.3 mL, 0.3 
mmol) was added to an ice cold solution of (29) in anhydrous THF (1 mL). The 
reaction was stirred in ice for 20 mins, before being stirred at room temperature 
for 1 h under an inert atmosphere of argon. The solvent was removed under 
reduced pressure to form a brown residue, Purification by silica gel column 
chromatography (gradient hexane to 4:1 hexane / ethyl acetate) formed the title 
compound as a colourless oil (40.2 mg, 51 %). 1H NMR (600 MHz, CDCl3) 7.02 
(1 H, dd, J 8, 2, H5), 6.97 (1 H, d, J 2, H3), 6.65 (1 H, d, J 8, H3), 4.54 (2 H, s, H11), 
4.04 (4 H, s, H7), 2.94 (1 H, s, H16), 1.45 (9 H, s, H14), 1.44 (18 H, s, H10); 13C 
NMR (151 MHz, CDCl3) 170.3 (C12), 167.7 (C8), 150.3 (C1), 139.3 (C2), 126.0 
(C5), 123.3 (C3), 115.4 (C4), 113.2 (C6), 83.8 (C16), 82.3 (C9), 81.4 (C15), 81.2 
(C13), 66.2 (C11), 54.5 (C7), 28.1 (C10), 28.0 (C14); ASAP-LRMS [C26H38NO7]+ (+) 
m/z 530; ASAP-HRMS calcd for [C26H38NO7]+ 476.2648 found 476.2648. 
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7.6.31 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-4-(naphthalen-1-ylethynyl) 
phenyl)azanediyl)diacetate, (31) 
 
 
Compound (25) (119 mg, 0.22 mmol) and 1-bromonapthalene (29 µL, 
0.22 mmol) were dissolved in anhydrous THF (1.1 mL) and the solution was 
degassed by three freeze-pump-thaw cycles. Triethylamine (0.6 mL), Pd(dppf)Cl2 
(21.2 mg, 0.03 mmol) and copper iodide (42.1 mg, 0.22 mmol) were then added 
and the solution was degassed once more. Tetrabutylammonium fluoride (TBAF, 
1 M solution in THF, 0.3 mL, 0.3 mmol) was then added before the brown solution 
was degassed with three final freeze-pump-thaw cycles. The reaction mixture 
was stirred at 65 oC for 18 h under an inert atmosphere of argon, before the 
solvent was removed under reduced pressure to form a dark brown / black 
residue. Purification by column chromatography (gradient hexane to 1:1 hexane 
/ ethyl acetate formed the title compound as an orange oil (23.1 mg, 20 %). 
1H NMR (700 MHz, CDCl3) 8.39 (1 H, d, J 8, H20’), 7.85 (1 H, d, J 8, H17’), 7.81 
(1 H, d, J 8, H20), 7.71 (1 H, dd, J 2, 1, H18), 7.58 – 7.56 (1 H, m, H19’), 7.53 – 7.50 
(1 H, m, H18’), 7.45 – 7.42 (1 H, m, H19), 7.22 (1 H, dd, J 8, 2, H5), 7.05 (1 H, d, J 
2, H3), 6.85 (1 H, d, J 8, H6), 4.68 (2 H, s, H7), 4.27 (2 H, q, J 7, H9), 4.23 (4 H, s, 
H11), 4.20 (4 H, q, J 7, H13), 1.30 (3 H, t, J 7, H10), 1.27 (6 H, t, J 7, H14); 13C NMR 
(176 MHz, CDCl3) 171.0 (C12), 168.5 (C8), 149.0 (C2), 140.2 (C1), 133.2 (C17), 
130.1 (C18), 128.5 (C20), 128.3 (C17’), 126.2 (C20’), 126.7 (C19’), 126.5 (C5), 126.4 
(C18’), 126.3 (C21’), 125.3 (C19), 121.1 (C21), 119.2 (C6), 117.5 (C3), 116.5 (C4), 
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94.3 (C15), 86.6 (C16), 66.2 (C7), 61.3 (C9), 60.8 (C13), 53.8 (C11), 14.2 (C14), 14.1 
(C10)  ESI-LRMS [C30H32NO7]+ (+) m/z 518.2; ESI-HRMS calcd for [C30H32NO7]+ 
518.2173 found 518.2179. 
7.6.32 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-5-(naphthalen-1-ylethynyl) 
phenyl)azanediyl)diacetate, (32) 
 
Compound (26) (321.7 mg, 0.59 mmol) and 1-bromonapthalene (76 µL, 
0.54 mmol) were dissolved in anhydrous THF (2.4 mL) and the solution was 
degassed by three freeze-pump-thaw cycles. Triethylamine (1.6 mL), Pd(dppf)Cl2 
(49.0 mg, 0.07 mmol) and copper iodide (35 mg, 0.18 mmol) were then added 
and the solution was degassed once more. Tetrabutylammonium fluoride (TBAF, 
1 M solution in THF, 0.8 mL, 0.8 mmol) was then added before the brown solution 
was degassed with three final freeze-pump-thaw cycles. The reaction mixture 
was stirred at 65 oC for 19 h under an inert atmosphere of argon, before the 
solvent was removed under reduced pressure to form a dark brown / black 
residue. Purification by silica gel column chromatography (gradient hexane to 1:1 
hexane / ethyl acetate) formed the title compound as a pale yellow / orange oil 
(83.8 mg, 30 %).1H NMR (600 MHz, CDCl3) 8.40 (1 H, d, J 9, H20’), 7.86 (1 H, d, 
J 8, H17’), 7.83 (1 H, d, J 8, H20), 7.73 (1 H, dd, J 7, 1, H18), 7.59 – 7.56 (1 H, m, 
H19), 7.54 – 7.51 (1 H, m, H18’), 7.46 – 7.43 (1 H, m, H19’), 7.22 (1 H, dd, J 8, 2, 
H5), 7.18 (1 H, d, J 1.9, H3), 6.80 (1 H, d, J 8, H6), 4.69 (2 H, s, H11), 4.28 – 4.19 
(10 H, m, H7 and H9 and H13), 1.31 – 1.25 (9 H, m, H10 and H14); 13C NMR 
(151 MHz, CDCl3) 171.1 (C8), 168.6 (C12), 150.2 (C1), 139.6 (C2), 133.2 (C17), 
133.2 (C21’), 130.2 (C20), 128.5 (C18), 128.5 (C18’), 126.6 (C19;), 126.3 (C5), 126.2 
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(C20’), 126.2 (C19’), 125.3 (C19), 123.2 (C3), 121.1 (C21), 117.4 (C4), 114.2 (C6), 
94.3 (C15), 86.3 (C16), 66.1 (C11), 61.3 (C7 or C9 or C13), 60.8 (C7 or C9 or C13), 
53.7 (C7 or C9 or C13), 14.2 (C10), 14.1 (C14); ESI-LRMS [C30H32NO7]+ (+) m/z 
518.2; ESI-HRMS calcd for [C30H32NO7]+ 518.2191 found 518.2179.   
7.6.33 Diethyl 2,2'-((2-((ethoxy(methyl)phosphoryl)methoxy)-4-(naphthalen-
1-ylethynyl)phenyl)azanediyl)diacetate, (33) 
	
 
Compound (27) (252.5 mg, 0.434 mmol) and 1-bromonapthalene (58 µL, 
0.41 mmol) were dissolved in anhydrous THF (1.8 mL) and the solution was 
degassed by three freeze-pump-thaw cycles. Triethylamine (1.2 mL), Pd(dppf)Cl2 
(43.9 mg, 0.06 mmol) and copper iodide (61.2 mg, 0.32 mmol) were then added 
and the solution was degassed once more. Tetrabutylammonium fluoride (TBAF, 
1 M solution in THF, 0.6 mL, 0.6 mmol) was then added before the brown solution 
was degassed with three final freeze-pump-thaw cycles. The reaction mixture 
was stirred at 65 oC for 19 h under an inert atmosphere of argon, before the 
solvent was removed under reduced pressure to form a dark brown / black 
residue. Purification by column chromatography (gradient 100 % hexane to 
100 % ethyl acetate) formed the title compound as a pale brown oil (24.1 mg, 10 
%). 1H NMR (700 MHz, CDCl3) 8.39 (1 H, d, J 8, H20’), 7.85 (1 H, d, J 9, H17’), 
7.82 (1 H, d, J 8, H20), 7.72 (1 H, dd, J 7, 2, H18), 7.60 – 7.57 (1 H, m, H19’), 
7.53 – 7.51 (1 H, m, H18’), 7.46 – 7.43 (1 H, m, H19), 7.25 (1 H, dd, J 6, 2, H5), 
7.15 (1 H, d, J 2, H3), 6.90 (1 H, d, J 8, H6), 4.36 – 4.09 (14 H, m, H7, H9, H11 and 
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H13), 1.68 (3 H, d, J 15, H8), 1.37 (3 H, t, J 7, H10), 1.26 (6 H, t, J 7, H14); 31P NMR 
(101 MHz, CDCl3) + 53.8; 13C NMR (176 MHz, CDCl3) 170.7 (s, C12), 150.1 (s, 
C2), 139.8 (s, C1), 133.2 (s, C17), 130.2 (s, C18), 128.3 (s, C17’), 128.6 (s, C20), 
126.7 (s, C19’) 126.5 (s, C5), 126.4 (s, C21’), 126.3 (s, C20’), 126.2 (s, C18’), 125.3 
(s, C19), 120.9 (s, C21), 120.0 (s, C6) 117.1 (d, J 7, C3) 94.0 (s, C15), 87.0 (s, C16), 
64.6 (s, C7, C9, C11 or H13), 65.2 (s, C7, C9, C11 or H13), 60.9 (s, C7, C9, C11 or 
H13), 53.3 (s, C7, C9, C11 or H13), 16.6 (s, C10), 14.2 (s, C14), 12.6 (d, J 97, C8); 
ESI-LRMS [C30H35NO7P]+ (+) m/z 552.1; ESI-HRMS calcd for [C30H35NO7P]+ 
552.2153 found 552.2151. 
7.6.34 Ethyl 2-((2-(ethoxy(methyl)phosphoryl)-4-(naphthalen-1-ylethynyl) 
phenyl)amino)acetate, (34) 
 
 
Compound (28) (109.7 mg, 0.24 mmol) and 1-bromonapthalene (31 µL, 
0.22 mmol) were dissolved in anhydrous THF (1 mL) and the solution was 
degassed by three freeze-pump-thaw cycles. Triethylamine (0.7 mL), Pd(dppf)Cl2 
(40.6 mg, 0.06 mmol) and copper iodide (42.1 mg, 0.22 mmol) were then added 
and the solution was degassed once more. Tetrabutylammonium fluoride (TBAF, 
1 M solution in THF, 0.35 mL, 0.35 mmol) was then added before the brown 
solution was degassed with three final freeze-pump-thaw cycles. The reaction 
mixture was stirred at 65 oC for 18 h under an inert atmosphere of argon, before 
the solvent was removed under reduced pressure to form a dark brown / black 
residue. Purification by column chromatography (gradient 100 % hexane to 
100 % ethyl acetate formed the title compound as an orange oil (77.8 mg, 20 %).  
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1H NMR (700 MHz, CDCl3) 8.40 (1 H, d, J 8, H20’), 7.85- 7.83 (2 H, m, H17’ and 
NH), 7.80 (1 H, d, J 8, H20), 7.71 (1 H, dd, J 7, 1, H18), 7.65 (1 H, dd, J 15, 2, H3), 
7.60 – 7.56 (2 H, m, H5 and H19’), 7.52 – 7.50 (1 H, m, H18’), 7.44 – 7.42 (1 H, m, 
H19), 6.51 (1 H, dd, J 9, 6, H6), 4.24 (2 H, q, J 7, H12), 4.19 – 3.93 (4 H, m, H10 
and H8), 1.73 (3 H, d, J 15, H7), 1.35 (3 H, t, J 7, H9), 1.28 (3 H, t, J 7, H13); 
13C NMR (176 MHz, CDCl3) 170.1 (s, C11), 151.0 (d, J 6, C1), 137.1 (d, J 2, C5), 
136.2 (d, J 10, C3), 133.2 (d, J 14, C2), 130.0 (s, C18), 128.3 (s, C17’ and C20), 
126.6 (s, C19’), 126.4 (s, C18’), 126.2 (s, C20’), 125.3 (s, C19), 121.2 (s, C21), 112.5 
(s, C17’ or C21’), 111.7 (s, C17’ or C21’), 111.1 (s, C4), 110.0 (d, J 10, H6), 94.1 
(s, C14), 86.1 (s, C15), 61.4 (s, C12), 60.9 (d, J 6, C8), 45.1 (s, C10), 16.44 (d, J 106, 
C7), 16.4 (d, J 7, C9), 16.1 (s, C13); 31P NMR (283 MHz, CDCl3) + 46.7; ESI-LRMS 
[C25H27NO7P]+ (+) m/z 436.4; ESI-HRMS calcd for [C25H27NO7P]+ 436.1678 found 
436.1672. 
7.6.35 2,2'- ((2-(Carboxymethoxy)-4-(naphthalen-1-ylethynyl) phenyl) 
azanediyl)diacetic acid, NapL1 (35) 
 
 
The ethyl ester of NapL1 (31) (51.3 mg, 0.1 mmol) was dissolved in CD3OD 
(2.25 mL) and NaOD (0.4 M in D2O, 0.75 mL). The pale yellow solution was stirred 
under an inert atmosphere of argon at room temperature for 19 h. Hydrolysis was 
confirmed by 1H NMR spectrometry, and ESI-LRMS. The solution was lyophilised 
to form the title compound as an off white solid, in quantitative conversion 34 mg. 
1H NMR (700 MHz, D2O) 8.30 (1 H, d, J 8, H16’), 7.85 (1 H, d, J 8, H13’), 7.82 (1 H, 
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d, J 8, H16), 7.65 (1 H, dd, J 7, 1, H14), 7.57 – 7.54 (1 H, m, H15’), 7.51 – 7.48 (1 
H, m, H14’), 7.41 – 7.39 (1 H, m, H15), 7.09 (1 H, dd, J 8, 2, H5), 6.87 (1 H, d, J 2, 
H3), 6.65 (1 H, br. d, H6), 4.35 (2 H, s, H7); 13C NMR (176 MHz, D2O) 179.5 (C10), 
177.2 (C8), 148.7 (C2), 141.0 (C1), 132.9 (C17 or C17’), 132.5 (C17 or C17’), 130.2 
(C14), 128.7 (C16), 128.4 (C13’), 127.2 (C15’), 126.8 (C14’), 125.7 (C16’), 125.6 (C15), 
125.5 (C5), 120.1 (C13), 117.1 (C6), 115.9 (C3), 95.1 (C11), 85.9 (C12), 67.8 (C7), 
56.7 (C9); ESI-LRMS [C24H20NO7]+ (+) m/z 434.1; ESI-HRMS calcd for 
[C24H20NO7]+ 434.1240 found 434.1247; Reverse phase HPLC (0 % - 100 % - 
0% CH3CN in ammonium bicarbonate buffer (25 mM), tR = 7.1 min); 7BCD= 0.3 %. 
*H9 missing from the 1H NMR spectrum because of deuterium exchange.  
7.6.36 2,2'- ((2-(Carboxymethoxy)-5- (naphthalen-1- ylethynyl)phenyl) 
azanediyl)diacetic acid, NapL2 (36) 
	
 
The ethyl ester of NapL2 (32) (41.3 mg, 0.8 mmol) was dissolved in CD3OD 
(2.25 mL) and NaOD (0.4 M in D2O, 0.75 mL). The pale yellow solution was stirred 
under an inert atmosphere of argon at room temperature for 19 h. Hydrolysis was 
confirmed by 1H NMR spectrometry, and ESI-LRMS. The solution was lyophilised 
to form the title compound as an off white solid, in quantitative conversion 
(28 mg). 1H NMR (700 MHz, D2O) 8.31 (1 H, d, J 8, H16’), 7.85 (1 H, d, J 8, H13’), 
7.83 (1 H, d, J 8, H16), 7.67 (1 H, d, J 7, H14), 7.55 (1 H, t, J 8, H15’), 7.49 (1 H, t, 
J 8, H14’), 7.41 (1 H, t, J 7, H15), 7.08 (1 H, d, J 8, H5), 6.98 (1 H, br s, H3), 6.62 
(1 H, d, J 9, H6); 4.37 (2 H, s, H10), 3.75 (4 H, s, H7); 13C NMR (176 MHz, D2O) 
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179.5 (C8), 177.0 (C10), 150.5 (C1), 139.9 (C2), 132.9 (C17), 132.5 (C17’), 130.0 
(C16), 128.8 (C14), 128.4 (C13’), 127.2 (C15’), 126.8 (C14’), 125.7 (C4), 125.6 (C15) 
125.0 (C5), 120.7 (C3), 120.0 (C13), 114.8 (C4), 113.0 (C6), 94.9 (C11), 85.6 (C12), 
67.4 (C10), 55.6 (C7); ESI-LRMS [C24H20NO7]+ (+) m/z 434.1; ESI-HRMS calcd for 
[C24H20NO7]+ 434.1240 found 434.1247; Reverse phase HPLC (0 % - 100 % - 
0% CH3CN in ammonium bicarbonate buffer (25 mM), tR = 6.6 min); 7BCD= 1.3	%.	
7.6.37 2,2'-((2-((Hydroxy(methyl)phosphoryl)methoxy)-4-(naphthalen-1-
ylethynyl)phenyl)azanediyl)diacetic acid, NapL4 (37) 
 
 
The ethyl ester of NapL4 (33) (11 mg, 0.02 mmol) was dissolved in CD3OD 
(2 mL) and NaOD (0.4 M in D2O, 0.5 mL). The pale yellow solution was stirred 
under an inert atmosphere of argon at room temperature for 48 h. Ester hydrolysis 
was confirmed by 1H NMR spectrometry, and ESI-LRMS. The solution was 
lyophilised to form the title compound as a pale brown solid, in quantitative 
conversion (7 mg). QToF-LRMS [C24H21NO7P]– (-) m/z 466.1; ESI-HRMS calcd 
for [C24H21NO7P]– (-) 466.1056 found 466.1044. Reverse phase HPLC (0 % - 
100 % - 0% CH3CN in ammonium bicarbonate buffer (25 mM), tR = 7.1 min); 7BCD = 0.7 %. 
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7.6.38 2-((2-(Hydroxy(methyl)phosphoryl)-4-(naphthalen-1-ylethynyl) 
phenyl)amino)acetic acid, NapL6 (38) 
	
 
The ethyl ester of NapL6 (34) (46.0 mg, 0.10 mmol) was dissolved in 
CD3OD (1.8 mL) and NaOD (0.4 M in D2O, 0.2 mL). The pale yellow solution was 
stirred under an inert atmosphere of argon at room temperature for 4 d. Ester 
hydrolysis was confirmed by 1H NMR spectrometry, and ESI-LRMS. The solution 
was then lyophilised to form the title compound as a pale brown solid, in 
quantitative conversion (30 mg). QToF-LRMS [C21H17NO4P]– (-) m/z 466.1; ESI-
HRMS calcd for [C21H17NO4P]– (-) 378.0905 found 378.0895. 1H NMR 
(400 MHz, D2O) 8.19 (1 H, d, J 8), 7.69 – 7.60 (3 H, m), 7.48 – 7.47 (1 H, d, J 7), 
7.43 (1 H, t, J 7),  7.36 – 7.21 (4 H, m), 6.27 (1 H, m), 1.32 (3 H, d, J 14); 31P (176 
MHz, D2O) + 31.7; Reverse phase HPLC (0 % - 100 % - 0% CH3CN in ammonium 
bicarbonate buffer (25 mM), tR = 6.6 min); 7BCD= 0.8 %. 
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7.6.39 [1, 4, 7- Tris(ethoxycarbonylmethyl)] 1, 4, 7, 10- tetraazacyclodecane 
hydrobromide, (39)14 
 
Ethyl bromoacetate (2 mL, 18.1 mmol) was added dropwise to an ice cold 
suspension of sodium hydrogen carbonate (1.64 g, 19.52 mmol) and 1,4,7,10-
tetraazacyclododecane (0.99 g, 5.73 mmol) in anhydrous acetonitrile (35 mL). 
The reaction mixture was slowly left to warm to room temperature and stirred for 
48 h under an inert atmosphere of argon. Inorganic material was removed by 
filtration and the solvent was removed under reduced pressure to form a yellow 
oil. Purification by column chromatography (gradient CH2Cl2 to 90 % CH2Cl2 / 
10 % MeOH) formed the title compound as a pale yellow oil that slowly solidified 
to an off white solid (1.63 g, 66 %). m.p. 94-96 oC (lit. 92-94 oC)14; 1H NMR 
(400 MHz, CDCl3) 10.05 (2 H, br s, NH2), 4.19 (6 H, q, J 7, H3), 3.50 (6 H, s, H1), 
3.42 – 2.89 (16 H, br m, cyclen -H), 1.29 (9 H, t, J 7, H4); 13C NMR (101 MHz, 
CDCl3) 171.1 (C2), 60.8 (C3), 57.3 (C1), 51.7, 51.4, 49.4, 47.4 (4 x cyclen –CH2), 
14.3 (C4); ESI-LRMS [C20H39N4O6]+ (+) m/z 431.1; ESI-HRMS calcd for 
[C20H39N4O6]+ 431.2870 found 431.2865. 
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7.6.40 [1, 4, 7- Tris(tert-butylcarbonylmethyl)]1,4,7,10- tetraazacyclodecane 
hydrobromide, (40)15 
 
tert-Butyl bromoacetate (2.0 mL, 13.6 mmol) was added to a solution of 
1,4,7,10-tetraazacyclododecane (0.9 g, 5.1 mmol) and sodium hydrogen 
carbonate (1.4 g, 17.0 mmol) in anhydrous acetonitrile (30 mL). The reaction 
mixture was stirred at room temperature overnight for 19 h under an inert 
atmosphere of argon. Inorganic impurities were removed by filtration before the 
solvent was removed under reduced pressure to form an off white solid. 
Purification by recrystallisation from a minimum amount of hot toluene formed the 
title compound as a white solid (1.3 g, 43 %). m.p. = 182-184 oC (lit. 
183-184 oC)15; 1H NMR (400 MHz, CDCl3) 10.62 (2 H, br s, NH2), 3.38 (4 H, s), 
3.28 (s, 2H), 3.16- 3.06 (2 H, br s), 2.75 – 2.92 (12 H, m), 1.52 (9 H, s, H8), 1.45 
(18 H, s, H4); 13C NMR (101 MHz, CDCl3) 170.4 (C2 and C6), 85.08 (C3 or C7), 
82.74 (C3 or C7), 54.3, 52.5, 50.4, 48.1, 28.2 (C8), 28.1 (C4); ESI-LRMS 
[C26H51N4O6]+ (+) m/z 515.4; ESI-HRMS calcd for [C26H51N4O6]+ 515.3809 found 
513.3798. 
7.6.41 4-Bromo-2-methyl pyridine-N-oxide, (41)16 
 
m-CPBA (12.09 g, 46.2 mmol) was added to an ice-cold solution of 
4-bromo-2-methyl pyridine (4.2 mL, 35.6 mmol) in anhydrous CHCl3 (110 mL). 
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The solution was stirred at room temperature for 17 h under an inert atmosphere 
of argon. The inorganic impurities were removed by filtration, before the organic 
layer was washed with NaHCO3 (30 mL). The aqueous layer was washed with 
CH2Cl2 (3 x 20 mL). Organic extracts were combined and dried over MgSO4, and 
the solvent was removed under reduced pressure to form a yellow oil. Purification 
by alumina gel column chromatography (gradient CH2Cl2 to 95 % CH2Cl2 / 5 % 
MeOH) formed the title compound as a pale yellow oil (5.4 g, 81 %). 1H NMR 
(400 MHz, CDCl3) 8.10 (1 H, d, J 7, H2), 7.42 (1 H, d, J 3, H5), 7.29 (1 H, dd, J 7, 
3, H3), 2.50 (3 H, s, H7); 13C NMR (101 MHz, CDCl3) 150.4, 140.1, 129.4, 126.8, 
118.4, 17.8.  
7.6.42 4-Bromo-2-(hydroxymethyl)pyridine, (42)16 
	
 
Trifluoroacetic anhydride (16 mL, 115.0 mmol) was added to a solution of 
4-bromo-2-methyl pyridine-N-oxide (2.2 g, 11.5 mmol) in anhydrous CHCl3 
(32 mL). The solution was heated at 60 oC for 20 h under an inert atmosphere of 
argon. The reaction mixture was then cooled to room temperature, and the 
solvent was removed under reduced pressure for form a light brown oil. The 
brown residue was dissolved in CH2Cl2 (20 mL) before NaOH (2 M) was added 
and the reaction mixture was stirred at room temperature under argon for 16 h. 
The organic layer was extracted with CH2Cl2 (3 x 30 mL) and dried over MgSO4. 
The solvent was removed under reduced pressure to form a dark brown oil. 
Purification by silica gel column chromatography (gradient 100 % CH2Cl2 to 95 % 
CH2Cl2 / 5 % CH3OH) formed the title compound as a pale brown oil, that slowly 
solidified to a fluffy off-white solid on standing at room temperature (1.4 g, 64 %). 
m.p. 34-36 oC; 1H NMR (700 MHz, CDCl3) 8.37 (1 H, d, J 5, H2), 7.49 (1 H, d, J 1, 
H5), 7.39 (1 H, dd, J 5, 1, H3), 4.75 (2 H, s, H7), 13C NMR (176 MHz, CDCl3) 160.8 
(C6), 149.1 (C2), 133.7 (C4), 125.8 (C3), 124.0 (C5), 63.8 (C7); ESI-LRMS 
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[C6H7NO79Br]+ (+) m/z 188.1; ESI-HRMS calcd for [C6H7NO79Br]+ 187.9711 found 
187.9688.  
7.6.43 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-4-((2-(hydroxymethyl) 
pyridine-4-yl)ethynyl)phenyl)azanediyl)diacetate, (43) 
	
 
Compound (25) (973.0 mg, 1.80 mmol) and 4-bromo-2-(hydroxymethyl) 
pyridine (42) (310.7 mg, 1.66 mmol) were dissolved in anhydrous THF (8 mL) 
and the solution was degassed by three freeze-pump-thaw cycles. Triethylamine 
(4.8 mL), Pd(dppf)Cl2 (132.4 mg, 0.018 mmol) and CuI (110.6 mg, 0.58 mmol) 
were then added and the solution was degassed once more. 
Tetrabutylammonium fluoride (TBAF, 1 M solution in THF, 0.5 mL, 0.5 mmol) was 
then added before the brown solution was degassed with three final freeze-pump-
thaw cycles. The reaction mixture was stirred at 65 oC for 3 h under an inert 
atmosphere of argon, before the solvent was removed under reduced pressure 
to form a dark brown / black residue. Purification by column chromatography 
(gradient hexane to ethyl acetate (with 1 % triethylamine)) formed the title 
compound as a yellow / brown oil (580.2 mg, 65 %). 1H NMR (700 MHz, CDCl3,) 
8.53 (1 H, br s, H18), 7.29 – 7.69 (2 H, br m, H19 and H21), 7.12 (1 H, dd, J 9, 2, 
H4), 6.94 (1 H, d, J, 2, H6), 6.79 (1 H, d, J 8, H3), 4.76 (2 H, br s, H23), 4.63 (2 H, 
s, H7), 4.24 (2 H, q, J 7, H9), 4.21 (4 H, s, H11), 4.19 (4 H, q, J 7, H13), 1.29 (3 H, 
t, J 7, H10), 1.25 (6 H, t, J 7, H14); 13C NMR (176 MHz, CDCl3) 170.9 (C12), 168.4 
(C8), 148.7 (C1), 141.0 (C2), 131.3 (C19 or C21), 128.3 (C19 or C21), 126.8 (C4), 
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118.9 (C3), 117.5 (C6), 66.2 (C7), 61.33 (C9), 60.89 (C13), 53.8 (C11),14.2 (C14), 
14.1 (C10); ESI-LRMS [C26H31N2O8]+ (+) m/z 499.2; ESI-HRMS calcd for 
[C26H31N2O8]+ 499.2080 found 499.2080. 
*Protons from the pyridine spin system are very broad, carbons (C18, C19, C20, 
C21 and C22) are missing from the spectrum.  
7.6.44 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-4-((2-(((methylsulfonyl)oxy) 
methyl)pyridin-4-yl)ethynyl)phenyl)azanediyl)diacetate, (44) 
 
Mesyl chloride (39 µL, 0.5 mmol) was added to an ice cold solution of (43) 
(169.0 mg, 0.339 mmol) and triethylamine (0.15 mL, 1.1 mmol) in anhydrous THF 
(2 mL). The orange solution was stirred in ice for 20 mins before being gradually 
warmed to room temperature and stirred for a further 1 h under argon. The 
reaction mixture was diluted with CH2Cl2 (20 mL) and washed with brine. Organic 
extracts were combined and dried over MgSO4. The solvent was removed under 
reduced pressure to form the title compound as a brown oil, which was used in 
subsequent steps without any additional purification. ESI-LRMS [C27H33N2O10S]+ 
(+) m/z 577.2; ESI-HRMS calcd for [C27H33N2O10S]+ 577.1858 found 577.1856. 
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7.6.45 Diethyl 2,2'-((4-((2-(bromomethyl)pyridin-4-yl)ethynyl)-2-(2-ethoxy-2-
oxoethoxy)phenyl)azanediyl)diacetate, (45) 
	
 
Phosophorus tribromide (PBr3) (71 µL, 0.75 mmol) was added to an ice 
cold solution of (43) (338.3 mg, 0.68 mmol) in anhydrous CH2Cl2 (6 mL). The 
reaction was warmed to room temperature and stirred at room temperature for 1 
h under an inert atmosphere of argon. Reaction completion was determined by 
ESI-MS. The solvent was removed under reduced pressure to form the title 
compound as a pale brown oil which was used in subsequent steps without any 
further purification. ESI-LRMS [C26H30N2O879Br]+ (+) m/z 561.1; ESI-HRMS calcd 
for [C26H30N2O879Br]+ 561.1238 found 561.1241. 
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7.6.46 Triethyl-2,2',2''-(10-((4-((4-(bis(2-ethoxy-2-oxoethyl)amino)-3-(2-
ethoxy-2-oxoethoxy)phenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-tetraaza-
cyclododecane-1,4,7-triyl)triacetate, (46) 
 
 
Caesium carbonate (632.4 mg, 1.94 mmol) and sodium iodide (73.8 mg, 
0.49 mmol) were added to a solution of (45) (154.1 mg, 0.275 mmol) and [1,4,7-
tris(ethoxycarbonylmethyl)]-1,4,7,10-tetraazacyclodecane hydrobromide (139.2 
mg, 0.273 mmol) in anhydrous acetonitrile (3 mL). The reaction mixture was 
stirred at 60 oC for 16 h under an inert atmosphere of argon. After reaction 
completion, the suspension was diluted with ethyl acetate, and all inorganic 
impurities were collected by filtration. The solvent was removed under reduced 
pressure to form a dark brown residue. Purification by silica gel column 
chromatography (gradient 100 % CH2Cl2 to 90 % CH2Cl2 / 10 % MeOH) formed 
the title compound as a pale yellow oil (160 mg). ESI-LRMS [C46H66N6O13]+ (+) 
m/z 910.9; ESI-HRMS calcd for [C46H66N6O13]+ 911.4766 found 911.4774. 
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7.6.47 [Eu.L1(H2O)] 
 
Compound (46) (64.3 mg, 0.07 mmol) was dissolved in CD3OD (3 mL) and 
NaOD (0.4 M in D2O, 0.80 mL). The pale yellow solution was stirred under an 
inert atmosphere of argon at room temperature for 18 h, ester hydrolysis was 
confirmed by 1H NMR spectrometry, and ESI-LRMS. The solution was lyophilised 
to form the title compound as a white solid (61.4 mg), which was used in 
subsequent steps without any further purification. ESI-LRMS [C34H43N6O13]+ (+) 
m/z 743.2. The ethyl ester hydrolysed product (61.4 mg, 0.029 mmol) was 
dissolved in H2O (3 mL). The pH was adjusted to 5.5 using HCl (aq, 1 M) and 
EuCl3.6H2O (42.8 mg, 0.12 mmol) was added. The resulting yellow solution was 
stirred at 65 oC for 18 h under an inert atmosphere of argon. The pH was adjusted 
to pH 8 and precipitated Eu(OH)3 was removed by syringe filtration. Purification 
was achieved by reverse phase HPLC (0 % - 100 % - 0% CH3CN in ammonium 
bicarbonate buffer (25 mM), tR = 1.13 min). The solvent was lyophilised to form 
the title compound as a pale yellow solid (13 mg); ESI-LRMS [C46H39N6O13151Eu]- 
(-) m/z 890.3; ESI-HRMS calcd for [C46H39N6O13151Eu]+ 890.1774 found 
890.1767; 7BCD= 13.0 %.  
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7.6.48 Diethyl 2,2'-((2-(2-ethoxy-2-oxoethoxy)-5-((2-(hydroxylmethyl)- 
pyridin-4-yl)ethynyl)phenyl)azanediyl)diacetate, (47) 
 
Compound (26) (185.6 mg, 0.34 mmol) and 4-bromo-2-(hydroxymethyl) 
pyridine (63.8 mg, 0.34 mmol) were dissolved in anhydrous THF (1.6 mL) and 
the solution was degassed by three freeze-pump-thaw cycles. Triethylamine (1 
mL), Pd(dppf)Cl2 (26.2 mg, 0.036 mmol) and copper iodide (22.4 mg, 0.11 mmol) 
were then added and the solution was degassed once more. 
Tetrabutylammonium fluoride (TBAF, 1 M solution in THF, 0.5 mL, 0.5 mmol) was 
then added before the brown solution was degassed with three final freeze-pump-
thaw cycles. The reaction mixture was stirred at 65 oC for 3 h under an inert 
atmosphere of argon, before the solvent was removed under reduced pressure 
to form a dark brown / black residue. Purification by column chromatography 
(gradient hexane to ethyl acetate (with 1 % triethylamine)) formed the title 
compound as a yellow oil (73.4 mg, 42 %). Rf (silica, 100 % ethyl acetate) = 0.38. 
1H NMR (700 MHz, CDCl3) 8.57 (1 H, br s, H18), 7.38 (2 H, br s, H19 and H21), 
7.10 (1 H, dd, J 8, 2, H5), 7.08 (1 H, d, J 2, H3), 6.73 (1 H, d, J 8, H6), 4.78 (2 H, 
br s, H23), 4.66 (2 H, s, H11), 4.24 (2 H, q, J 7 H13), 4.17 – 4.21 (8 H, m, H7 and 
H9), 1.24 – 1.28 (9 H, m, H10 and H14); 13C NMR (700 MHz, CDCl3) 171.0 (C8), 
168.3 (C12), 150.7 (C1), 139.5 (C2), 126.5 (C5), 123.4 (C3), 113.9 (C6), 65.8 (C11), 
61.2 (C13), 60.8 (C7 or C9), 53.6 (C7 or C9), 14.2 (C10), 14.1 (C14); ESI-LRMS 
[C26H31N2O8]+ (+) m/z 499.2; ESI-HRMS calcd for [C26H31N2O8]+ 499.2080 found 
499.2068. 
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*Protons from the pyridine spin system are very broad, carbons (C18, C19, C20, 
C21 and C22) are missing from the spectrum.  
7.6.49 Diethyl 2,2'-((5-((2-(bromomethyl)pyridin-4-yl)ethynyl)-2-(2-ethoxy-2-
oxoethoxy)phenyl)azanediyl)diacetate, (48) 
 
Phosphorus tribromide (PBr3) (38 µL, 0.40 mmol) was added to an ice cold 
solution of (47) (132.7 mg, 0.27 mmol) in anhydrous CH2Cl2 (3 mL). The solution 
was stirred at 0 oC for 1 h before being stirred at room temperature for 2 h under 
an inert atmosphere of argon. The solvent was removed under reduced pressure 
to form a yellow residue. Purification by column chromatography (gradient 100 % 
CH2Cl2 to 95 % CH2Cl2 / 5 % MeOH) to form the title compound as a yellow oil 
(88.6 mg, 59 %). 1H NMR (700 MHz, CDCl3) 8.55 (1 H, br s, H18), 7.57 (1 H, br s, 
H21), 7.35 (1 H, br d, J 5, H19), 7.10 – 7.13 (2 H, m, H3 and H5), 6.74 (1 H, d, J 8, 
H6), 4.68 (2 H,s, H11), 4.62 (2 H, s, H23), 4.17 – 4.21 (8 H, m, H7 and H9), 
1.24 – 1.29 (9 H, m, H10 and H14); 13C NMR (176 MHz, CDCl3) 170.9 (C8), 168.2 
(C12), 155.8 (C22), 151.1 (C1), 147.8 (C18), 139.6 (C2), 126.8 (C3 or C5), 126.0 
(C21) 125.1 (C19), 123.7 (C20), 123.6 (C3 or C5), 115.2 (C4), 113.8 (C6), 97.0 (C15), 
85.2 (C16), 65.8 (C7 or C9), 61.4 (C13), 60.8 (C11), 53.6 (C7 or C9), 31.6 (C23), 14.21 
(C10), 14.11 (C14); ESI-LRMS [C26H29N2O779Br]+ (+) m/z 561.1; ESI-HRMS calcd 
for [C26H29N2O779Br]+ 561.1236 found 561.1236. 
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7.6.50 Triethyl-2,2',2''-(10-((4-((3-(bis(2-ethoxy-2-oxoethyl)amino)-4-(2-
ethoxy-2-oxoethoxy)phenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-tetraaza-
cyclododecane-1,4,7-triyl)triacetate, (49) 
	
 
Caesium carbonate (341.8 mg, 1.05 mmol) and sodium iodide (32.2 mg, 
0.21 mmol) were added to a solution of (48) (97.5 mg, 0.17 mmol) and [1,4,7-
tris(ethoxycarbonylmethyl)]-1,4,7,10-tetraazacyclodecane hydrobromide (81.8 
mg, 0.158 mmol). The reaction mixture was stirred at 60 oC for 16 h under an 
inert atmospgere of argon. After completion the solution was diluted with ethyl 
acetate and all inorganic impurities were collected by filtration. The solvent was 
removed under reduced pressure to form a dark brown residue. Purification by 
silica gel column chromatography (gradient 100 % CH2Cl2 to 90 % CH2Cl2 / 10 % 
MeOH) formed the title compound as a pale yellow oil (42.1 mg, 29 %). 1H NMR 
(400 MHz, CDCl3) 8.20 (1 H, d, J 5, H18), 7.31 (1 H, br s, H21), 7.23 (1 H, dd, J 5, 
2, H19), 7.14 – 7.12 (2 H, m, H3 and H5), 6.77 (1 H, d, J 9, H6), 4.70 (2 H, s, H23), 
4.30 – 4.16 (22 H, m), 1.30 (18 H, m, H10, H14 and H27); ESI-LRMS [C46H66N6O13]+ 
(+) m/z 910.9; ESI-HRMS calcd for [C46H66N6O13]+ 911.4766 found 911.4794. 
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7.6.51 [Eu.L2(H2O)] 
 
Compound (49) (41.5 mg, 0.046 mmol) was dissolved in CD3OD (2 mL) 
and NaOD (0.4 M in D2O, 0.70 mL). The pale yellow solution was stirred under 
an inert atmosphere of argon at room temperature for 20 h, ester hydrolysis was 
confirmed by 1H NMR spectrometry, and ESI-LRMS. The solution was lyophilised 
to form the title compound as a white solid (35 mg), which was used in 
subsequent steps without further purification.  ESI-LRMS [C34H43N6O13]+ (+) m/z 
743.2; ESI-HRMS calcd for [C34H43N6O13]+ 743.2888 found 743.2893. The ethyl 
ester hydrolysed product of (49) (22 mg, 0.029 mmol) was dissolved in H2O 
(2 mL). The pH was adjusted to 5.5 using HCl (aq, 1 M) and EuCl3.6H2O (21.7 mg, 
0.069 mmol) was added. The resulting yellow solution was stirred at 65 oC for 
18 h under an inert atmosphere of argon. The pH was adjusted to pH 8 and the 
Eu(OH)3 precipitate was removed by syringe filtration. The solvent was 
lyophilised to form a pale yellow solid. Purification by reverse phase HPLC 
(0 % - 100 % - 0% CH3CN in ammonium bicarbonate buffer (25 mM), tR = 5.6 min) 
to form the title compound as a pale yellow solid (8 mg); ESI-LRMS 
[C46H39N6O13151Eu]- (-) m/z 890.3; ESI-HRMS calcd for [C46H39N6O13151Eu]+ 
890.1774 found 890.1778; 7BCD= 11.2 %.  
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7.6.52 [Tb.L2(H2O)] 
	
The complex [Tb.L2(H2O)] was synthesised in a procedure analogous to 
that used for the synthesis of [EuL2(H2O)], using (49) (18.9 mg, 0.025 mmol) and 
TbCl3.6H2O (16.4 mg, 0.04 mmol) in H2O (1.8 mL). Purification by reverse phase 
HPLC (0 % - 100 % - 0% CH3CN in ammonium bicarbonate buffer (25 mM), 
tR = 5.7 min) to form the title compound as a pale yellow solid (4 mg); ESI-LRMS 
[C46H39N6O13Tb]+ (+) m/z 900.4; ESI-HRMS calcd for [C46H39N6O13Tb]+ 900.1907 
found 900.1937. 
7.6.53 tert-Butyl 2-(2-{bis[2-(tert-butoxy)-2-oxoethyl]amino}-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate, (50)17 
	
 
Pd(dppf)Cl2 (11.8 mg, 0.016 mmol) was added to a solution of 7 (264.2 
mg, 0.5 mmol), bis(pinacolato)diboron (B2pin2) (155.2 mg, 0.61 mmol) and 
potassium acetate (158.4 mg, 1.61 mmol) in 1,4-dioxane (1.4 mL). The solution 
was degassed via four freeze-pump-thaw cycles, and heated in a microwave 
reactor for 30 mins at 120 oC. The reaction mixture was suspended between 
CH2Cl2 (20 mL) and water (10 mL) and the aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL). The organic extracts were combined, dried over MgSO4, and 
the solvent was removed under reduced pressure to form a dark brown residue. 
Purification by silica gel column chromatography (gradient hexane to 80 / 20 
(hexane / ethyl acetate)) formed the title compound as a pale yellow solid (203.1 
mg, 70 %). Rf (silica, 80 / 20 (hexane / ethyl acetate)) = 0.36;  m.p = 136-138 oC; 
1H (CDCl3, 700 MHz) 7.30 (1 H, dd, J 8, 2, H5), 7.27 (1 H, d, J 2, H3), 6.70 (1 H, 
d, J 8, H6), 4.53 (2 H, s, H11), 4.07 (4 H, s, H7), 1.44 (18 H, s, H10), 1.43 (9 H, s, 
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H14), 1.28 (12 H, s, H16); 11B (CDCl3, 128 MHz) + 30.7; 13C (CDCl3, 176 MHz) 
170.8 (C8, C12), 167.9 (d, J 1, C4),152.1 (C1), 138.8 (C2), 129.0 (C5), 125.8 (C3), 
112.4 (C6),  83.4 (C15), 82.1 (C13), 80.9 (C9), 66.0 (C11), 54.5 (C7), 28.1 (C10), 28.0 
(C14), 24.9 (C16); ASAP-LRMS [C30H48BNO9]+ (+) m/z 578.3; ASAP-HRMS calcd 
for [C30H48BNO9]+ 577.3511 found 577.3537.   
7.6.54 Di-tert-butyl 2,2'-((2-(2-(tert-butoxy)-2-oxoethoxy)-5-(2-(hydroxyl-
methyl)pyridin-4-yl)phenyl)azanediyl)diacetate, (51) 
 
Compound (50) (205.2 mg, 0.35 mmol), 4-bromo-2-(hydroxymethyl) 
pyridine (42) (69.1 mg, 0.37 mmol) and sodium carbonate (151.3 mg, 1.48 mmol) 
were dissolved in a mixture of DME (1.4 mL) and water (0.6 mL). The solution 
was degassed by three freeze-pump-thaw cycles, before the addition of 
Pd(PPh3)4 (41.8 mg, 0.036 mmol). The reaction mixture was stirred at 85 oC for 
18 h, before the solvent was removed under reduced pressure to form a dark 
brown / black residue. Purification by column chromatography (gradient hexane 
to ethyl acetate (with 1 % triethylamine)) formed the title compound as a yellow 
oil (111.6 mg, 51 %). 1H NMR (600 MHz, CDCl3) 8.53 (1 H, d, J 5.22, H16), 7.36 
(1 H, br s, H19), 7.34 (1 H, dd, J 5, 1, H17), 7.17 (1 H, dd, J 8, 2, H5), 7.12 (1 H, d, 
J 2, H3), 6.82 (1 H, d, J 8, H6), 4.78 (2 H, s, H21), 4.58 (2 H, s, H11), 4.12 (4 H, s, 
H7), 1.47 (9 H, s, H14), 1.43 (18 H, s, H10); 13C NMR (151 MHz, CDCl3) 170.4 (C8), 
167.8 (C12), 159.3 (C20), 150.7 (C1), 148.9 (C18), 148.7 (C20), 140.0 (C2), 131.4 
(C4), 120.4 (C17), 120.0 (C5), 118.0 (C3), 117.7 (C19), 113.9 (C6), 82.4 (C13), 81.2 
(C9), 66.3 (C7), 64.2 (C11), 54.6 (C21), 28.1 (C10 and C14);  ESI-LRMS 
[C30H43N2O8]+ (+) m/z 599.3; ESI-HRMS calcd for [C30H43N2O8]+ 559.3019 found 
599.2999. 
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7.6.55 Di-tert-butyl 2,2'-((5-(2-(bromomethyl)pyridin-4-yl)-2-(2-(tert-butoxy)-
2-oxoethoxy)phenyl)azanediyl)diacetate, (52) 
 
 
Phosphorus tribromide (PBr3) (52 µL, 0.55 mmol) was added to an ice cold 
solution of (51) (252.3 mg, 0.45 mmol) in anhydrous CH2Cl2 (3 mL) The reaction 
was warmed to room temperature and stirred at room temperature for 1 h, 
reaction completion was determined by ESI-MS by the disappearance of the 
starting material peak. The solvent was removed under reduced pressure to form 
the title compound as a yellow oil which was used in subsequent steps without 
any further purification. ESI-LRMS [C30H42N2O779Br]+ (+) m/z 621.2; ESI-HRMS 
calcd for [C30H42N2O779Br]+ 621.2175 found 621.2165. 
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7.6.56 Tri-tert-butyl 2,2',2''-(10-((4-(3-(bis(2-(tert-butoxy)-2-oxoethyl) 
amino)–4-(3,3-dimethyl-2-oxobutoxy)phenyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate, (53) 
	
 
Caesium carbonate (620.0 mg, 1.9 mmol) and sodium iodide (120.2 mg, 
0.8 mmol) were added to a solution of (52) (201.1 mg, 0.32 mmol) and [1,4,7- 
tris(ethoxycarbonylmethyl)]-1,4,7,10-tetraazacyclodecane hydrobromide, (40) 
(81.8 mg, 0.158 mmol) in anhydrous acetonitrile (2 mL). The reaction mixture was 
stirred at 60 oC for 17 h under an inert atmospgere of argon. After completion the 
solution was diluted with ethyl acetate (15 mL) and all inorganic impurities were 
collected by filtration. The solvent was removed under reduced pressure to form 
a dark brown residue. Purification by silica gel column chromatography (gradient 
100 % CH2Cl2 to 90 % CH2Cl2 / 10 % MeOH) formed the title compound as a pale 
yellow oil (118.3 mg). ESI-LRMS [C56H91N6O13]+ (+) m/z 1056.8; ESI-HRMS calcd 
for [C56H91N6O13]+ 1055.6644 found 1055.6678. 
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7.6.57 [Eu.bL2(H2O)] 
 
Compound (53) (47.1 mg, 0.045 mmol) was dissolved in CH2Cl2 (1 mL) 
and TFA (1 mL). The pale brown solution was stirred under an inert atmosphere 
of argon at room temperature for 20 h, ester hydrolysis was confirmed by 1H NMR 
spectrometry, and ESI-LRMS. The solvent was lyophilised to form the title 
compound as a white solid (39 mg), which was used in subsequent steps without 
further purification. The tert-butyl ester hydrolysed product (39 mg, 0.029 mmol) 
was dissolved in H2O (4 mL). The pH was adjusted to 5.5 using NaOH (aq, 1 M) 
and EuCl3.6H2O (21.7 mg, 0.069 mmol) was added. The resulting yellow solution 
was stirred at 65 oC for 18 h. The pH was adjusted to pH 8 and Eu(OH)3 was 
removed by filtration. The solvent was lyophilised to form a pale yellow solid. 
Purification by reverse phase HPLC (0 % - 100 % - 0% CH3CN in ammonium 
bicarbonate buffer (25 mM), tR = 1.06 min) to form the title compound as a pale 
yellow solid (21 mg); ESI-LRMS [C32H40N6O13151Eu]+ (-) m/z 867.1; ESI-HRMS 
calcd for [C32H40N6O13151Eu]+ 867.1840 found 867.1852. 
7.6.58 [Tb.bL2(H2O)] 
	
The complex [Tb.bL2(H2O)] was synthesised in a procedure analogous to 
that used for the synthesis [Eu.bL2(H2O)], using (53) (30.2 mg, 0.04 mmol) and 
TbCl3.6H2O (35.5 mg, 0.09 mmol) in H2O (3.0 mL). Purification by reverse phase 
HPLC (0 % - 100 % - 0% CH3CN in ammonium bicarbonate buffer (25 mM), 
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tR = 1.63 min) to form the title compound as a white solid yellow solid (4 mg); ESI-
LRMS [C32H40N6O13Tb]+ (+) m/z 875.2; ESI-HRMS calcd for [C32H39N6O13Tb]+ 
875.1908 found 875.1907; 7BCD= 3.4 % (aerated), 7BCD= 5.4 % (deoxygenated).  
7.6.59 [Gd.bL2(H2O)] 
	
The complex [Gd.bL2(H2O)] was synthesised in a procedure analogous to 
that used for the synthesis [Eu.bL2(H2O)], using (53) (79 mg, 0.11 mmol) and 
GdCl3.6H2O (8 mg, 0.22 mmol) in H2O (5.0 mL). Purification by reverse phase 
HPLC (0 % - 100 % - 0% CH3CN in ammonium bicarbonate buffer (25 mM), 
tR = 1.48 min) to form the title compound as a white solid yellow solid (11 mg); 
ESI-LRMS [C32H40N6O13155Gd]+ (+) m/z 871.2; ESI-HRMS calcd for 
[C32H40N6O13155Gd]+ 871.1908 found 871.1907.  
7.6.60 2, 2’-Bipyridine-N-oxide, (54)18 
	
 
 3-Chloroperoxybenzoic acid (3.1 g, 77%, 13.8 mmol) was dissolved in 
CHCl3 (55 mL) and added dropwise to a solution of 2,2’-bipyridine (2.0 g, 
12.8 mmol) in CHCl3 (7 mL) at 0 oC. The pale yellow solution was stirred at room 
temperature for 20 h. The reaction mixture was washed with Na2CO3 
(5 %, 3 x 20 mL), the aqueous extracts were then combined and washed with 
CHCl3 (3 x 50 mL). The organic extracts were combined, dried over MgSO4, the 
solvent was removed under reduced pressure to form a yellow oil. Purification by 
alumina column chromatography (gradient 100 % CH2Cl2 to 95 % CH2Cl2 / 5 % 
MeOH) formed the title compound as an off while solid (1.54 g, 71 %). m.p. 
56-57 oC (Lit 56-57 oC)19; 1H (700 MHz, CDCl3,) 8.87 (1 H, d, J 8, H2’), 8.70 (1 H, 
d, J 5, H5’), 8.29 (1 H, d, J 7, H2), 8.16 (1 H, dd, J 8, 2, H5), 7.81 (1 H, td, J 8, 2, 
H3’), 7.33 (2 H, m, H4’ and H4), 7.25 (1 H, m, H3); 13C (176 MHz, CDCl3,) 149.6 
(C6), 149.4 (C5’), 147.3 (C6’), 140.7 (C2), 136.2 (C3’), 127.9 (C5), 125.6 (C4 / C4’), 
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125.5 (C2’), 125.2 (C3’), 124.2 (C4 / C4’); ESI-LRMS [C10H8N2O]+ (+) m/z 174.0; 
ESI-HRMS calcd for [C10H8N2O]+ 173.0707 found, 173.0715.   
7.6.61 4-Nitro-2, 2’-bipyridine-N-oxide, (55)18 
	
 
2, 2’-Bipyridine-N-oxide (3.409 g, 19.8 mmol) and potassium nitrate 
(10.9 g, 107.8 mmol) were dissolved in H2SO4 (97 %, 26 mL). The solution was 
stirred at 80 oC for 24 h before the addition of further KNO3 (6 g, 59.3 mmol) and 
H2SO4 (97 %,10 mL). The solution was stirred for a further 24 h, cooled to room 
temperature, poured onto ice, and basified to pH 10 with NaOH (2 M). The pale 
yellow precipitate formed was extraction into CH2Cl2 (3 x 100 mL) and dried over 
MgSO4. The solvent was removed under reduced pressure to form the title 
compound as a pale yellow solid (2.05 g, 48 %) and was used in subsequent 
steps without further purification. m.p. 184-185 oC (Lit = 184-186 oC)19; 
1H (400 MHz, CDCl3) 9.19 (1 H, d, J 3, H5), 8.91 (1 H, dt, J 8, 1, H5’), 8.81 (1 H, 
ddd, J 5, 2, 1, H2’), 8.38 (1 H, d, J 7, H2), 8.09 (1 H, ddd, J 7, 4, H3), 7.88 (1 H, td, 
J 8, 2, H4’), 7.45 (1 H, ddd, J 8, 5, 4, H3’); 13C (101 MHz, CDCl3) 149.8 (C2’), 148.0 
(C6’), 147.6 (C6), 142.8 (C4), 142.0 (C2), 136.7 (C4’), 125.3 (C5’), 125.1 (C3’), 122.6 
(C5), 118.8 (C3); ESI-LRMS [C10H8N3O3]+ (+) m/z 218.1; ESI-HRMS calcd for 
[C10H8N3O3]+ 218.0566 found, 218.0574. 
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7.6.62 4-Bromo-2, 2’-bipyridine-N-oxide, (56)18 
	
 
 Acetyl bromide (10 mL, 0.135 mol) was added to a solution of 4-nitro-2,2’-
bipyridine-N-oxide (1.40 g, 6.45 mmol) in glacial acetic acid (17 mL) and heated 
at 120 oC for 7 h under an inert atmosphere of argon. Once cooled to room 
temperature, the reaction mixture was poured onto ice and basified to pH 12 with 
NaOH (2 M). The reaction mixture was extracted into CHCl3 (3 x 200 mL) and 
dried over MgSO4. The solvent was removed under reduced pressure to form an 
off white solid (1.49 g, 90 %). The title product, from 1H NMR was a mixture of 4-
bromo-2,2’-bipyridine-N-oxide and the de-oxygenated product 4-bromo-2,2’-
bipyridine, and was used in the subsequent step without any purification. ESI-
LRMS [C10H779BrN3O3]+ (+) m/z 251.1.  
7.6.63 4-Bromo-2, 2’-bipyridine [bpyr-Br], (57)18 
	
 
 Phosphorus tribromide (PBr3) (11.4 g, 4 mL, 42.0 mmol) was added to a 
solution of 4-bromo-2,2’-bipyridine-N-oxide (1.49 g, 5.96 mmol) in anhydrous 
CHCl3 (24 mL) at 0 oC. The yellow solution was heated at 65 oC for 3 h under an 
inert atmosphere of argon. After cooling to room temperature the solvent was 
removed under reduced pressure to form a dark brown residue, and was 
cautiously quenched with NaOH (2 M, 100 mL). The resulting solution was 
extracted into CH2Cl2 (3 x 100 mL) and dried over MgSO4. The solvent was 
removed under reduced pressure to form the title compound as an off-white solid 
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(1.31 g, 92 %) that was used in subsequent steps without any further purification. 
m.p. 52-54 oC (Lit = 51-53 oC)19; 1H (400 MHz, CDCl3) 8.71 (1 H, ddd, J 5, 2, 1, 
H2’), 8.65 (1 H, dd, J 2, 1, H5), 8.51 (1 H, dd, J 5, 1, H2), 8.41 (1 H, dt, J 8, 1, H5’), 
7.85 (1 H, td, J 8, 2, H4’), 7.50 (1 H, dd, J 5, 2, H3), 7.36 (1 H, ddd, J 8, 5, 1, H3’); 
13C (400 MHz, CDCl3) 157.4 (C6), 154.8 (C6’), 149.8 (C2), 149.3 (2’), 137.0 (C4’), 
134.0 (C4), 126.9 (C3), 124.5 (C5), 124.4 (C3), 121.4 (C5’); ESI-LRMS 
[C10H779BrN2]+ (+) m/z 235.3; ESI-HRMS calcd for [C10H779BrN2]+ 234.9871 found 
234.9878.   
7.6.64 [Ru(2,2’-bipyridine)2(4-bromo-2,2’-bipyridine)][PF6]2, (58)20 
 
AgNO3 (51.4 mg, 0.30 mmol) was added to a solution of Ru(bpy)2Cl2.2H2O 
(61.9 mg, 0.12 mmol) in anhydrous methanol (5 mL). The reaction mixture was 
stirred at room temperature in the dark for 3 h under an inert atmosphere of argon. 
The suspension was filtered through a celite plug and the filtrate was added to 
4-bromo-2-2’-bipyridine, (57) (32.2 mg, 0.14 mmol). The dark red solution was 
heated at 65 oC in the dark for 21 h under an intert atmosphere of argon. The 
solution was removed under reduced pressure, dissolved in the minimum amount 
of acetonitrile and dropped onto a saturated solution of KPF6. The precipitate was 
isolated by centrifuge and washed with water and ether to form the title compound 
as a orange / red solid (40.9 mg, 49 %);1H (700 MHz, (CD3)2CO) 9.03 (1 H, t, J 
2), 8.92 (1 H, d, J 8), 8.81 – 8.79 (4 H, m), 8.23 – 8.18 (6 H, m), 8.07 (1 H, d, J 
6), 8.04 – 8.01 (3 H, m), 7.94 (1 H, dd, J 6, 2), 7.75 – 7.73 (1 H, m), 7.61 – 7.55 
(5 H, m); 13C (CDCl3, 176 MHz) 158.4, 157.3, 157.2, 157.1, 157.0, 156.2, 152.3, 
152.0, 151.9, 151.8, 151.7, 138.1, 138.0, 133.8, 130.8, 128.4, 127.7, 125.1, 
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124.2;  ESI-LRMS [C30H2379BrN6Ru]2+ (+) m/z 324.2; ESI-HRMS calcd for 
[C30H2379BrN6Ru]2+ 324.0107 found, 324.0091. 
7.6.65 [Ru(bpy)2(bpy-tBu-APTRA)][PF6]2, (59) 
 
 Pd(PPh3)4 (10.4 mg, 0.009 mmol) was added to a solution of 
[Ru(bpy)2(bpyBr)][PF6]2 (64.9 mg, 0.069 mmol), (50) (48.3 mg, 0.084 mmol) and 
Na2CO3 (44.5 mg in 280 µL H2O, 0.42 mmol) in DMSO (5.3 mL). The reaction 
mixture was degassed by three free-pump-thaw cycles, and heated under an 
inert atmosphere of argon at 85 oC for 22 h. After cooling to room temperature 
the solution was diluted with acetonitrile (3 mL), an insoluble black precipitate 
was removed by centrifuge, and washed with acetonitrile. The combined yellow 
filtrates were added to a saturated solution of KPF6, the precipitate formed was 
isolated using a centrifuge and washed with water and ether. Recrystallisation 
from methanol / diethyl ether formed the title compound as an orange / red solid 
(38.7 mg, 43 %); 1H (700 MHz, (CD3)2CO) 8.98 – 8.96 (2 H, m), 8.82 – 8.80 (4 H, 
m), 8.23 – 8.19 (5 H, m), 8.16 (1 H, d, J 5), 8.05 – 8.04 (4 H, m), 7.98 (1 H, d, J 
6), 7.76 (1 H, dd, J 6, 2), 7.59 – 7.56 (5 H, m), 7.52 (1 H, dd, J 8, 2) 7.39 (1 H, d, 
J 2), 7.06 (1 H, d, J 9), 4.74 (2 H, s), 4.18 (4 H, s), 1.47 (9 H, s), 1.39 (18 H, s); 
13C (CDCl3, 151 MHz) 170.0 (C18), 167.5 (C14), 157.4 (Cq), 157.3 (Cq), 157.2 
(Cq), 157.2 (Cq), 157.2 (Cq), 157.2 (Cq), 151.8 (Cq), 151.7 (CH), 151.7 (CH), 
N
N
2
3 4
5
6
6'
5'
4'
3'
2'
O
N
OO
O
O
7
8
9
10 11 12
13
14
15
16
17
OO
Ru
N
N
N
(PF6)2
18
19
20
21
22
23
24
25
26
27
28
29
30
2+
N
Chapter 7. Experimental  
	
276 
	
151.5 (CH), 149.5 (CH), 140.4 (Cq), 138.0 (CH), 137.9 (CH), 128.6 (Cq), 127.8 
(CH), 124.4 (CH), 124.3 (CH), 121.1 (CH), 121.1 (CH), 120.5 (-CH), 118.2 (CH), 
114.2 (CH), 81.6 (C15), 80.4 (C19), 65.7 (C17), 54.2 (C13), 27.4 (C20), 27.3 (C16);  
ESI-LRMS [C54H57N6O7Ru]2+ (+) m/z 509.7; ESI-HRMS calcd for 
[C54H57N6O7Ru]2+ 509.6768 found, 509.6731. 
7.6.66 [Ru(bpy)2(bpy-APTRA)][PF6]2, [Ru.bL2], (60) 
	
 
[Ru(bpy)2(bpy-tBu-APTRA)][PF6]2, (59) (38.2 mg, 0.05 mmol) was 
dissolved in anhydrous CH2Cl2 (1 mL) and TFA (1 mL) and stirred at room 
temperature for 24 h under an inert atmosphere of argon. The solvent was 
removed under reduced pressure. CH2Cl2 was added and the solvent was 
removed under reduced pressure to form an orange residue. The complex was 
dissolved in the minimum amount of CH3OH and precipitated out of a saturated 
solution of KPF6, to form the title compound in quantitative conversion.  
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7.6.67 [Ir(ppy)2(bpy-Br)]PF6, (61) 21 
 
[Ir(ppy)2(µCl)]2 (121.2 mg, 0.11 mmol) was suspended in methanol 
(7.8 mL), before 4-bromo-2,2’-bipyridine, (57) (58.7 mg, 0.25) was added in a 
solution of CH2Cl2 (6 mL). The reaction mixture was heated at 65 oC for 2 h, before 
being cooled to room temperature. The solvent was removed under reduced 
pressure to form an orange solid which was dissolved in the minimum amount of 
acetonitrile / water (1:1) and added drowse to a saturated solution of KPF6. The 
orange precipitate formed was collected using a centrifuge and washed with 
water. The solvent was removed under reduced pressure to form the title 
compound as a yellow solid. 1H (400 MHz, (CD3)2CO) 9.10 (1 H, s), 8.97 (1 H, d, 
J 8), 8.34 (1 H, td, J 8,2), 8.25 (2 H, m), 8.12 (1 H, d, J 6), 8.01 – 7.94 (5 H, m), 
7.91 (2 H, d, J, 8), 7.85 (1 H, d, J 6), 7.76 (1 H, m), 7.20 – 7.15 (2 H, m), 
7.07 – 7.03 (2 H, m, H), 6.95 – 6.91 (2 H, m), 6.35 (2 H, d, J, 8); ESI-LRMS 
[C32H2479Br191IrN4]+ (+) m/z 733.1; ESI-HRMS calcd for [C32H2479Br191IrN4]+ 
733.0712 found, 733.0709.   
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7.6.68 [Ir(ppy)2(bpy-tBuAPTRA)]PF6, (62) 
 
 (PdPPh3)4 (16.9 mg, 0.015 mmol) was added to a solution of 
[Ir(ppy)2(bpy-Br)]PF6 (61) (112.8 mg, 0.12 mmol) (119.4 mg, 0.2 mmol) and 
Na2CO3 (78 mg in 480 µL H2O, 0.74 mmol) in DMSO (9 mL). The reaction mixture 
was degassed by three free-pump-thaw cycles, and heated at 85 oC under an 
inert atmosphere of argon for 20 h. After cooling to room temperature the solution 
was diluted with acetonitrile (4 mL), an insoluble black precipitate was removed 
by centrifuge, and washed with acetonitrile. The combined yellow filtrates were 
added to a saturated solution of KPF6, the precipitate formed was isolated using 
a centrifuge and washed with water. Purification by alumina column 
chromatography (gradient 100 % hexane to 100 % ethyl acetate) formed the title 
compound as a bright yellow solid (40 mg, 25 %) Rf (silica, ethyl acetate) = 0.7; 
1H (600 MHz, CH3OD) 8.80 (2 H, m,), 8.15 (1 H, t, J 8,), 8.10 (2 H, t, J 8), 8.02 
(1 H, d, J 5), 7.94 (1 H, d, J 6), 7.82 (4 H, m), 7.71 (1 H, d, J 6), 7,67 (1 H, br m), 
7.63 (1 H, d, J 6), 7.52 (1 H, br t, J 5), 7.46 (1 H, dd, J 2, 8), 7.34 (1 H, d, J 2), 
7.04 (2 H, t, J 7), 7.00 (3 H, m), 6.87 (2 H, td, J 7, 2), 6.30 (2 H, dd, J 4, 8), 4.68 
(2 H, s), 4.12 (4 H, s), 1.47 (9 H, s), 1.40 (18 H, s); 13C (151 MHz, MeOD) 171.1, 
168.0, 167.8, 156.2, 151.7, 151.2, 150.5, 150.2, 150.1, 148.6, 148.5, 143.8, 
140.0, 139.1, 138.2, 131.4, 130.1, 129.0, 128.0, 124.7, 124.6, 124,5, 123.1, 
122.2, 121.3, 121.0, 119.6, 118.3, 113.8, 82.2, 81.2, 65.5, 54.5, 26.9, 26.9; 
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ESI-LRMS [C55H59191IrN5O7]+ (+) m/z 1108.6; ESI-HRMS calcd for 
[C55H59191IrN5O7]+ 1104.4021 found, 1104.4031.   
7.6.69 [Ir(ppy)2(bpy-APTRA)]PF6, (63) 
 
[Ir(ppy)2(bpy-tBu-APTRA)]PF6, (62) (40.0 mg, 0.04 mmol) was dissolved 
in anhydrous CH2Cl2 (1 mL) and TFA (1 mL) and stirred at room temperature for 
24 h under an inert atmosphere of argon. The solvent was removed under 
reduced pressure. CH2Cl2 was added and the solvent was removed under 
reduced pressure to form an orange residue. The complex was dissolved in the 
minimum amount of CH3OH and precipitated out of a saturated solution of KPF6. 
to form the title compound in quantitative conversion.  
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8. Appendix  
8.1 pKa and binding studies  
	
	
	
	
	
	
	
Figure A.1 (Left) emission spectrum of NapL1; (right) fitting of the emission intensity 
against the added concentration addition of Ca2+ (λex = 330 nm). Ligand concentration 
= 5 μM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K 
	
		
	
	
	
	
Figure A.2 (Left) emission spectrum of NapL1; (right) fitting of the emission intensity 
against the added concentration of Zn2+ (λex = 330 nm).  Ligand concentration = 5 μM in 
50 mM HEPES, 100 mM KCl, pH 7.21, 298 K. 
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Figure A.3 (Left) emission spectrum of NapL2; (right) fitting of the emission intensity 
against the added concentration of Mg2+ (λex = 326 nm). Ligand concentration = 10 μM in 
50 mM HEPES, 100 mM KCl, pH 7.21, 298 K 
	
	
	
	
	
	
	
	
Figure A.4 (Left) emission spectrum of NapL2; (right) fitting of the emission intensity 
against the added concentration of Ca2+ (λex = 326 nm). Ligand concentration = 10 μM in 
50 mM HEPES, 100 mM KCl, pH 7.21, 298 K 
 
	
	
	
	
	
Figure A.5 (Left) emission spectrum of NapL2; (right) fitting of the emission intensity 
against the added concentration of Zn2+ (λex = 326 nm). Ligand concentration = 10 μM in 
50 mM HEPES, 100 mM KCl, pH 7.21, 298 K. 
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Figure A.6 (Left) emission spectrum of NapL4; (right) fitting of the emission intensity 
against the added concentration of Zn2+ (λex = 330 nm).  Ligand concentration = 10 μM in 
50 mM HEPES, 100 mM KCl, pH 7.21, 298 K. 
	
	
	
	
	
	
	
Figure A.7 The calculation for the dissociation constant based on Equation 7.8 
(Section 7.4).	Comparable dissociation constants were calculated for the binding of Mg2+ to 
NapL1, to that	measured from www.supramolecular.org in a 1:1 binding model.   
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Figure	A.8	Normalised	emission	spectrum	of	[Tb.L2]	in	aerated	and	deoxygenated	solutions.	
λex	=	315	nm,	298	K	in	H2O.			
	
	
	
	
	
	
	
Figure	A.9	Normalised	emission	spectrum	of	[Tb.L2]	in	an	ethanol	glass	at	77	K.	λex	=	315	nm.		
	
Figure A.10 Normalised emission spectra of of [Gd.L1] in ethanol at room temperature 
(298 K, red) and 77 K (transparent glass, blue). The shortest-wavelength phosphorescence 
band was assumed to be the 0-0 transition,  !E$= 320 nm. +00	F= 14 ms (!E$= 320 nm, !E"= 450 nm).  
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Figure	A.11	(Left)	excitation	spectrum	of	[Eu.L1];	(right)	fitting	of	the	excitation	at	313	nm	
against	the	pH.	[Eu.L1]	concentration	=	5	μM	in	100	mM	KCl,	298	K,	λem	=	613	nm.				
	
	
	
	
	
	
	
Figure	A.12	(Left)	excitation	spectrum	of	[Eu.L2];	(right)	fitting	of	the	excitation	at	305	nm	
against	the	pH.	[Eu.L1]	concentration	=	5	μM	in	100	mM	KCl,	298	K,	(λem	=	613	nm).				
	
	
	
	
	
	
	
Figure	A.13	(Left)	excitation	spectrum	of	[Tb.bL2];	(right)	fitting	of	the	excitation	at	313	nm	
against	the	pH.	[Eu.L1]	concentration	=	5	μM	in	100	mM	KCl,	298	K,	(λem	=	544	nm).				
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Figure	A.14	(Left)	excitation	spectrum	of	[Eu.L1];	(right)	fitting	of	the	excitation	ratio	at	287	nm	
and	313	nm	against	the	added	concentration	of	Ca2+	(λem	=	613	nm).	Complex	concentration	=	
5	μM	in	50	mM	HEPES,	100	mM	KCl,	pH	7.21,	298	K.		
	
	
	
	
	
	
	
	
Figure	A.15	(Left)	excitation	spectrum	of	[Eu.L1];	(right)	fitting	of	the	excitation	ratio	at	287	nm	
and	313	nm	against	the	added	concentration	of	Zn2+	(λem	=	613	nm).	Complex	concentration	=	
5	μM	in	50	mM	HEPES,	100	mM	KCl,	pH	7.21,	298	K.		
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Figure	A.16	(Left)	excitation	spectrum	of	[Eu.L2];	(right)	fitting	of	the	excitation	ratio	at	307	nm	
against	the	added	concentration	of	Ca2+	(λem	=	613	nm).	Complex	concentration	=	5	μM	in	
50	mM	HEPES,	100	mM	KCl,	pH	7.21,	298	K.		
	
	
	
	
	
	
	
	
Figure A.17 (Left) excitation spectrum of [Eu.L2]; (right) fitting of the excitation ratio at 307 
nm against the added concentration of Zn2+ (λem = 613 nm). Complex concentration = 5 μM 
in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K.  
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Figure A.18 The ratiometric emission response following the addition of Zn2+ to [Tb.bL2]. 
The dissociation constant was calculated from a ratio of the ΔJ = 2 (486 nm) and ΔJ = 1 
(544 nm) emission bands. [Tb.bL2] concentration = 5 μM in 50 mM HEPES, 100 mM KCl, 
pH = 7.21,  λex = 280 nm, 298 K. 
	
Figure A.19 The non-ratiometric emission response following the addition of Ca2+ to 
[Tb.bL2]. [Tb.bL2] concentration = 5 μM in 50 mM HEPES, 100 mM KCl, pH = 7.21,  λex = 
280 nm, 298 K. 
	
	
	
	
Figure A.20 (Left) excitation spectrum of [Tb.bL2]; (right) fitting of the excitation ratio at 
277 nm against the added concentration of Ca2+ (λem = 544 nm). Complex concentration = 
5 μM in 50 mM HEPES, 100 mM KCl, pH 7.21, 298 K.  
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Figure A.21 (Left) excitation spectrum of [Tb.bL2]; (right) fitting of the excitation ratio at 
277	nm against the added concentration of Zn2+ (λem = 544 nm). Complex concentration = 
5 μM in	50 mM HEPES, 100 mM KCl, pH 7.21, 298 K 
	
	
	
	
	
	
	
	
Figure A.22 (Left) emission spectrum of [Eu.L2]; (right) fitting of the emission intensity 
against	the added concentration of BSA, λex = 318 nm, 298 K.  
	
Figure A.23 The effect of the luminescence lifetime of [Eu.L2], following the addition of 
BSA. λex = 318 nm, λem = 613 nm 298 K.  
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Figure A.24 (Left) The emission spectrum of [Eu.L2] in NCS following the addition of Mg2+. 
(Right) the fitting of the emission intensity against the concentration of Mg2+. [Eu.L2] 
concentration = 5 μM, λex = 343 nm,298 K.  
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
52000
54000
56000
58000
60000
62000
64000
0 0.005 0.01
In
te
ns
ity
	61
3	
nm
	
Concentration	(mM)
0
20000
40000
60000
80000
100000
120000
400 500 600 700
Fl
uo
re
sc
en
ce
	in
te
ns
ity
Wavelength	(nm)	
Kd = 0.7(4) mM 
Mg2+ 
Chapter 8. Appendix  
	
292 
	
8.2 Analytical reverse-phase HPLC traces 
Reverse phase HPLC was performed at 295 K using a Shimadzu system 
consisting of a Degassing Unit (DGU-20A5R), a Prominence Preparative Liquid 
Chromatograph (LC-20AP).  
Analytical column 1: Shimadzu ShimPacl VP-ODS.  
Analytical column 2: Chromolith RP-18 
Table 8.1 Method used for all analytical and semi-preparative HPLC analysis 
Time (min) Solvent A (%) Solvent B (%) 
0 100 0 
3 100 0 
13 0 100 
16 0 100 
25 100 0 
 
	
Figure A.25 The analytical reverse-phase HPLC trace for APDAP. Column 1, conditions 
are shown in Table 8.1. λabs = 280 nm.  
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Figure A.26 The analytical reverse-phase HPLC trace for NapL1. Column 1, conditions are 
shown in Table 8.1. λabs = 340 nm. 
	
Figure A.27 The analytical reverse-phase HPLC trace for NapL2. Column 2, conditions are 
shown in Table 8.1. λabs = 280 nm. 
	
Figure A.28 The analytical reverse-phase HPLC trace for NapL4. Column 1, conditions are 
shown in Table 8.1. λabs = 340 nm. 
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Figure A.29 The analytical reverse-phase HPLC trace for NapL6. Column 2, conditions are 
shown in Table 8.1. λabs = 330 nm. 
	
Figure A.30 The analytical reverse-phase HPLC trace for [Eu.L1]. Column 1, conditions 
are shown in Table 8.1. λabs = 280 nm. 
	
Figure A.31 The analytical reverse-phase HPLC trace for [Eu.L2]. Column 1, conditions 
are shown in Table 8.1. λabs = 340 nm. 
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Figure A.32 The analytical reverse-phase HPLC trace for [Tb.L2]. Column 1, conditions 
are shown in Table 8.1. λabs = 340 nm. 
	
Figure A.33 The analytical reverse-phase HPLC trace for [Eu.bL2] . Column 1, conditions 
are shown in Table 8.1. λabs = 280 nm. 
	
Figure A.34 The analytical reverse-phase HPLC trace for [Tb.bL2]. Column 1, conditions 
are shown in Table 8.1. λabs = 280 nm. 
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8.3 Key ligands and complexes  
8.3.1 APDAP 
 
 
8.3.2 The naphthalene series  
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8.3.3 Key lanthanide complexes 
	
 
8.3.4 Ruthenium(II) and Iridium(III) complexes 
	
 
N N
NN
OO
O
O
OO
Eu
[Eu.L1] [Eu.L2]
N
N
O
O
O
O
O
O
O
N N
NN
OO
O
O
OO
Ln N
O
N
O
O
O
O
O
O
N N
NN
OO
O
O
OO
Ln
[Tb.bL2]
N
O
N
O
O
O
O
O
O
(Ln = Eu3+, Tb3+)
[Ru.bL2]2+
N
N
N
N
Ir
O
N
O O
O
O
OO
+
N
N
N
N
N
N
Ru
O
N
O O
O
O
OO
2+
[Ir.bL2]+
Chapter 8. Appendix  
	
298 
	
8.4 Conferences Attended  
• Molecular Photophysics Conference I, Newcastle, 2015. 
• 42nd International Conference of Coordination Chemistry (ICCC), Brest, 
France 2016. Poster presentation ‘Synthesis of magnesium-selective 
ligands and the incorporation into fluorescence-based sensors’. 
• Rennes-Durham Symposium, Durham, May 2017. 
8.5 Departmental Seminars attended  
8.5.1 First year  
	
• Bacterial superglue, spontaneous amide bond formation, and polymers to 
fish for cancer cells. Dr M. Howarth. University of Oxford, 2014. 
• Protein Reactions with Anticancer Metallodrugs. Prof. Peter O’Connor. 
University of Warwick, 2014. 
• Time-resolved radiation chemistry; interaction of excess electrons with 
water and nucleobases. Prof. D. Neumark. University of California, 
Berkeley, 2014. 
• Design of New Chemical Tools for Cancer. Dr. John Spencer. University 
of Sussex, 2014. 
• Surprising ‘twist and turns’ in supramolecular self-assembly formations. 
Prof. T. Gunnlaugsson. Trinity College Dublin, 2015. 
• π-Conjugated organophosphorus oligomers for optoelectronic 
applications. Prof. M. Hissler. Institute des Sciences Chimique de Rennes, 
2015. 
• New peptide ligands for metal ions: from MRI contrast agents to DNA 
binding proteins. Dr A. Peacock. University of Birmingham, 2015  
• Durham Lecture 1; Carbon Materials, Devices, Medicine and Nanocars. 
Prof. James Tour Rice University, Texas, 2015. 
• Durham Lecture 2; Graphene, Composites and Devices. Prof. James Tour 
Rice University, Texas, 2015. 
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• Durham Lecture 3: Nanomedicine for Stroke, Traumatic Brain Injury, 
Autoimmune disease and drug delivery. Prof. James Tour. Rice University, 
Texas, 2015.  
8.5.2 Second year  
	
• Musgrave Lecture 2016, Prof Steven V Ley FRS University of Cambridge. 
• ‘Chemical Probes for Epigenetic Targets’, Prof Paul Brennan, University 
of Oxford.  
• ‘Using Chemical Biology to Manipulate the Peroxisome’, Dr Stuart 
Warriner, University of Leeds.  
• 'Targeted Design of Photoactive Organic- Inorganic Hybrid Materials for 
Energy and Lighting Applications’, Dr Rachel C Evans, Trinity College 
Dublin. 
• ‘New Main Group Metal Mediated Strategies for Ring Functionalisation’, 
Prof. Eva Hevia, University of Strathclyde.  
• ‘Catalysis on Gold’, Prof. Graham Hutchings FRS, Cardiff University.  
• ‘Targeting the Tumour Microenvironment’, Dr Robert Elmes, Maynooth 
University.  
• ‘Versatility of Tetrazole Ligands in Luminescence Metal Complexes for 
Applications in Life Sciences’, Dr Max Massi, Curtin University, Perth.  
• ‘Using Organometallics as catalysts; from drug precursors to little black 
dresses’, Dr Patrick McGowan, University of Leeds.  
• Durham Lecture Series 2016: Presented by Sir J Fraser Stoddart. 
 
8.5.2 Third year  
	
•  ‘Strategies for the Development of Lanthanide-Based Chemosensors', 
Prof. Kellie Tuck, Monash University, 2017. 
• ‘Lanthanide Based MRI Probes for A-beta-Amloid’, Prof. Carlos FGC 
Geraldes, Coimbra, 2017. 
• ‘Ionic Liquids: Solvents for Sustainable Chemistry’ Prof. Tom Welton, 
Imperial College London, 2017. 
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• Imposter Syndrome: ‘ Floating to Professor on a Magic Carpet of Success’, 
Prof. Tom Welton, Imperial College London, 2017. 
• Development of gold and palladium catalysed reactions, D. Ai-Lan Lee, 
Herriot-Watt University, 2016.  
• ‘Metal-based chemical entities for applications in chemical biology and 
medicine’, Prof. Angela Casini, Cardiff University, 2016.  
• ‘Synthesis of conjugated polymers for organic electronics: Making use of 
triplet excited states’, Dr Hugo Bronstein, University College London, 
2016.
